Cytokine inhibitors

ABSTRACT

The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.10/939,324, filed Sep. 10, 2004, which claims priority to U.S.Provisional Application No. 60/502,569, filed Sep. 11, 2003, U.S.Provisional Application No. 60/531,234, filed Dec. 18, 2003, U.S.Provisional Application No. 60/575,704, filed May 28, 2004, and U.S.Provisional Application No. 60/585,012, filed Jul. 2, 2004, the entirecontents of which are herein incorporated by reference.

FIELD OF THE INVENTION

The present invention relates to low molecular weight compounds andcompositions thereof, useful as cytokine inhibitors, and theirpreparation. The invention further relates to methods of prevention andtreatment of cytokine mediated diseases.

BACKGROUND OF THE INVENTION

Tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1) areproinflammatory cytokines that mediate inflammatory responses associatedwith infectious agents and other cellular stresses. Overproduction ofcytokines such as IL-1 and TNF-α is believed to underlie the progressionof many inflammatory diseases including rheumatoid arthritis (RA),Crohn's disease, inflammatory bowel disease, multiple sclerosis,endotoxin shock, osteoporosis, Alzheimer's disease, congestive heartfailure, and psoriasis among others (Dinarello, C. A. et al., Rev.Infect. Diseases 1984, 6:51; Salituro et al., Curr. Med. Chem. 1999,6:807-823; Henry et al., Drugs Fut. 1999, 24:1345-1354). An acceptedtherapeutic approach for potential drug intervention in these conditionsis the reduction of proinflammatory cytokines such as TNF-α (alsoreferred to as TNFa) and interleukin-1β (IL-1b).

Recent data from clinical trials support the use of protein antagonistsof cytokines, for example soluble TNFa receptor fusion protein(etanercept) (Moreland et al., Ann. Intern. Med. 1999, 130:478-486) orthe monoclonal TNFa antibody (Enbrel) for the treatment of rheumatoidarthritis, Crohn's disease, juvenile chronic arthritis and psoriaticarthritis (Rankin et al., Br. J. Rheumatol. 1995, 34:334-342; Galadariet al. Int J Dermatol. 2003, 42:231-7; Reimold, Am J Med Sci. 2003325(2):75-92). Thus, small molecules that inhibit or antagonize theeffects of cytokines such as, for example, TNFa and or IL-1b areexpected to be beneficial for the treatment rheumatoid arthritis,Crohn's disease, juvenile chronic arthritis and psoriatic arthritis.

Il-1 is detected in synovial fluid and in cartilage matrix joints ofpatients with osteoarthritis. IL-1 antagonists have been shown todiminish the degradation of cartilage matrix components in a variety ofexperimental models of arthritis (Chevalier, Biomed Pharmacother. 1997,51:58).

Il-1 receptor antagonists have been evaluated in humans (Bresnihan etal., Arthritis Rheum. 1998, 41:2196-2204). Efficacy has beendemonstrated for the treatment of rheumatoid arthritis (Antril, Amgen).Il-1 receptor antagonist also demonstrated reduced mortality in a groupof patients with septic shock syndrome (Dinarello, Nutrition 1995,11:492).

Cytokines such as IL-1 and TNFa are potent stimulators of nitric oxide(NO) production. NO is a mediator of cardiovascular homeostasis,neurotransmission, immune function and a modulator of bone remodelingwith effects on osteoblasts and osteoclasts (van't Hof, Immunology 2001,103(3):255-61 Evans, et al., J. Bone Miner. Res. 1996, 11:300).

IL-1 has also been linked to beta-cell destruction which is one of thehallmarks of insulin dependent diabetes mellitus. Although other factorscan also mediate beta-cell damage, Il-1 is linked to this processthrough its effect on cyclooxygenase II (COX-2) and inducible NOsynthase (McDaniel et al., Proc Soc Exp Biol Med. 1996, 211:24).

IL-1 has also been shown to induce uveitis in rats which could beinhibited with IL-1 blockers. (Xuan et al., J. Ocular Pharmacol. andTher. 1998, 14: 31). Cytokines including IL-1, TNFa and GM-CSF have beenshown to stimulate proliferation of acute myelogenous leukemia blasts(Bruserud, Leukemia Res. 1996, 20: 65). IL-1 was shown to be essentialfor the development of both irritant and allergic contact dermatitis.Epicutaneous sensitization can be prevented by the administration of ananti-IL-1 monoclonal antibody before epicutaneous application of anallergen (Muller, et al., Am J Contact Dernat. 1996, 7: 177). Dataobtained from IL-1 knock out mice indicates the critical involvement infever for this cytokine (Kluger et al., Clin Exp Pharmacol Physiol.1998, 25: 141). A variety of cytokines including TNFa, IL-1, IL-6 andIL-8 initiate the acute-phase reaction which is stereotyped in fever,malaise, myalgia, headaches, cellular hypermetabolism and multipleendocrine and enzyme responses (Beisel, Am J Clin Nutr. 1995, 62: 813).The production of these inflammatory cytokines rapidly follows trauma orpathogenic organism invasion.

Rhinovirus triggers the production of various proinflammatory cytokines,predominantly IL-8, which results in symptomatic illnesses such as acuterhinitis (Winther et al., Am J Rhinol. 1998, 12: 17).

Cytokine inhibitors are also expected to block inducible COX-2, anenzyme involved in inflammation (M. K. O'Banion et al., Proc. Natl.Acad. Sci. USA 1992, 89:4888). Cytokine inhibitors such as, for example,IL-1 receptor antagonist (IL-1ra) would be expected to show efficacyagainst disorders where COX-2 inhibitors (such as the NSAIDs) would beused. These disorders include but are not limited to inflammatorydiseases, chronic pain and cardiovascular disease.

Several cytokines are known to be elevated in inflammatory bowel disease(IBD) conditions. An imbalance of IL-1 and IL-1ra has been described inpatients with IBD. Insufficient production of IL-1ra could at leastpartially contribute to the pathogenesis of IBD (Cominelli, et al.Aliment Pharmacol. Ther. 1996, 10:49).

Beta-amyloid protein deposits, neurofibrillary tangles and cholinergicdysfunction throughout the hippocampal region have been observed inAlzheimer's disease patients. Sustained levels of cytokines, such as,for example IL-1 and/or TNFa could be at least partially responsible forthe damage in the brains of Alzheimer's disease patients (Grammas,Neurobiol. Aging 2001, 22(6):837-42; Rempel, J. Neurochem. 2001,78(3):640-645).

Cytokines such as TNFa and Il-1 have been also implicated in thepathogenesis of human immunodeficiency virus (HIV) infection and acuteinflammatory events (Kreuzer, Clin. Exp. Immunol. 1997, 109(1):54-58;Baqui, Immunopharmacol Immunotoxicol 2000, 22(3):401-421). Theconcentrations of cytokines and receptors are elevated in bone marrowsupernatant of HIV-infected patients with hematologic abnormalities, andthese concentrations were shown to correlate with clinical parameters inthese patients (Dallalio, J. Investig. Med. 1999, 47(9):477-483).

Proinflammatory cytokines such as TNFa and IL-1b and interleukin-6(IL-6) are important mediators of septic shock, cardiopulmonarydysfunction, acute respiratory distress syndrome (ARDS) and multipleorgan failure. Patients admitted with presumed sepsis have elevatedcytokine levels compared with patients with sepsis who are dischargedand with those patients with presumed noninfectious systemicinflammatory response syndrome (SIRS) suggesting an association betweencytokines and subsequent septic complications in these patients(Terregino, Ann. Emerg. Med. 2000, 35(1):26-34).

Cytokine imbalance is also implicated in cachexia and muscle degradationassociated with HIV infection. The serum concentrations of inflammatory(IL-1b, TNFa, IL-6) and regulatory cytokines (Interleukin twelve) havebeen studied in ten AIDS cachectic patients and compared to a controlgroup. A cytokine imbalance and a significant increase inproinflammatory cytokines (IL-1, IL-6, TNFa) was observed in the patientgroup (Baronzio, In Vivo 1999, 13(6):499-502).

Obesity is associated with an increase incidence of infection, diabetesand cardiovascular disease. Abnormalities in TNFa expression have beennoted for each of the above conditions (Loffreda, et al., FASEB J. 1998,12: 57). It has been proposed that elevated levels of TNFa are involvedin other eating related disorders such as anorexia and bulimia nervosa.Pathophysiological parallels are drawn between anorexia nervosa andcancer cachexia (Holden, et al., Med Hypotheses 1996, 47: 423). Aninhibitor of TNFa production, HU-211, was shown to improve the outcomeof closed brain injury in an experimental model (Shohami, et al., JNeuroimmunol. 1997, 72: 169).

There is mounting evidence that inflammation plays a role in thedevelopment of coronary heart disease (CHD) and coronary artery disease(CAD). Elevated concentrations of acute phase reactants, such asC-reactive protein (CRP), are found in patients with acute coronarysyndromes, and predict future risk in apparently healthy subjects.Cytokines such as TNFa, Il-1 and Il-6 have been suggested to promoteatherosclerosis and heart disease. Coronary disease patients arecharacterized by increased serum concentrations of TNFa. It seems likelythat immune activation (TNFa, soluble TNF receptors 1 and 2 (sTNFR 1,sTNFR 2), and interleukin-10 (IL-10)) in coronary patients is related toserum lipid levels (Mizia-Stec, Acta Cardiol. 2003, 58(1):9-15).

A large percentage of acute coronary syndrome is the consequence ofunstable plaque rupturing, followed by thrombus formation. Acharacteristic of these unstable plaque is an increase in inflammatorycells (macrophages and T lymphocytes). The serum concentration of CRP(C-reactive protein) might reflect the amount of inflammation withinatherosclerotic plaque and thus might provide a measurement of theinstability of the plaque. CRP is believed therefore to have apredictive value for the occurrence of plaque rupture. Furthermore,there are indications that CRP itself is active in the inflammatoryprocess. Studies have shown that so-called high-sensitivity CRP (hsCRP)measurements could be used as a tool for determining the risk for acutecoronary syndromes. Antiinflammatory agents, capable of reducing thelevels of hsCRP might contribute to reducing the risk of plaque rupture(Abjil, Ned Tijdschr Geneeskd 2003, 147(1):15-20; Branger, J. Immunol.2002, 168(8):4070-7).

Elevated TNFa levels have also been found to be associated withcongestive heart failure, and levels of cytokines have been correlatedwith the severity of the disease. Serum levels of TNFa are elevated inpatients with heart failure, and both cardiac and infiltrating cells ofthe myocardium can produce this proinflammatory cytokine. Studies inboth animal models and clinical investigations suggest that anti-TNFatherapies may limit the pathophysiologic consequences of congestiveheart failure (McTiernan, Curr. Cardiol. Rep. 2000, 2(3):189-97).Furthermore, treatment with etanercept (a soluble TNF receptor) led to asignificant dose-dependent improvement in left ventricular ejectionfraction and remodeling, and there was a trend toward improvement inpatient functional status, as determined by clinical composite score(Bozkurt, Circulation 2001 Feb. 27;103(8):1044-7).

TNFa levels are elevated in airways of patients with chronic obstructivepulmonary disease and it may contribute to the pathogenesis of thisdisease (M. A. Higham et al., Eur. Respiratory J. 2000, 15: 281).Circulating TNFa may also contribute to weight loss associated with thisdisease (N. Takabatake et al., Amer. J. Resp. & Crit. Care Med. 2000,161 (4 Pt 1): 1179). Elevated TNFa levels have also been found to beassociated with congestive heart failure and the level has beencorrelated with severity of the disease (A. M. Feldman et al., J. Amer.College of Cardiology 2000, 35: 537). In addition, TNFa has beenimplicated in reperfusion injury in lung (Borjesson et al., Amer. J.Physiol. 2000, 278: L3-12), kidney (Lemay et al., Transplantation 2000,69: 959), and the nervous system (Mitsui et al., Brain Res. 1999, 844:192). Proinflammatory cytokines are also known to play roles inischemia-reperfusion injury of the heart, kidney, small bowel, skin, andliver. For example, TNFa and IL-1beta were shown to help regulate thedevelopment of lung ischemia-reperfusion injury. They appear to promoteinjury by altering expression of proinflammatory and anti-inflammatorycytokines. Neutrophil recruitment and lung neutrophil accumulation wasmarkedly reduced among animals receiving anti-TNFa and anti-IL-1beta andcombination blockade afforded even greater protection (Krishnadasan, J.Thorac. Cardiovasc. Surg. 2003, 125(2):261-72). In brain injury,pretreatment with intravenous anti-TNFa antibody reduced cortical andsubcortical injury, enhanced cerebral blood flow during reperfusion, andimproved the neurologic outcome. This supports the contention that TNFais a deleterious cytokine in stroke, whereas circulating antibodyagainst TNF-alpha may protect brain from reperfusion injury (Lavine, J.Cereb. Blood Flow Metab. 1998, 18(1):52-8; Mitsui, Brain Res. 1999,844(1-2):192-5). TNFa is also believed to be released from the kidney inresponse to, and has been implicated in the pathogenesis of, renalischemia-reperfusion injury (Donnahoo, J. Urol. 1999, 162(1):196-203).

Skeletal mass is maintained by a balance between cells which resorb bone(osteoclasts) and cells which form bone (osteoblasts). Recentobservations have identified members of the TNF family of ligands andreceptors as critical regulators of osteoclastogenesis (Horowitz,Cytokine Growth Factor Rev 2001, 12(1):9-18) and it was suggested thatcytokines such as TNFa and IL-1 alpha may play an important role inpathological bone resorption. Data support the concept that TNFa isinvolved critically in osteoclastogenesis and bone resorption duringperiprosthetic osteolysis and suggest that TNFa inhibitors may be usefulas therapeutic agents for the treatment of diseases involving boneresorption (Childs, J. Bone Miner. Res. 2001, 16(2):338-47; Abu-Amer, J.Biol. Chem. 2000, 275(35):27307-10).

Periodontal disease is a significant cause of tooth loss among adultsand is characterized by the alteration and permanent destruction of thedeeper periodontal tissues. Studies showed that IL-1 and TNF antagonistssignificantly reduced the loss of connective tissue attachment and theloss of alveolar bone height. This suggests that the loss of connectivetissue attachment and progression of periodontal disease can be retardedby antagonists to cytokines such as IL-1 (Delima, J. Clin. Periodontol.2001, 28(3):233-40).

TNFa plays a role in many aspects of glomerulonephritis progression.Studies showed that neutralization of endogenous TNFa is effective inpreventing acute glomerular inflammation and crescent formation (Karkar,Nephrol. Dial. Transplant 2001, 16(3):518-24).

Ulcerative colitis (UC) and Crohn's disease (CD) comprise a series ofinflammatory bowel diseases (IBD) resulting from chronic upregulation ofthe mucosal immune system and elevated levels of cytokines such as, forexample, TNFa, IL1-b and IL-6. Strategies aimed at reducing cytokinelevels, such as TNFa in patients with inflammatory bowel disease includethe mouse/human chimeric monoclonal antibody infliximab, the humanizedmonoclonal antibody CDP571, the human soluble TNF p55 receptor onercept,the human monoclonal antibody D2E7 (adalimumab), the anti-TNF humanantibody Fab′ fragment-polyethelene glycol (PEG) conjugate CDP870, andthe small molecules thalidomide and CNI-1493 MAP-kinase inhibitor(Escher et al., Inflamm. Bowel. Dis. 2003 January; 9(1):34-58; Sandboret al., Best Pract. Res. Clin. Gastroenterol. 2003, 17(1):105-17).

Abnormalities in the immune response are believed to play a role in thepathogenesis of hypertension. Studies showed that hypertensive patientshad an increased IL-1 and IL-6 production capacity when whole blood wasstimulated ex vivo with lipopolysaccharide (Peeters, Eur. J. Clin.Invest. 2001, (1):31-6). Inducible nitric oxide synthase (iNOS) presentin vascular smooth muscle cells (VSMC) were suggested to play a role inthe generation of nitric oxide (NO) in the vascular wall, regulatingblood vessel tone in normotension and hypertension. IL-1 beta was shownto control iNOS gene expression at the transcriptional level (Singh, Am.J. Hypertens. 1996, (9):867-77) suggesting that agents inhibitingcytokines such as IL-1 inhibitors could be useful for the treatment ofhypertension.

Diseases that are effected by IL-8 include myocardial ischemia andreperfusion, inflammatory bowel disease and many others.

The proinflammatory cytokine IL-6 has been implicated with the acutephase response. IL-6 is a growth factor in a number in oncologicaldiseases including multiple myeloma and related plasma cell dyscrasias(Treon, et al., Current Opinion in Hematology 1998, 5: 42). It has alsobeen shown to be an important mediator of inflammation within thecentral nervous system. Elevated levels of IL-6 are found in severalneurological disorders including AIDS dementia complex, Alzheimer'sdisease, multiple sclerosis, systemic lupus erythematosus, CNS traumaand viral and bacterial meningitis (Gruol, et al., MolecularNeurobiology 1997, 15: 307). IL-6 also plays a significant role inosteoporosis. In murine models it has been shown to effect boneresorption and to induce osteoclast activity (Ershler et al.,Development and Comparative Immunol. 1997, 21: 487). Marked cytokinedifferences, such as IL-6 levels, exist in vivo between osteoclasts ofnormal bone and bone from patients with Paget's disease (Mills, et al.,Calcif Tissue Int. 1997, 61: 16). A number of cytokines have been shownto be involved in cancer cachexia. The severity of key parameters ofcachexia can be reduced by treatment with anti IL-6 antibodies or withIL-6 receptor antagonists (Strassmann, et al., Cytokins Mol Ther. 1995,1: 107). Several infectious diseases, such as influenza, indicate IL-6and IFN alpha as key factors in both symptom formation and in hostdefense (Hayden, et al., J Clin Invest. 1998, 101: 643). Overexpressionof IL-6 has been implicated in the pathology of a number of diseasesincluding multiple myeloma, rheumatoid arthritis, Castleman's disease,psoriasis and post-menopausal osteoporosis (Simpson, et al., ProteinSci. 1997, 6: 929). Compounds that interfered with the production ofcytokines including IL-6, and TNFa were effective in blocking a passivecutaneous anaphylaxis in mice (Scholz et al., J. Med. Chem. 1998, 41:1050).

GM-CSF is another proinflammatory cytokine with relevance to a number oftherapeutic diseases. It influences not only proliferation anddifferentiation of stem cells but also regulates several other cellsinvolved in acute and chronic inflammation. Treatment with GM-CSF hasbeen attempted in a number of disease states including burn-woundhealing, skin-graft resolution as well as cytostatic and radiotherapyinduced mucositis (Masucci, Medical Oncology 1996, 13: 149). GM-CSF alsoappears to play a role in the replication of human immunodeficiencyvirus (HIV) in cells of macrophage lineage with relevance to AIDStherapy (Crowe et al., Journal of Leukocyte Biology 1997, 62: 41).Bronchial asthma is characterized by an inflammatory process in lungs.Involved cytokines include GM-CSF amongst others (Lee, J R CollPhysicians Lond 1998, 32: 56).

Interferon-gamma (IFN-gamma) has been implicated in a number ofdiseases. It has been associated with increased collagen deposition thatis a central histopathological feature of graft-versus-host disease(Parkman, Curr Opin Hematol. 1998, 5: 22). Following kidneytransplantation, a patient was diagnosed with acute myelogenousleukemia. Retrospective analysis of peripheral blood cytokines revealedelevated levels of GM-CSF and IFN-gamma. These elevated levels coincidedwith a rise in peripheral blood white cell count (Burke, et al., LeukLymphoma. 1995, 19: 173). The development of insulin-dependent diabetes(Type 1) can be correlated with the accumulation in pancreatic isletcells of T-cells producing IFN-gamma (Ablumunits, et al., J Autoimmun.1998, 11: 73). IFN-gamma along with TNFa, IL-2 and IL-6 lead to theactivation of most peripheral T-cells prior to the development oflesions in the central nervous system for diseases such as multiplesclerosis (MS) and AIDS dementia complex (Martino et al., Ann Neurol.1998, 43: 340). Atherosclerotic lesions result in arterial disease thatcan lead to cardiac and cerebral infarction. Many activated immune cellsare present in these lesions, mainly T-cells and macrophages. Thesecells produce large amounts of proinflammatory cytokines such as TNFa,IL-1 and IFN-gamma. These cytokines are thought to be involved inpromoting apoptosis or programmed cell death of the surrounding vascularsmooth muscle cells resulting in the atherosclerotic lesions (Geng,Heart Vessels 1997, Suppl 12: 76). Allergic subjects produce mRNAspecific for IFN-gamma following challenge with Vespula venom (Bonay, etal., Clin Exp Immunol. 1997, 109: 342). The expression of a number ofcytokines, including IFN-gamma has been shown to increase following adelayed type hypersensitivity reaction thus indicating a role forIFN-gamma in atopic dermatitis (Szepietowski, et al., Br J Dermatol.1997, 137: 195). Histopathologic and immunohistologic studies wereperformed in cases of fatal cerebral malaria. Evidence for elevatedIFN-gamma amongst other cytokines was observed indicating a role in thisdisease (Udomsangpetch et al., Am J Trop Med Hyg. 1997, 57: 501). Theimportance of free radical species in the pathogenesis of variousinfectious diseases has been established. The nitric oxide synthesispathway is activated in response to infection with certain viruses viathe induction of proinflammatory cytokines such as IFN-gamma. (Akaike,et al., Proc Soc Exp Biol Med. 1998, 217: 64). Patients, chronicallyinfected with hepatitis B virus (HBV) can develop cirrhosis andhepatocellular carcinoma. Viral gene expression and replication in HBVtransgenic mice can be suppressed by a post-transcriptional mechanismmediated by IFN-gamma, TNFa and IL-2 (Chisari, et al., Springer SeminImmunopathol. 1995, 17: 261). IFN-gamma can selectively inhibit cytokineinduced bone resorption. It appears to do this via the intermediacy ofnitric oxide (NO) which is an important regulatory molecule in boneremodeling. NO may be involved as a mediator of bone disease for suchdiseases as: the rheumatoid arthritis, tumor associated osteolysis andpostmenopausal osteoporosis (Evans, et al., J Bone Miner Res. 1996, 11:300). Studies with gene deficient mice have demonstrated that the IL-12dependent production of IFN-gamma is critical in the control of earlyparasitic growth. Although this process is independent of nitric oxidethe control of chronic infection does appear to be NO dependent(Alexander et al., Philos Trans R Soc Lond B Biol Sci 1997, 352: 1355).NO is an important vasodilator and convincing evidence exists for itsrole in cardiovascular shock (Kilboum, et al., Dis Mon. 1997, 43: 277).IFN-gamma is required for progression of chronic intestinal inflammationin such diseases as Crohn's disease and inflammatory bowel disease (IBD)presumably through the intermediacy of CD4+lymphocytes probably of theTHI phenotype (Sartor, Aliment Pharmacol Ther. 1996, 10 Suppl 2: 43). Anelevated level of serum IgE is associated with various atopic diseasessuch as bronchial asthma and atopic dermatitis. The level of IFN-gammawas negatively correlated with serum IgE suggesting a role for IFN-gammain atopic patients (Teramoto et al., Clin Exp Allergy 1998, 28: 74).

Recently it was shown that cytokine pathways play a role in thederivation and maintenance of embryonic stem cells (ES cells) (Proc NatlAcad Sci USA. 2004, 101: 6027), suggesting the potential application ofcytokine inhibitors in conjunction with stem cell therapy.

WO 01/01986 discloses particular compounds alleged to having the abilityto inhibit TNFa. The specific inhibitors disclosed are structurallydistinct from the novel compounds disclosed in the present applicationdisclosed herein below. Certain compounds disclosed in WO 01/01986 areindicated to be effective in treating the following diseases: dementiaassociated with HIV infection, glaucoma, optic-neuropathy, opticneuritis, retinal ischemia, laser induced optic damage, surgery ortrauma-induced proliferative vitreoretinopathy, cerebral ischemia,hypoxia-ischemia, hypoglycemia, domoic acid poisoning, anoxia, carbonmonoxide or manganese or cyanide poisoning, Huntington's disease,Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosisand other demyelinating diseases, amyotrophic lateral sclerosis, headand spinal cord trauma, seizures, convulsions, olivopontocerebellaratrophy, neuropathic pain syndromes, diabetic neuropathy, HIV-relatedneuropathy, MERRF and MELAS syndromes, Leber's disease, Wemicke'sencephalopathy, Rett syndrome, homocysteinuria, hyperprolinemia,hyperhomocysteinemia, nonketotic hyperglycinemia, hydroxybutyricaminoaciduria, sulfite oxidase deficiency, combined systems disease,lead encephalopathy, Tourett's syndrome, hepatic encephalopathy, drugaddiction, drug tolerance, drug dependency, depression, anxiety andschizophrenia. WO 02/32862 discloses that inhibitors of pro-inflammatorycytokines including TNFa are allegedly useful for treating acute andchronic inflammation in the lung caused by inhalation of smoke such ascigarette smoke. TNFa antagonists are apparently also useful for thetreatment of endometriosis, see EP 1022027 A1. Infliximab, in clinicaltrials for RA, has also been indicated to be useful for treating variousinflammatory diseases including Behcet's disease, uveitis and ankylosingspondylitis. Pancreatitis may also be regulated by inflammatory mediatorproduction (J Surg Res 2000, 90(2):95-101; Shock 1998, 10(3):160-75.)

It is known in the art that anti-inflammatory compounds such as cytokineinhibitors can be used in combination with other active ingredients inthe treatment of diseases and pathological conditions. For example,cytokine inhibitors have been combined with anti-cholinergics for thepurpose of treating respiratory tract diseases (see WO03/084539 andcorresponding US application 2003/0225089, and WO2004/004725 andcorresponding US application 2004/0044020). Combination therapy withcytokine inhibitors and a variety of other active ingredients isdisclosed in US patent application 2004/0110755.

The need for new therapies is especially important in the case ofarthritic diseases. The primary disabling effect of osteoarthritis,rheumatoid arthritis and septic arthritis is the progressive loss ofarticular cartilage and thereby normal joint function.

TNFa plays an important role in many cell types in mediating responsesto an external stimulus, such as, for example, an infection, trauma or amitogen.

Thus, a need exists for therapeutics useful in the treatment of cytokinemediated diseases. While some protein therapeutics have been developed,they suffer from bioavailability and stability problems. In particular,there is a need for low molecular weight compounds that inhibit TNFaand/or IL-1b production.

SUMMARY OF THE INVENTION

The present invention provides low molecular weight compounds andpharmaceutical compositions thereof. In particular, compounds of theinvention are useful as cytokine release inhibitory agents. There arefurther provided methods for the preparation of such compounds and theiruse in the prevention and treatment of various diseases mediated bycytokines.

Thus, there are provided in accordance with one aspect of the inventioncytokine inhibitors comprising:

a targeting moiety, TM, comprising at least an amide group having anamide NH, the targeting moiety capable of forming one or more hydrogenbonds with a target protein, and wherein the targeting moiety is not aurea group;

a pocket-expanding moiety, PEM, directly attached to the targetingmoiety, the pocket-expanding moiety comprising a planar moiety attachedto a bulky non-planar hydrophobic moiety, wherein the non-planar moietycan form hydrophobic interactions with a target protein;

an orienting moiety, OM, comprising a planar hydrophobic moiety andattached to a different atom of the targeting moiety than thepocket-expanding moiety, wherein the orienting moiety is capable offorming a π-π or edge-to-face aromatic interaction with a targetprotein.

In this aspect of the invention, cytokine inhibitors have the structurePEM-TM-OM. At a concentration of 10 μM such compounds typically inhibitinduced TNFa-release from a cell by about 50% or greater than 50%.

The targeting moiety can hydrogen bond to residues at the binding siteof the target protein and may further include additional hydrogen bonddonor or acceptor groups that also form hydrogen bonds to the targetprotein. Targeting moieties include amide and thioamide groups, methylamide and thioamide groups, carbamates, hydroxymethyl amides,alpha-ketoamides, diamides, and the like. Cyclic targeting moieties arealso contemplated such as imidazolinone, imidazoline dione and trione.

The pocket-expanding moiety is of sufficient size to force aconformational change in the target protein, resulting in an expandedbinding pocket therein. Such moieties include, for example, pyrazolyl,oxazolyl, phenyl or the like, each substituted by bulky moieties. Bulkymoieties fill a large volume of space in comparison to, for example, amethyl group and include groups such as t-butyl, norbornyl, and thelike.

The orienting moiety, by binding to a hydrophobic pocket on the targetprotein, provides the proper orientation of the targeting moiety andpocket-expanding moiety for binding of the cytokine inhibitor to itstarget protein. The planar hydrophobic moieties which make up theorienting moiety have either few or no polar groups. Such moietiesinclude, for example, phenyl, naphthyl, indazolyl, and the like.

In other embodiments, the cytokine inhibitors further comprise ahydrophilic moiety having at least one functionality selected from thegroup consisting of a hydrogen-bond donor, hydrogen-bond acceptor, basicheteroatom, or acidic heteroatom, wherein the hydrophilic moiety isindirectly attached to the hydrophobic orienting moiety and is capableof forming a hydrogen bond with the backbone of the protein. Typicallythe hydrophilic moiety is attached to the orienting moiety by a linkerchain of atoms of from about 2 to about 10 angstroms in length. Thehydrophilic moiety binds in or near an ATP-binding pocket on the targetprotein, forming at least one hydrogen bond with a residue of theATP-binding pocket. Hydrophilic moieties include morpholinyl,piperazinyl, and pyrimidinyl groups, among others. Such moieties may beattached to the orienting moiety by, for example, oxy, ethylene,methyleneoxy and ethyleneoxy chains.

In certain embodiments of the cytokine inhibitors of the invention, thepocket-expanding moiety is not a substituted 5-member heterocyclyl ringif the cytokine inhibitor is PEM-CHR″C(O)NH—OM, wherein R″ is H or C₁₋₆alkyl, optionally partially or fully halogenated. In other embodiments,the targeting moiety is not a substituted tricyclic heterocyclyl ringhaving a nitrogen atom ring member bonded to the amide carbonyl of thetargeting moiety.

There is provided in accordance with another aspect of the invention, afirst group of compounds having Formula IA,

stereoisomers thereof, tautomers thereof, solvates thereof, prodrugsthereof, and pharmaceutically acceptable salts thereof, wherein:

X is C(O), C(S) or CH₂;

G is a C₃₋₁₀ carbocyclyl, 5-8 membered monocyclic heterocyclyl, or 8-11membered bicyclic heterocyclyl containing 1 or more heteroatoms selectedfrom O, N or S; wherein G is substituted by one or more R¹, R² or R³;

Ar is indazolyl, indolyl, isoindolyl, imidazolyl, benzimidazolyl,pyrazolyl, pyrazolinyl, pyrrolyl, pyrrolinyl, pyridinyl, pyridazinyl,quinolinyl, isoquinolinyl, phthalazinyl, dihydroindolyl,benzoisoxazolyl, dihydrobenzoisoxazolyl, dihydroisoindolyl,benzoisothiazolyl, benzoisothiazolyl dioxide, C₆₋₁₀ aryl, —(C₁₋₃alkyl)-(C₆₋₁₀ aryl), —(Y)—(C₀₋₃ alkyl)-(C₆₋₁₀ aryl), or —(Y)—(C₀₋₃alkyl)-(5-10 member heteroaryl), each of which is optionally substitutedwith one or more R⁴ or R⁵;

each Y is independently —CHZ—, —CZ₂—, —CHR—, —O—, —C(═CHR)—,—C(═C—CO₂R)—;

each Z is independently F, Cl, —OR, —NR₂, —SR, —NHCONHR, or —NHCOR;

L is a covalent bond or a saturated or unsaturated branched orunbranched C₁₋₁₀ carbon chain, wherein one or more methylene groups areoptionally independently replaced by heteroatoms chosen from O, NR andS(O)_(m); and wherein L is optionally substituted with 0-2 oxo groupsand one or more C₁₋₄ branched or unbranched alkyl optionally substitutedby one or more F, Cl, Br, or I;

each m is independently 0, 1 or 2;

Q is hydrogen, —NR′R′, cycloalkyl, aryl, heterocyclyl, C₁₋₆ alkoxy, C₁₋₆alkyl-S(O)_(m), or phenyl-S(O)_(m), wherein the cycloalkyl, aryl,heterocyclyl, C₁₋₆ alkoxy, C₁₋₆ alkyl-S(O)_(m), or phenyl-S(O)_(m) iseach optionally substituted with one or more R²⁷;

each R is independently hydrogen or substituted or unsubstituted C₁₋₆alkyl;

each R′ is independently hydrogen, substituted or unsubstituted C₁₋₈alkyl, substituted or unsubstituted (C₀₋₄ alkyl)-(C₆₋₁₀ aryl) orsubstituted or unsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—OR, —NR′R′, —SiR₃, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R², R⁴ and R⁵ is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂;

each R″ is independently substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted C₀₋₄ alkyl-C₆₋₁₀ aryl or substituted orunsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R³ is independently substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈ alkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)N(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈ alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);

each R⁶ is a C₁₋₆ branched or unbranched alkyl optionally partially orfully halogenated and optionally substituted with R²⁶;

each R²⁶ is independently cyano, morpholino, piperidinyl, piperazinyl,imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄alkyl)amino optionally partially or fully halogenated;

R²⁰ is substituted or unsubstituted C₁₋₁₀ alkyl, substituted orunsubstituted C₀₋₆ alkyl-phenyl, substituted or unsubstituted C₀₋₆alkyl-heterocyclyl, OR′ or NR′₂;

R²¹ is hydrogen or C₁₋₄ branched or unbranched alkyl optionallypartially or fully halogenated; and

each R²², R²³ and R²⁴ is independently hydrogen, substituted orunsubstituted C₁₋₁₀ alkyl, wherein the C₁₋₁₀ alkyl is optionallyinterrupted by one or more O, N or S, substituted or unsubstituted C₀₋₆alkyl-phenyl, substituted or unsubstituted C₀₋₆ alkyl-heterocyclyl; orR²³ and R²⁴ taken together optionally form a heterocyclic or heteroarylring;

each R²⁷ is independently F, Cl, Br, I, cyano, —C(O)R′, —C(O)NR′₂,—C(O)OR′, —OR′, —NR′R′, —SiR′₃, —S(O)_(m)R′, substituted orunsubstituted straight or branched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀alkynyl, substituted or unsubstituted C₃₋₁₀ cycloalkyl, substituted orunsubstituted C₅₋₈ cycloalkenyl, substituted or unsubstituted C₇₋₂₀aralkyl, substituted or unsubstituted 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

provided however that when Ar is —(Y)—(C₆₋₁₀ aryl) and G isN-(substituted or unsubstituted phenyl)-pyrazolyl, the pyrazolyl isadditionally substituted with one or more R¹, R² or R³; and IA is notN-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-2-(4-chloro-phenyl)-acetamide.

In certain embodiments of the first group of compounds of Formula IA,the compound at a concentration of 10 μM inhibits induced TNFa-releasefrom a cell by about 50% or greater than 50%.

In some embodiments of the first group of compounds of Formula IA, G is

phenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl,tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl, indanyl,indenyl, benzofuran-3-one;

pyrazolyl, pyrrolyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl,isoxazolyl, furanyl, thienyl, pyridinyl, pyridonyl, quinolinyl,dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl,tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, 4H-benzo[1,4]oxazine-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, phthalimidyl;

pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, thiazolinyl,imidazolinyl, tertrahydropyridinyl, homopiperidinyl, pyrrolinyl,tetrahydropyrimidinyl, decahydroquinolinyl, decahydroisoquinolinyl,thiomorpholinyl, thiazolidinyl, dihydrooxazinyl, dihydropyranyl,oxocanyl, heptacanyl, thioxanyl or dithianyl.

In other embodiments of the first group of compounds of Formula IA, G isphenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl,tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl, indanyl,indenyl, or benzofuran-3-one. In yet others, G is pyrazolyl, pyridinyl,pyridonyl, quinolinyl, dihydroquinolinyl, tetrahydroquinoyl,isoquinolinyl, tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl,pyrazinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, benzo[1,4]oxazin-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, or phthalimidyl. Alternatively, G ispyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, isoxazolinyl,thiazolinyl, imidazolinyl, tertrahydropyridinyl, homopiperidinyl,pyrrolinyl, tetrahydropyrimidinyl, decahydroquinolinyl,decahydroisoquinolinyl, thiomorpholinyl, thiazolidinyl, dihydrooxazinyl,dihydropyranyl, oxocanyl, heptacanyl, thioxanyl or dithianyl. In otherembodiments, G is phenyl, naphthyl, pyrazolyl, pyrrolyl, pyrrolidinyl,imidazolyl, imidazolonyl, thiazolyl, oxazolyl, isoxazolyl, furanyl,thienyl, or pyridinyl.

In certain embodiments of the first group of compounds of Formula IA, Aris indazolyl, indolyl, isoindolyl, imidazolyl, benzimidazolyl,pyrazolyl, pyrazolinyl, pyrrolyl, pyrrolinyl, pyridinyl, pyridazinyl,quinolinyl, isoquinolinyl, phthalazinyl, dihydroindolyl,benzoisoxazolyl, dihydrobenzoisoxazolyl, dihydroisoindolyl,benzoisothiazolyl, benzoisothiazolyl dioxide, or C₆₋₁₀ aryl. In somesuch embodiments, Ar is substituted with at least one R⁴ or R⁵.Alternatively, Ar is indazolyl, isoindolyl, pyrazolyl, pyrrolinyl,phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, indenylor imidazolyl. In still other such embodiments, Ar is indazolyl, phenyl,tetrahydronapthyl or naphthyl.

In certain embodiments of compounds having Formula IA, Ar is —(C₁₋₃alkyl)-(C₆₋₁₀ aryl), —(Y)—(C₀₋₃ alkyl)-(C₆₋₁₀ aryl), or —(Y)—(C₀₋₃alkyl)-(5-10 member heteroaryl). In some such embodiments, Ar issubstituted with at least one R⁴ or R⁵. In some such embodiments, Y is—CZ₂— and each Z is independently F, —OR or —CHR. For example, Y is—CF₂—. In others, Y is —CHR or —CHZ— and Z is —OR. Thus, for example, Yis —CHOH—. Alternatively, Y is —O— or —CH₂—. In still other suchembodiments, the C₆₋₁₀ aryl is phenyl or naphthyl, and/or the 5-10member heteroaryl is quinolinyl, isoquinolinyl, phthalazinyl, orquinazolinyl. In yet other such embodiments Ar is —(C₁₋₃ alkyl)-(C₆₋₁₀aryl).

In some embodiments of the first group of compounds of Formula IA, oneor more methylene groups of L are independently replaced by hetero atomsselected from O, N or S(O)_(m). In others, L is a covalent bond, a C₁-C₉alkoxy, —C(O)O—, —NH— or —O—.

As noted above, Q, other than —H or —NR′R′, is optionally substitutedwith R²⁷. In certain embodiments of the first group of compounds ofFormula IA Q is phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl,imidazolyl, pyrrolyl, pyrrolidinyl, benzimidazolyl, furanyl, thienyl,pyranyl, naphthylpyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl,tetrazolyl, pyrazolo[3,4-b]pyrimidinyl, purinyl,pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, tubercidinyl,oxazo[4,5-b]pyridinyl, or imidazo[4,5-b]pyridinyl, tetrahydropyranyl,tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl,morpholino, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinyl, piperidinyl, piperidinonyl, tetrahydropyrimidonyl,cyclohexanone, cyclohexanolol, pentamethylene sulfide, pentamethylenesulfoxide, pentamethylene sulfone, tetramethylene sulfide,tetramethylene sulfoxide or tetramethylene sulfone, C₁₋₆ alkoxy,secondary or tertiary amine wherein the amino nitrogen is covalentlybonded to C₁₋₃ alkyl or C₁₋₅ alkoxyalkyl, phenylamino; C₁₋₆alkyl-S(O)_(m) or phenyl-S(O)_(m). In some such embodiments, R²⁷ is C₁₋₆alkyl, C₁₋₆ alkoxy, hydroxy amino, substituted or unsubstituted 5-10member heterocyclyl, mono- or di-(C₁₋₃ alkyl)amino, mono- ordi-(phenyl-C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m), phenyl-C₁₋₃-alkoxy orphenylamino wherein the phenyl ring is optionally substituted with oneto two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy.

In some other embodiments of the first group of compounds of Formula IA,Q is hydrogen, phenyl, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinonyl, oxazepinyl, diazepinonyl, imidazolyl, pyridinyl ormorpholino. In others, Q is morpholino, piperazinyl, pyrimidinyl orpyridinyl. In some such embodiments, R²⁷ is —C(O)OR′, —NR′R′,substituted or unsubstituted straight or branched C₁₋₁₀ alkyl,substituted or unsubstituted C₇₋₂₀ aralkyl, or substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m). Alternatively, Q is pyrimidinyl andR²⁷ is —NR′R′ or substituted or unsubstituted saturated or unsaturated3-11 member heterocyclyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m). In yet other such embodiments, Q ispyridinyl, and R²⁷ is —NR′R′, substituted or unsubstituted C₁₋₆ alkyl,or substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m).

In some embodiments of the first group of compounds of Formula IA, whenR⁴ and R⁵ are absent, -L-Q is not —H.

In some embodiments of the first group of compounds of Formula IA, eachR¹ is independently

C₃₋₁₀ branched or unbranched alkyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclohexanyl, or bicycloheptanyl, which are optionally partially orfully halogenated and optionally substituted with one to three C₁₋₃alkyl groups optionally partially or fully halogenated, cyano, hydroxylC₁₋₃ alkyl or aryl, or an analogue of cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are replaced independently by O, S(O)_(m), CHOH,C═O, C═S or NH;

C₃₋₁₀ branched or unbranched alkenyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₁₋₅ branchedor unbranched alkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, isothiazolyl; each of the aforementioned being optionally,partially or fully halogenated, C₁₋₆ branched or unbranched alkyloptionally partially or fully halogenated, cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, hydroxy, cyano, C₁₋₃alkoxy optionally partially or fully halogenated, NH₂C(O) or mono- ordi-(C₁₋₃ alkyl)aminocarboxyl; and wherein the C₃₋₁₀ branched orunbranched alkenyl is optionally interrupted by one or more O, N orS(O)_(m);

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

cyano, F, Cl, Br, or I;

methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl;

silyl containing three C₁₋₄ independently branched or unbranched alkylgroups optionally partially or fully halogenated;

C₂₋₆ branched or unbranched alkyl-C(O), C₂₋₆ branched or unbranched-S,C₂₋₆ branched or unbranched-S(O), C₂₋₆ branched or unbranched-S(O)₂;

C₂₋₆ branched or unbranched alkynyl optionally partially or fullyhalogenated, wherein one or more methylene groups are optionallyreplaced by O, NH and S(O)_(m) and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms.

In other embodiments of the first group of compounds of Formula IA, eachR¹ is independently C₃₋₁₀ branched or unbranched alkyl optionallypartially or fully halogenated, and optionally substituted with one tothree C₃₋₁₀ cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl,pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl,thienyl, furyl, isoxazolyl, or isothiazolyl; each of which is optionallysubstituted with 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl whichis optionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl. For example, each R¹ is independently C₃₋₁₀branched or unbranched alkyl.

In some embodiments of the first group of compounds of Formula IA, eachR² is independently —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂,—NO₂, —S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′or —SO₂NR′₂. Alternatively, each R² is independently —NR′₂, —NO₂,—C(O)NR′₂, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂.

In some embodiments of the first group of compounds of Formula IA, eachR³ is independently

hydrogen or phenyl, naphthyl, or heterocyclyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl,pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl,oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl,indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, carboxy-mono- or di-(C₁₋₅ alkyl)amino;

a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl andbenzocycloheptenyl, or a fused heterocycle selected fromcyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine,cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine,cyclopentanopyridazine, cyclopentanoindole, cyclohexanoindole,cyclobenzimidazole, cyclopentanoimidazole, cyclohexanoimidazole,cyclopentanothiophene and cyclohexanothiophene; wherein the fused arylor fused heterocyclic ring is optionally, independently substituted with1 to 3 groups selected from phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, isothiazolyl, C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,cyano, C₁₋₃ alkoxy optionally partially or fully halogenated, phenyloxy,naphthyloxy, heterocyclyloxy, heteroaryloxy, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino, heterocyclic orheteroaryl amino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₄alkyl-C(O), C₁₋₅ alkylamino-S(O)₂, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₅alkyl, R¹²—C₁₋₅ alkyl, R¹³—C₁₋₅ alkoxy, R¹⁴—C(O)—C₁₋₅ alkyl, R¹⁵—C₁₋₅alkyl(R¹⁶)N;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl, or bicycloheptanyl, which areoptionally partially or fully halogenated and optionally substitutedwith one to three C₁₋₃ alkyl groups optionally partially or fullyhalogenated, cyano, hydroxyl C₁₋₃ alkyl or aryl; or an analogue ofcyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are independently replaced by O, S(O)_(m), CHOH,C═O, C═S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl, bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

C₁₋₄ alkyl or alkylene-phenyl-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-phenyl-S(O)_(m)—C₀₋₄ alkyl or alkylene;

C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, or C₁₋₅mono- or di-alkylamino optionally substituted with R¹⁹;

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,cycloheptyloxy, which are optionally partially or fully halogenated andoptionally substituted with one to three C₁₋₃ alkyl groups optionallypartially or fully halogenated wherein one to three ring methylenegroups are replaced independently by O, S(O)_(m), CHOH, C═O, C═S or NH;

R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—;

C₂₋₆ alkenyl substituted by R²³R²⁴NC(O)—;

C₂₋₆ alkynyl branched or unbranched carbon chain optionally partially orfully halogenated, wherein one or more methylene groups are optionallyreplaced by O, NH or S(O)_(m), and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms; or

benzoyl or naphthoyl; and wherein

each R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, R¹⁹, and R²⁵ isindependently cyano, morpholino, piperidinyl, piperazinyl, imidazolyl,phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄ alkyl)aminooptionally partially or fully halogenated;

each R¹¹ and R¹⁶ is independently hydrogen or C₁₋₄ branched orunbranched alkyl optionally partially or fully halogenated; and

R¹⁸ is independently hydrogen or C₁₋₄ branched or unbranched alkyloptionally independently substituted with oxo or R²⁵.

In some such embodiments, each R³ is independently phenyl, naphthyl, orheterocyclyl, each of which is optionally partially or fully halogenatedand optionally substituted with 1-3 of phenyl, naphthyl, pyridinyl,pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl,2,5-pyrrolidin-dione, imidazolyl, pyrazolyl, thienyl, furyl,tetrahydrofuryl, isoxazolyl, thiazolyl, oxazolyl, triazolyl, tetrazolyl,isothiazolyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl,benzofuranyl, benzoxazolyl, benzoisooxazolyl, benzpyrazolyl,benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, or carboxy-mono- or di-(C₁₋₅ alkyl)amino. Inothers, each R³ is independently phenyl, pyridazinyl or pyridyl, each ofwhich is optionally partially or fully halogenated and optionallysubstituted with C₁₋₆ branched or unbranched alkyl which is optionallypartially or fully halogenated, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino; C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionallypartially or fully halogenated or optionally substituted with R¹⁷,amino, OR¹⁸, C₁₋₅ mono- or di-alkylamino optionally substituted withR¹⁹; R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—. For example, R³ can be phenyl or tolyl.

In some embodiments of the first group of compounds of Formula IA, X isC═O.

In another aspect of the invention there are provided a first group ofcompounds having Formula IB:

stereoisomers thereof, tautomers thereof, solvates thereof, prodrugsthereof, and pharmaceutically acceptable salts thereof, wherein:

X is C(O), C(S) or CH₂;

G is a C₃₋₁₀ carbocyclyl, 5-8 membered monocyclic heterocyclyl, or 8-11membered bicyclic heterocyclyl containing 1 or more heteroatoms selectedfrom O, N or S; wherein G is substituted by one or more R¹, R² or R³;

Ar is indazolyl, indolyl, isoindolyl, imidazolyl, benzimidazolyl,pyrazolyl, pyrazolinyl, pyrrolyl, pyrrolinyl, pyridinyl, pyridazinyl,quinolinyl, isoquinolinyl, phthalazinyl, dihydroindolyl,benzoisoxazolyl, dihydrobenzoisoxazolyl, dihydroisoindolyl,benzoisothiazolyl, benzoisothiazolyl dioxide, C₆₋₁₀ aryl, —(C₁₋₃alkyl)-(C₆₋₁₀ aryl), —(Y)—(C₀₋₃ alkyl)-(C₆₋₁₀ aryl), or —(Y)—(C₀₋₃alkyl)-(5-10 member heteroaryl), each of which is optionally substitutedwith one or more R⁴ or R⁵;

each Y is independently —CHZ—, —CZ₂—, —CHR—, —C(═CHR)—, —C(═C—CO₂R)—;

each Z is independently F, Cl, —OR, —NR₂, —SR, —NHCONHR, or —NHCOR;

L is a covalent bond or a saturated or unsaturated branched orunbranched C₁₋₁₀ carbon chain, wherein one or more methylene groups areoptionally independently replaced by heteroatoms chosen from O, NR andS(O)_(m); and wherein L is optionally substituted with 0-2 oxo groupsand one or more C₁₋₄ branched or unbranched alkyl optionally substitutedby one or more F, Cl, Br, or I;

each m is independently 0, 1 or 2;

Q is hydrogen, —NR′R′, cycloalkyl, aryl, heterocyclyl, C₁₋₆ alkoxy, C₁₋₆alkyl-S(O)_(m), or phenyl-S(O)_(m), wherein the cycloalkyl, aryl,heterocyclyl, C₁₋₆ alkoxy, C₁₋₆ alkyl-S(O)_(m), or phenyl-S(O)_(m) iseach optionally substituted with one, or more R²⁷; provided that if R⁴and R⁵ are absent, -L-Q is not —H;

each R is independently hydrogen or substituted or unsubstituted C₁₋₆alkyl;

each R′ is independently hydrogen, substituted or unsubstituted C₁₋₈alkyl, substituted or unsubstituted (C₀₋₄ alkyl)-(C₆₋₁₀ aryl) orsubstituted or unsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—OR, —NR′R′, —SiR₃, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R², R⁴ and R⁵ is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂;

each R″ is independently substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted C₀₋₄ alkyl-C₆₋₁₀ aryl or substituted orunsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R³ is independently substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈ alkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)N(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈ alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);

each R⁶ is a C₁₋₆ branched or unbranched alkyl optionally partially orfully halogenated and optionally substituted with R²⁶;

each R²⁶ is independently cyano, morpholino, piperidinyl, piperazinyl,imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄alkyl)amino optionally partially or fully halogenated;

R²⁰ is substituted or unsubstituted C₁₋₁₀ alkyl, substituted orunsubstituted C₀₋₆ alkyl-phenyl, substituted or unsubstituted C₀₋₆alkyl-heterocyclyl, OR′ or NR′₂;

R²¹ is hydrogen or C₁₋₄ branched or unbranched alkyl optionallypartially or fully halogenated; and

each R²², R²³ and R²⁴ is independently hydrogen, substituted orunsubstituted C₁₋₁₀ alkyl, wherein the C₁₋₁₀ alkyl is optionallyinterrupted by one or more O, N or S, substituted or unsubstituted C₀₋₆alkyl-phenyl, substituted or unsubstituted C₀₋₆ alkyl-heterocyclyl; orR²³ and R²⁴ taken together optionally form a heterocyclic or heteroarylring;

each R²⁷ is independently F, Cl, Br, I, cyano, —C(O)R′, —C(O)NR′₂,—C(O)OR′, —OR′, —NR′R′, —SiR′₃, —S(O)_(m)R′, substituted orunsubstituted straight or branched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀alkynyl, substituted or unsubstituted C₃₋₁₀ cycloalkyl, substituted orunsubstituted C₅₋₈ cycloalkenyl, substituted or unsubstituted C₇₋₂₀aralkyl, substituted or unsubstituted 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m).

In some embodiments of the first group of compounds of Formula IB, thecompound at a concentration of 10 μM inhibits induced TNFa-release froma cell by about 50% or greater than 50%.

In certain embodiments of the first group of compounds of Formula IB, Gis

phenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl,tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl, indanyl,indenyl, benzofuran-3-one;

pyrazolyl, pyrrolyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl,isoxazolyl, furanyl, thienyl, pyridinyl, pyridonyl, quinolinyl,dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl,tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, 4H-benzo[1,4]oxazine-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, phthalimidyl;

pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, thiazolinyl,imidazolinyl, tertrahydropyridinyl, homopiperidinyl, pyrrolinyl,tetrahydropyrimidinyl, decahydroquinolinyl, decahydroisoquinolinyl,thiomorpholinyl, thiazolidinyl, dihydrooxazinyl, dihydropyranyl,oxocanyl, heptacanyl, thioxanyl or dithianyl.

In other embodiments of the first group of compounds of Formula IB, G isphenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl,tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl, indanyl,indenyl, or benzofuran-3-one. Alternatively, G is pyrazolyl, pyridinyl,pyridonyl, quinolinyl, dihydroquinolinyl, tetrahydroquinoyl,isoquinolinyl, tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl,pyrazinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, benzo[1,4]oxazin-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, or phthalimidyl. In others, G ispyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, isoxazolinyl,thiazolinyl, imidazolinyl, tertrahydropyridinyl, homopiperidinyl,pyrrolinyl, tetrahydropyrimidinyl, decahydroquinolinyl,decahydroisoquinolinyl, thiomorpholinyl, thiazolidinyl, dihydrooxazinyl,dihydropyranyl, oxocanyl, heptacanyl, thioxanyl or dithianyl. In yetother embodiments, G is phenyl, naphthyl, pyrazolyl, pyrrolyl,pyrrolidinyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl, isoxazolyl,furanyl, thienyl, or pyridinyl.

In certain embodiments of the first group of compounds of Formula IB, Aris indazolyl, indolyl, isoindolyl, imidazolyl, benzimidazolyl,pyrazolyl, pyrazolinyl, pyrrolyl, pyrrolinyl, pyridinyl, piperidinyl,pyridazinyl, quinolinyl, isoquinolinyl, phthalazinyl, dihydroindolyl,benzoisoxazolyl, dihydrobenzoisoxazolyl, dihydroisoindolyl,benzoisothiazolyl, benzoisothiazolyl dioxide, or C₆₋₁₀ aryl. In somesuch embodiments, Ar is substituted with at least one R⁴ or R⁵. Inothers, Ar is indazolyl, isoindolyl, pyrazolyl, pyrrolinyl, phenyl,naphthyl, dihydronaphthyl, tetrahydronapthyl, indanyl, indenyl, orimidazolyl. For example, Ar is indazolyl, phenyl, naphthyl, ortetrahydronaphthyl. In other embodiments, Ar is —(C₁₋₃ alkyl)-(C₆₋₁₀aryl), —(Y)—(C₀₋₃ alkyl)-(C₆₋₁₀ aryl), or —(Y)—(C₀₋₃ alkyl)-(5-10 memberheteroaryl). In some such embodiments Ar is substituted with at leastone R⁴ or R⁵. In others, Y is —CHR or —CHZ— and Z is —OR. For example, Yis —CH₂—. In still other such embodiments, the C₆₋₁₀ aryl is phenyl ornaphthyl or the 5-10 member heteroaryl is quinolinyl, isoquinolinyl,phthalazinyl, or quinazolinyl. Alternatively, Ar is —(C₁₋₃ alkyl)-(C₆₋₁₀aryl).

In some embodiments of the first group of compounds of Formula IB, oneor more methylene groups of L are independently replaced by hetero atomsselected from O, N or S(O)_(m). Alternatively, L is a covalent bond, aC₁-C₉ alkoxy, —C(O)O—, —NH— or —O—.

As noted above, Q, other than —H or —NR′R′, is optionally substitutedwith R²⁷. In certain embodiments of the first group of compounds ofFormula IB Q is phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl,imidazolyl, pyrrolyl, pyrrolidinyl, benzimidazolyl, furanyl, thienyl,pyranyl, naphthylpyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl,tetrazolyl, pyrazolo[3,4-b]pyrimidinyl, purinyl,pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, tubercidinyl,oxazo[4,5-b]pyridinyl, or imidazo[4,5-b]pyridinyl; tetrahydropyranyl,tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl,morpholino, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinyl, piperidinyl, piperidinonyl, tetrahydropyrimidonyl,cyclohexanone, cyclohexanolol, pentamethylene sulfide, pentamethylenesulfoxide, pentamethylene sulfone, tetramethylene sulfide,tetramethylene sulfoxide or tetramethylene sulfone; C₁₋₆ alkoxy,secondary or tertiary amine wherein the amino nitrogen is covalentlybonded to C₁₋₃ alkyl or C₁₋₅ alkoxyalkyl, phenylamino; C₁₋₆alkyl-S(O)_(m) or phenyl-S(O)_(m). In some such embodiments, R²⁷ is C₁₋₆alkyl, C₁₋₆ alkoxy, hydroxy amino, substituted or unsubstituted 5-10member heterocyclyl, mono- or di-(C₁₋₃ alkyl)amino, mono- ordi-(phenyl-C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m), phenyl-C₁₋₃-alkoxy orphenylamino wherein the phenyl ring is optionally substituted with oneto two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy. Alternatively, Q is hydrogen,phenyl, thiomorpholino sulfoxide, thiomorpholino sulfone, piperazinonyl,oxazepinyl, diazepinonyl, imidazolyl, pyridinyl or morpholino. In yetother embodiments, Q is morpholino, piperazinyl, pyrimidinyl orpyridinyl. In some such embodiments, R²⁷ is —C(O)OR, —NR′R′, substitutedor unsubstituted straight or branched C₁₋₁₀ alkyl, substituted orunsubstituted C₇₋₂₀ aralkyl, or substituted or unsubstituted saturatedor unsaturated 3-11 member heterocyclyl or heterocyclylalkyl containing1, 2, 3, or 4 heteroatoms selected independently from N, O, S(O)_(m).Alternatively, Q is pyrimidinyl and R²⁷ is —NR′R′ or substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclylcontaining 1, 2, 3, or 4 heteroatoms selected independently from N, O,S(O)_(m). In yet other embodiments, Q is pyridinyl, and R²⁷ is —NR′R′ orsubstituted or unsubstituted C₁₋₆ alkyl, or substituted or unsubstitutedsaturated or unsaturated 3-11 member heterocyclyl or heterocyclylalkylcontaining 1, 2, 3, or 4 heteroatoms selected independently from N, O,S(O)_(m).

In some embodiments of the first group of compounds of Formula IB eachR¹ is independently:

C₃₋₁₀ branched or unbranched alkyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclohexanyl, or bicycloheptanyl, which are optionally partially orfully halogenated and optionally substituted with one to three C₁₋₃alkyl groups optionally partially or fully halogenated, cyano, hydroxylC₁₋₃ alkyl or aryl, or an analogue of cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are replaced independently by O, S(O)_(m), CHOH,C═O, C═S or NH;

C₃₋₁₀ branched or unbranched alkenyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₁₋₅ branchedor unbranched alkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, isothiazolyl; each of the aforementioned being optionally,partially or fully halogenated, C₁₋₆ branched or unbranched alkyloptionally partially or fully halogenated, cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, hydroxy, cyano, C₁₋₃alkoxy optionally partially or fully halogenated, NH₂C(O) or mono- ordi-(C₁₋₃ alkyl)aminocarboxyl; and wherein the C₃₋₁₀ branched orunbranched alkenyl is optionally interrupted by one or more O, N orS(O)_(m);

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

cyano, F, Cl, Br, or I;

methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl;

silyl containing three C₁₋₄ independently branched or unbranched alkylgroups optionally partially or fully halogenated;

C₂₋₆ branched or unbranched alkyl-C(O), C₂₋₆ branched or unbranched-S,C₂₋₆ branched or unbranched-S(O), C₂₋₆ branched or unbranched-S(O)₂;

C₂₋₆ branched or unbranched alkynyl optionally partially or fullyhalogenated, wherein one or more methylene groups are optionallyreplaced by O, NH and S(O)_(m) and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms.

In other embodiments of the first group of compounds of Formula IB, eachR¹ is independently C₃₋₁₀ branched or unbranched alkyl optionallypartially or fully halogenated, and optionally substituted with one tothree C₃₋₁₀ cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl,pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl,thienyl, furyl, isoxazolyl, or isothiazolyl; each of which is optionallysubstituted with 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl whichis optionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl. For example, each R¹ is independently C₃₋₁₀branched or unbranched alkyl.

In certain embodiments of the first group of compounds of Formula IB,each R² is independently —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂,—NR′₂, —NO₂, —S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′,—NR′C(O)OR′ or —SO₂NR′₂. In others, R² is independently —NR′₂, —NO₂,—C(O)NR′₂, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂.

In some embodiments of the first group of compounds of Formula IB eachR³ is independently

hydrogen or phenyl, naphthyl, or heterocyclyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl,pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl,oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl,indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, carboxy-mono- or di-(C₁₋₅ alkyl)amino;

a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl andbenzocycloheptenyl, or a fused heterocycle selected fromcyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine,cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine,cyclopentanopyridazine, cyclopentanoindole, cyclohexanoindole,cyclobenzimidazole, cyclopentanoimidazole, cyclohexanoimidazole,cyclopentanothiophene and cyclohexanothiophene; wherein the fused arylor fused heterocyclic ring is optionally, independently substituted with1 to 3 groups selected from phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, isothiazolyl, C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,cyano, C₁₋₃ alkoxy optionally partially or fully halogenated, phenyloxy,naphthyloxy, heterocyclyloxy, heteroaryloxy, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino, heterocyclic orheteroaryl amino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₄alkyl-C(O), C₁₋₅ alkylamino-S(O)₂, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₅alkyl, R¹²—C₁₋₅ alkyl, R¹³—C₁₋₅ alkoxy, R¹⁴—C(O)—C₁₋₅ alkyl, R¹⁵—C₁₋₅alkyl(R¹⁶)N;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl, or bicycloheptanyl, which areoptionally partially or fully halogenated and optionally substitutedwith one to three C₁₋₃ alkyl groups optionally partially or fullyhalogenated, cyano, hydroxyl C₁₋₃ alkyl or aryl; or an analogue ofcyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are independently replaced by O, S(O)_(m), CHOH,C═O, C═S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl, bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

C₁₋₄ alkyl or alkylene-phenyl-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-phenyl-S(O)_(m)—C₀₋₄ alkyl or alkylene;

C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, or C₁₋₅mono- or di-alkylamino optionally substituted with R¹⁹;

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,cycloheptyloxy, which are optionally partially or fully halogenated andoptionally substituted with one to three C₁₋₃ alkyl groups optionallypartially or fully halogenated wherein one to three ring methylenegroups are replaced independently by O, S(O)_(m), CHOH, C═O, C═S or NH;

R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—;

C₂₋₆ alkenyl substituted by R²³R²⁴NC(O)—;

C₂₋₆ alkynyl branched or unbranched carbon chain optionally partially orfully halogenated, wherein one or more methylene groups are optionallyreplaced by O, NH or S(O)_(m), and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms; or

benzoyl or naphthoyl; and wherein

each R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, R¹⁹, R²⁵ and R²⁶ isindependently cyano, morpholino, piperidinyl, piperazinyl, imidazolyl,phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄ alkyl)aminooptionally partially or fully halogenated;

each R¹¹ and R¹⁶ is independently hydrogen or C₁₋₄ branched orunbranched alkyl optionally partially or fully halogenated;

R¹⁸ is independently hydrogen or C₁₋₄ branched or unbranched alkyloptionally independently substituted with oxo or R²⁵.

In some such embodiments, each R³ is independently phenyl, naphthyl, orheterocyclyl, each of which is optionally partially or fully halogenatedand optionally substituted with 1-3 of phenyl, naphthyl, pyridinyl,pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl,2,5-pyrrolidin-dione, imidazolyl, pyrazolyl, thienyl, furyl,tetrahydrofuryl, isoxazolyl, thiazolyl, oxazolyl, triazolyl, tetrazolyl,isothiazolyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl,benzofuranyl, benzoxazolyl, benzoisooxazolyl, benzpyrazolyl,benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, or carboxy-mono- or di-(C₁₋₅ alkyl)amino. Inothers, each R³ is independently phenyl, pyridazinyl or pyridyl, each ofwhich is optionally partially or fully halogenated and optionallysubstituted with C₁₋₆ branched or unbranched alkyl which is optionallypartially or fully halogenated, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino; C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionallypartially or fully halogenated or optionally substituted with R¹⁷,amino, OR¹⁸, C₁₋₅ mono- or di-alkylamino optionally substituted withR¹⁹; R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—. For example, each R³ can be phenyl or tolyl.

In certain embodiments of the first group of compounds of Formula IB, Xis C═O.

There is provided in accordance with another aspect of the invention, asecond group of compounds having Formula IA:

stereoisomers thereof, tautomers thereof, solvates thereof, prodrugsthereof, and pharmaceutically acceptable salts thereof, wherein:

X is C(O) or C(S);

G is a C₃₋₁₀ carbocyclyl, a 5-8 membered monocyclic heterocyclyl, or a8-11 membered bicyclic heterocyclyl containing 1 or more heteroatomsselected from O, N or S; wherein G is substituted by one or more R¹, R²or R³;

Ar is —(Y)—(C₀₋₃ alkyl)-(bicyclic aryl), or —(Y)—(C₀₋₃ alkyl)-(bicyclicheteroaryl), wherein the bicyclic heteroaryl is indazolyl, isoindolyl,quinolinyl, isoquinolinyl, phthalazinyl, dihydroindolyl, benzofuranyl,benzoxazolyl, benzoisoxazolyl, dihydrobenzoisoxoazolyl,dihydroisoindolyl, benzimidazolyl, benzothienyl, benzothiazolyl,benzoisothiazolyl, or benzoisothiazolyl dioxide, and wherein Ar isoptionally substituted with one or more R⁴ or R⁵; provided however, thatthe bicyclic aryl is not1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthyl;

Y is —C(O)—, —C(NNRC(O)OR)—, —C(NNRR)—, —C(NNHC(O)NRR)— or —C(NOR)—;

L is a covalent bond or a saturated or unsaturated branched orunbranched C₁₋₁₀ carbon chain, wherein one or more methylene groups areoptionally independently replaced by heteroatoms chosen from O, NR andS(O)_(m); and wherein L is optionally substituted with 0-2 oxo groupsand one or more C₁₋₄ branched or unbranched alkyl optionally substitutedby one or more F, Cl, Br, or I;

each m is independently 0, 1 or 2;

Q is hydrogen, —NR′R′, cycloalkyl, aryl, heterocyclyl, C₁₋₆ alkoxy, C₁₋₆alkyl-S(O)_(m), or phenyl-S(O)_(m), wherein the cycloalkyl, aryl,heterocyclyl, C₁₋₆ alkoxy, C₁₋₆ alkyl-S(O)_(m), or phenyl-S(O)_(m) iseach optionally substituted with one or more R²⁷; and provided that ifR⁴ and R⁵ are absent, -L-Q is not —H;

each R is independently hydrogen or substituted or unsubstituted C₁₋₆alkyl;

each R′ is independently hydrogen, substituted or unsubstituted C₁₋₈alkyl, substituted or unsubstituted (C₀₋₄ alkyl)-(C₆₋₁₀ aryl) orsubstituted or unsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—OR, —NR′R′, —SiR₃, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R², R⁴ and R⁵ is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂;

each R″ is independently substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted C₀₋₄ alkyl-C₆₋₁₀ aryl or substituted orunsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R³ is independently H, substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈ alkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)N(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈ alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);

each R⁶ is a C₁₋₆ branched or unbranched alkyl optionally partially orfully halogenated and optionally substituted with R²⁶;

each R²⁶ is independently cyano, morpholino, piperidinyl, piperazinyl,imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄alkyl)amino optionally partially or fully halogenated;

R²⁰ is substituted or unsubstituted C₁₋₁₀ alkyl, substituted orunsubstituted C₀₋₆ alkyl-phenyl, substituted or unsubstituted C₀₋₆alkyl-heterocyclyl, OR′ or NR′₂;

R²¹ is hydrogen or C₁₋₄ branched or unbranched alkyl optionallypartially or fully halogenated; and

each R²², R²³ and R²⁴ is independently hydrogen, substituted orunsubstituted C₁₋₁₀ alkyl, wherein the C₁₋₁₀ alkyl is optionallyinterrupted by one or more O, N or S, substituted or unsubstituted C₀₋₆alkyl-phenyl, substituted or unsubstituted C₀₋₆ alkyl-heterocyclyl; orR²³ and R²⁴ taken together optionally form a heterocyclic or heteroarylring;

each R²⁷ is independently F, Cl, Br, I, cyano, —C(O)R′, —C(O)NR′₂,—C(O)OR′, —OR′, —NR′R′, —SiR′₃, —S(O)_(m)R′, substituted orunsubstituted straight or branched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀alkynyl, substituted or unsubstituted C₃₋₁₀ cycloalkyl, substituted orunsubstituted C₅₋₈ cycloalkenyl, substituted or unsubstituted C₇₋₂₀aralkyl, substituted or unsubstituted 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

provided however that when Ar is —(Y)-(bicyclic aryl) and G isN-(substituted or unsubstituted phenyl)-pyrazolyl, the pyrazolyl isadditionally substituted with one or more R¹, R² or R³; and IA is notN-(4-chloro-3-methyl-isothiazol-5-yl)-2-[2-(2,2-dimethyl-propyl)-benzooxazol-5-yl]-2-oxo-acetamide.

In certain embodiments of compounds of Formula IA, the compound at aconcentration of 10 μM inhibits induced TNFa-release from a cell byabout 50% or greater than 50%.

In certain embodiments of the second group of compounds of Formula IA, Gis

phenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl, cyclopropyl,tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl, indanyl,indenyl, benzofuran-3-one;

pyrazolyl, pyrrolyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl,isoxazolyl, furanyl, thienyl, pyridinyl, pyridonyl, quinolinyl,dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl,tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, 4H-benzo[1,4]oxazine-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, phthalimidyl;

pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, thiazolinyl,imidazolinyl, tertrahydropyridinyl, homopiperidinyl, pyrrolinyl,tetrahydropyrimidinyl, decahydroquinolinyl, decahydroisoquinolinyl,thiomorpholinyl, thiazolidinyl, dihydrooxazinyl, dihydropyranyl,oxocanyl, heptacanyl, thioxanyl or dithianyl.

In other embodiments, G is phenyl, naphthyl, cyclopropyl,benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl,benzocycloheptanyl, benzocycloheptenyl, indanyl, indenyl, orbenzofuran-3-one. Alternatively, G is pyrazolyl, pyridinyl, pyridonyl,quinolinyl, dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl,tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, benzo[1,4]oxazin-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, or phthalimidyl. In others, G ispyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, isoxazolinyl,thiazolinyl, imidazolinyl, tertrahydropyridinyl, homopiperidinyl,pyrrolinyl, tetrahydropyrimidinyl, decahydroquinolinyl,decahydroisoquinolinyl, thiomorpholinyl, thiazolidinyl, dihydrooxazinyl,dihydropyranyl, oxocanyl, heptacanyl, thioxanyl or dithianyl. In yetother embodiments, G is phenyl, naphthyl, cyclopropyl, pyrazolyl,pyrrolyl, pyrrolidinyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl,isoxazolyl, furanyl, thienyl, or pyridinyl.

In certain embodiments of the second group of compounds of Formula IA,Ar is —(Y)—(C₀₋₃ alkyl)-(bicyclic aryl), and the bicyclic aryl isnaphthyl, tetrahydronaphthyl, dihydronaphthyl, indenyl, indanyl orazulenyl. In some such embodiments, Ar is substituted with at least oneR⁴ or R⁵. In others, Y is —C(O)—, —C(NNRC(O)OR)— or —C(NOR)—.Alternatively, Ar is —C(O)-(bicyclic aryl) or —C(NOR)-(bicyclic aryl)and the the bicyclic aryl can be naphthyl, dihydronapthyl,tetrahydronaphthyl, indanyl, indenyl or azulenyl. In other embodiments,Ar is —(Y)—(C₀₋₃ alkyl)-(bicyclic heteroaryl). In some such embodiments,Ar is substituted with at least one R⁴ or R⁵. In others, Y is —C(O)—,—C(NNRC(O)OR)— or —C(NOR)—. In yet others, Ar is —C(O)-(bicyclicheteroaryl) or —C(NOR)-(bicyclic heteroaryl). For example, the bicyclicheteroaryl is quinolinyl, isoquinolinyl, phthalazinyl, or quinazolinyl.

In certain embodiments of the second group of compounds of Formula IA,one or more methylene groups of L are independently replaced by heteroatoms selected from O, N or S(O)_(m). Alternatively, L is a covalentbond, a C₁-C₉ alkoxy, —C(O)O—, —NH— or —O—.

In certain embodiments of the second group of compounds of Formula IA, Qis hydrogen, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl,imidazolyl, pyrrolyl, pyrrolidinyl, benzimidazolyl, furanyl, thienyl,pyranyl, naphthylpyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl,tetrazolyl, pyrazolo[3,4-b]pyrimidinyl, purinyl,pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, tubercidinyl,oxazo[4,5-b]pyridinyl, or imidazo[4,5-b]pyridinyl; tetrahydropyranyl,tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl,morpholino, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinyl, piperazinonyl, oxazepinyl, diazepanonyl, piperidinyl,piperidinonyl, tetrahydropyrimidonyl, cyclohexanone, cyclohexanolol,pentamethylene sulfide, pentamethylene sulfoxide, pentamethylenesulfone, tetramethylene sulfide, tetramethylene sulfoxide ortetramethylene sulfone; C₁₋₆ alkoxy, secondary or tertiary amine whereinthe amino nitrogen is covalently bonded to C₁₋₃ alkyl or C₁₋₅alkoxyalkyl, phenylamino; C₁₋₆ alkyl-S(O)_(m) or phenyl-S(O)_(m). Insome such embodiments, R²⁷ is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy amino,substituted or unsubstituted 5-10 member heterocyclyl, mono- or di-(C₁₋₃alkyl)amino, mono- or di-(phenyl-C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m),phenyl-C₁₋₃-alkoxy or phenylamino wherein the phenyl ring is optionallysubstituted with one to two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy.

In other embodiments of the second group of compounds of Formula IA, Qis hydrogen, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinonyl, oxazepinyl, diazepinonyl, imidazolyl, pyridinyl ormorpholino. In yet other embodiments, Q is morpholino, piperazinyl,pyrimidinyl or pyridinyl. In some such embodiments, R²⁷ is —C(O)OR,—NR′R′, substituted or unsubstituted straight or branched C₁₋₁₀ alkyl,substituted or unsubstituted C₇₋₂₀ aralkyl, or substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m). For example, Q is pyrimidinyl and R²⁷is —NR′R′ or substituted or unsubstituted saturated or unsaturated 3-11member heterocyclyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m). Alternatively, Q is pyridinyl, andR²⁷ is —NR′R′, substituted or unsubstituted C₁₋₆ alkyl, or substitutedor unsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m).

In certain embodiments of the second group of compounds of Formula IA,each R¹ is independently:

C₃₋₁₀ branched or unbranched alkyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclohexanyl, or bicycloheptanyl, which are optionally partially orfully halogenated and optionally substituted with one to three C₁₋₃alkyl groups optionally partially or fully halogenated, cyano, hydroxylC₁₋₃ alkyl or aryl, or an analogue of cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are replaced independently by O, S(O)_(m), CHOH,C═O, C═S or NH;

C₃₋₁₀ branched or unbranched alkenyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₁₋₅ branchedor unbranched alkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, isothiazolyl; each of the aforementioned being optionally,partially or fully halogenated, C₁₋₆ branched or unbranched alkyloptionally partially or fully halogenated, cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, hydroxy, cyano, C₁₋₃alkoxy optionally partially or fully halogenated, NH₂C(O) or mono- ordi-(C₁₋₃ alkyl)aminocarboxyl; and wherein the C₃₋₁₀ branched orunbranched alkenyl is optionally interrupted by one or more O, N orS(O)_(m);

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

cyano, F, Cl, Br, or I;

methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl;

silyl containing three C₁₋₄ independently branched or unbranched alkylgroups optionally partially or fully halogenated;

C₂₋₆ branched or unbranched alkyl-C(O), C₂₋₆ branched or unbranched-S,C₂₋₆ branched or unbranched-S(O), C₂₋₆ branched or unbranched-S(O)₂;

C₂₋₆ branched or unbranched alkynyl optionally partially or fullyhalogenated, wherein one or more methylene groups are optionallyreplaced by O, NH and S(O)_(m) and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms. Alternatively, each R¹ is independently C₃₋₁₀branched or unbranched alkyl optionally partially or fully halogenated,and optionally substituted with one to three C₃₋₁₀ cycloalkyl, hydroxyphenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, orisothiazolyl; each of which is optionally substituted with 1 to 5halogen, C₁₋₆ branched or unbranched alkyl which is optionally partiallyor fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈ cycloalkenyl, hydroxy,cyano, C₁₋₃ alkoxy which is optionally partially or fully halogenatedand NH₂C(O) or mono- or di-(C₁₋₃ alkyl)aminocarbonyl. For example, neach R¹ is independently C₃₋₁₀ branched or unbranched alkyl.

In certain embodiments of the second group of compounds of Formula IA,each R² is independently —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂,—NR′₂, —NO₂, —S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′,—NR′C(O)OR′ or —SO₂NR′₂. Alternatively, R² is independently —NR′₂, —NO₂,—C(O)NR′₂, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂.

In certain embodiments of the second group of compounds of Formula IA,each R³ is independently

hydrogen or phenyl, naphthyl, or heterocyclyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl,pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl,oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl,indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, carboxy-mono- or di-(C₁₋₅ alkyl)amino;

a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl andbenzocycloheptenyl, or a fused heterocycle selected fromcyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine,cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine,cyclopentanopyridazine, cyclopentanoindole, cyclohexanoindole,cyclobenzimidazole, cyclopentanoimidazole, cyclohexanoimidazole,cyclopentanothiophene and cyclohexanothiophene; wherein the fused arylor fused heterocyclic ring is optionally, independently substituted with1 to 3 groups selected from phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, isothiazolyl, C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,cyano, C₁₋₃ alkoxy optionally partially or fully halogenated, phenyloxy,naphthyloxy, heterocyclyloxy, heteroaryloxy, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino, heterocyclic orheteroaryl amino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₄alkyl-C(O), C₁₋₅ alkylamino-S(O)₂, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₅alkyl, R¹²—C₁₋₅ alkyl, R¹³—C₁₋₅ alkoxy, R¹⁴—C(O)—C₁₋₅ alkyl, R¹⁵—C₁₋₅alkyl(R¹⁶)N;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl, or bicycloheptanyl, which areoptionally partially or fully halogenated and optionally substitutedwith one to three C₁₋₃ alkyl groups optionally partially or fullyhalogenated, cyano, hydroxyl C₁₋₃ alkyl or aryl; or an analogue ofcyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are independently replaced by O, S(O)_(m), CHOH,C═O, C═S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl, bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

C₁₋₄ alkyl or alkylene-phenyl-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-phenyl-S(O)_(m)—C₀₋₄ alkyl or alkylene;

C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, or C₁₋₅mono- or di-alkylamino optionally substituted with R¹⁹;

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,cycloheptyloxy, which are optionally partially or fully halogenated andoptionally substituted with one to three C₁₋₃ alkyl groups optionallypartially or fully halogenated wherein one to three ring methylenegroups are replaced independently by O, S(O)_(m), CHOH, C═O, C═S or NH;

R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—;

C₂₋₆ alkenyl substituted by R²³R²⁴NC(O)—;

C₂₋₆ alkynyl branched or unbranched carbon chain optionally partially orfully halogenated, wherein one or more methylene groups are optionallyreplaced by O, NH or S(O)_(m), and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms; or

benzoyl or naphthoyl; and wherein

each R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, R¹⁹, and R²⁵ isindependently cyano, morpholino, piperidinyl, piperazinyl, imidazolyl,phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄ alkyl)aminooptionally partially or fully halogenated;

each R¹¹ and R¹⁶ is independently hydrogen or C₁₋₄ branched orunbranched alkyl optionally partially or fully halogenated; and

R¹⁸ is independently hydrogen or C₁₋₄ branched or unbranched alkyloptionally independently substituted with oxo or R²⁵.

In some such embodiments of the second group of compounds of Formula IA,each R³ is independently phenyl, naphthyl, or heterocyclyl, each ofwhich is optionally partially or fully halogenated and optionallysubstituted with 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl,isoquinolyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl,benzoisooxazolyl, benzpyrazolyl, benzothiofuranyl, cinnolinyl,pterindinyl, phthalazinyl, naphthylpyridinyl, quinoxalinyl,quinazolinyl, purinyl, indazolyl, C₁₋₆ branched or unbranched alkylwhich is optionally partially or fully halogenated, cyclopropyl,cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclohexanyl, bicycloheptanyl, phenyl C₁₋₅ alkyl, naphthyl C₁₋₅ alkyl,hydroxy, oxo, cyano, C₁₋₃ alkoxy optionally partially or fullyhalogenated, phenyloxy, naphthyloxy, heterocyclyloxy, nitro, amino,mono- or di-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino,heterocyclylamino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl,C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅ alkyl, mono- or di-(C₁₋₃alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃ alkyl)amino —S(O)₂,R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl, R¹⁰—C₁₋₅ alkyl(R¹¹)N,or carboxy-mono- or di-(C₁₋₅ alkyl)amino. In other such embodiments, R³is phenyl, pyridazinyl or pyridyl, each of which is optionally partiallyor fully halogenated and optionally substituted with C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,hydroxy, oxo, cyano, C₁₋₃ alkoxy optionally partially or fullyhalogenated, nitro, amino, or mono- or di-(C₁₋₃ alkyl)amino;C₁₋₆ alkylor C₁₋₆ alkoxy, each optionally partially or fully halogenated oroptionally substituted with R¹⁷, amino, OR¹⁸, C₁₋₅ mono- ordi-alkylamino optionally substituted with R¹⁹; R²⁰C(O)N(R²¹)—, R²²O—,R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— or R²⁶C(O)(CH₂)_(m)N(R²¹)—.

In some embodiments of the second group of compounds of Formula IA, X isC═O.

In certain embodiments of the second group of compounds of Formula IA,Ar is —(Y)-naphthyl-, Y is —C(O)—, or —C(═NOH)— and G is selected fromphenyl, pyridinyl, pyrazolyl, pyrrolyl, imidazolyl, oxazolyl,isoxazolyl, furanyl or thienyl. In others, Ar is —(Y)-naphthyl-, Y is—C(O)—, or —C(═NOH)— and G is phenyl or pyridyl. In some suchembodiments, each R¹ is independently a substituted or unsubstitutedstraight or branched C₁₋₁₀ alkyl and each R³ can be independentlyR²³R²⁴N—C(O)—, R²⁰—C(O)—NR²¹—, or OR²². In some such embodiments, eachR² is independently —NR′SO₂R″, —Cl, —Br, —F, —C(O)—NR′_(2,) substitutedor unsubstituted straight or branched C₁₋₆ alkyl, —NR′₂, or —OR′.

In other embodiments of the second group of compounds of Formula IA, Aris —(Y)-naphthyl-, Y is —C(O)—, or —C(═NOH)—, and G is pyrazolyl,thienyl or isoxazolyl. In some such embodiments, each R¹ isindependently a substituted or unsubstituted straight or branched C₁₋₁₀alkyl each R³ can be independently phenyl or pyridinyl, optionallysubstituted with one, two, or three —F, —Cl, substituted orunsubstituted C₁₋₆ branched or unbranched alkyl or substituted orunsubstituted C₁₋₄ alkoxy.

There is provided in accordance with another aspect of the invention, asecond group of compounds having Formula IB:

stereoisomers thereof, tautomers thereof, solvates thereof, prodrugsthereof, and pharmaceutically acceptable salts thereof, wherein:

X is C(O) or C(S);

G is a G′-(Y)— wherein G′ is a C₃₋₁₀ carbocyclyl, 5-8 memberedmonocyclic heterocyclyl, or 8-11 membered bicyclic heterocyclyl otherthan indolyl containing 1 or more heteroatoms selected from O, N or S,wherein G′ is substituted by one or more R¹, R² or R³;

Ar is bicyclic aryl or 8-11 membered bicyclic heteroaryl containing 1 ormore heteroatoms selected from O, N or S, wherein Ar is optionallysubstituted with one or more R⁴ or R⁵;

Y is independently —C(O)—, —C(NNRC(O)OR)—, —C(NNRR)—, —C(NNC(O)NRR) or—C(NOR)—;

L is a covalent bond or a saturated or unsaturated branched orunbranched C₁₋₁₀ carbon chain, wherein one or more methylene groups areoptionally independently replaced by heteroatoms chosen from O, NR andS(O)_(m); and wherein L is optionally substituted with 0-2 oxo groupsand one or more C₁₋₄ branched or unbranched alkyl optionally substitutedby one or more F, Cl, Br, or I;

each m is independently 0, 1 or 2;

Q is hydrogen, —NR′R′, cycloalkyl, aryl, heterocyclyl, C₁₋₆ alkoxy, C₁₋₆alkyl-S(O)_(m), or phenyl-S(O)_(m), wherein the cycloalkyl, aryl,heterocyclyl, C₁₋₆ alkoxy, C₁₋₆ alkyl-S(O)_(m), or phenyl-S(O)_(m) iseach optionally substituted with one or more R²⁷; and provided that ifR⁴ and R⁵ are absent, -L-Q is not —H;

each R is independently hydrogen or substituted or unsubstituted C₁₋₆alkyl;

each R′ is independently hydrogen, substituted or unsubstituted C₁₋₈alkyl, substituted or unsubstituted (C₀₋₄ alkyl)-(C₆₋₁₀ aryl) orsubstituted or unsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—OR, —NR′R′, —SiR₃, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R², R⁴ and R⁵ is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂;

each R″ is independently substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted C₀₋₄ alkyl-C₆₋₁₀ aryl or substituted orunsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R³ is independently substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈ alkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)N(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈ alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);

each R⁶ is a C₁₋₆ branched or unbranched alkyl optionally partially orfully halogenated and optionally substituted with R²⁶;

each R²⁶ is independently cyano, morpholino, piperidinyl, piperazinyl,imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄alkyl)amino optionally partially or fully halogenated;

R²⁰ is substituted or unsubstituted C₁₋₁₀ alkyl, substituted orunsubstituted C₀₋₆ alkyl-phenyl, substituted or unsubstituted C₀₋₆alkyl-heterocyclyl, OR′ or NR′₂;

R²¹ is hydrogen or C₁₋₄ branched or unbranched alkyl optionallypartially or fully halogenated; and

each R²², R²³ and R²⁴ is independently hydrogen, substituted orunsubstituted C₁₋₁₀ alkyl, wherein the C₁₋₁₀ alkyl is optionallyinterrupted by one or more O, N or S, substituted or unsubstituted C₀₋₆alkyl-phenyl, substituted or unsubstituted C₀₋₆ alkyl-heterocyclyl; orR²³ and R²⁴ taken together optionally form a heterocyclic or heteroarylring;

each R²⁷ is independently F, Cl, Br, I, cyano, —C(O)R′, —C(O)NR′₂,—C(O)OR′, —OR′, —NR′R′, —SiR′₃, —S(O)_(m)R′, substituted orunsubstituted straight or branched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀alkynyl, substituted or unsubstituted C₃₋₁₀ cycloalkyl, substituted orunsubstituted C₅₋₈ cycloalkenyl, substituted or unsubstituted C₇₋₂₀aralkyl, substituted or unsubstituted 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

provided however that IB is not2-[6-(2-biphenyl-4-yl-2-oxo-acetylamino)-indol-1-ylmethyl]-benzoic acid.

In certain embodiments of the second group of compounds of Formula IB,the compound at a concentration of 10 μM inhibits induced TNFa-releasefrom a cell by about 50% or greater than 50%.

In some embodiments of the second group of compounds of Formula IB, G′is

phenyl, naphthyl, cyclopropyl, benzocyclobutanyl, dihydronaphthyl,tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl, indanyl,indenyl, benzofuran-3-one;

pyrazolyl, pyrrolyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl,isoxazolyl, furanyl, thienyl, pyridinyl, pyridonyl, quinolinyl,dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl,tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, 4H-benzo[1,4]oxazine-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, phthalimidyl;

pyrrolidinyl, tetrahydropyranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, thiazolinyl,imidazolinyl, tertrahydropyridinyl, homopiperidinyl, pyrrolinyl,tetrahydropyrimidinyl, decahydroquinolinyl, decahydroisoquinolinyl,thiomorpholinyl, thiazolidinyl, dihydrooxazinyl, dihydropyranyl,oxocanyl, heptacanyl, thioxanyl or dithianyl.

In other embodiments of the second group of compounds of Formula IB, G′is phenyl, naphthyl, cyclopropyl, benzocyclobutanyl, dihydronaphthyl,tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl, indanyl,indenyl, or benzofuran-3-one. In others, G′ is pyrazolyl, pyridinyl,pyridonyl, quinolinyl, dihydroquinolinyl, tetrahydroquinoyl,isoquinolinyl, tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl,pyrazinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, benzo[1,4]oxazin-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, or phthalimidyl. Alternatively, G′ ispyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, isoxazolinyl,thiazolinyl, imidazolinyl, tertrahydropyridinyl, homopiperidinyl,pyrrolinyl, tetrahydropyrimidinyl, decahydroquinolinyl,decahydroisoquinolinyl, thiomorpholinyl, thiazolidinyl, dihydrooxazinyl,dihydropyranyl, oxocanyl, heptacanyl, thioxanyl or dithianyl. In yetother embodiments, G′ is phenyl, naphthyl, pyrazolyl, cyclopropyl,pyrrolyl, pyrrolidinyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl,isoxazolyl, furanyl, thienyl, or pyridinyl.

In certain embodiments of the second group of compounds of Formula IB, Yis —C(O)—, —C(NNRC(O)OR)— or —C(NOR)—.

In certain embodiments of the second group of compounds of Formula IB,Ar is naphthyl, dihydronapthyl, tetrahydronaphtyl, indenyl or azulenyl.Alternatively, Ar is indazolyl, isoindolyl, quinolinyl, isoquinolinyl,phthalazinyl, indolyl, dihydroindolyl, benzofuranyl, benzoxazolyl,benzoisoxazolyl, dihydrobenzoisoxoazolyl, dihydroisoindolyl,benzimidazolyl, benzothienyl, benzothiazolyl, benzoisothiazolyl orbenzoisothiazolyl dioxide.

In certain embodiments of the second group of compounds of Formula IB,one or more methylene groups of L are independently replaced by heteroatoms selected from O, N or S(O)_(m). Alternatively, L is a covalentbond, a C₁-C₉ alkoxy, —C(O)O—, —NH— or —O—.

In certain embodiments of the second group of compounds of Formula IB, Qis hydrogen, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl,imidazolyl, pyrrolyl, pyrrolidinyl, benzimidazolyl, furanyl, thienyl,pyranyl, naphthylpyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl,tetrazolyl, pyrazolo[3,4-b]pyrimidinyl, purinyl,pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, tubercidinyl,oxazo[4,5-b]pyridinyl, or imidazo[4,5-b]pyridinyl; tetrahydropyranyl,tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl,morpholino, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinyl, piperazinonyl, oxazepinyl, diazepanonyl, piperidinyl,piperidinonyl, tetrahydropyrimidonyl, cyclohexanone, cyclohexanolol,pentamethylene sulfide, pentamethylene sulfoxide, pentamethylenesulfone, tetramethylene sulfide, tetramethylene sulfoxide ortetramethylene sulfone; C₁₋₆ alkoxy, secondary or tertiary amine whereinthe amino nitrogen is covalently bonded to C₁₋₃ alkyl or C₁₋₅alkoxyalkyl, phenylamino; C₁₋₆ alkyl-S(O)_(m) or phenyl-S(O)_(m). Insome such embodiments, R²⁷ is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy amino,substituted or unsubstituted 5-10 member heterocyclyl, mono- or di-(C₁₋₃alkyl)amino, mono- or di-(phenyl-C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m),phenyl-C₁₋₃-alkoxy or phenylamino wherein the phenyl ring is optionallysubstituted with one to two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy.

In other embodiments of compounds of Formula IB, Q is hydrogen,thiomorpholino sulfoxide, thiomorpholino sulfone, piperazinonyl,oxazepinyl, diazepinonyl, imidazolyl, pyridinyl or morpholino. In yetothers, Q is morpholino, piperazinyl, pyrimidinyl or pyridinyl. In somesuch embodiments, R²⁷ is —C(O)OR, —NR′R′, substituted or unsubstitutedstraight or branched C₁₋₁₀ alkyl, substituted or unsubstituted C₇₋₂₀aralkyl, substituted or unsubstituted saturated or unsaturated 3-11member heterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4heteroatoms selected independently from N, O, S(O)_(m). For example, Qis pyrimidinyl, and R²⁷ is —NR′R′ or substituted or unsubstitutedsaturated or unsaturated 3-11 member heterocyclyl containing 1, 2, 3, or4 heteroatoms selected independently from N, O, S(O)_(m.) Alternatively,Q is pyridinyl, and R²⁷ is —NR′R′, substituted or unsubstituted C₁₋₆alkyl, or substituted or unsubstituted saturated or unsaturated 3-11member heterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4heteroatoms selected independently from N, O, S(O)_(m).

In certain embodiments of the second group of compounds of Formula IB,each R¹ is independently:

C₃₋₁₀ branched or unbranched alkyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclohexanyl, or bicycloheptanyl, which are optionally partially orfully halogenated and optionally substituted with one to three C₁₋₃alkyl groups optionally partially or fully halogenated, cyano, hydroxylC₁₋₃ alkyl or aryl, or an analogue of cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are replaced independently by O, S(O)_(m), CHOH,C═O, C═S or NH;

C₃₋₁₀ branched or unbranched alkenyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₁₋₅ branchedor unbranched alkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, isothiazolyl; each of the aforementioned being optionally,partially or fully halogenated, C₁₋₆ branched or unbranched alkyloptionally partially or fully halogenated, cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, hydroxy, cyano, C₁₋₃alkoxy optionally partially or fully halogenated, NH₂C(O) or mono- ordi-(C₁₋₃ alkyl)aminocarboxyl; and wherein the C₃₋₁₀ branched orunbranched alkenyl is optionally interrupted by one or more O, N orS(O)_(m);

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

cyano, F, Cl, Br, or I;

methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl;

silyl containing three C₁₋₄ independently branched or unbranched alkylgroups optionally partially or fully halogenated;

C₂₋₆ branched or unbranched alkyl-C(O), C₂₋₆ branched or unbranched-S,C₂₋₆ branched or unbranched-S(O), C₂₋₆ branched or unbranched-S(O)₂;

C₂₋₆ branched or unbranched alkynyl optionally partially or fullyhalogenated, wherein one or more methylene groups are optionallyreplaced by O, NH and S(O)_(m) and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms.

In other embodiments, each R¹ is independently C₃₋₁₀ branched orunbranched alkyl optionally partially or fully halogenated, andoptionally substituted with one to three C₃₋₁₀ cycloalkyl, hydroxyphenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, orisothiazolyl; each of which is optionally substituted with 1 to 5halogen, C₁₋₆ branched or unbranched alkyl which is optionally partiallyor fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈ cycloalkenyl, hydroxy,cyano, C₁₋₃ alkoxy which is optionally partially or fully halogenatedand NH₂C(O) or mono- or di-(C₁₋₃ alkyl)aminocarbonyl. For example, eachR¹ is independently C₃₋₁₀ branched or unbranched alkyl.

In certain embodiments of the second group of compounds of Formula IB,each R² is independently —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂,—NR′₂, —NO₂, —S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′,—NR′C(O)OR′ or —SO₂NR′₂. In others, each R² is independently —NR′₂,—NO₂, —C(O)NR′₂, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂.

In certain embodiments of the second group of compounds of Formula IB,each R³ is independently

hydrogen or phenyl, naphthyl, or heterocyclyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl,pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl,oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl,indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, carboxy-mono- or di-(C₁₋₅ alkyl)amino;

a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl andbenzocycloheptenyl, or a fused heterocycle selected fromcyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine,cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine,cyclopentanopyridazine, cyclopentanoindole, cyclohexanoindole,cyclobenzimidazole, cyclopentanoimidazole, cyclohexanoimidazole,cyclopentanothiophene and cyclohexanothiophene; wherein the fused arylor fused heterocyclic ring is optionally, independently substituted with1 to 3 groups selected from phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, isothiazolyl, C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,cyano, C₁₋₃ alkoxy optionally partially or fully halogenated, phenyloxy,naphthyloxy, heterocyclyloxy, heteroaryloxy, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino, heterocyclic orheteroaryl amino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₄alkyl-C(O), C₁₋₅ alkylamino-S(O)₂, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₅alkyl, R¹²—C₁₋₅ alkyl, R¹³—C₁₋₅ alkoxy, R¹⁴—C(O)—C₁₋₅ alkyl, R¹⁵—C₁₋₅alkyl(R¹⁶)N;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl, or bicycloheptanyl, which areoptionally partially or fully halogenated and optionally substitutedwith one to three C₁₋₃ alkyl groups optionally partially or fullyhalogenated, cyano, hydroxyl C₁₋₃ alkyl or aryl; or an analogue ofcyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are independently replaced by O, S(O)_(m), CHOH,C═O, C═S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl, bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

C₁₋₄ alkyl or alkylene-phenyl-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-phenyl-S(O)_(m)—C₀₋₄ alkyl or alkylene;

C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, or C₁₋₅mono- or di-alkylamino optionally substituted with R¹⁹;

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,cycloheptyloxy, which are optionally partially or fully halogenated andoptionally substituted with one to three C₁₋₃ alkyl groups optionallypartially or fully halogenated wherein one to three ring methylenegroups are replaced independently by O, S(O)_(m), CHOH, C═O, C═S or NH;

R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—;

C₂₋₆ alkenyl substituted by R²³R²⁴NC(O)—;

C₂₋₆ alkynyl branched or unbranched carbon chain optionally partially orfully halogenated, wherein one or more methylene groups are optionallyreplaced by O, NH or S(O)_(m), and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms; or

benzoyl or naphthoyl; and wherein

each R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, R¹⁹, and R²⁵ isindependently cyano, morpholino, piperidinyl, piperazinyl, imidazolyl,phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄ alkyl)aminooptionally partially or fully halogenated;

each R¹¹ and R¹⁶ is independently hydrogen or C₁₋₄ branched orunbranched alkyl optionally partially or fully halogenated; and

R¹⁸ is independently hydrogen or C₁₋₄ branched or unbranched alkyloptionally independently substituted with oxo or R²⁵.

In some such embodiments, each R³ is independently phenyl, naphthyl, orheterocyclyl, each of which is optionally partially or fully halogenatedand optionally substituted with 1-3 of phenyl, naphthyl, pyridinyl,pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl,2,5-pyrrolidin-dione, imidazolyl, pyrazolyl, thienyl, furyl,tetrahydrofuryl, isoxazolyl, thiazolyl, oxazolyl, triazolyl, tetrazolyl,isothiazolyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl,benzofuranyl, benzoxazolyl, benzoisooxazolyl, benzpyrazolyl,benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, or carboxy-mono- or di-(C₁₋₅ alkyl)amino. In othersuch embodiments, R³ is phenyl, pyridazinyl or pyridyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith C₁₋₆ branched or unbranched alkyl which is optionally partially orfully halogenated, hydroxy, oxo, cyano, C₁₋₃ alkoxy optionally partiallyor fully halogenated, nitro, amino, or mono- or di-(C₁₋₃ alkyl)amino;C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, C₁₋₅ mono-or di-alkylamino optionally substituted with R¹⁹; R²⁰C(O)N(R²¹)—, R²²O—,R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— or R²⁶C(O)(CH₂)_(m)N(R²¹)—.

In some embodiments of the second group of compounds of Formula IB, X isC═O.

In certain embodiments of the second group of compounds of Formula IB,Ar is naphthyl, G is G′-(Y)—, Y is —C(O)— or —C(═NOH)— and G′ isselected from phenyl, pyridinyl, pyrazolyl, pyrrolyl, imidazolyl,oxazolyl, isoxazolyl, furanyl or thienyl. In others, Ar is naphthyl, Gis G′-(Y)—, Y is —C(O)— or —C(═NOH)— and G′ is phenyl or pyridinyl,substituted by one or more R¹, R² or R³. In some such embodiments, eachR¹ is independently a substituted or unsubstituted straight or branchedC₁₋₁₀ alkyl. In these, each R³ can be independently R²³R²⁴N—C(O)—,R²⁰—C(O)—NR²¹—, or OR²². In others such embodiments each R² isindependently —NR′SO₂R″, —Cl, —Br, —F, —C(O)—NR′₂, substituted orunsubstituted straight or branched C₁₋₆ alkyl, —NR′₂, or —OR′.

In other embodiments of the second group of compounds of Formula IB, Aris -naphthyl- and G is G′-(Y)—, wherein Y is selected from —C(O)— and—C(═NOH)— and G′ is pyrazolyl, isoxazolyl or furanyl, substituted by oneor more R¹, R² or R³. In some such embodiments, each R¹ is independentlya substituted or unsubstituted straight or branched C₁₋₁₀ alkyl. Inthese, each R³ can be independently substituted or unsubstituted C₁₋₆alkyl, pyridinyl or phenyl, optionally substituted with one to three —F,—Cl, substituted or unsubstituted C₁₋₆ branched or unbranched alkyl, orsubstituted or unsubstituted C₁₋₃ alkoxy.

There is provided in accordance with another aspect of the invention, athird group of compounds having Formula IA:

stereoisomers thereof, tautomers thereof, solvates thereof, prodrugsthereof, and pharmaceutically acceptable salts thereof, wherein:

X is C(O) or C(S);

G is a C₃₋₅ cycloalkyl, pyrazolyl, thiazolyl, oxazolyl, isothiazolyl,thiadiazolyl, oxadiazolyl, pyrrolinyl, pyridazinyl, pyrrolyl,imidazolyl, imidazolonyl, isoxazolyl, furanyl, thienyl, pyridonyl,naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, indenyl,quinolinyl, dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl,tetrahydroisoquinoyl, pyrimidinyl, pyrazinyl, benzimidazolyl,benzthiazolyl, benzoxazolyl, benzofuranyl, benzothiophenyl,benzpyrazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl,benzoxazolonyl, 4H-benzo[1,4]oxazine-3-onyl, benzodioxolyl,benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl, indolinyl,indolonyl, indolinonyl, phthalimidyl, pyrrolidinyl, tetrahydrofuranyl,tetrahydrothiophenyl, piperidinyl, piperazinyl, morpholinyl,tetrahydropyranyl, dioxanyl, tetramethylene sulfonyl, tetramethylenesulfoxidyl, oxazolinyl, thiazolinyl, imidazolinyl, tetrahydropyridinyl,homopiperidinyl, pyrrolinyl, tetrahydropyrimidinyl, decahydroquinolinyl,decahydroisoquinolinyl, thiomorpholinyl, thiazolidinyl, dihydrooxazinyl,dihydropyranyl, oxocanyl, heptacanyl, thioxanyl or dithianyl; wherein Gis substituted by one or more R¹, R² or R³;

Ar is —(Y)—(C₀₋₃ alkyl)-(phenyl), or —(Y)—(C₀₋₃ alkyl)-(monocyclicheteroaryl), wherein Ar is optionally substituted with one or more R⁴ orR⁵;

Y is —C(O)—, —C(NNRC(O)OR)—, —C(NNRR)—, —C(NNHC(O)NRR)— or —C(NOR)—,

L is a covalent bond or a saturated or unsaturated branched orunbranched C₁₋₁₀ carbon chain, wherein one or more methylene groups areoptionally independently replaced by heteroatoms chosen from O, NR andS(O)_(m); and wherein L is optionally substituted with 0-2 oxo groupsand one or more C₁₋₄ branched or unbranched alkyl optionally substitutedby one or more F, Cl, Br, or I;

each m is independently 0, 1 or 2;

Q is hydrogen, —NR′R′, cycloalkyl, aryl, heterocyclyl, C₁₋₆ alkoxy, C₁₋₆alkyl-S(O)_(m), or phenyl-S(O)_(m), wherein the cycloalkyl, aryl,heterocyclyl, C₁₋₆ alkoxy, C₁₋₆ alkyl-S(O)_(m), or phenyl-S(O)_(m) iseach optionally substituted with one or more R²⁷; provided that if R⁴and R⁵ are absent, -L-Q is not —H;

each R is independently hydrogen or substituted or unsubstituted C₁₋₆alkyl;

each R′ is independently hydrogen, substituted or unsubstituted C₁₋₈alkyl, substituted or unsubstituted (C₀₋₄ alkyl)-(C₆₋₁₀ aryl) orsubstituted or unsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—OR, —NR′R′, —SiR₃, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R², R⁴ and R⁵ is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂;

each R″ is independently substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted C₀₋₄ alkyl-C₆₋₁₀ aryl or substituted orunsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R³ is independently substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈ alkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)N(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈ alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);

each R⁶ is a C₁₋₆ branched or unbranched alkyl optionally partially orfully halogenated and optionally substituted with R²⁶;

each R²⁶ is independently cyano, morpholino, piperidinyl, piperazinyl,imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄alkyl)amino optionally partially or fully halogenated;

R²⁰ is substituted or unsubstituted C₁₋₁₀ alkyl, substituted orunsubstituted C₀₋₆ alkyl-phenyl, substituted or unsubstituted C₀₋₆alkyl-heterocyclyl, OR′ or NR′₂;

R²¹ is hydrogen or C₁₋₄ branched or unbranched alkyl optionallypartially or fully halogenated; and

each R²², R²³ and R²⁴ is independently hydrogen, substituted orunsubstituted C₁₋₁₀ alkyl, wherein the C₁₋₁₀ alkyl is optionallyinterrupted by one or more O, N or S, substituted or unsubstituted C₀₋₆alkyl-phenyl, substituted or unsubstituted C₀₋₆ alkyl-heterocyclyl; orR²³ and R²⁴ taken together optionally form a heterocyclic or heteroarylring;

each R²⁷ is independently F, Cl, Br, I, cyano, —C(O)R′, —C(O)NR′₂,—C(O)OR′, —OR′, —NR′R′, —SiR′₃, —S(O)_(m)R′, substituted orunsubstituted straight or branched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀alkynyl, substituted or unsubstituted C₃₋₁₀ cycloalkyl, substituted orunsubstituted C₅₋₈ cycloalkenyl, substituted or unsubstituted C₇₋₂₀aralkyl, substituted or unsubstituted 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

provided however that when Ar is phenyl and G is N-(substituted orunsubstituted phenyl)-pyrazolyl, the pyrazolyl is additionallysubstituted with one or more R¹, R² or R³; and IA is not2-[6-(2-biphenyl-4-yl-2-oxo-acetylamino)-indol-1-ylmethyl]-benzoic acid.

In certain embodiments of the third group of compounds of Formula IA,the compound at a concentration of 10 μM inhibits induced TNFa-releasefrom a cell by about 50% or greater than 50%.

In certain embodiments of the third group of compounds of Formula IA, Gis cyclopropyl, cyclobutyl or cyclopentyl. In others, G is cyclopropyl,pyrazolyl, pyrrolyl, pyrrolidinyl, imidazolyl, imidazolonyl, thiazolyl,oxazolyl, isoxazolyl, furanyl, or thienyl.

In some embodiments of the third group of compounds of Formula IA, Ar is—(Y)—(C₀₋₃ alkyl)-(phenyl) and Y is —C(O)—, —C(NNRC(O)OR)— or —C(NOR)—.In some such embodiments, Ar is substituted by at least one R⁴ or R⁵. Inothers, Ar is —C(O)— (phenyl). In yet other embodiments, Ar is—(Y)—(C₀₋₃ alkyl)-(monocyclic heteroaryl), and the monocyclic heteroarylis pyrazolyl, imidazolyl, pyrazolinyl, pyrrolyl, pyrrolinyl, pyridinyl,pyrimidinyl or pyridazinyl. In some such embodiments, Ar is substitutedby at least one R⁴ or R⁵. Alternatively, Y is —C(O)—, —C(NNRC(O)OR)— or—C(NOR)—. In yet others, Ar is —C(O)-(monocyclic heteroaryl) or—C(NOR)-(monocyclic heteroaryl). For example, the monocyclic heteroarylcan be pyrazolyl, imidazolyl, pyrazolinyl, pyrrolyl, pyrrolinyl,pyridinyl, pyrimidyl, or pyridazinyl.

In certain embodiments of the third group of compounds of Formula IA,one or more methylene groups of L are independently replaced by heteroatoms selected from O, N or S(O)_(m). In others, L is a covalent bond, aC₁-C₉ alkoxy, —C(O)O—, —NH— or —O—.

In certain embodiments of the third group of compounds of Formula IA, Qis hydrogen, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl,imidazolyl, pyrrolyl, pyrrolidinyl, benzimidazolyl, furanyl, thienyl,pyranyl, naphthylpyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl,tetrazolyl, pyrazolo[3,4-b]pyrimidinyl, purinyl,pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, tubercidinyl,oxazo[4,5-b]pyridinyl, or imidazo[4,5-b]pyridinyl; tetrahydropyranyl,tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl,morpholino, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinyl, piperazinonyl, oxazepinyl, diazepanonyl, piperidinyl,piperidinonyl, tetrahydropyrimidonyl, cyclohexanone, cyclohexanolol,pentamethylene sulfide, pentamethylene sulfoxide, pentamethylenesulfone, tetramethylene sulfide, tetramethylene sulfoxide ortetramethylene sulfone; C₁₋₆ alkoxy, secondary or tertiary amine whereinthe amino nitrogen is covalently bonded to C₁₋₃ alkyl or C₁₋₅alkoxyalkyl, phenylamino; C₁₋₆ alkyl-S(O)_(m) or phenyl-S(O)_(m). Insome such embodiments, R²⁷ is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy amino,substituted or unsubstituted 5-10 member heterocyclyl, mono- or di-(C₁₋₃alkyl)amino, mono- or di-(phenyl-C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m),phenyl-C₁₋₃-alkoxy or phenylamino wherein the phenyl ring is optionallysubstituted with one to two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy.

In other embodiments, Q is hydrogen, thiomorpholino sulfoxide,thiomorpholino sulfone, piperazinonyl, oxazepinyl, diazepinonyl,imidazolyl, pyridinyl or morpholino. In yet others, Q is morpholino,piperazinyl, pyrimidinyl or pyridinyl. In some such embodiments, R²⁷ is—C(O)OR, —NR′R′, substituted or unsubstituted straight or branched C₁₋₁₀alkyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m). For example, Q is pyrimidinyl, andR²⁷ is —NR′R′ or substituted or unsubstituted saturated or unsaturated3-11 member heterocyclyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m). Alternatively, Q is pyridinyl, andR²⁷ is —NR′R′, substituted or unsubstituted C₁₋₆ alkyl, or substitutedor unsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m).

In certain embodiments of the third group of compounds of Formula IA,each R¹ is independently:

C₃₋₁₀ branched or unbranched alkyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclohexanyl, or bicycloheptanyl, which are optionally partially orfully halogenated and optionally substituted with one to three C₁₋₃alkyl groups optionally partially or fully halogenated, cyano, hydroxylC₁₋₃ alkyl or aryl, or an analogue of cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are replaced independently by O, S(O)_(m), CHOH,C═O, C═S or NH;

C₃₋₁₀ branched or unbranched alkenyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₁₋₅ branchedor unbranched alkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, isothiazolyl; each of the aforementioned being optionally,partially or fully halogenated, C₁₋₆ branched or unbranched alkyloptionally partially or fully halogenated, cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, hydroxy, cyano, C₁₋₃alkoxy optionally partially or fully halogenated, NH₂C(O) or mono- ordi-(C₁₋₃ alkyl)aminocarboxyl; and wherein the C₃₋₁₀ branched orunbranched alkenyl is optionally interrupted by one or more O, N orS(O)_(m);

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

cyano, F, Cl, Br, or I;

methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl;

silyl containing three C₁₋₄ independently branched or unbranched alkylgroups optionally partially or fully halogenated;

C₂₋₆ branched or unbranched alkyl-C(O), C₂₋₆ branched or unbranched-S,C₂₋₆ branched or unbranched-S(O), C₂₋₆ branched or unbranched-S(O)₂;

C₂₋₆ branched or unbranched alkynyl optionally partially or fullyhalogenated, wherein one or more methylene groups are optionallyreplaced by O, NH and S(O)_(m) and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms.

In some other embodiments of the third group of compounds of Formula IA,each R¹ is independently C₃₋₁₀ branched or unbranched alkyl optionallypartially or fully halogenated, and optionally substituted with one tothree C₃₋₁₀ cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl,pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl,thienyl, furyl, isoxazolyl, or isothiazolyl; each of which is optionallysubstituted with 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl whichis optionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl. For example, each R¹ is independently C₃₋₁₀branched or unbranched alkyl.

In certain embodiments of the third group of compounds of Formula IA,each R² is independently —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂,—NR′₂, —NO₂, —S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′,—NR′C(O)OR′ or —SO₂NR′₂. Alternatively, each R² is independently —NR′₂,—NO₂, —C(O)NR′₂, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂.

In some embodiments of the third group of compounds of Formula IA, eachR³ is independently

hydrogen or phenyl, naphthyl, or heterocyclyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl,pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl,oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl,indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, carboxy-mono- or di-(C₁₋₅ alkyl)amino;

a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl andbenzocycloheptenyl, or a fused heterocycle selected fromcyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine,cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine,cyclopentanopyridazine, cyclopentanoindole, cyclohexanoindole,cyclobenzimidazole, cyclopentanoimidazole, cyclohexanoimidazole,cyclopentanothiophene and cyclohexanothiophene; wherein the fused arylor fused heterocyclic ring is optionally, independently substituted with1 to 3 groups selected from phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, isothiazolyl, C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,cyano, C₁₋₃ alkoxy optionally partially or fully halogenated, phenyloxy,naphthyloxy, heterocyclyloxy, heteroaryloxy, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino, heterocyclic orheteroaryl amino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₄alkyl-C(O), C₁₋₅ alkylamino-S(O)₂, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₅alkyl, R¹²—C₁₋₅ alkyl, R¹³—C₁₋₅ alkoxy, R¹⁴—C(O)—C₁₋₅ alkyl, R¹⁵—C₁₋₅alkyl(R¹⁶)N;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl, or bicycloheptanyl, which areoptionally partially or fully halogenated and optionally substitutedwith one to three C₁₋₃ alkyl groups optionally partially or fullyhalogenated, cyano, hydroxyl C₁₋₃ alkyl or aryl; or an analogue ofcyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are independently replaced by O, S(O)_(m), CHOH,C═O, C═S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl, bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

C₁₋₄ alkyl or alkylene-phenyl-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-phenyl-S(O)_(m)—C₀₋₄ alkyl or alkylene;

C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, or C₁₋₅mono- or di-alkylamino optionally substituted with R¹⁹;

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,cycloheptyloxy, which are optionally partially or fully halogenated andoptionally substituted with one to three C₁₋₃ alkyl groups optionallypartially or fully halogenated wherein one to three ring methylenegroups are replaced independently by O, S(O)_(m), CHOH, C═O, C═S or NH;

R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—;

C₂₋₆ alkenyl substituted by R²³R²⁴NC(O)—;

C₂₋₆ alkynyl branched or unbranched carbon chain optionally partially orfully halogenated, wherein one or more methylene groups are optionallyreplaced by O, NH or S(O)_(m), and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms; or

benzoyl or naphthoyl; and wherein

each R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, R¹⁹, and R²⁵ isindependently cyano, morpholino, piperidinyl, piperazinyl, imidazolyl,phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄ alkyl)aminooptionally partially or fully halogenated;

each R¹¹ and R¹⁶ is independently hydrogen or C₁₋₄ branched orunbranched alkyl optionally partially or fully halogenated; and

R¹⁸ is independently hydrogen or C₁₋₄ branched or unbranched alkyloptionally independently substituted with oxo or R²⁵.

In some such embodiments of the third group of compounds of Formula IA,each R³ is independently phenyl, naphthyl, or heterocyclyl, each ofwhich is optionally partially or fully halogenated and optionallysubstituted with 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl,isoquinolyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl,benzoisooxazolyl, benzpyrazolyl, benzothiofuranyl, cinnolinyl,pterindinyl, phthalazinyl, naphthylpyridinyl, quinoxalinyl,quinazolinyl, purinyl, indazolyl, C₁₋₆ branched or unbranched alkylwhich is optionally partially or fully halogenated, cyclopropyl,cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclohexanyl, bicycloheptanyl, phenyl C₁₋₅ alkyl, naphthyl C₁₋₅ alkyl,hydroxy, oxo, cyano, C₁₋₃ alkoxy optionally partially or fullyhalogenated, phenyloxy, naphthyloxy, heterocyclyloxy, nitro, amino,mono- or di-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino,heterocyclylamino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl,C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅ alkyl, mono- or di-(C₁₋₃alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃ alkyl)amino —S(O)₂,R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl, R¹⁰—C₁₋₅ alkyl(R¹¹)N,or carboxy-mono- or di-(C₁₋₅ alkyl)amino. In others, R³ is phenyl,pyridazinyl or pyridyl, each of which is optionally partially or fullyhalogenated and optionally substituted with C₁₋₆ branched or unbranchedalkyl which is optionally partially or fully halogenated, hydroxy, oxo,cyano, C₁₋₃ alkoxy optionally partially or fully halogenated, nitro,amino, or mono- or di-(C₁₋₃ alkyl)amino; C₁₋₆ alkyl or C₁₋₆ alkoxy, eachoptionally partially or fully halogenated or optionally substituted withR¹⁷, amino, OR¹⁸, C₁₋₅ mono- or di-alkylamino optionally substitutedwith R¹⁹; R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)—or R²⁶C(O)(CH₂)_(m)N(R²¹)—.

In some embodiments of the third group of compounds of Formula IA, X isC═O.

In certain embodiments of the third group of compounds of Formula IA, Aris —(Y)-phenyl-, Y is —C(O)—, or —C(═NOH)— and G is selected frompyrazolyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, furanyl orthienyl. In others, Ar is —(Y)-phenyl-, Y is —C(O)—, or —C(═NOH)—, and Gis pyrazolyl, thienyl or isoxazolyl. In some such embodiments, each R¹is independently a substituted or unsubstituted straight or branchedC₁₋₁₀ alkyl. In these embodiments, each R³ can be independently phenylor pyridinyl, optionally substituted with one, two, or three —F, —Cl,substituted or unsubstituted C₁₋₆ branched or unbranched alkyl orsubstituted or unsubstituted C₁₋₄ alkoxy.

There is provided in accordance with another aspect of the invention, athird group of compounds having Formula IB:

stereoisomers thereof, tautomers thereof, solvates thereof, prodrugsthereof, and pharmaceutically acceptable salts thereof, wherein:

X is C(O) or C(S);

G is a G′-(Y)— wherein G′ is a C₃₋₁₀ cycloalkyl, phenyl, naphthyl,tetrahydronaphthyl other than1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthyl, pyrazolyl, thiazolyl,pyridinyl, oxazolyl, isoxazolyl, isothiazolyl, thiadiazolyl,oxadiazolyl, pyridazinyl, imidazolyl, furanyl other than furan-2-yl,thienyl other than thien-2-yl, dihydronaphthyl, indanyl, indenyl,quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl, benzimidazolyl,benzthiazolyl, benzoxazolyl, benzpyrazolyl, or homopiperidinyl; whereinG′ is substituted by one or more R¹, R² or R³;

Ar is phenyl, pyrimidinyl, pyrazolyl, thiazolyl, thiadiazolyl, oxazolyl,isoxazolyl, oxadiazolyl, isothiazolyl, pyrrolinyl, pyridazinyl,pyrrolyl, imidazolyl, furanyl, thienyl, pyrimidinyl, pyrazinyl; whereinAr is optionally substituted with one or more R⁴ or R⁵;

Y is independently —C(O)—, —C(NNRC(O)OR)—, —C(NNRR)—, —C(NNC(O)NRR)— or—C(NOR)—;

L is a covalent bond or a saturated or unsaturated branched orunbranched C₁₋₁₀ carbon chain, wherein one or more methylene groups areoptionally independently replaced by heteroatoms chosen from O, NR andS(O)_(m); and wherein L is optionally substituted with 0-2 oxo groupsand one or more C₁₋₄ branched or unbranched alkyl optionally substitutedby one or more F, Cl, Br, or I;

each m is independently 0, 1 or 2;

Q is hydrogen, —NR′R′, cycloalkyl, aryl, heterocyclyl, C₁₋₆ alkoxy, C₁₋₆alkyl-S(O)_(m), or phenyl-S(O)_(m), wherein the cycloalkyl, aryl,heterocyclyl, alkoxy, C₁₋₆ alkyl-S(O)_(m), or phenyl-S(O)_(m) is eachoptionally substituted with one or more R²⁷; and provided that if R⁴ andR⁵ are absent, -L-Q is not —H;

each R is independently hydrogen or substituted or unsubstituted C₁₋₆alkyl;

each R′ is independently hydrogen, substituted or unsubstituted C₁₋₈alkyl, substituted or unsubstituted (C₀₋₄ alkyl)-(C₆₋₁₀ aryl) orsubstituted or unsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—NR′R′, —OR, —SiR₃, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R², R⁴ and R⁵ is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂;

each R″ is independently substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted C₀₋₄ alkyl-C₆₋₁₀ aryl or substituted orunsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R³ is independently substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈ alkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)N(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈ alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);

each R⁶ is a C₁₋₆ branched or unbranched alkyl optionally partially orfully halogenated and optionally substituted with R²⁶;

each R²⁶ is independently cyano, morpholino, piperidinyl, piperazinyl,imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄alkyl)amino optionally partially or fully halogenated;

R²⁰ is substituted or unsubstituted C₁₋₁₀ alkyl, substituted orunsubstituted C₀₋₆ alkyl-phenyl, substituted or unsubstituted C₀₋₆alkyl-heterocyclyl, OR′ or NR′₂;

R²¹ is hydrogen or C₁₋₄ branched or unbranched alkyl optionallypartially or fully halogenated; and

each R²², R²³ and R²⁴ is independently hydrogen, substituted orunsubstituted C₁₋₁₀ alkyl, wherein the C₁₋₁₀ alkyl is optionallyinterrupted by one or more O, N or S, substituted or unsubstituted C₀₋₆alkyl-phenyl, substituted or unsubstituted C₀₋₆ alkyl-heterocyclyl; orR²³ and R²⁴ taken together optionally form a heterocyclic or heteroarylring;

each R²⁷ is independently F, Cl, Br, I, cyano, —C(O)R′, —C(O)NR′₂,—C(O)OR′, —OR′, —NR′R′, —SiR′₃, —S(O)_(m)R′, substituted orunsubstituted straight or branched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀alkynyl, substituted or unsubstituted C₃₋₁₀ cycloalkyl, substituted orunsubstituted C₅₋₈ cycloalkenyl, substituted or unsubstituted C₇₋₂₀aralkyl, substituted or unsubstituted 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

provided however that when Ar-L-Q is —N-(substituted or unsubstitutedphenyl)-pyrazolyl and G is phenyl, naphthyl, indane ortetrahydronaphthyl, the pyrazolyl is additionally substituted with oneor more R⁴ or R⁵; and that IB is notN-{2-chloro-4-[2-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-oxo-acetylamino]-5-hydroxy-phenyl}-2-(3-pentadecyl-benzenesulfonyl)-butyramideor5-(4-ethoxy-phenyl)-1-p-tolyl-4-p-tolylaminooxalyl-1H-pyrazole-3-carboxylicacid methyl ester.

In certain embodiments of the third group of compounds of Formula IB,the compound at a concentration of 10 μM inhibits induced TNFa-releasefrom a cell by about 50% or greater than 50%.

In some embodiments of the third group of compounds of Formula IB, G′ isphenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,tetrahydronaphthyl, pyrazolyl, thiazolyl, pyridinyl, oxazolyl,isoxazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl,imidazolyl, furanyl, thienyl, dihydronaphthyl, indanyl, indenyl,quinolinyl, isoquinolinyl, pyrimidinyl, or pyrazinyl. In others, G′ isphenyl, naphthyl, pyrazolyl, cyclopropyl, imidazolyl, thiazolyl,oxazolyl, isoxazolyl, furanyl, thienyl, or pyridinyl.

In certain embodiments of the third group of compounds of Formula IB, Yis —C(O)—, —C(NNRC(O)OR)— or —C(NOR)—.

In some embodiments of the third group of compounds of Formula IB, Ar isphenyl, pyrazoly, imidazolyl, pyrazolinyl, pyrrolyl, pyrrolinyl,pyridinyl, or pyrimidinyl.

In other embodiments of the third group of compounds of Formula IB, oneor more methylene groups of L are independently replaced by hetero atomsselected from O, N or S(O)_(m). Alternatively, L is a covalent bond, aC₁-C₉ alkoxy, —C(O)O—, —NH— or —O—.

In certain embodiments of the third group of compounds of Formula IB, Qis hydrogen, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl,imidazolyl, pyrrolyl, pyrrolidinyl, benzimidazolyl, furanyl, thienyl,pyranyl, naphthylpyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl,tetrazolyl, pyrazolo[3,4-b]pyrimidinyl, purinyl,pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, tubercidinyl,oxazo[4,5-b]pyridinyl, or imidazo[4,5-b]pyridinyl; tetrahydropyranyl,tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl,morpholino, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinyl, piperazinonyl, oxazepinyl, diazepanonyl, piperidinyl,piperidinonyl, tetrahydropyrimidonyl, cyclohexanone, cyclohexanolol,pentamethylene sulfide, pentamethylene sulfoxide, pentamethylenesulfone, tetramethylene sulfide, tetramethylene sulfoxide ortetramethylene sulfone; C₁₋₆ alkoxy, secondary or tertiary amine whereinthe amino nitrogen is covalently bonded to C₁₋₃ alkyl or C₁₋₅alkoxyalkyl, phenylamino; C₁₋₆ alkyl-S(O)_(m) or phenyl-S(O)_(m). Insome such embodiments, R²⁷ is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy amino,substituted or unsubstituted 5-10 member heterocyclyl, mono- or di-(C₁₋₃alkyl)amino, mono- or di-(phenyl-C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m),phenyl-C₁₋₃-alkoxy or phenylamino wherein the phenyl ring is optionallysubstituted with one to two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy.

In other embodiments of the third group of compounds of Formula IB, Q ishydrogen, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinonyl, oxazepinyl, diazepinonyl, imidazolyl, pyridinyl ormorpholino. In yet others, Q is morpholino, piperazinyl, pyrimidinyl orpyridinyl. In some such embodiments, R²⁷ is —C(O)OR, —NR′R′, substitutedor unsubstituted straight or branched C₁₋₁₀ alkyl, substituted orunsubstituted C₇₋₂₀ aralkyl, substituted or unsubstituted saturated orunsaturated 3-11 member heterocyclyl or heterocyclylalkyl containing 1,2, 3, or 4 heteroatoms selected independently from N, O, S(O)_(m). Forexample, Q is pyrimidinyl, and R²⁷ is —NR′R′ or substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclylcontaining 1, 2, 3, or 4 heteroatoms selected independently from N, O,S(O)_(m). Alternatively, Q is pyridinyl, and R²⁷ is —NR′R′, substitutedor unsubstituted C₁₋₆ alkyl, or substituted or unsubstituted saturatedor unsaturated 3-11 member heterocyclyl or heterocyclylalkyl containing1, 2, 3, or 4 heteroatoms selected independently from N, O, S(O)_(m).

In certain embodiments of the third group of compounds of Formula IB,each R¹ is independently:

C₃₋₁₀ branched or unbranched alkyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclohexanyl, or bicycloheptanyl, which are optionally partially orfully halogenated and optionally substituted with one to three C₁₋₃alkyl groups optionally partially or fully halogenated, cyano, hydroxylC₁₋₃ alkyl or aryl, or an analogue of cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are replaced independently by O, S(O)_(m), CHOH,C═O, C═S, or NH;

C₃₋₁₀ branched or unbranched alkenyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₁₋₅ branchedor unbranched alkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, isothiazolyl; each of the aforementioned being optionally,partially or fully halogenated, C₁₋₆ branched or unbranched alkyloptionally partially or fully halogenated, cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, hydroxy, cyano, C₁₋₃alkoxy optionally partially or fully halogenated, NH₂C(O) or mono- ordi-(C₁₋₃ alkyl)aminocarboxyl; and wherein the C₃₋₁₀ branched orunbranched alkenyl is optionally interrupted by one or more O, N orS(O)_(m);

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

cyano, F, Cl, Br, or I;

methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl;

silyl containing three C₁₋₄ independently branched or unbranched alkylgroups optionally partially or fully halogenated;

C₂₋₆ branched or unbranched alkyl-C(O), C₂₋₆ branched or unbranched-S,C₂₋₆ branched or unbranched-S(O), C₂₋₆ branched or unbranched-S(O)₂;

C₂₋₆ branched or unbranched alkynyl optionally partially or fullyhalogenated, wherein one or more methylene groups are optionallyreplaced by O, NH and S(O)_(m) and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms.

In other embodiments of the third group of compounds of Formula IB, eachR¹ is independently C₃₋₁₀ branched or unbranched alkyl optionallypartially or fully halogenated, and optionally substituted with one tothree C₃₋₁₀ cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl,pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl,thienyl, furyl, isoxazolyl, or isothiazolyl; each of which is optionallysubstituted with 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl whichis optionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl. For example, each R¹ is independently C₃₋₁₀branched or unbranched alkyl.

In certain embodiments of the third group of compounds of Formula IB,each R² is independently —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂,—NR′₂, —NO₂, —S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′,—NR′C(O)OR′ or —SO₂NR′₂. alternatively, each R² is independently —NR′₂,—NO₂, —C(O)NR′₂, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂.

In certain embodiments of the third group of compounds of Formula IB, R³is independently

hydrogen or phenyl, naphthyl, or heterocyclyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl,pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl,oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl,indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, carboxy-mono- or di-(C₁₋₅ alkyl)amino;

a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl andbenzocycloheptenyl, or a fused heterocycle selected fromcyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine,cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine,cyclopentanopyridazine, cyclopentanoindole, cyclohexanoindole,cyclobenzimidazole, cyclopentanoimidazole, cyclohexanoimidazole,cyclopentanothiophene and cyclohexanothiophene; wherein the fused arylor fused heterocyclic ring is optionally, independently substituted with1 to 3 groups selected from phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, isothiazolyl, C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,cyano, C₁₋₃ alkoxy optionally partially or fully halogenated, phenyloxy,naphthyloxy, heterocyclyloxy, heteroaryloxy, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino, heterocyclic orheteroaryl amino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₄alkyl-C(O), C₁₋₅ alkylamino-S(O)₂, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₅alkyl, R¹²—C₁₋₅ alkyl, R¹³—C₁₋₅ alkoxy, R¹⁴—C(O)—C₁₋₅ alkyl, R¹⁵—C₁₋₅alkyl(R¹⁶)N;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl, or bicycloheptanyl, which areoptionally partially or fully halogenated and optionally substitutedwith one to three C₁₋₃ alkyl groups optionally partially or fullyhalogenated, cyano, hydroxyl C₁₋₃ alkyl or aryl; or an analogue ofcyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are independently replaced by O, S(O)_(m), CHOH,C═O, C═S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl, bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

C₁₋₄ alkyl or alkylene-phenyl-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-phenyl-S(O)_(m)—C₀₋₄ alkyl or alkylene;

C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, or C₁₋₅mono- or di-alkylamino optionally substituted with R¹⁹;

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,cycloheptyloxy, which are optionally partially or fully halogenated andoptionally substituted with one to three C₁₋₃ alkyl groups optionallypartially or fully halogenated wherein one to three ring methylenegroups are replaced independently by O, S(O)_(m), CHOH, C═O, C═S or NH;

R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—;

C₂₋₆ alkenyl substituted by R²³R²⁴NC(O)—;

C₂₋₆ alkynyl branched or unbranched carbon chain optionally partially orfully halogenated, wherein one or more methylene groups are optionallyreplaced by O, NH or S(O)_(m), and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms; or

benzoyl or naphthoyl; and wherein

each R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, R¹⁹, and R²⁵ isindependently cyano, morpholino, piperidinyl, piperazinyl, imidazolyl,phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄ alkyl)aminooptionally partially or fully halogenated;

each R¹¹ and R¹⁶ is independently hydrogen or C₁₋₄ branched orunbranched alkyl optionally partially or fully halogenated; and

R¹⁸ is independently hydrogen or C₁₋₄ branched or unbranched alkyloptionally independently substituted with oxo or R²⁵.

In some such embodiments of the third group of compounds of Formula IB,each R³ is independently phenyl, naphthyl, or heterocyclyl, each ofwhich is optionally partially or fully halogenated and optionallysubstituted with 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl,isoquinolyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl,benzoisooxazolyl, benzpyrazolyl, benzothiofuranyl, cinnolinyl,pterindinyl, phthalazinyl, naphthylpyridinyl, quinoxalinyl,quinazolinyl, purinyl, indazolyl, C₁₋₆ branched or unbranched alkylwhich is optionally partially or fully halogenated, cyclopropyl,cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclohexanyl, bicycloheptanyl, phenyl C₁₋₅ alkyl, naphthyl C₁₋₅ alkyl,hydroxy, oxo, cyano, C₁₋₃ alkoxy optionally partially or fullyhalogenated, phenyloxy, naphthyloxy, heterocyclyloxy, nitro, amino,mono- or di-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino,heterocyclylamino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl,C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅ alkyl, mono- or di-(C₁₋₃alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃ alkyl)amino —S(O)₂,R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl, R¹⁰—C₁₋₅ alkyl(R¹¹)N,or carboxy-mono- or di-(C₁₋₅ alkyl)amino. In other such embodiments, R³is phenyl, pyridazinyl or pyridyl, each of which is optionally partiallyor fully halogenated and optionally substituted with C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,hydroxy, oxo, cyano, C₁₋₃ alkoxy optionally partially or fullyhalogenated, nitro, amino, or mono- or di-(C₁₋₃ alkyl)amino; C₁₋₆ alkylor C₁₋₆ alkoxy, each optionally partially or fully halogenated oroptionally substituted with R¹⁷, amino, OR¹⁸, C₁₋₅ mono- ordi-alkylamino optionally substituted with R¹⁹; R²⁰C(O)N(R²¹)—, R²²O—,R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— or R²⁶C(O)(CH₂)_(m)N(R²¹)—.

In certain embodiments of the third group of compounds of Formula IB, Xis C═O.

In some embodiments of the third group of compounds of Formula IB, Ar isphenyl, G is G′-(Y)—, Y is —C(O)— or —C(═NOH)— and G′ is selected fromphenyl, pyridinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, furanylor thienyl. In others, Ar is phenyl, G is G′-(Y)—, Y is —C(O)— or—C(═NOH)— and G′ is phenyl or pyridinyl, substituted by one or more R¹,R² or R³. In some such embodiments, each R¹ is independently asubstituted or unsubstituted straight or branched C₁₋₁₀ alkyl. In these,each R³ can be independently R²³R²⁴N—C(O)—, R²⁰—C(O)—NR²¹—, or OR²².Alternatively, each R² is independently —NR′SO₂R″, —Cl, —Br, —F,—C(O)—NR′₂, substituted or unsubstituted straight or branched C₁₋₆alkyl, —NR′₂, or —OR′.

In other embodiments of the third group of compounds of Formula IB, Aris phenyl and G is G′-(Y)—, wherein Y is selected from —C(O)— and—C(═NOH)— and G′ is pyrazolyl, isoxazolyl or furanyl, substituted by oneor more R¹, R² or R³. In some such embodiments, each R¹ is independentlya substituted or unsubstituted straight or branched C₁₋₁₀ alkyl. Inthese, each R³ can be independently substituted or unsubstituted C₁₋₆alkyl, pyridinyl or phenyl, optionally substituted with one to three —F,—Cl, substituted or unsubstituted C₁₋₆ branched or unbranched alkyl, orsubstituted or unsubstituted C₁₋₃ alkoxy.

There is provided in accordance with another aspect of the invention,compounds having Formula IC:

G-Ring-Ar-L-Q

stereoisomers thereof, tautomers thereof, solvates thereof, prodrugsthereof, and pharmaceutically acceptable salts thereof, wherein:

Ring is maleimide, succinimide, imidazolidinone, imidazolidine-dione,imidazolidine-trione, triazolidin-dione, or triazine-dione;

G is a C₃₋₁₀ carbocyclyl, C₄₋₁₂ carbocyclylalkyl, 5-8 memberedmonocyclic heterocyclyl or heterocyclylalkyl, 8-11 membered bicyclicheterocyclyl or heterocyclylalkyl, wherein the heterocyclyl ringscontain 1 or more heteroatoms selected from O, N or S; and G issubstituted by one or more R¹, R² or R³;

Ar is indazolyl, indolyl, isoindolyl, imidazolyl, benzimidazolyl,pyrazolyl, pyrazolinyl, pyrrolyl, pyrrolinyl, pyridinyl, pyridazinyl,quinolinyl, isoquinolinyl, phthalazinyl, dihydroindolyl, benzofuranyl,benzoxazolyl, benzoisoxazolyl, dihydrobenzoisoxazolyl,dihydroisoindolyl, benzothiazolyl, benzoisothiazolyl, benzoisothiazolyldioxide, C₆₋₁₀ aryl, or —(C₁₋₃ alkyl)-(C₆₋₁₀ aryl), wherein Ar isoptionally substituted with one or more R⁴ or R⁵;

L is a covalent bond or a saturated or unsaturated branched orunbranched C₁₋₁₀ carbon chain, wherein one or more methylene groups areoptionally independently replaced by heteroatoms chosen from O, NR andS(O)_(m); and wherein L is optionally substituted with 0-2 oxo groupsand one or more C₁₋₄ branched or unbranched alkyl optionally substitutedby one or more F, Cl, Br, or I;

each m is independently 0, 1 or 2;

Q is hydrogen, —NR′R′, cycloalkyl, aryl, heterocyclyl, C₁₋₆ alkoxy, C₁₋₆alkyl-S(O)_(m), or phenyl-S(O)_(m), wherein the cycloalkyl, aryl,heterocyclyl, C₁₋₆ alkoxy, C₁₋₆ alkyl-S(O)_(m), or phenyl-S(O)_(m) iseach optionally substituted with one or more R²⁷; and provided that ifR⁴ and R⁵ are absent, -L-Q is not —H;

each R is independently hydrogen or substituted or unsubstituted C₁₋₆alkyl;

each R′ is independently hydrogen, substituted or unsubstituted C₁₋₈alkyl, substituted or unsubstituted (C₀₋₄ alkyl)-(C₆₋₁₀ aryl) orsubstituted or unsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—OR, —NR′R′, —SiR₃, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R², R⁴ and R⁵ is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂;

each R″ is independently substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted C₀₋₄ alkyl-C₆₋₁₀ aryl or substituted orunsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R³ is independently substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈ alkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)N(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈ alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);

each R⁶ is a C₁₋₆ branched or unbranched alkyl optionally partially orfully halogenated and optionally substituted with R²⁶;

each R²⁶ is independently cyano, morpholino, piperidinyl, piperazinyl,imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄alkyl)amino optionally partially or fully halogenated;

R²⁰ is substituted or unsubstituted C₁₋₁₀ alkyl, substituted orunsubstituted C₀₋₆ alkyl-phenyl, substituted or unsubstituted C₀₋₆alkyl-heterocyclyl, OR′ or NR′₂;

R²¹ is hydrogen or C₁₋₄ branched or unbranched alkyl optionallypartially or fully halogenated; and

each R²², R²³ and R²⁴ is independently hydrogen, substituted orunsubstituted C₁₋₁₀ alkyl, wherein the C₁₋₁₀ alkyl is optionallyinterrupted by one or more O, N or S, substituted or unsubstituted C₀₋₆alkyl-phenyl, substituted or unsubstituted C₀₋₆ alkyl-heterocyclyl; orR²³ and R²⁴ taken together optionally form a heterocyclic or heteroarylring; and

each R²⁷ is independently F, Cl, Br, I, cyano, —C(O)R′, —C(O)NR′₂,—C(O)OR′, —OR′, —NR′R′, —SiR′₃, —S(O)_(m)R′, substituted orunsubstituted straight or branched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀alkynyl, substituted or unsubstituted C₃₋₁₀ cycloalkyl, substituted orunsubstituted C₅₋₈ cycloalkenyl, substituted or unsubstituted C₇₋₂₀aralkyl, substituted or unsubstituted 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m).

In certain embodiments of compounds of Formula IC, the compound at aconcentration of 10 μM inhibits induced TNFa-release from a cell byabout 50% or greater than 50%.

In certain embodiments of compounds of Formula IC, G is

phenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl, cyclopropyl,tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl, indanyl,indenyl, benzofuran-3-one;

pyrazolyl, pyrrolyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl,isoxazolyl, furanyl, thienyl, pyridinyl, pyridonyl, quinolinyl,dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl,tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, 4H-benzo[1,4]oxazine-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, phthalimidyl;

pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, thiazolinyl,imidazolinyl, tertrahydropyridinyl, homopiperidinyl, pyrrolinyl,tetrahydropyrimidinyl, decahydroquinolinyl, decahydroisoquinolinyl,thiomorpholinyl, thiazolidinyl, dihydrooxazinyl, dihydropyranyl,oxocanyl, heptacanyl, thioxanyl or dithianyl.

In other embodiments of compounds of Formula IC, G is phenyl, naphthyl,cyclopropyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl,benzocycloheptanyl, benzocycloheptenyl, indanyl, indenyl, orbenzofuran-3-one. In yet others, G is pyrazolyl, pyridinyl, pyridonyl,quinolinyl, dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl,tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, benzo[1,4]oxazin-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, or phthalimidyl. In still others, Gis pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, isoxazolinyl,thiazolinyl, imidazolinyl, tertrahydropyridinyl, homopiperidinyl,pyrrolinyl, tetrahydropyrimidinyl, decahydroquinolinyl,decahydroisoquinolinyl, thiomorpholinyl, thiazolidinyl, dihydrooxazinyl,dihydropyranyl, oxocanyl, heptacanyl, thioxanyl or dithianyl. Forexample, G is phenyl, naphthyl, cyclopropyl, pyrazolyl, pyrrolyl,pyrrolidinyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl, isoxazolyl,furanyl, thienyl, or pyridinyl.

In certain embodiments of compounds of Formula IC, Ar is indazolyl,indolyl, isoindolyl, imidazolyl, benzimidazolyl, pyrazolyl, pyrazolinyl,pyrrolyl, pyrrolinyl, pyridinyl, pyridazinyl, quinolinyl, isoquinolinyl,phthalazinyl, dihydroindolyl, benzoisoxazolyl, dihydrobenzoisoxazolyl,dihydroisoindolyl, benzoisothiazolyl, benzoisothiazolyl dioxide, C₆₋₁₀aryl. In some such embodiments, Ar is substituted with at least one R⁴or R⁵. Alternatively, Ar is indazolyl, isoindolyl, pyrazolyl,pyrrolinyl, phenyl, naphthyl, tetrahydronaphthyl, dihydronaphthyl,indanyl, indenyl or imidazolyl. For example, Ar is indazolyl, phenyl,naphthyl, or tetrahydronaphthyl.

In some embodiments of compounds of Formula IC, one or more methylenegroups of L are independently replaced by hetero atoms selected from O,N or S(O)_(m). Alternatively, L is a covalent bond, a C₁-C₉ alkoxy,—C(O)O—, —NH— or —O—.

In certain embodiments of compounds of Formula IC, Q is hydrogen,phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, imidazolyl,pyrrolyl, pyrrolidinyl, benzimidazolyl, furanyl, thienyl, pyranyl,naphthylpyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl,tetrazolyl, pyrazolo[3,4-b]pyrimidinyl, purinyl,pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, tubercidinyl,oxazo[4,5-b]pyridinyl, or imidazo[4,5-b]pyridinyl; tetrahydropyranyl,tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl,morpholino, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinyl, piperazinonyl, oxazepinyl, diazepanonyl, piperidinyl,piperidinonyl, tetrahydropyrimidonyl, cyclohexanone, cyclohexanolol,pentamethylene sulfide, pentamethylene sulfoxide, pentamethylenesulfone, tetramethylene sulfide, tetramethylene sulfoxide ortetramethylene sulfone; C₁₋₆ alkoxy, secondary or tertiary amine whereinthe amino nitrogen is covalently bonded to C₁₋₃ alkyl or C₁₋₅alkoxyalkyl, phenylamino; C₁₋₆ alkyl-S(O)_(m) or phenyl-S(O)_(m). Insome such embodiments, R²⁷ is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy amino,substituted or unsubstituted 5-10 member heterocyclyl, mono- or di-(C₁₋₃alkyl)amino, mono- or di-(phenyl-C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m),phenyl-C₁₋₃-alkoxy or phenylamino wherein the phenyl ring is optionallysubstituted with one to two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy.

In other embodiments of compounds of Formula IC, Q is hydrogen,thiomorpholino sulfoxide, thiomorpholino sulfone, piperazinonyl,oxazepinyl, diazepinonyl, imidazolyl, pyridinyl or morpholino. In yetothers, Q is morpholino, piperazinyl, pyrimidinyl or pyridinyl. In somesuch embodiments, R²⁷ is —C(O)OR, —NR′R′, substituted or unsubstitutedstraight or branched C₁₋₁₀ alkyl, substituted or unsubstituted C₇₋₂₀aralkyl, or substituted or unsubstituted saturated or unsaturated 3-11member heterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4heteroatoms selected independently from N, O, S(O)_(m). For example, Qis pyrimidinyl, and R²⁷ is —NR′R′ or substituted or unsubstitutedsaturated or unsaturated 3-11 member heterocyclyl containing 1, 2, 3, or4 heteroatoms selected independently from N, O, S(O)_(m). Alternatively,Q is pyridinyl, and R²⁷ is —NR′R′, substituted or unsubstituted C₁₋₆alkyl, or substituted or unsubstituted saturated or unsaturated 3-11member heterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4heteroatoms selected independently from N, O, S(O)_(m).

In certain embodiments of compounds of Formula IC, each R¹ isindependently:

C₃₋₁₀ branched or unbranched alkyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclohexanyl, or bicycloheptanyl, which are optionally partially orfully halogenated and optionally substituted with one to three C₁₋₃alkyl groups optionally partially or fully halogenated, cyano, hydroxylC₁₋₃ alkyl or aryl, or an analogue of cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are replaced independently by O, S(O)_(m), CHOH,C═O, C═S or NH;

C₃₋₁₀ branched or unbranched alkenyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₁₋₅ branchedor unbranched alkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, isothiazolyl; each of the aforementioned being optionally,partially or fully halogenated, C₁₋₆ branched or unbranched alkyloptionally partially or fully halogenated, cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, hydroxy, cyano, C₁₋₃alkoxy optionally partially or fully halogenated, NH₂C(O) or mono- ordi-(C₁₋₃ alkyl)aminocarboxyl; and wherein the C₃₋₁₀ branched orunbranched alkenyl is optionally interrupted by one or more O, N orS(O)_(m);

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

cyano, F, Cl, Br, I;

methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl;

silyl containing three C₁₋₄ independently branched or unbranched alkylgroups optionally partially or fully halogenated;

C₂₋₆ branched or unbranched alkyl-C(O), C₂₋₆ branched or unbranched-S,C₂₋₆ branched or unbranched-S(O), C₂₋₆ branched or unbranched-S(O)₂;

C₂₋₆ branched or unbranched alkynyl optionally partially or fullyhalogenated, wherein one or more methylene groups are optionallyreplaced by O, NH and S(O)_(m) and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms.

In other embodiments of compounds of Formula IC, each R¹ isindependently C₃₋₁₀ branched or unbranched alkyl optionally partially orfully halogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl. For example, each R¹ is independently C₃₋₁₀branched or unbranched alkyl.

In certain embodiments of compounds of Formula IC, each R² isindependently —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂. Alternatively, each R² is independently —NR′₂, —NO₂,—C(O)NR′₂, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂.

In certain embodiments of compounds of Formula IC, each R³ isindependently

hydrogen, phenyl, naphthyl, or heterocyclyl, each of which is optionallypartially or fully halogenated and optionally substituted with 1-3 ofphenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl, pyrazolyl,thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl, oxazolyl,triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl, indolyl,benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, carboxy-mono- or di-(C₁₋₅ alkyl)amino;

a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl andbenzocycloheptenyl, or a fused heterocycle selected fromcyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine,cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine,cyclopentanopyridazine, cyclopentanoindole, cyclohexanoindole,cyclobenzimidazole, cyclopentanoimidazole, cyclohexanoimidazole,cyclopentanothiophene and cyclohexanothiophene; wherein the fused arylor fused heterocyclic ring is optionally, independently substituted with1 to 3 groups selected from phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, isothiazolyl, C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,cyano, C₁₋₃ alkoxy optionally partially or fully halogenated, phenyloxy,naphthyloxy, heterocyclyloxy, heteroaryloxy, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino, heterocyclic orheteroaryl amino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₄alkyl-C(O), C₁₋₅ alkylamino-S(O)₂, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₅alkyl, R¹²—C₁₋₅ alkyl, R¹³—C₁₋₅ alkoxy, R¹⁴—C(O)—C₁₋₅ alkyl, R¹⁵—C₁₋₅alkyl(R¹⁶)N;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl, or bicycloheptanyl, which areoptionally partially or fully halogenated and optionally substitutedwith one to three C₁₋₃ alkyl groups optionally partially or fullyhalogenated, cyano, hydroxyl C₁₋₃ alkyl or aryl; or an analogue ofcyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are independently replaced by O, S(O)_(m), CHOH,C═O, C═S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl, bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

C₁₋₄ alkyl or alkylene-phenyl-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-C(O)—C₀₋₄ alkyl or alkylene, C₁₋₄ alkyl oralkylene-phenyl-S(O)_(m)—C₀₋₄ alkyl or alkylene;

C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, or C₁₋₅mono- or di-alkylamino optionally substituted with R¹⁹;

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,cycloheptyloxy, which are optionally partially or fully halogenated andoptionally substituted with one to three C₁₋₃ alkyl groups optionallypartially or fully halogenated wherein one to three ring methylenegroups are replaced independently by O, S(O)_(m), CHOH, C═O, C═S or NH;

R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—;

C₂₋₆ alkenyl substituted by R²³R²⁴NC(O)—;

C₂₋₆ alkynyl branched or unbranched carbon chain optionally partially orfully halogenated, wherein one or more methylene groups are optionallyreplaced by O, NH or S(O)_(m), and wherein said alkynyl group isoptionally independently substituted with 0-2 oxo groups, pyrrolidinyl,pyrrolyl, one or more C₁₋₄ branched or unbranched alkyl optionallysubstituted by one or more halogen atoms, nitrile, morpholino,piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, orC₁₋₄ branched or unbranched alkylamino optionally substituted by one ormore halogen atoms; or

benzoyl or naphthoyl; and wherein

each R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, R¹⁹, and R²⁵ isindependently cyano, morpholino, piperidinyl, piperazinyl, imidazolyl,phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄ alkyl)aminooptionally partially or fully halogenated;

each R¹¹ and R¹⁶ is independently hydrogen or C₁₋₄ branched orunbranched alkyl optionally partially or fully halogenated; and

R¹⁸ is independently hydrogen or C₁₋₄ branched or unbranched alkyloptionally independently substituted with oxo or R²⁵.

In some such embodiments of compounds of Formula IC, each R³ isindependently phenyl, naphthyl, or heterocyclyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl,pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl,oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl,indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, or carboxy-mono- or di-(C₁₋₅ alkyl)amino. In othersuch embodiments R³ is phenyl, pyridazinyl or pyridyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith C₁₋₆ branched or unbranched alkyl which is optionally partially orfully halogenated, hydroxy, oxo, cyano, C₁₋₃ alkoxy optionally partiallyor fully halogenated, nitro, amino, or mono- or di-(C₁₋₃ alkyl)amino;C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, C₁₋₅ mono-or di-alkylamino optionally substituted with R¹⁹; R²⁰C(O)N(R²¹)—, R²²O—,R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— or R²⁶C(O)(CH₂)_(m)N(R²¹)—.

In certain embodiments of compounds of Formula IC, Ring is maleimide,succinimide or triazine-dione. In others, Ring is succinimid-1,4-diyl,maleimide-1,4-diyl, imidazolidin-2-one-1,3-diyl,imidazolidine-2,4,5-trione-1,3-diyl,[1,2,4]triazolidine-3,5-dione-1,4-diyl, or2H-[1,2,4]triazine-3,5-dione-4,6-diyl.

In another aspect of the invention there are provided compounds havingFormula II:

stereoisomers thereof, tautomers thereof, solvates thereof, andpharmaceutically acceptable salts thereof, wherein:

G is a C₃₋₁₀ carbocyclyl, 5-8 membered monocyclic heterocyclyl, or 8-11membered bicyclic heterocyclyl containing 1 or more heteroatoms selectedfrom O, N or S; wherein G is substituted by one or more R¹, R² or R³;

X′ is CR′═CR′, CR′═N, NR′, CR′₂, O or S;

Ar is phenyl, naphthyl, quinoline, isoquinoline, tetrahydronaphthyl,pyridinyl, pyridazinyl, quinolinyl, isoquinolinyl, phthalazinyl,tetrahydroquinoline, tetrahydroisoquinoline, benzimidazole, benzofuran,indanyl, indenyl, indole, or the structure —(Y′)—(C₀₋₃ alkyl)-(C₆₋₁₀aryl), each being optionally substituted with one or more R⁴ groups;

Y′ is absent or is —O— or —NH—;

L is a covalent bond or saturated or unsaturated branched or unbranchedC₁₋₁₀ carbon chain, wherein one or more methylene groups are optionallyindependently replaced by heteroatoms chosen from O, NR and S(O)_(m);and wherein L is optionally substituted with 0-2 oxo groups and one ormore C₁₋₄ branched or unbranched alkyl optionally substituted by one ormore F, Cl, Br, or I;

each m is independently 0, 1 or 2;

Q is hydrogen, —NR′R′, cycloalkyl, aryl, heterocyclyl, C₁₋₆ alkoxy, C₁₋₆alkyl-S(O)_(m), or phenyl-S(O)_(m), wherein the cycloalkyl, aryl,heterocyclyl, C₁₋₆ alkoxy, C₁₋₆ alkyl-S(O)_(m), or phenyl-S(O)_(m) iseach optionally substituted with one or more R²⁷;

each R is independently hydrogen or substituted or unsubstituted C₁₋₆alkyl;

each R′ is independently hydrogen, substituted or unsubstituted C₁₋₈alkyl or substituted or unsubstituted —(C₀₋₄ alkyl)-(C₆₋₁₀ aryl) orsubstituted or unsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—NR′R′, —OR, —SiR₃, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R² and R⁴ is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂;

each R″ is independently substituted or unsubstituted C₁₋₈ alkyl,substituted or unsubstituted (C₀₋₄ alkyl)-(C₆₋₁₀ aryl) or substituted orunsubstituted (C₀₋₄ alkyl)-(5-10 member heterocyclyl);

each R³ is independently H, substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈ alkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)N(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈ alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);

R⁶ is a C₁₋₆ branched or unbranched alkyl optionally partially or fullyhalogenated and optionally substituted with R²⁶;

each R²⁶ is independently cyano, morpholino, piperidinyl, piperazinyl,imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄alkyl)amino optionally partially or fully halogenated;

R²⁰ is C₁₋₁₀ branched or unbranched alkyl optionally partially or fullyhalogenated, phenyl, pyridinyl, OR′ or NR′₂;

R²¹ is hydrogen or C₁₋₄ branched or unbranched alkyl optionallypartially or fully halogenated; and

each R²², R²³ and R²⁴ is independently hydrogen, C₁₋₆ branched orunbranched alkyl optionally substituted by carbonylamino- mono- ordi-C₁₋₃ alkyl or amino-mono or di-C₁₋₃ alkyl or wherein said C₁₋₆ alkylis optionally partially or fully halogenated and optionally interruptedby one or more O, N or S, phenyl, pyridine, mono- or di-C₀₋₄ branched orunbranched alkyl optionally partially or fully halogenated andalkylamino; or R²³ and R²⁴ taken together optionally form a heterocyclicor heteroaryl ring; and

each R²⁷ is independently F, Cl, Br, I, cyano, —C(O)R′, —C(O)NR′₂,—C(O)OR′, —OR′, —NR′R′, —SiR′₃, —S(O)_(m)R′, substituted orunsubstituted straight or branched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀alkynyl, substituted or unsubstituted C₃₋₁₀ cycloalkyl, substituted orunsubstituted C₅₋₈ cycloalkenyl, substituted or unsubstituted C₇₋₂₀aralkyl, substituted or unsubstituted 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m).

In certain embodiments of compounds of Formula II, the compound at aconcentration of 10 μM inhibits induced TNFa-release from a cell byabout 50% or greater than 50%.

In certain embodiments of compounds of Formula II, G is

phenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl,tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl, indanyl,indenyl, benzofuran-3-one;

pyrazolyl, pyrrolyl, imidazolyl, imidazolonyl, thiazolyl, oxazolyl,isoxazolyl, furanyl, thienyl, pyridinyl, pyridonyl, quinolinyl,dihydroquinolinyl, tetrahydroquinoyl, isoquinolinyl,tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzofuranyl,benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, 4H-benzo[1,4]oxazine-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, phthalimidyl;

pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylenesulfonyl, tetramethylene sulfoxidyl, oxazolinyl, thiazolinyl,imidazolinyl, tertrahydropyridinyl, homopiperidinyl, pyrrolinyl,tetrahydropyrimidinyl, decahydroquinolinyl, decahydroisoquinolinyl,thiomorpholinyl, thiazolidinyl, dihydrooxazinyl, dihydropyranyl,oxocanyl, heptacanyl, thioxanyl or dithianyl.

In other embodiments of compounds of Formula II, G is phenyl, naphthyl,benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl,benzocycloheptanyl, benzocycloheptenyl, indanyl, indenyl,benzofuran-3-one, or 4H-benzo[1,4]oxazine-3-one. In yet others, G ispyrazolyl, pyridinyl, pyridonyl, quinolinyl, dihydroquinolinyl,tetrahydroquinoyl, isoquinolinyl, tetrahydroisoquinoyl, pyridazinyl,pyrimidinyl, pyrazinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl,benzofuranyl, benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,dihydrobenzothiophenyl, benzoxazolonyl, benzo[1,4]oxazin-3-onyl,benzodioxolyl, benzo[1,3]dioxol-2-onyl, tetrahydrobenzopyranyl, indolyl,indolinyl, indolonyl, indolinonyl, or phthalimidyl. In still others, Gis pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperazinyl,morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylene sulfonyl,tetramethylene sulfoxidyl, oxazolinyl, thiazolinyl, imidazolinyl,tertrahydropyridinyl, homopiperidinyl, pyrrolinyl,tetrahydropyrimidinyl, decahydroquinolinyl, decahydroisoquinolinyl,thiomorpholinyl, thiazolidinyl, dihydrooxazinyl, dihydropyranyl,oxocanyl, heptacanyl, thioxanyl or dithianyl. In certain embodiments, Gis phenyl, pyrazolyl, pyrrolyl, pyrrolidinyl, imidazolyl, imidazolonyl,thiazolyl, oxazolyl, isoxazolyl, furanyl, thienyl, or pyridinyl.

In certain embodiments of compounds of Formula II, Ar is indazolyl,isoindolyl, pyrazolyl, imidazolyl, or imidazolonyl. In some suchembodiments, Ar is substituted with at least one R⁴. Alternatively, Aris indazolyl, optionally substituted with one or more R⁴. In yet otherembodiments, Ar is phenyl or naphthyl. In some such embodiments, Ar issubstituted with at least one R⁴.

In yet other embodiments of compounds of Formula II, Ar is —(Y′)—(C₀₋₃alkyl)-(C₆₋₁₀ aryl). In some such embodiments, Ar is substituted with atleast one R⁴. In others, the C₆₋₁₀ aryl is phenyl or naphthyl.Alternatively, Y′ is —NH—.

In certain embodiments of compounds of Formula II, one or more methylenegroups of L are independently replaced by hetero atoms selected from O,N or S(O)_(m). In others, L is a bond, a C₁-C₉ alkoxy, —C(O)O—, —NH— or—O—.

In some embodiments of compounds of Formula II, Q is hydrogen, phenyl,naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, imidazolyl, pyrrolyl,pyrrolidinyl, benzimidazolyl, furanyl, thienyl, pyranyl,naphthylpyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl,tetrazolyl, pyrazolo[3,4-b]pyrimidinyl, purinyl,pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, tubercidinyl,oxazo[4,5-b]pyridinyl, or imidazo[4,5-b]pyridinyl; tetrahydropyranyl,tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl,morpholino, thiomorpholino sulfoxide, thiomorpholino sulfone,piperazinyl, piperidinyl, piperidinonyl, tetrahydropyrimidonyl,cyclohexanone, cyclohexanolol, pentamethylene sulfide, pentamethylenesulfoxide, pentamethylene sulfone, tetramethylene sulfide,tetramethylene sulfoxide or tetramethylene sulfone; C₁₋₆ alkoxy,secondary or tertiary amine wherein the amino nitrogen is covalentlybonded to C₁₋₃ alkyl or C₁₋₅ alkoxyalkyl, phenylamino; C₁₋₆alkyl-S(O)_(m) or phenyl-S(O)_(m). In some such embodiments, R²⁷ is C₁₋₆alkyl, C₁₋₆ alkoxy, hydroxy amino, substituted or unsubstituted 5-10member heterocyclyl, mono- or di-(C₁₋₃ alkyl)amino, mono- ordi-(phenyl-C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m), phenyl-C₁₋₃-alkoxy orphenylamino wherein the phenyl ring is optionally substituted with oneto two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy.

In other embodiments of compounds of Formula II, Q is hydrogen,thiomorpholino sulfoxide, thiomorpholino sulfone, piperazinonyl,oxazepinyl, diazepinonyl, imidazolyl, pyridinyl or or morpholino. In yetothers, Q is morpholino, piperazinyl, pyrimidinyl or pyridinyl. In somesuch embodiments, R²⁷ is —C(O)OR, —NR′R′, substituted or unsubstitutedstraight or branched C₁₋₁₀ alkyl, substituted or unsubstituted C₇₋₂₀aralkyl, or substituted or unsubstituted saturated or unsaturated 3-11member heterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4heteroatoms selected independently from N, O, S(O)_(m). For example, Qis pyrimidinyl, and R²⁷ is —NR′R′, or substituted or unsubstitutedsaturated or unsaturated 3-11 member heterocyclyl containing 1, 2, 3, or4 heteroatoms selected independently from N, O, S(O)_(m). Alternatively,Q is pyridinyl, and R²⁷ is —NR′R′, substituted or unsubstituted C₁₋₆alkyl, or substituted or unsubstituted saturated or unsaturated 3-11member heterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4heteroatoms selected independently from N, O, S(O)_(m).

In certain embodiments of compounds of Formula II, each R¹ isindependently

C₃₋₁₀ branched or unbranched alkyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclohexanyl, or bicycloheptanyl, which are optionally partially orfully halogenated and optionally substituted with one to three C₁₋₃alkyl groups optionally partially or fully halogenated, cyano, hydroxylC₁₋₃ alkyl or aryl; or an analogue of cyclopropyl, cyclobutyl,cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are replaced independently by O, S(O)_(m), CHOH,C═O, C═S or NH;

C₃₋₁₀ branched or unbranched alkenyl optionally partially or fullyhalogenated, and optionally substituted with one to three C₁₋₅ branchedor unbranched alkyl, phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl,thienyl, furyl, isoxazolyl, isothiazolyl; each of the aforementionedbeing optionally, partially or fully halogenated, C₁₋₆ branched orunbranched alkyl optionally partially or fully halogenated, cyclopropyl,cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, hydroxyl, cyano,C₁₋₃ alkoxy optionally partially or fully halogenated, NH₂C(O) or mono-or di-(C₁₋₃ alkyl)aminocarboxyl; the C₃₋₁₀ branched or unbranchedalkenyl is optionally interrupted by one or more O, N or S(O)_(m);

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

cyano, F, Cl, Br, or I;

methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl;

silyl containing C₁₋₄ independently branched or unbranched alkyl groupsoptionally partially or fully halogenated;

C₂₋₆ branched or unbranched alkyl-C(O), C₂₋₆ branched or unbranched-S,C₂₋₆ branched o unbranched-S(O), C₂₋₆ branched or unbranched-S(O)₂

C₂₋₆ alkynyl branched or unbranched carbon chain optionally partially orfully halogenated, wherein one or more methylene groups are optionallypartially or fully halogenated, wherein one or more methylene groups areoptionally replaced by O, NH and S(O)_(m) and wherein said alkynyl groupis optionally independently substituted with 0-2 oxo groups,pyrrolidinyl, pyrrolyl, one or more C₁₋₄ branched or unbranched alkyloptionally substituted by one or more halogen atoms, nitrile,morpholino, piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl,tetrazolyl, or C₁₋₄ branched or unbranched alkylamino optionallysubstituted by one or more halogen atoms.

In other embodiments of compounds of Formula II, each R¹ isindependently C₃₋₁₀ branched or unbranched alkyl optionally partially orfully halogenated, and optionally substituted with one to three C₃₋₁₀cycloalkyl, hydroxy phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,isoxazolyl, or isothiazolyl; each of which is optionally substitutedwith 1 to 5 halogen, C₁₋₆ branched or unbranched alkyl which isoptionally partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈cycloalkenyl, hydroxy, cyano, C₁₋₃ alkoxy which is optionally partiallyor fully halogenated and NH₂C(O) or mono- or di-(C₁₋₃alkyl)aminocarbonyl. For example, each R¹ is independently C₃₋₁₀branched or unbranched alkyl.

In certain embodiments of compounds of Formula II, each R³ isindependently

hydrogen or phenyl, naphthyl, or heterocyclyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl,pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl,oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl,indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)-C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅ alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅ alkyl(R¹¹)N, carboxy-mono- or di-(C₁₋₅ alkyl)amino;

a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl andbenzocycloheptenyl, or a fused heterocycle selected fromcyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine,cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine,cyclopentanopyridazine, cyclopentanoindole, cyclohexanoindole,cyclobenzimidazole, cyclopentanoimidazole, cyclohexanoimidazole,cyclopentanothiophene and cyclohexanothiophene; wherein the fused arylor fused heterocyclic ring is optionally, independently substituted with1 to 3 groups selected from phenyl, naphthyl, pyridinyl, pyrimidinyl,pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione,imidazolyl, pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl,thiazolyl, oxazolyl, triazolyl, isothiazolyl, C₁₋₆ branched orunbranched alkyl which is optionally partially or fully halogenated,cyano, C₁₋₃ alkoxy optionally partially or fully halogenated, phenyloxy,naphthyloxy, heterocyclyloxy, heteroaryloxy, nitro, amino, mono- ordi-(C₁₋₃ alkyl)amino, phenylamino, naphthylamino, heterocyclic orheteroaryl amino, NH₂C(O), a mono- or di-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₄alkyl-C(O), C₁₋₅ alkylamino-S(O)₂, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₅alkyl, R¹²—C₁₋₅ alkyl, R¹³—C₁₋₅ alkoxy, R¹⁴—C(O)-C₁₋₅ alkyl, R¹⁵—C₁₋₅alkyl(R¹⁶)N;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl, or bicycloheptanyl, which areoptionally partially or fully halogenated and optionally substitutedwith one to three C₁₋₃ alkyl groups optionally partially or fullyhalogenated, cyano, hydroxyl C₁₋₃ alkyl or aryl; or an analogue ofcyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,bicyclopentanyl, bicyclohexanyl or bicycloheptanyl wherein one to threering methylene groups are replaced independently by O, S(O)_(m), CHOH,C═O, C═S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,cycloheptadienyl, bicyclohexenyl, bicycloheptenyl, each optionallysubstituted with one to three C₁₋₃ alkyl groups;

C₁₋₄ branched or unbranched alkyl-phenyl-C(O)—C₀₋₄ branched orunbranched alkyl, C₁₋₄ branched or unbranched alkyl-C(O)—C₀₋₄ branchedor unbranched alkyl, C₁₋₄ branched or unbranchedalkyl-phenyl-S(O)_(m)—C₀₋₄ branched or unbranched alkyl;

C₁₋₆ branched or unbranched alkyl or C₁₋₆ branched or unbranched alkoxyeach is optionally partially or fully halogenated or optionallysubstituted with R¹⁷;

C₁₋₆ branched or unbranched alkyl optionally substituted with OR¹⁸;amino or C₁-C₅ branched or unbranched mono- or di-alkylamino optionallysubstituted with R¹⁹;

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,cycloheptyloxy, which are optionally partially or fully halogenated andoptionally substituted with one to three C₁₋₃ alkyl groups optionallypartially or fully halogenated wherein one to three ring methylenegroups are replaced independently by O, S(O)_(m), CHOH, C═O, C═S or NH;

R²⁰C(O)N(R²¹)—, R²²—, R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— orR²⁶C(O)(CH₂)_(m)N(R²¹)—;

C₂₋₆ alkenyl substituted by R²³R²⁴NC(O)—;

C₂₋₆ alkynyl branched or unbranched carbon chain optionally partially orfully halogenated, wherein one or more methylene groups are optionallypartially or fully halogenated, wherein one or more methylene groups areoptionally replaced by O, NH and S(O)_(m) or S and wherein said alkynylgroup is optionally independently substituted with 0-2 oxo groups,pyrrolidinyl, pyrrolyl, one or more C₁₋₄ branched or unbranched alkyloptionally substituted by one or more halogen atoms, nitrile,morpholino, piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl,tetrazolyl, or C₁₋₄ branched or unbranched alkylamino optionallysubstituted by one or more halogen atoms; or

benzoyl or naphthoyl; and wherein

each R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, R¹⁹, and R²⁵ isindependently cyano, morpholino, piperidinyl, piperazinyl, imidazolyl,phenyl, pyridinyl, tetrazolyl, or mono or di-(C₀₋₄ alkyl)aminooptionally partially or fully halogenated;

each R¹¹ and R¹⁶ is independently hydrogen or C₁₋₄ branched orunbranched alkyl optionally partially or fully halogenated; and

R¹⁸ is independently hydrogen or C₁₋₄ branched or unbranched alkyloptionally independently substituted with oxo or R²⁵.

In some such embodiments of compounds of Folinula II, each R³ isindependently phenyl, naphthyl, or heterocyclyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith 1-3 of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, pyrrolyl, pyrrolidinyl, 2,5-pyrrolidin-dione, imidazolyl,pyrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl,oxazolyl, triazolyl, tetrazolyl, isothiazolyl, quinolyl, isoquinolyl,indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzoisooxazolyl,benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,naphthylpyridinyl, quinoxalinyl, quinazolinyl, purinyl, indazolyl, C₁₋₆branched or unbranched alkyl which is optionally partially or fullyhalogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenylC₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, hydroxy, oxo, cyano, C₁₋₃ alkoxyoptionally partially or fully halogenated, phenyloxy, naphthyloxy,heterocyclyloxy, nitro, amino, mono- or di-(C₁₋₃ alkyl)amino,phenylamino, naphthylamino, heterocyclylamino, NH₂C(O), a mono- ordi-(C₁₋₃ alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅alkyl, mono- or di-(C₁₋₃ alkyl)amino —C₁₋₅ alkyl, amino-S(O)₂, di-(C₁₋₃alkyl)amino —S(O)₂, R⁷—C₁₋₅ alkyl, R⁸—C₁₋₅alkoxy, R⁹—C(O)—C₁₋₅ alkyl,R¹⁰—C₁₋₅alkyl(R¹¹)N, or carboxy-mono- or di-(C₁₋₅ alkyl)amino. Inothers, R³ is phenyl, pyridazinyl or pyridyl, each of which isoptionally partially or fully halogenated and optionally substitutedwith C₁₋₆ branched or unbranched alkyl which is optionally partially orfully halogenated, hydroxy, oxo, cyano, C₁₋₃ alkoxy optionally partiallyor fully halogenated, nitro, amino, or mono- or di-(C₁₋₃ alkyl)amino;C₁₋₆ alkyl or C₁₋₆ alkoxy, each optionally partially or fullyhalogenated or optionally substituted with R¹⁷, amino, OR¹⁸, C₁₋₅ mono-or di-alkylamino optionally substituted with R¹⁹; R²⁰C(O)N(R²¹)—, R²²O—,R²³R²⁴NC(O)—, R²⁶(CH₂)_(m)C(O)N(R²¹)— or R²⁶C(O)(CH₂)_(m)N(R²¹)—. Forexample, R³ is phenyl or tolyl.

In certain embodiments of compounds of Formula II, X′ is NR′, CR′═N orCR′═CR′.

In accordance with yet another aspect of the invention, there areprovided the following compounds, including representative examples ofthe compounds of Formula IA, IB, IC and II:

1H-Indazole-3-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

3-tert-Butyl-5-phenyl-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-hydroxy-3-morpholin-4-ylmethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-hydroxy-3-methyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-3-methyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-chloro-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-3-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[7-chloro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylaminol-benzamide;

N-[5-tert-Butyl-2-methoxy-3-(piperidine-1-carbonyl)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-2-hydroxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzoicacid;

N-(2-Benzenesulfonyl-5-tert-butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1-Bicyclo[2.2.1]hept-2-yl-5-phenylamino-3-p-tolyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;

3-p-Tolyl-5-p-tolylamino-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;

1-Bicyclo[2.2.1]hept-2-yl-3-p-tolyl-5-p-tolylamino-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2,2-difluoro-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N′-naphthalen-1-yl-oxalamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[(Z)-methoxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]acetamide;

2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylamino)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-ethanol;

1-(3-tert-Butyl-phenyl)-4-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-[1,2,4]triazolidine-3,5-dione;

4-(3-tert-Butyl-phenyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-[1,2,4]triazolidine-3,5-dione;

(E)-3-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acrylicacid methyl ester;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,5-dioxo-2,5-dihydro-pyrrol-1-yl}-phenyl)-methanesulfonamide;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,5-dioxo-pyrrolidin-1-yl}-phenyl)-methanesulfonamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-oxo-2-[4-(2-piperidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-acetamide;

3-tert-Butyl-1-p-tolyl-5-(3-trifluoromethyl-phenyl)-1,6-dihydro-imidazo[4,5-c]pyrazole;

1-(2-Morpholin-4-yl-ethyl)-1H-indazole-3-carboxylic acid(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide;

N-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-2-(2,4,6-trimethyl-phenyl)-acetamide;

1-Phenyl-cyclopropanecarboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

N-[5-tert-Butyl-2-(2,5-difluoro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-(4-methoxy-naphthalen-1-yl)-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3-chloro-benzoyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N[5-tert-Butyl-2-(3-methanesulfonyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

4-[(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)-methyl]-piperidine-1-carboxylicacid tert-butyl ester;

N-[3-(Benzenesulfonyl-carbamoylmethyl-amino)-5-tert-butyl-2-methoxy-phenyl]-2-naphthalen-1-yl-2-oxo-acetamide;

N-(3-tert-Butyl-isoxazol-5-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-ethanesulfonylamino-2-methoxy-phenyl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-succinamicacid methyl ester;

2-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-2-(3-chloro-phenyl)-2H-pyrazole-3-carboxylic acid[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-amide;

2-(3-Bromo-4-methoxy-phenyl)-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[3-fluoro-4-(2-morpholin-4-yl-ethoxy)-phenyl]-acetamide;

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-(2,2-dimethyl-propyl)-amine;

2-(4-Benzyloxy-phenyl)-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-(4-sulfamoyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-2-methoxy-3-(1-naphthalen-1-yl-3,5-dioxo-[1,2,4]triazolidin-4-yl)-benzamide;

2-(4-Bromo-naphthalen-1-yl)-N-(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-2-oxo-acetamide;

5-tert-Butyl-2-hydroxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2-(4-methoxy-naphthalen-1-yl)-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-methylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-[2-(1-oxo-1λ⁴-thiomorpholin-4-yl)-ethoxy]-naphthalen-1-yl}-acetamide;

5-tert-Butyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-thiophene-2-carboxylicacid methyl ester;

N-[5-tert-Butyl-2-(3-methanesulfonyl-phenyl)-2H-pyrazol-3-yl]-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-((2R,6R)-2,6-dimethyl-morpholin-4-yl)-ethoxy]-naphthalen-1-yl}-2-oxo-acetamide;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[7-chloro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-N-cyclopropyl-2-methoxy-3-[2-(4-methoxy-naphthalen-1-yl)-2-oxo-acetylamino]-benzamide;

4-tert-Butyl-N-[4-(2-piperidin-1-yl-ethoxy)-naphthalen-1-yl]-benzamide;

N-(2-Acetyl-5-tert-butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-N-cyclopropyl-3-{2-hydrazono-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-2-methoxy-benzamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-hydroxy-2-(4-methoxy-naphthalen-1-yl)-propionamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-phenyl-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-hydrazono-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

2,3-Dihydro-indole-1-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

N-(3,4-Dimethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-cyclohexyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(3,5-difluoro-phenyl)-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-oxo-2-(4-pyridin-3-yl-naphthalen-1-yl)-acetamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-diethylamino-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-[2-(3-oxo-[1,4]diazepan-1-yl)-ethyl]-naphthalen-1-yl]-acetamide;

5-tert-Butyl-N-ethyl-2-methoxy-3-[2-(4-methoxy-naphthalen-1-yl)-2-oxo-acetylamino]-benzamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-oxo-2-{4-[6-(tetrahydro-pyran-4-ylamino)-pyridin-3-yl]-naphthalen-1-yl]-acetamide;

5-tert-Butyl-3-ethanesulfonylamino-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-benzamide;

2-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-oxo-N-m-tolyl-acetamide;

N-(2,5-Dimethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

Pyrrolidine-1-carboxylic acid(5-tert-butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylaminol-phenyl)-amide;

2-(4-Bromo-phenyl)-N-(5-tert-butyl-2-methoxy-phenyl)-acetamide;

N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-oxo-2-{4-[2-((S)-1-phenyl-ethylamino)-pyrimidin-4-ylamino]-naphthalen-1-yl}-acetamide;

5-tert-Butyl-3-[1-(2,3-dimethyl-phenyl)-3,5-dioxo-[1,2,4]triazolidin-4-yl]-2-methoxy-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-naphthalen-2-yl-acetamide;

5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-methoxy-2-(4-methoxy-naphthalen-1-yl)-propionamide;

5-tert-Butyl-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylmethyl]-3-nitro-benzamide;

N-(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2,5-difluoro-phenyl)-acetamide;

N-(3,5-Di-tert-butyl-2-methoxy-phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N′-[1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-ylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxamide;

N-[2-(4-Amino-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

5-tert-Butyl-3-{2-[(Z)-methoxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-thiophene-2-carboxylicacid amide;

Ethanesulfonic acid(5-tert-butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,5-dioxo-2,5-dihydro-pyrrol-1-yl}-phenyl)-amide;

5-tert-Butyl-N-cyclopropylmethyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

5-Fluoro-1H-indazole-3-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

N-[5-tert-Butyl-2-methoxy-3-(2-methoxy-acetylamino)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

7-Bicyclo[2.2.1]hept-2-yl-9-p-tolyl-2-p-tolylamino-7,9-dihydro-purin-8-one;

N-(5-tert-Butyl-2-isopropoxy-3-methanesulfonylamino-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3,4-dimethyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

3-tert-Butyl-1-(3,4-dichloro-phenyl)-5-phenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-[4-(2-thiomorpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

5-Nitro-1H-pyrazole-3-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

1-(2-Amino-4-tert-butyl-6-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-pyridinium;

N-(5-tert-Butyl-2-isopropoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,5-bis-trifluoromethyl-benzamide;

2-(tert-Butyl-dimethyl-silanyloxy)-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(4-methoxy-phenyl)-acetamide;

N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

5-tert-Butyl-2-methoxy-3-[2-(4-methoxy-naphthalen-1-yl)-2-oxo-acetylamino]-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-phenyl-acetamide;

5-tert-Butyl-2-methoxy-N-(2-methoxy-ethyl)-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

(E)-3-(5-tert-Butyl-3-ethanesulfonylamino-2-methoxy-phenylcarbamoyl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acrylicacid methyl ester;

1-Isopropyl-3-phenyl-5-phenylamino-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

2-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)-2-[(Z)-hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

2-(5-tert-Butyl-2-methoxy-phenyl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2,4-dimethoxy-phenyl)-acetamide;

(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-carbamicacid methyl ester;

3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1-carboxylicacid adamantan-1-ylamide;

3-tert-Butyl-5-phenyl-1-(4-trifluoromethyl-phenyl)-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,4,5-trioxo-imidazolidin-1-yl}-phenyl)-methanesulfonamide;

3-tert-Butyl-1-(3-chloro-phenyl)-5-phenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

5-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2-carboxylicacid amide;

2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-(2,6-dimethyl-morpholin-4-yl)-ethyl]-naphthalen-1-yl}-2-oxo-acetamide;

N-(5-tert-Butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-methoxy-3-(propane-1-sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1-carboxylicacid tert-butylamide;

1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-(2,3-dichlorophenyl)-3′-(carbamicacid ethyl ester)-urea ;2-(3,5-Difluoro-phenyl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1-carboxylicacid amide;

N-Allyl-5-tert-butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino-benzamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[(Z)-methoxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

3-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-pyrrole-2,5-dione;

2-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[(Z)-hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

3-tert-Butyl-5-o-tolyl-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[(E)-hydroxyimino]-2-phenyl-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-hydroxy-2-phenyl-acetamide;

N-(3-Acetylamino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1H-Indazole-3-carboxylic acid(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide;

5-tert-Butyl-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-3-nitro-benzamide;

5-tert-Butyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-acetylamino}-thiophene-2-carboxylicacid amide;

N-[3-(4-Acetyl-piperazine-1-carbonyl)-5-tert-butyl-2-methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-N-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-4-methyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

2-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-N-(2-phenyl-cyclopropyl)-acetamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2,3-dimethoxy-phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2-chloro-phenyl)-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-(4-methyl-piperazin-1-yl)-ethyl]-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-(1H-indol-3-yl)-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(4-tert-Butyl-6-trifluoromethyl-pyrimidin-2-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-o-tolyl-acetamide;

5-tert-Butyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-thiophene-2-carboxylicacid methylamide;

N-[5-tert-Butyl-2-(3,5-dichloro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-((2R,6S)-2,6-dimethyl-morpholin-4-yl)-ethoxy]-naphthalen-1-yl}-2-oxo-acetamide;

3-tert-Butyl-1,5-diphenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-imidazol-1-yl-ethyl)-naphthalen-1-yl]-2-oxo-acetamide;

3-tert-Butyl-5-(3-chloro-phenyl)-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-methoxy-3-phenylmethanesulfonylamino-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-[4-(2-pyridin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-imidazolidine-2,4,5-trione;

N-[5-tert-Butyl-2-(3-chloro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-Methoxy-1H-indazole-3-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

N-[5-tert-Butyl-2-(6-chloro-pyridazin-3-yl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2-methoxy-phenyl)-acetamide;

5-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

[(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-methanesulfonyl-amino]aceticacid ethyl ester;

N-(5-tert-Butyl-4-methyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-(2,5-dichloro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-[1,4]oxazepan-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1-(5-tert-Butyl-2-methoxy-3-benzamide)-3-(4-methoxy-phenyl)-3′-(carbamicacid ethyl ester)-urea;

N-[5-tert-Butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]-2-(4-methoxy-naphthalen-1-yl)-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-4-chloro-benzamide;

N-(2-Bromo-5-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

3-Isopropyl-5-phenyl-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

3,5-Di-tert-butyl-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

5-tert-Butyl-N-cyclopentyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

2-[5-tert-Butyl-2-(3-fluoro-4-methyl-phenyl)-2H-pyrazol-3-yl]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(4-methoxy-phenyl)-2-oxo-acetamide;

1,3-Di-tert-butyl-5-phenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

4-(4-Bromo-naphthalen-1-yl)-1-(3-tert-butyl-phenyl)-[1,2,4]triazolidine-3,5-dione;

N-[5-tert-Butyl-2-(morpholine-4-carbonyl)-thiophen-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

3-tert-Butyl-5-(3-methoxy-phenyl)-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide;

1-tert-Butyl-5-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylamino]-3-p-tolyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;

2-[5-tert-Butyl-2-(3-fluoro-phenyl)-2H-pyrazol-3-yl]-2-[(Z)-hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

5-tert-Butyl-2-p-tolyl-2H-pyrazole-3-carboxylic acid[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylmethyl]-amide;

2-[5-tert-Butyl-2-(3-fluoro-phenyl)-2H-pyrazol-3-yl]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-N-cyclopropylmethyl-2-methoxy-3-[2-(4-methoxy-naphthalen-1-yl)-2-oxo-acetylamino]-benzamide;

N-[5-tert-Butyl-3-(3,3-diethyl-ureido)-2-methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(4-fluoro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-oxo-2-[4-(2-piperazin-1-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-carbamicacid isopropyl ester;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-dimethylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

4-(3-tert-Butyl-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazol-5-yl)-2-methoxy-phenol;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(3,4-dichloro-phenyl)-acetamide;

N-[3-(3-Allyl-ureido)-5-tert-butyl-2-methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-N,N-diethyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-[1,4]oxazepan-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(3-tert-Butyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-N-ethyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylaminol-benzamide;

N-[5-tert-Butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(4-ureido-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[4-(2-dimethylamino-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-oxo-2-[4-(2-piperidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-(3-fluoro-4-methyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

Indazole-1-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

N-[3,5-Bis-(1,1-dimethyl-propyl)-2-methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1-Benzyl-3-tert-butyl-5-phenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

2-(5-tert-Butyl-2-methoxy-3-nitro-phenyl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

4-{2-[4-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylaminooxalyl)-naphthalen-1-yloxyl-ethyl}-piperazine-1-carboxylicacid ethyl ester;

2-Hydroxy-N-(5-isopropyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

1-Bicyclo[2.2.1]hept-2-yl-3-phenyl-5-phenylamino-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;

N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-3-(2-dimethylamino-acetylamino)-2-methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-3-{6-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-3,5-dioxo-2,5-dihydro-3H-[1,2,4]triazin-4-yl}-phenyl)-methanesulfonamide;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

(R)-N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2-phenyl-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-dimethylamino-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[2-(3-Amino-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

2-[5-tert-Butyl-2-(3-chloro-phenyl)-2H-pyrazol-3-yl]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1,5-Diphenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-[1,3,4]thiadiazol-2-yl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-3-{2-hydroxy-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ethylamino}-2-methoxy-phenyl)-methanesulfonamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-4-chloro-benzamide;

N-(5-tert-Butyl-2-ethoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-carbamicacid 2-methoxy-ethyl ester;

(R)-N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-methoxy-2-phenyl-acetamide;

2-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-hydroxy-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

2-Amino-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-naphthalen-1-yl-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acrylamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-imidazol-1-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(4-Bromo-3-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

4-(4-Benzyloxy-phenyl)-1-(3-tert-butyl-phenyl)-[1,2,4]triazolidine-3,5-dione;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[8-chloro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-chloro-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2-carboxylicacid dimethylamide;

1-(5-tert-Butyl-isoxazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione;

N-(4-Chloro-3-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1-Benzoyl-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

N′-[1-(5-tert-Butyl-3-ethylcarbamoyl-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]-hydrazinecarboxylicacid ethyl ester;

3-tert-Butyl-5-(3-fluoro-phenyl)-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

2-[3-Bromo-4-(2-morpholin-4-yl-ethoxy)-phenyl]-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-acetamide;

2-(2-Chloro-5-trifluoromethyl-phenyl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3-chloro-benzenesulfonyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid p-tolyl ester;

N-(5-tert-Butyl-2-diethylamino-3-methanesulfonylamino-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-methoxy-3-(propane-1-sulfonylamino)-phenyl]-2-(4-methoxy-naphthalen-1-yl)-2-oxo-acetamide;

Propane-1-sulfonic acid(5-tert-butyl-2-methoxy-3-{4-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-3,5-dioxo-[1,2,4]triazolidin-1-yl}-phenyl)-amide;

3-Amino-5-tert-butyl-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylmethyl]-benzamide;

2-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-N-(3-trifluoromethyl-phenyl)-acetamide;

4-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-6-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1yl]-2H-[1,2,4]triazine-3,5-dione;

N-[5-tert-Butyl-2-(4-trifluoromethyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-methoxy-3-(propane-1-sulfonulamino)-phenyl]-2-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-phenyl-acetamide;

N-[5-tert-Butyl-2-methoxy-3-(propane-1-sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-{4-[2-(2,6-dimethyl-morpholin-4yl)-ethoxy]-naphthalen-1-yl}-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(4-methoxy-naphthalen-1-yl)-acetamide;

3-tert-Butyl-1-cyclohexyl-5-phenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

3-tert-Butyl-5-(4-fluoro-phenyl)-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-methoxy-3-{4-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-3,5-dioxo-[1,2,4]triazolidin-1-yl}-phenyl)-methanesulfonamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-2-(3-oxo-piperazin-1-yl)-ethyl]-naphthalen-1-yl}-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-[4-(3-pyridin-4-yl-propoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-(4-methanesulfonyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)-2,5-dihydro-pyrrole-1-carboxylicacid tert-butyl ester;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-imidazol-1-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3,5-dimethyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-5-tert-Butyl-3-[carbamoylmethyl-(propane-1-sulfonyl)-amino]-2-methoxy-phenyl}-2-naphthalen-1-yl-2-oxo-acetamide;

N′-[1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-ylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]-hydrazinecarboxylicacid ethyl ester;

5-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-benzamide;

N-[5-tert-Butyl-2-(3-nitro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[3-chloro-4-(2-morpholin-4-yl-ethoxy)-phenyl]-2-oxo-acetamide;

N-(3-Benzenesulfonylamino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1-carboxylicacid cyclohexylamide;

N-[5-tert-Butyl-2-methoxy-3-(2,2,2-trifluoro-ethanesulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N′-[1-(5-tert-Butyl-3-carbamoyl-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxylicacid ethyl ester;

5-tert-Butyl-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-3-(propane-1-sulfonylamino)-benzamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-hydroxy-2-(4-methoxy-naphthalen-1-yl)-acetamide;

(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-carbamicacid 2-dimethylamino-ethyl ester;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[7-fluoro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

3-tert-Butyl-1-(4-chloro-phenyl)-5-phenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-(4-methoxy-naphthalen-1-yl)-2-oxo-acetamide;

2-[5-tert-Butyl-2-(3,4-dimethyl-phenyl)-2H-pyrazol-3-yl]-2-[(Z)-hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-(4-methoxy-naphthalen-1-yl)-2-oxo-acetamide;

N-[5-(1,1-Dimethyl-propyl)-2-p-tolyl-2H-pyrazol-3-yl]-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(2-Chloro-5-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[2,3-dichloro-4-(2-morpholin-4-yl-ethoxy)-phenyl]-2-oxo-acetamide;

N-(3-Methanesulfonylamino-2-methoxy-5-methyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

4-{2-[4-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylaminooxalyl)-naphthalen-1-yl]-ethyl}-piperazine-1-carboxylicacid ethyl ester;

(1-Benzyl-1H-benzoimidazol-2-yl)-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amine;

N-(3,5-Di-tert-butyl-2-hydroxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-naphthalen-1-yl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

4-{2-[4-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylaminooxalyl)-naphthalen-1-yloxy]-ethyl}-piperazine-1-carboxylicacid ethyl ester;

5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-(1-methyl-1H-indol-3-yl)-2-oxo-acetamide;

4-Phenyl-piperidine-4-carboxylic acid(5-tert-butyl-2-methoxy-phenyl)-amide;

5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-benzamide;

N-[2-(4-Acetyl-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2,3-difluoro-phenyl)-acetamide;

N-[5-tert-Butyl-3-(carbamoylmethyl-methanesulfonyl-amino)-2-methoxy-phenyl]-2-naphthalen-1-yl-2-oxo-acetamide;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[2-methyl-4-(2-morpholin-4-yl-ethoxy)-phenyl]-2-oxo-acetamide;

N-[2-(4-Amino-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-carbamicacid phenyl ester;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-isobutoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(4-tert-Butyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3-methyl-benzoyl)-2H-pyrazol-3-yl-2-[4-(2-motpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylaminol-thiophene-2-carboxylicacid amide;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-chloro-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione;

(S)-N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2-phenyl-acetamide;

N-[5-tert-Butyl-2-(2,3-dimethyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(4-nitro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-[(Z)-Hydroxyimino]-N-(3-methanesulfonylamino-2-methoxy-5-methyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-(morpholine-4-carbonyl)-thiophen-3-yl]-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-phenyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N′-[1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-ylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxylicacid ethyl ester;

N′-[1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-ylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]-hydrazinecarboxamide;

N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-N-pyridin-2-yl-benzamide;

N-[5-tert-Butyl-3-(3,3-dimethyl-ureido)-2-methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-3-{2-[7-chloro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-2-methoxy-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-m-tolyl-acetamide;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-pyrrolidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2-phenyl-propionamide;

2-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-N-quinolin-3-yl-acetamide;

1-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione;

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-(3-trifluoromethyl-benzyl)-amine;

N-[5-tert-Butyl-2-methoxy-3-(morpholine-4-carbonyl)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-3-(3-isopropyl-ureido)-2-methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-methoxy-2-(4-methoxy-naphthalen-1-yl)-acetamide;

N-(3-Amino-5-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide;

3-Methyl-1,5-diphenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-isoxazol-3-yl)-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-2-(2-phenyl-cyclopropyl)-acetamide;

2-{4-[2-(4-Acetyl-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}-N-(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-oxo-acetamide;

2-(1H-Indol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3-fluoro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3,4-dichloro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(2,5-dimethyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-2-oxo-acetamide;

1H-Indazole-3-carboxylic acid(5-tert-butyl-2-pyridin-2-yl-2H-pyrazol-3-yl)-amide;

N-(4-Chloro-3-trifluoromethyl-phenyl)-2-(4-methoxy-naphthalen-1-yl)-2-oxo-acetamide;

N-[5-(1,1-Dimethyl-butyl)-2-p-tolyl-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1H-Indazole-3-carboxylic acid[5-tert-butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]-amide;

1H-Indazole-3-carboxylic acid[5-tert-butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-amide;

N′-[1-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N′-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-oxalamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-methylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[(Z)-methoxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

5-tert-Butyl-N-cyclopropyl-3-[2-[(E)-hydroxyimino]-2-(4-methoxy-naphthalen-1-yl)-acetylamino]-2-methoxy-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-(2,6-dimethyl-morpholin-4-yl)-ethoxyl-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[8-fluoro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(3-fluoro-phenyl)-acetamide;5-tert-Butyl-N-furan-2-ylmethyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

N-[5-tert-Butyl-2-(3-trifluoromethyl-benzoyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-methoxy-3-(propane-1-sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

1-(5-tert-Butyl-isoxazol-3-yl)-3-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione;

1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-3′-(carbamicacid ethyl ester)-urea;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-oxo-2-{4-[2-(3-oxo-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}-acetamide;

2-{4-[2-(4-Acetyl-piperazin-1-yl)-ethyl]-naphthalen-1-yl}-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-acetamide;

N-(5-tert-Butyl-2-phenylacetyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-[2-(3-oxo-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}-acetamide;

2-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[(Z)-hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-(3-ureido-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[(Z)-methoxyimino]-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-methoxy-3-(3-oxo-piperazine-1-carbonyl)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1-carboxylicacid propylamide;

5-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2-morpholin-4yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}-2-oxo-acetamide;

N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1yl]-2-oxo-acetamide;

5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-N-propyl-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2-(4-methoxy-phenyl)-acetamide;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(3-phenoxy-phenyl)-acetamide;

N-(5-Isopropyl-2-methyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-oxo-acetamide;

7-Isopropyl-9-phenyl-2-phenylamino-7,9-dihydro-purin-8-one;

(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-carbamicacid pyridin-3-ylmethyl ester;

N-(5-tert-Butyl-3methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-ethylamino-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(3,5-Di-tert-butyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-Amino-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-naphthalen-2-yl-acetamide;

N-[5-tert-Butyl-2-(3-fluoro-4-methyl-phenyl)-2H-pyrazol-3-yl]-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

2-[5-tert-Butyl-2-(3,4-difluoro-phenyl)-2H-pyrazol-3-yl]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2-methylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(2,3-dichloro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[3,5-Bis-(1,1-dimethyl-propyl)-2-hydroxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

4-{2-[4-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylaminooxalyl)-naphthalen-1-yloxy]-ethyl}-piperazine-1-carboxylicacid tert-butyl ester;

3-tert-Butyl-1-naphthalen-2-yl-5-phenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

2-Biphenyl-4-yl-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-acetamide;

5-tert-Butyl-N-isopropyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylaminol-benzamide;

N-(5-tert-Butyl-3-diethylaminomethyl-2-hydroxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

6-Hydroxy-nicotinic acid3-[5-tert-butyl-2-methoxy-3-(propane-1-sulfonylamino)-phenylcarbamoyl]-1H-indazol-5-yl]ester;

N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(4-morpholin-4-yl-pyrimidin-2-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1,3,5-Triphenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-cyclohexyl-acetamide;

2-[5-tert-Butyl-2-(2-chloro-phenyl)-2H-pyrazol-3-yl]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

7-Cyclohexylmethyl-9-phenyl-2-phenylamino-7,9-dihydro-purin-8-one;

5-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylaminol-thiophene-2-carboxylicacid methylamide;

5-tert-Butyl-N-cyclopropylmethyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-benzamide;

N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N′-[1-(5-tert-Butyl-3-carbamoyl-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]-hydrazinecarboxylicacid ethyl ester;

4-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-1-(2,3-dimethyl-phenyl)-[1,2,4]triazolidine-3,5-dione;

N-(4-Fluoro-3-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1-Benzyl-3-phenyl-5-phenylamino-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-naphthalen-2-yl-acetamide;

2-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-ylcarbamoyl]-pyrrole-1-carboxylicacid tert-butyl ester;

N-(2,5-Di-tert-butyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-N-((1S,2R)-2-phenyl-cyclopropyl)-acetamide;

2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

N-(2-Methoxy-5-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[2-(4-Bromo-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione;

5-tert-Butyl-2-methoxy-N-methyl-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylaminol-benzamide;

N-(5-tert-Butyl-2-methoxy-3-piperidin-1-ylmethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-naphthalen-1-yl-2-oxo-acetamide;

N-(2,5-Di-tert-butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid 4-methoxy-phenylester;

N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-naphthalen-1-yl-2-oxo-acetamide;

5-tert-Butyl-N-ethyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-2-methoxy-benzamide;

4-{2-[4-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylaminooxalyl)-naphthalen-1-yl]-ethyl}-piperazine-1-carboxylicacid tert-butyl ester;

5-tert-Butyl-N-ethyl-2-hydroxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-naphthalen-1-yl-acetamide;

N-(5-tert-Butyl-2-ethoxy-3-methanesulfonylamino-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N′-[1-(5-tert-Butyl-3-ethylcarbamoyl-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxamide;

2-{4-[2-(4-Acetyl-piperazin-1-yl)-ethoxy]-naphthalen-1-yl]-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-acetamide;

5-tert-Butyl-N-ethyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylaminol-benzamide;

5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamine}-benzoicacid;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2-carboxylicacid amide;

2-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-N-m-tolyl-acetamide;

5-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2-carboxylicacid methyl ester;

N′-[1-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]-hydrazinecarboxamide;

N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-Isopropyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(2-Benzoyl-5-tert-butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

6-Bromo-1H-indazole-3-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

5-tert-Butyl-N-ethyl-3-{2-hydrazono-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-2-methoxy-benzamide;

N-(5-tert-Butyl-3-ethanesulfonylamino-2-methoxy-phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-thiophen-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(4-chloro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N′-[1-(5-tert-Butyl-3-carbamoyl-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxamide;

N-[5-tert-Butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-3-{2-[7-chloro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-N-cyclopropyl-2-methoxy-benzamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}-2-oxo-acetamide;

1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-imidazolidin-2-one;

N-(5-tert-Butyl-thiophen-3-yl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

5-tert-Butyl-N-cyclopropyl-3-[2-[(Z)-hydroxyimino]-2-(4-methoxy-naphthalen-1-yl)-acetylamino]-2-methoxy-benzamide;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(4-morpholin-4-yl-pyrimidin-2-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-[2-Methoxy-5-(1-methyl-1-phenyl-ethyl)-phenyl]-2-[4-(2-motpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-[5-tert-Butyl-2-(3,4-dimethyl-phenyl)-2H-pyrazol-3-yl]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2-carboxylicacid amide;

5-tert-Butyl-N-isobutyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylaminol-benzamide;

2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[(Z)-hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

3-tert-Butyl-1-(2,3-dichloro-phenyl)-5-phenyl-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(3,5-Di-tert-butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-thiophene-2-carboxylicacid dimethylamide;

N-(5-tert-Butyl-2-methoxy-3-methyl-phenyl)-2-[(Z)-hydroxyimino]-2-[4-[2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N′-[1-(5-tert-Butyl-3-cyclopropylcarbamoyl-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxylicacid ethyl ester;

N-Indan-5-yl-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3-chloro-4-fluoro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-3-(imidazole-1-carbonyl)-2-methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(2,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(2,4-difluoro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

1H-Indazole-3-carboxylic acid (5-tert-butyl-2-methoxy-phenyl)-amide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-[2-(5-oxo-[1,4]diazepan-1-yl)-ethoxy]-naphthalen-1-yl}-acetamide;

3-tert-Butyl-1-p-tolyl-5-(4-trifluoromethyl-phenyl)-1,6-dihydro-imidazo[4,5-c]pyrazole;

N-(5-tert-Butyl-3-ethanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1-carboxylicacid isopropylamide;

N-(5-tert-Butyl-[1,3,4]thiadiazol-2-yl)-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-acetamide;

N-[2-(3-Amino-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1-carboxylicacid phenylamide;

2-(5-tert-Butyl-2-methyl-furan-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-o-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-(3-methoxy-phenyl)-acetamide;

5-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2-carboxylicacid amide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-[5-tert-Butyl-2-(2,4-dichloro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(3-hydroxy-propoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(3-tert-Butyl-isoxazol-5-yl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

1H-Indole-3-carboxylic acid (5-tert-butyl-2-methoxy-phenyl)-amide;

N-[5-tert-Butyl-2-methoxy-3-(propane-1-sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

7-Bicyclo[2.2.1]hept-2-yl-9-phenyl-2-phenylamino-7,9-dihydro-purin-8-one;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2,4-dichloro-phenyl)-acetamide;

5-tert-Butyl-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-benzamide;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[2,3-dimethyl-4-(2-morpholin-4-yl-ethoxy)-phenyl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-(3-fluoro-phenyl)-acetamide;

1-(5-tert-Butyl-2-methoxy-3-benzamide)-3-(2,3-dimethylphenyl)-3′-(carbamicacid ethyl ester)-urea;

2-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-oxo-N-(3-trifluoromethyl-phenyl)-acetamide;

7-Benzyl-9-phenyl-2-phenylamino-7,9-dihydro-purin-8-one;

2,5-Dihydro-1H-pyrrole-2-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-oxo-2-{4-[2-(5-oxo-[1,4]diazepan-1-yl)-ethoxy]-naphthalen-1-yl}-acetamide;

N-[5-tert-Butyl-2-(3-cyano-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-3-phenylacetylamino-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(2-Chloro-5-trifluoromethyl-phenyl)-N-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-piperidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione;

2-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)-2-hydroxy-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

5-tert-Butyl-3-{2-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2-carboxylicacid amide;

N′-[1-(5-tert-Butyl-3-ethylcarbamoyl-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxylicacid ethyl ester;

N-(3-Methanesulfonylamino-5-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-hydroxy-3-piperidin-1-ylmethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(1-Methyl-1H-indol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-methoxy-phenyl)-2-oxo-2-{4-[2-((S)-1-phenyl-ethylamino)-pyrimidin-4-ylamino]-naphthalen-1-yl}-acetamide;

N-[5-tert-Butyl-2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N′-[1-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxylicacid ethyl ester;

N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide;

N-(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-isobutyramide;

N-[5-tert-Butyl-2-(4-methyl-benzoyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(2-chloro-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

N-[5-tert-Butyl-2-(3-chloro-4-methyl-phenyl)-2H-pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;

2-(4-Bromo-phenyl)-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-acetamide;

2-(5-tert-Butyl-2-methyl-furan-3-yl)-N-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide;

4-(4-{4-[2-(5-tert-Butyl-2-methyl-furan-3-yl)-2-oxo-acetylamino]-naphthalen-1-ylamino}-phenoxy)-pyridine-2-carboxylicacid methylamide;

N-[5-tert-Butyl-2-methoxy-3-(propane-1-sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide;

5-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-oxo-2-{4-[6-(tetrahydro-pyran-4-ylamino)-pyridin-3-yl]-naphthalen-1-yl}-acetamide;

3-[2-(4-Bromo-naphthalen-1-yl)-2-oxo-acetylamino]-5-tert-butyl-N-cyclopropyl-2-methoxy-benzamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(6-morpholin-4-yl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide;

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-oxo-2-(4-pyridin-3-yl-naphthalen-1-yl)-acetamide;

N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-oxo-2-(4-pyridin-3-yl-naphthalen-1-yl)-acetamide;

2-(4-Chloro-3-trifluoromethyl-phenyl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide;or

4-{4-[2-(4-Chloro-3-trifluoromethyl-phenyl)-2-oxo-acetylamino]-phenoxy}-pyridine-2-carboxylicacid methylamide.

In yet another aspect, the invention provides pharmaceuticalcompositions comprising a compound as described herein (e.g., a compoundof Formula IA, IB, IC or II) and a pharmaceutically acceptable carrier.

In accordance with a further aspect of the invention, there are providedmethods for preparing cytokine inhibitors of the present invention. Forexample, methods for preparing compounds of Formula IA comprise reactingG-NH₂ with Q-L-Ar—X—OH in the presence of a coupling agent and a base,or reacting G-NH₂ with Q-L-Ar—X—X″ in the presence of a base, to yield acompound of Formula IA, wherein the variables G, Q, L are defined as inany of the compounds described herein, X is C(O) or C(S), and X″ is anactivating moiety. Compounds of IB may be similarly prepared usingG-X—X″ and Q-L-Ar—NH₂.

In yet another aspect of the invention, there are provided methods forpreparing compounds of Formula II where X′ is NH, comprising heatingG(NO)—NH—CH₂—Ar-L-Q with a suitable organoamine to yield a compound ofFormula II, wherein G, Ar, L, and Q are as defined as in Formula II.

In another aspect of the invention, there are provided compounds ofFormula III, suitable for preparing compounds of the invention such ascompounds of Formula IB.

In compounds of Formula III, the pyrazole moiety is substituted at the1-position, 3-position, or at both by one or more R¹, R² or R³;

X′″ is OR^(x) or an activating moiety;

R^(x) is H, substituted or unsubstituted C₁₋₄ alkyl, or substituted orunsubstituted aralkyl;

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—OR, —SiR₃, —NR′R′, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R² is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂; and

each R³ is independently H, substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈ alkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈ alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);and

R, R′, R″, R²⁰, R²¹, R²³, R²⁴, R²⁶, and m are as defined in any of thecompounds described herein.

In another aspect, the invention provides methods of preventing ortreating diseases mediated by cytokines which comprise administering toa subject in need of such treatment a therapeutically effective amountof a compound as described herein, e.g., a compound according to FormulaIA, IB, IC and/or II. Such cytokine-mediated diseases include rheumatoidarthritis, osteoarthritis, Crohn's disease, ulcerative colitis,psoriatic arthritis, traumatic arthritis, rubella arthritis,inflammatory bowel disease, multiple sclerosis, psoriasis, graft versushost disease, systemic lupus erythematosus, toxic shock syndrome,irritable bowel syndrome, muscle degeneration, allograft rejections,pancreatitis, insulinitis, glomerulonephritis, diabetic nephropathy,renal fibrosis, chronic renal failure, gout, leprosy, acute synovitis,Reiter's syndrome, gouty arthritis. Behcet's disease, spondylitis,endometriosis, non-articular inflammatory conditions, such asintervertbral disk syndrome conditions, bursitis, tendonitis,tenosynovitis or fibromyalgic syndrome; and acute or chronic pain,including but not limited to neurological pain, neuropathics,polyneuropathies, diabetes-related polyneuropathies, trauma, migraine,tension and cluster headache, Horton's disease, varicose ulcers,neuralgias, musculo-skeletal pain, oseo-traumatic pain, fractures,algodystrophy, spondylarthritis, fibermyalgia, phantom limb pain, backpain, vertebral pain, post-surgery pain, herniated invertebraldisc-induced sciatica, cancer-related pain, vascular pain, visceralpain, childbirth, or HIV-related pain. Other cytokine mediated diseasesare stroke, chronic heart failure, endotoxemia, reperfusion injury,ischemia reperfusion, myocardial ischemia, restenosis, thrombosis,angiogenesis, Coronary Heart Disease, Coronary Artery Disease, acutecoronary syndrome, Takayasu arteritis, cardiac failure such as heartfailure, cardiomyopathy, myocarditis, vasculitis, vascular restenosis,valvular disease or coronary artery bypass; hypercholesteremia, diseaseor conditions related to blood coagulation or fibrinolysis, such as forexample, acute venous thrombosis, pulmonary embolism, thrombosis duringpregnancy, hemorrhagic skin necrosis, acute or chronic disseminatedintravascular coagulation (DIC), clot formation from surgery, long bedrest or long periods of immobilization, venous thrombosis, fulminantmeningococcemia, acute thrombotic strokes, acute coronary occlusion,acute peripheral arterial occlusion, massive pulmonary embolism,axillary vein thrombosis, massive iliofemoral vein thrombosis, occludedarterial or venous cannulae, cardiomyopathy, venocclusive disease of theliver, hypotension, decreased cardiac output, decreased vascularresistant, pulmonary hypertension, diminishing lung compliance,leukopenia or thrombocytopenia; or atherosclerosis. Yet others areallergic conjunctivitis, uveitis, glaucoma, optic neuritis, retinalischemia, diabetic retinopathy, laser induced optic damage, or surgeryor trauma-induced proliferative vitreoretinopathy. Cytokine mediateddiseases further include allergic rhinitis, asthma, adult respiratorydistress syndrome, chronic pulmonary inflammation, chronic obstructivepulmonary disease, emphysema, bronchitis, mucus hypersecretion,silicosis, SARS infection and respiratory tract inflammation. Alsoincluded are psoriasis, eczema, atopic dermatitis, contact dermatitis,or acne. Yet other cytokine mediated diseases are Guillain-Barresyndrome, Parkinson's disease, Huntington's disease, Alzheimer'sdisease, amyotrophic lateral sclerosis, multiple sclerosis and otherdemyelinating diseases, viral and bacterial meningitis, CNS trauma,spinal cord injury, seizures, convulsions, olivopontocerebellar atrophy,AIDS dementia complex, MERRF and MELAS syndromes, Leber's disease,Wemicke's encephalophathy, Rett syndrome, homocysteinuria,hyperprolinemia, hyperhomocysteinemia, nonketotic hyperglycinemia,hydroxybutyric aminoaciduria, sulfite oxidase deficiency, combinedsystems disease, lead encephalopathy, Tourett's syndrome, hepaticencephalopathy, drug addiction, drug tolerance, drug dependency,depression, anxiety and schizophrenia, aneurism, or epilepsy. In anotheraspect of the invention, the cytokine mediated diseases include boneresorption diseases, osteopetrosis, osteoporosis, or osteoarthritis.Also included are diabetes, systemic cachexia, cachexia secondary toinfection or malignancy, cachexia secondary to acquired immunedeficiency syndrome (AIDS), obesity, anorexia or bulimia nervosa.Additonally, the cytokine mediated disease can be sepsis, HIV, HCV,malaria, infectious arthritis, leishmaniasis, Lyme disease, cancer,including but not limited to breast cancer, colon cancer, lung cancer,prostatic cancer, multiple myeloma, acute myelogenous leukemia,myelodysplastic syndrome, non-Hodgkins lymphoma, or follicular lymphoma,Castleman's disease, or drug resistance.

In another aspect, the invention provides methods of treatingneutrophil-mediated diseases which comprise administering to a subjectin need of such treatment a therapeutically effective amount of acompound as described herein, including a compound according to FormulaIA, IB, IC and/or II, wherein the neutrophil-mediated disease isbronchial asthma, rhinitis, influenza, stroke, myocardial infarction,thermal injury, adult respiratory distress syndrome (ARDS), multipleorgan injury secondary to trauma, acute glomerulonephritis, dermatoseswith acute inflammatory components, acute purulent meningitis,hemodialysis, leukopheresis, granulocyte transfusion associatedsyndromes, or necrotizing enterocolitis.

Combination therapy with cytokine inhibitors provides a beneficialtherapeutic effect, particularly an additive or over-additive effect oran overall reduction of side effects of therapy. Such a beneficialtherapeutic effect is desirable in the treatment of cytokine mediateddiseases as described herein, and in particular in the treatment ofrheumatoid arthritis, Crohn's disease and psoriasis. Thus, in anotheraspect the invention provides methods of treating a cytokine mediateddisease including administering one or more, typically one, of theactive ingredients (hereafter referred to as A) described hereintogether with one or more, typically one, cytokine inhibitor of theinvention. An additive or over-additive effect of the pharmaceuticalcombinations according to the invention provides for dose reduction,side-effect reduction and/or interval extension when compared to theindividual compounds and A and the cytokine inhibitor used inmonotherapy in the usual way. The effects mentioned above are observedboth when the two active substances are administered simultaneously in asingle active substance formulation and when they are administeredsuccessively in separate formulations. In the case of A being aninjectable, especially a biological agent, other benefits of adding thecytokine inhibitor may be seen. For example, cost reduction by way ofinterval and/or dose reduction.

A variety of active ingredients A are contemplated for use in thecombinations of the invention. For example, non-steroidanti-inflammatory drugs (NSAIDs), which are widely used for thetreatment of inflammation, pain and fever, may be used. Such NSAIDSinclude acetaminophen, aspirin, ibuprofen, choline magnesium salicylate,choline salicylate, diclofenac, diflunisal, etodolac, fenoprofencalcium, flurbiprofen, indomethacin, ketoprofen, carprofen, indoprofen,ketorolac tromethamine, magnesium salicylate, meclofenamate sodium,mefenamic acid, oxaprozin, piroxicam, sodium salicylate, sulindac,tolmetin, meloxicam, rofecoxib, celecoxib, etoricoxib, valdecoxib,nabumetone, naproxen, lomoxicam, nimesulide, indoprofen, remifenzone,salsalate, tiaprofenic acid, flosulide, and the like.

Angiogenesis inhibitors may serve as A, such as compounds directedagainst VEGF, taxol, pentoxyfylline and thalidomide.

Biological agents shall be understood to mean any natural orartificial/synthetic biological molecule or fragment thereof as known inthe art, such as antibodies, proteins, fusion proteins, receptors,nucleic acids, lipids, carbohydrates and the like. Therefore, activeingredient A includes biological agents, such as etanercept, infliximab,alefacept, adalimumab, efalizumab, anakinra, IL-1RA, alpha-interferon,interferon beta 1-B, CTLA-4, and other antibodies or receptor constructsdirected against TNF-alpha, ILl-6, LFA-1, and C5.

Also within the scope of the invention for active ingredient A aresteroids, such as glucocorticoids, and vitamin D3 and analogs thereof(cholecalciferols), alone (the latter being used mostly for psoriasis)or in combination. Steroids include budesonide, dexamethasone,fluocinonide, hydrocortisone, betamethasone, halobetasol (ulobetasol),methylprednisolone, prednisolone, clobetasone, deflazacort, fluocinoloneacetonide, fluticasone, triamcinolone acetonide, mometasone anddiflucortolone. Among vitamin D3 derivatives are calcipotriol,tacalcitol, maxacalcitol, and tacalitol, the calciotropic hormones,1α,2,5-dihydroxyvitamin D3, and parathyroid hormone-related peptide.

Many types of immunomodulatory, immunosuppressive or cytostatic drugscan be used in combination with cytokine inhibitors. Exemplary agentsinclude hydroxychloroquine, D-penicillamine, sulfasalazine, auranofin,gold sodium thiomalate, minocycline, dapsone, chlorambucil,mercaptopurine, tacrolimus, sirolimus, pimecrolimus, mycophenolatemofetil, cyclosporine, leflunomide, methotrexate, azathioprine,cyclophosphamide, macrolid, ascomycin, hydroxyurea, 6-thioguanine,(Orfanos C E., 1999, Cutis 64(5):347-53); alefacept, leflunomide,infliximab, etanercept, efalizumab, anti-CD4, anti-CD25, peptide T,LFA3TIP, ICAM-1 ISIS 2302, DAB₃₈₉, CTLA-4Ig, anti-CD80, for exampleIDEC-114 or ABX-IL8, DAB-IL-2, IL-10, anti-TAC, basiliximab anddaclizumab. In addition, agents or therapies which act on other targetsor immune mediated products are suitable as the active ingredient A.These include, for example, inhibitors of protein tyrosine kinases(PTKs) such as epidermal growth factor receptor (EGFR), E-selectininhibitors, and therapies widely used for psoriasis such as anthralin,coal tar, phototherapies including ultraviole,t B (UVB) or psoralenultraviolet A (PUVA), photodynamic therapy and laser therapy.

Retinoids therapy can also be used as active ingredient A. Thus, forexample, bexarotene, acitretin, etretinate and tazarotene, andhydroxyurea, 6-thioguanine and phototherapies are suitable activeingredients. (Orfanos C E., 1999, Cutis 64(5):347-53; see also Saurat JH., 1999, J. Am. Acad. Derm. 41(3 Pt 2):S2-6).

Active ingredients A useful in the invention further include smallmolecule inhibitors directed against enzymes involved in signaltransduction pathways or to cell adhesion molecules like LFA-1 orICAM-1.

In another aspect, there are provided the above-mentioned pharmaceuticalcombinations comprising A and the cytokine inhibitor, typically intherapeutically effective amounts, for use as pharmaceuticalcompositions with an anti-cytokine activity. Moreover, combinationscomprising A and a cytokine inhibitor can be used for preparing apharmaceutical composition for the treatment and/or prevention of acytokine mediated disease or condition. The pharmaceutical preparations,containing as active substance one or more compound combinationscomprising A and the cytokine inhibitor further include thepharmaceutically acceptable derivatives thereof, and may be optionallycombined with conventional excipients and/or carriers.

For therapeutic use, the pharmaceutical combinations of A and thecytokine inhibitor according to the invention may be administered in anyconventional dosage form in any conventional manner, including any ofthe routes described herein. Accordingly, routes of administrationinclude, but are not limited to, intravenous, intramuscular,subcutaneous, intrasynovial, by infusion, sublingual, transdermal, oral,topical and by inhalation. Typical modes of administration are oral,topical or intravenous.

The pharmaceutical combinations of A and the cytokine inhibitoraccording to the invention may be administered separately, or in acombination formulation with other active ingredients or adjuvants thatenhance stability of the inhibitors, facilitate administration ofpharmaceutical compositions containing them, provide increaseddissolution or dispersion, increase inhibitory activity, provide adjuncttherapy, or provide like advantages. Such combination therapiestypically utilize lower dosages of the conventional therapeutics, andavoid the possible toxicity and adverse side effects incurred when thoseagents are used as monotherapies. Pharmaceutical combinations of A andthe cytokine inhibitor may therefore be physically combined with theconventional therapeutics or other adjuvants into a singlepharmaceutical composition. The active ingredient A and/or the cytokineinhibitor may be used in the combination as a salt, solvate, tautomerand/or prodrug and as a single stereroisomer or mixtures ofstereoisomers, including racemates.

The proportions in which the two active substances, A and the cytokineinhibitor, may be used in the combinations according to the inventionare variable. Active substances A and the cytokine inhibitor areoptionally present in the form of their solvates or hydrates. Dependingon the choice of the compounds A and the cytokine inhibitor, the weightratios which may be used within the scope of the present invention varyon the basis of the different molecular weights of the various compoundsand their different potencies. Determination of ratios by weight isdependent on particular active ingredients of A and the cytokineinhibitor, and within the skill in the art.

In psoriasis, known combination treatments have been effective and areused as rotation therapy for maintenance of remission or as combinationtreatments if refractory to usual systemic products. Most of thecombinations are with different modes of action either to improveefficacy or to reduce side effects by reduction of the dosage. See Vande Kerkhof, P. 1997 Clinics in Dermatology, 15:831-834, which showed theinterest of topical steroids or Vitamin D with systemic agents. Twocombinations which are widely accepted include ultraviolet B (UVB) orpsoralens ultraviolet A (PUVA) plus retinoids; methotrexate, or thecombination of cyclosporin and retinoids.

A typical combination for treating psoriasis is the cytokine inhibitorcompound with immunotherapy drugs which include cyclosporin,pimecrolimus, tacrolimus, ascomycine, anti-CD4, anti-CD25, peptide T,LFA3TIP, DAB₃₈₉, CTLA-4Ig, E-selectin inhibitors, alefacept, infliximab,etanercept, efalizumab, and those disclosed in Griffiths, Christopher E.M., 1998 Hospital Medicine, Vol 59 No 7, and the obvious variantsthereof. Another typical combination for treating psoriasis is thecytokine inhibitor compound with methotrexate (MTX). It is expected thiscombination will be effective because of the good tolerability of MTX inthe short term and because of the acceptability if maintenance ofremission is obtained with good quality of life. Another typicalcombination for treating psoriasis is the cytokine inhibitor compoundwith cyclosporine, especially because of cyclosporine's efficiency forinduction of remission. Another embodiment of the invention comprisesadministration in the following sequence: induction with cytokineinhibitor and cyclosporine, followed by continuation with cytokineinhibitor after decrease of dosing and discontinuation of cyclosporine.Another typical combination for treating psoriasis is the cytokineinhibitor compound in combination with retinoids. Retinoids provideminimal efficacy with potential Cyt P450 interactions and risk ofteratogenicity, and this would be alleviated by continuation therapywith the cytokine inhibitor. Yet another typical combination fortreating psoriasis is the cytokine inhibitor compound, in combinationwith topical active ingredients A chosen from glucocorticoids, vitamin Dderivatives, topical retinoids and dithianol. A more typical combinationfor treating psoriasis is a cytokine inhibitor compound with vitamin Dderivatives, most typically calcipotriol or tacalcitol. Another typicalcombination for treating psoriasis is the cytokine inhibitor compound incombination with macrolids, most typically with ascomycin analoguestopically, and even more typically with those available orally such aspimecrolimus. Another typical combination for treating psoriasis is thecytokine inhibitor compound in combination with cell adhesion moleculesinhibitors, such as anti LFA3, anti LFA1. This includes adhesionmolecule blockage by recombinant fusion proteins like alefacept, antiLFA3-IgCl, or by anti-CD11 monoclonal antibodies, efalizumab, and theobvious variants thereof Cell adhesion molecules inhibitors appear toprovide an acceptable response rate with limited tolerability problems.Combination with a cytokine inhibitor could avoid the disadvantage oftheir injectable form, with CAM inhibitors being used intermittently.Another embodiment of the invention comprises administration in thefollowing sequence: induction with cytokine inhibitor and CAMinhibitors, followed by maintenance treatment with the cytokineinhibitor alone and retreatment with CAM inhibitors in case ofsignificant relapse.

Another typical combination for treating psoriasis is the cytokineinhibitor compound with another anti-TNF-alpha active ingredient. Atypical embodiment is one wherein the other anti-TNF-alpha activeingredient is chosen from infliximab or etanercept, typicallyinfliximab. Infliximab is believed to have a higher rate of response forinduction of remission, which recently was suggested to be maintained onthe long term. Within the scope of the invention is the use of topicalor general antisense inhibitors of TNF alpha, such as ICAM-1 ISIS 2302in combination with a cytokine inhibitor compound. Another typicalcombination for treating psoriasis is the cytokine inhibitor compoundwith anti-CD4, anti CD80 (IDEC-114 or ABX-IL8), DAB IL-2, DAB₃₈₉ IL-2,CTLA4-Ig, IL10, the IL2 receptor inhibitors such as daclizumab(anti-TAC), basiliximab. (See Tutrone, W. D., 2001, Biologic Therapy forPsoriasis vol 68; Tutrone, W. D., 2001, Biologic Therapy for Psoriasisvol 68; Ben-Bassat, H. 2001 Current Opinion in Investigational Drugs Vol2 No 11; Salim, A. et al, 2001 Current Opinion in Investigational DrugsVol 2 No 11).

Any of the above mentioned combinations within the scope of theinvention may be tested by animal models known in the art. Reference inthis regard may be made to: Schon, Michael P. 1999 Animal models ofPsoriasis—What can we learn from them. The Society for InvestigativeDermatology—Revies, Vol 112. No. 4, 405-410.

In Rheumatoid Arthritis, combination of immunosuppressive orimmunomodulatory agents is a long and well established therapeuticparadigm. Combination partners recruit from various therapeuticentities. Their identification is either based on empiracal datasupported by evolving knowledge about the underlying mechanisms or basedon a well defined mode of actions. These agents are generally referredto as Disease Modifying Antiheumatic Drugs (DMARDs) or Slow ActingAntiheumatic Drugs (SAARDs). Apart from the combinations listed below,combination of the cytokine inhibitor, with one or more agentsclassified as DMARD/SAARD or NSAID and/or corticosteroid, arecontemplated in this invention.

A typical combination for treating rheumatoid arthritis is the cytokineinhibitor compound combined with one or more of the followingimmunosuppressive, immunomodulatory, or cytostatic drugs, such as, forexample, hydroxychloroquine, D-penicillamine, sulfasalazine, auranofin,gold sodium thiomalate, minocycline, dapsone, chlorambucil,mercaptopurine, tacrolimus, sirolimus, mycophenolate mofetil,cyclosporine, leflunomide, methotrexate, azathioprine andcyclophosphamide. Another typical combination for treating rheumatoidarthritis is the cytokine inhibitor compound combined with angiogenesisinhibitors, such as compounds directed against VEGF, taxol,pentoxyfylline, thalidomide, interferon beta-1B and alpha-interferon.Yet another typical combination for treating rheumatoid arthritis is thecytokine inhibitor compound in combination with inhibitors of celladhesion, such as inhibitors of LFA-1 or ICAM-1.

A more typical combination for treating rheumatoid arthritis is thecytokine inhibitor compound combined with anti-TNF antibodies orTNF-receptor antagonists such as Etanercept, Infliximab, Adalimumab(D2E7), or biological agents such as CTLA-4, or biological agentsdirected against targets like CD-4, LFA-1, IL-6, ICAM-1, and C5. Inanother embodiment the cytokine inhibitor is combined with Infliximaband methotrexate. Another typical combination for treating rheumatoidarthritis is the cytokine inhibitor compound in combination with IL-1receptor antagonists, such as Kineret. Yet another typical combinationfor treating rheumatoid arthritis is the cytokine inhibitor compoundcombined with non-steroid anti-inflammatory drugs (NSAIDs), includingacetaminophen, aspirin, ibuprofen, choline magnesium salicylate, cholinesalicylate, diclofenac, diflunisal, etodolac, fenoprofen calcium,flurbiprofen, indomethacin, ketoprofen, carprofen, indoprofen, ketorolactromethamine, magnesium salicylate, meclofenamate sodium, mefenamicacid, oxaprozin, piroxicam, sodium salicylate, sulindac, tolmetin,meloxicam, rofecoxib, celecoxib, etoricoxib, valdecoxib, nabumetone,naproxen, lomoxicam, nimesulide, indoprofen, remifenzone, salsalate,tiaprofenic acid, flosulide, and the like. Another typical combinationfor treating rheumatoid arthritis is the cytokine inhibitor compoundcombined with glucocorticosteroids, such as betamethasone,dexamethasone, methylprednisolone, prednisolone, and deflazacort.

Any of the above mentioned combinations within the scope of theinvention may be tested by animal models known in the art. (See Wooley,P. H. 1998, Animal models of arthritis, in Klippel J. H., Dieppe, P. A.,(eds.) Rheumatology, second edition, 5.8.1-5.8.6. Mosby, London,Philadelphia, St. Louis, Sydney, Tokio).

In Crohn's disease, the following groups of drugs combined with thecytokine inhibitor may be effective: steroids such as budesonide, 5-ASAdrugs like mesalamine, immunosuppressants, biological agents andadhesion molecule inhibitors. A typical combination for treating Crohn'sdisease is the cytokine inhibitor compound with one or more of thefollowing: steroids including all those listed herein, 5-ASA,methotrexate and azathioprine. Another typical combination for treatingCrohn's disease is the cytokine inhibitor compound combined with IL-1receptor antagonists, such as Kineret. Yet another typical combinationfor treating Crohn's disease is the cytokine inhibitor compound withanti-TNF antibodies or TNF-receptor antagonists, such as Etanercept,Infliximab, Adalimumab (D2E7), or biological agents such as CTLA-4, orbiological agents directed against targets like CD-4, LFA-1, IL-6,ICAM-1, and C5. In another embodiment the cytokine inhibitor is combinedwith Infliximab and methotrexate. More typically, the cytokine inhibitoris combined with Infliximab. Another typical combination for treatingCrohn's disease is the cytokine inhibitor compound combined with IL-10,ISIS 2302 (anti ICAM 1), or Antegren (VCAM receptor antagonist).

It has been found that cytokine inhibitors possess inhibitory effects onthe procoagulant and profibrinolytic responses during human endotoxemia.The invention therefore also provides for a method of anticoagulant andfibrinolytic therapy for a disease or condition relating to bloodcoagulation or fibrinolysis, comprising administering to a patient inneed thereof a pharmaceutically effective a amount of the cytokineinhibitor. This administration may be of benefit given eitherprophylactically to patients at risk or therapeutically for patients whohave developed complications related to these pathways.

Also with the scope of the invention is combination therapy of thecytokine inhibitor and one or more other anticoagulant or fibrinolyticagents. These include recombinant tissue plasminogen activator (rtPA),streptokinase (SK), urokinase (UK), proUK, heparin, enoxoparin,dalteparin, coumarin anticoagulants, aspirin, dipyrimidamole, aggrennox,ticlopidine, clopidogrel (Plavix), abciximab, RheoPro, integrilin,aggrestat and the like. Particular dosages, formulations and methods ofadministration either alone or combined is within the skill in the art.

DETAILED DESCRIPTION OF THE INVENTION

The following terms are used throughout as defined below.

Generally, reference to a certain element such as hydrogen or H is meantto include all isotopes of that element. For example, if an R group isdefined to include hydrogen or H, it also includes deuterium andtritium. Hence, isotopically labeled compounds are within the scope ofthe invention.

The phrase “unsubstituted alkyl” refers to alkyl groups that do notcontain heteroatoms. Thus the phrase includes straight chain alkylgroups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl,octyl, nonyl, decyl, undecyl, dodecyl, and the like. The phrase alsoincludes branched chain isomers of straight chain alkyl groups,including but not limited to, the following which are provided by way ofexample: —CH(CH₃)₂, —CH(CH₃)(CH₂CH₃), —CH(CH₂CH₃)₂, —C(CH₃)₃,—C(CH₂CH₃)₃, —CH₂CH(CH₃)₂, —CH₂CH(CH₃)(CH₂CH₃), —CH₂CH(CH₂CH₃)₂,—CH₂C(CH₃)₃, —CH₂C(CH₂CH₃)₃, —CH(CH₃)CH(CH₃)(CH₂CH₃), —CH₂CH₂CH(CH₃)₂,—CH₂CH₂CH(CH₃) (CH₂CH₃), —CH₂CH₂CH(CH₂CH₃)₂, —CH₂CH₂C(CH₃)₃,—CH₂CH₂C(CH₂CH₃)₃, —CH(CH₃)CH₂CH(CH₃)₂, —CH(CH₃)CH(CH₃)CH(CH₃)₂,—CH(CH₂CH₃)CH(CH₃)CH(CH₃)(CH₂CH₃), and others. The phrase also includescyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl, and cyclooctyl and such rings substituted withstraight and branched chain alkyl groups as defined above. The phrasealso includes polycyclic alkyl groups such as, but not limited to,adamantyl, norbornyl, and bicyclo[2.2.2]octyl and such rings substitutedwith straight and branched chain alkyl groups as defined above. Thus,the phrase unsubstituted alkyl groups includes primary alkyl groups,secondary alkyl groups, and tertiary alkyl groups. Unsubstituted alkylgroups may be bonded to one or more carbon atom(s), oxygen atom(s),nitrogen atom(s), and/or sulfur atom(s) in the parent compound. Typicalunsubstituted alkyl groups include straight and branched chain alkylgroups and cyclic alkyl groups having 1 to 20 carbon atoms, and moretypical such groups have from 1 to 10 carbon atoms. Even more typicalsuch groups, also known as unsubstituted lower alkyl groups, have from 1to 5 carbon atoms. Typically, unsubstituted alkyl groups includestraight and branched chain alkyl groups having from 1 to 3 carbon atomsand include methyl, ethyl, propyl, and —CH(CH₃)₂.

The phrase “substituted alkyl” refers to an unsubstituted alkyl group asdefined above in which one or more bonds to a carbon(s) or hydrogen(s)are replaced by a bond to non-hydrogen and non-carbon atoms such as, butnot limited to, a halogen atom such as F, Cl, Br, and I; an oxygen atomin groups such as hydroxyl groups, alkoxy groups, aryloxy groups, andester groups; a sulfur atom in groups such as thiol groups, alkyl andaryl sulfide groups, sulfone groups, sulfonyl groups, and sulfoxidegroups; a nitrogen atom in groups such as amines, amides, alkylamines,dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides,imides, and enamines; a silicon atom in groups such as in trialkylsilylgroups, dialkylarylsilyl groups, alkyldiarylsilyl groups, andtriarylsilyl groups; and other heteroatoms in various other groups.Substituted alkyl groups also include groups in which one or more bondsto a carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatomsuch as oxygen in groups such as carbonyls, carboxyls, and esters;nitrogen in groups such as imines, oximes, hydrazones, and nitriles.Preferred substituted alkyl groups include, among others, alkyl groupsin which one or more bonds to a carbon or hydrogen atom is/are replacedby one or more bonds to fluorine atoms. One example of a substitutedalkyl group is the trifluoromethyl group and other alkyl groups thatcontain the trifluoromethyl group. Other alkyl groups include those inwhich one or more bonds to a carbon or hydrogen atom is replaced by abond to an oxygen atom such that the substituted alkyl group contains ahydroxyl, alkoxy, aryloxy group, or heterocyclyloxy group. Still otheralkyl groups include alkyl groups that have an amine, alkylamine,dialkylamine, arylamine, (alkyl)(aryl)amine, diarylamine,heterocyclylamine, (alkyl)(heterocyclyl)amine,(aryl)(heterocyclyl)amine, or diheterocyclylamine group.

The term “alkylene” refers to saturated, divalent straight or branchedchain hydrocarbyl groups typically having in the range of about 2 up toabout 20 carbon atoms, and “substituted alkylene” refers to alkylenegroups further bearing one or more substituents as set forth above.

The phrase “unsubstituted aryl” refers to aryl groups that do notcontain heteroatoms. Thus the phrase includes, but is not limited to,groups such as phenyl, biphenyl, anthracenyl, naphthyl by way ofexample. Although the phrase “unsubstituted aryl” includes groupscontaining condensed rings such as naphthalene, it does not include arylgroups that have other groups such as alkyl or halo groups bonded to oneof the ring members, as aryl groups such as tolyl are considered hereinto be substituted aryl groups as described below. A typicalunsubstituted aryl group is phenyl. Unsubstituted aryl groups may bebonded to one or more carbon atom(s), oxygen atom(s), nitrogen atom(s),and/or sulfur atom(s) in the parent compound, however.

The phrase “substituted aryl group” has the same meaning with respect tounsubstituted aryl groups that substituted alkyl groups had with respectto unsubstituted alkyl groups. However, a substituted aryl group alsoincludes aryl groups in which one of the aromatic carbons is bonded toone of the non-carbon or non-hydrogen atoms described above and alsoincludes aryl groups in which one or more aromatic carbons of the arylgroup is bonded to a substituted and/or unsubstituted alkyl (includingcycloalkyl), alkenyl, alkynyl, aralkyl, heterocyclyl orheterocyclylalkyl group as defined herein. This includes bondingarrangements in which two carbon atoms of an aryl group are bonded totwo atoms of an alkyl, alkenyl, or alkynyl group to define a fused ringsystem (e.g. dihydronaphthyl or tetrahydronaphthyl). Moreover,substituted aryl groups include aryl groups in which one or morearomatic carbons of the aryl group is bonded to an unsubstituted aryl oran aryl substituted with any of the groups described above exceptanother aryl. Thus, the phrase “substituted aryl” includes, but is notlimited to tolyl, and hydroxyphenyl among others.

The phrase “unsubstituted alkenyl” refers to straight and branched chainand cyclic groups such as those described with respect to unsubstitutedalkyl groups as defined above, except that at least one double bondexists between two carbon atoms. Examples include, but are not limitedto vinyl, —CH═CH(CH₃), —CH═C(CH₃)₂, —C(CH₃)═CH₂, —C(CH₃)═CH(CH₃),—C(CH₂CH₃)═CH₂, cyclohexenyl, cyclopentenyl, cyclohexadienyl,butadienyl, pentadienyl, and hexadienyl among others.

The phrase “substituted alkenyl” has the same meaning with respect tounsubstituted alkenyl groups that substituted alkyl groups had withrespect to unsubstituted alkyl groups. A substituted alkenyl groupincludes alkenyl groups in which a non-carbon or non-hydrogen atom isbonded to a carbon double bonded to another carbon and those in whichone of the non-carbon or non-hydrogen atoms is bonded to a carbon notinvolved in a double bond to another carbon. Typically unsubstitutedalkenyl groups have form 2 to 20 carbons, and in some embodiments suchgroups have from 2 to 10 carbons.

The term “alkenylene” refers to divalent straight or branched chainhydrocarbyl groups having at least one carbon—carbon double bond, andtypically having in the range of about 2 up to 20 carbon atoms, and“substituted alkenylene” refers to alkenylene groups further bearing oneor more substituents as set forth above.

The phrase “unsubstituted alkynyl” refers to straight and branched chaingroups such as those described with respect to unsubstituted alkylgroups as defined above, except that at least one triple bond existsbetween two carbon atoms. Examples include, but are not limited to—C≡CH, —C≡C(CH₃), —C≡C(CH₂CH₃), —CH₂C≡CH, —CH₂C≡C(CH₃), and—CH₂C≡C(CH₂CH₃) among others. Typically, unsubstituted alkynyl groupshave form 2 to 20 carbons, and in some embodiments such groups have from2 to 10 carbons.

The phrase “substituted alkynyl” has the same meaning with respect tounsubstituted alkynyl groups that substituted alkyl groups had withrespect to unsubstituted alkyl groups. A substituted alkynyl groupincludes alkynyl groups in which a non-carbon or non-hydrogen atom isbonded to a carbon triple bonded to another carbon and those in which anon-carbon or non-hydrogen atom is bonded to a carbon not involved in atriple bond to another carbon.

The phrase “unsubstituted aralkyl” refers to unsubstituted alkyl groupsas defined above in which a hydrogen or carbon bond of the unsubstitutedalkyl group is replaced with a bond to an aryl group as defined above.For example, methyl (—CH₃) is an unsubstituted alkyl group. If ahydrogen atom of the methyl group is replaced by a bond to a phenylgroup, such as if the carbon of the methyl were bonded to a carbon ofbenzene, then the compound is an unsubstituted aralkyl group (i.e., abenzyl group). Thus the phrase includes, but is not limited to, groupssuch as benzyl, diphenylmethyl, and 1-phenylethyl (—CH(C₆H₅)(CH₃)) amongothers.

The phrase “substituted aralkyl” has the same meaning with respect tounsubstituted aralkyl groups that substituted aryl groups had withrespect to unsubstituted aryl groups. However, a substituted aralkylgroup also includes groups in which a carbon or hydrogen bond of thealkyl part of the group is replaced by a bond to a non-carbon or anon-hydrogen atom. Examples of substituted aralkyl groups include, butare not limited to, —CH₂C(═O)(C₆H₅), and —CH₂(2-methylphenyl) amongothers.

The phrase “unsubstituted heterocyclyl” refers to both aromatic andnonaromatic ring compounds including monocyclic, bicyclic, andpolycyclic ring compounds containing 3 or more ring members of which oneor more is a heteroatom such as, but not limited to, N, O, and S.Although the phrase “unsubstituted heterocyclyl” includes condensedheterocyclic rings such as benzimidazolyl, it does not includeheterocyclyl groups that have other groups such as alkyl or halo groupsbonded to one of the ring members as compounds such as2-methylbenzimidazolyl are substituted heterocyclyl groups. Examples ofheterocyclyl groups include, but are not limited to: unsaturated 3 to 8membered rings containing 1 to 4 nitrogen atoms such as, but not limitedto pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridinyl,dihydropyridinyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g.4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl etc.),tetrazolyl, (e.g. 1H-tetrazolyl, 2H tetrazolyl, etc.); saturated 3 to 8membered rings containing 1 to 4 nitrogen atoms such as, but not limitedto, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl; condensedunsaturated heterocyclic groups containing 1 to 4 nitrogen atoms suchas, but not limited to, indolyl, isoindolyl, indolinyl, indolizinyl,benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl;unsaturated 3 to 8 membered rings containing 1 to 2 oxygen atoms and 1to 3 nitrogen atoms such as, but not limited to, oxazolyl, isoxazolyl,oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl,1,2,5-oxadiazolyl, etc.); saturated 3 to 8 membered rings containing 1to 2 oxygen atoms and 1 to 3 nitrogen atoms such as, but not limited to,morpholinyl; unsaturated condensed heterocyclic groups containing 1 to 2oxygen atoms and 1 to 3 nitrogen atoms, for example, benzoxazolyl,benzoxadiazolyl, benzoxazinyl (e.g., 2H-1,4-benzoxazinyl etc.);unsaturated 3 to 8 membered rings containing 1 to 3 sulfur atoms and 1to 3 nitrogen atoms such as, but not limited to, thiazolyl,isothiazolyl, thiadiazolyl (e.g. 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl,1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.); saturated 3 to 8 memberedrings containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms such as,but not limited to, thiazolodinyl; saturated and unsaturated 3 to 8membered rings containing 1 to 2 sulfur atoms such as, but not limitedto, thienyl, dihydrodithiinyl, dihydrodithionyl, tetrahydrothiophene,tetrahydrothiopyran; unsaturated condensed heterocyclic rings containing1 to 2 sulfur atoms and 1 to 3 nitrogen atoms such as, but not limitedto, benzothiazolyl, benzothiadiazolyl, benzothiazinyl (e.g.2H-1,4-benzothiazinyl, etc.), dihydrobenzothiazinyl (e.g.2H-3,4-dihydrobenzothiazinyl, etc.), unsaturated 3 to 8 membered ringscontaining oxygen atoms such as, but not limited to furyl; unsaturatedcondensed heterocyclic rings containing 1 to 2 oxygen atoms such asbenzodioxolyl (e.g. 1,3-benzodioxoyl, etc.); unsaturated 3 to 8 memberedrings containing an oxygen atom and 1 to 2 sulfur atoms such as, but notlimited to, dihydrooxathiinyl; saturated 3 to 8 membered ringscontaining 1 to 2 oxygen atoms and 1 to 2 sulfur atoms such as1,4-oxathiane; unsaturated condensed rings containing 1 to 2 sulfuratoms such as benzothienyl, benzodithiinyl; and unsaturated condensedheterocyclic rings containing an oxygen atom and 1 to 2 oxygen atomssuch as benzoxathiinyl. Heterocyclyl group also include those describedabove in which one or more S atoms in the ring is double-bonded to oneor two oxygen atoms (sulfoxides and sulfones). For example, heterocyclylgroups include tetrahydrothiophene oxide and tetrahydrothiophene1,1-dioxide. Typical heterocyclyl groups contain 5 or 6 ring members.Exemplary heterocyclyl groups include morpholine, piperazine,piperidine, pyrrolidine, imidazole, pyrazole, 1,2,3-triazole,1,2,4-triazole, tetrazole, thiophene, thiomorpholine, thiomorpholine inwhich the S atom of the thiomorpholine is bonded to one or more O atoms,pyrrole, homopiperazine, oxazolidin-2-one, pyrrolidin-2-one, oxazole,quinuclidine, thiazole, isoxazole, furan, and tetrahydrofuran.

The phrase “substituted heterocyclyl” refers to an unsubstitutedheterocyclyl group as defined above in which one or more of the ringmembers is bonded to a non-hydrogen atom such as described above withrespect to substituted alkyl groups and substituted aryl groups.Examples include, but are not limited to, 2-methylbenzimidazolyl,5-methylbenzimidazolyl, 5-chlorobenzthiazolyl, 1-methyl piperazinyl,2-phenoxy-thiophene, and 2-chloropyridinyl among others. In addition,substituted heterocyclyl groups also include heterocyclyl groups inwhich the bond to the non-hydrogen atom is a bond to a carbon atom thatis part of a substituted and unsubstituted aryl, substituted andunsubstituted aralkyl, unsubstituted heterocyclyl, or substitutedheterocyclyl in which the substituents include any of those describedabove except another heterocyclyl group. Examples include but are notlimited to 1-benzylpiperdinyl, 3-phenythiomorpholinyl,3-(pyrrolidin-1-yl)-pyrrolidinyl, and 4-(piperidin-1-yl)-piperidinyl.

The phrase “unsubstituted heterocyclylalkyl” refers to unsubstitutedalkyl groups as defined above in which a hydrogen or carbon bond of theunsubstituted alkyl group is replaced with a bond to a heterocyclylgroup as defined above. For example, methyl (—CH₃) is an unsubstitutedalkyl group. If a hydrogen atom of the methyl group is replaced by abond to a heterocyclyl group, such as if the carbon of the methyl werebonded to carbon 2 of pyridine (one of the carbons bonded to the N ofthe pyridine) or carbons 3 or 4 of the pyridine, then the compound is anunsubstituted heterocyclylalkyl group.

The phrase “substituted heterocyclylalkyl” has the same meaning withrespect to unsubstituted heterocyclylalkyl groups that substitutedaralkyl groups had with respect to unsubstituted aralkyl groups.However, a substituted heterocyclylalkyl group also includes groups inwhich a non-hydrogen atom is bonded to a heteroatom in the heterocyclylgroup of the heterocyclylalkyl group such as, but not limited to, anitrogen atom in the piperidine ring of a piperidinylalkyl group. Inaddition, a substituted heterocyclylalkyl group also includes groups inwhich a carbon bond or a hydrogen bond of the alkyl part of the group isreplaced by a bond to a substituted and unsubstituted aryl orsubstituted and unsubstituted aralkyl group. Examples include but arenot limited to phenyl-(piperidin-1-yl)-methyl andphenyl-(morpholin-4-yl)-methyl.

The phrase “unsubstituted alkoxy” refers to a hydroxyl group (—OH) inwhich the bond to the hydrogen atom is replaced by a bond to a carbonatom of an otherwise unsubstituted alkyl group as defined above.

The phrase “substituted alkoxy” refers to a hydroxyl group (—OH) inwhich the bond to the hydrogen atom is replaced by a bond to a carbonatom of an otherwise substituted alkyl group as defined above.

The term “protected” with respect to hydroxyl groups, amine groups, andsulfhydryl groups refers to forms of these functionalities which areprotected from undesirable reaction with a protecting group known tothose skilled in the art such as those set forth in Protective Groups inOrganic Synthesis, Greene, T. W.; Wuts, P. G. M., John Wiley & Sons, NewYork, N.Y., (3rd Edition, 1999) which can be added or removed using theprocedures set forth therein. Examples of protected hydroxyl groupsinclude, but are not limited to, silyl ethers such as those obtained byreaction of a hydroxyl group with a reagent such as, but not limited to,t-butyldimethyl-chlorosilane, trimethylchlorosilane,triisopropylchlorosilane, triethylchlorosilane; substituted methyl andethyl ethers such as, but not limited to methoxymethyl ether,methythiomethyl ether, benzyloxymethyl ether, t-butoxymethyl ether,2-methoxyethoxymethyl ether, tetrahydropyranyl ethers, 1-ethoxyethylether, allyl ether, benzyl ether; esters such as, but not limited to,benzoylformate, formate, acetate, trichloroacetate, and trifluoracetate.Examples of protected amine groups include, but are not limited to,amides such as, formamide, acetamide, trifluoroacetamide, and benzamide;imides, such as phthalimide, and dithiosuccinimide; carbamates such ast-butyl carbamate (Boc), fluorenylmethyl carbamate (Fmoc), and benzylcarbamate (Cbz); and others. Examples of protected sulthydryl groupsinclude, but are not limited to, thioethers such as S-t-butyl thioether,S-benzyl thioether, and S-4-picolyl thioether; substituted S-methylderivatives such as hemithio, dithio and aminothio acetals; and others.

A “pharmaceutically acceptable salt” includes a salt with an inorganicbase, organic base, inorganic acid, organic acid, or basic or acidicamino acid. As salts of inorganic bases, the invention includes, forexample, alkali metals such as sodium or potassium; alkaline earthmetals such as calcium and magnesium or aluminum; and ammonia. As saltsof organic bases, the invention includes, for example, trimethylamine,triethylamine, pyridine, picoline, ethanolamine, diethanolamine, andtriethanolamine. As salts of inorganic acids, the instant inventionincludes, for example, hydrochloric acid, hydroboric acid, nitric acid,sulfuric acid, and phosphoric acid. As salts of organic acids, theinstant invention includes, for example, formic acid, acetic acid,trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleicacid, citric acid, succinic acid, malic acid, methanesulfonic acid,benzenesulfonic acid, and p-toluenesulfonic acid. As salts of basicamino acids, the instant invention includes, for example, arginine,lysine and ornithine. Acidic amino acids include, for example, asparticacid and glutamic acid.

Certain compounds within the scope of Formulas IA, IB, IC and II arederivatives referred to as prodrugs. The expression “prodrug” denotes aderivative of a known direct acting drug, e.g. esters and amides, whichderivative has enhanced delivery characteristics and therapeutic valueas compared to the drug, and is transformed into the active drug by anenzymatic or chemical process; see Notari, R. E., “Theory and Practiceof Prodrug Kinetics,” Methods in Enzymology 112:309-323 (1985); Bodor,N., “Novel Approaches in Prodrug Design,” Drugs of the Future 6:165-182(1981); and Bundgaard, H., “Design of Prodrugs:Bioreversible-Derivatives for Various Functional Groups and ChemicalEntities,” in Design of Prodrugs (H. Bundgaard, ed.), Elsevier, New York(1985), Goodman and Gilmans, The Pharmacological Basis of Therapeutics,8th ed., McGraw-Hill, Int. Ed. 1992. The preceding references and allreferences listed herein are hereby incorporated in their entirety byreference.

Tautomers refers to isomeric forms of a compound that are in equilibriumwith each other. The concentrations of the isomeric forms will depend onthe environment the compound is found in and may be different dependingupon, for example, whether the compound is a solid or is in an organicor aqueous solution. For example, in aqueous solution, ketones aretypically in equilibrium with their enol forms. Thus, ketones and theirenols are referred to as tautomers of each other. As readily understoodby one skilled in the art, a wide variety of functional groups and otherstructures may exhibit tautomerism, and all tautomers of compoundshaving Formula IA, IB, and IC are within the scope of the presentinvention.

Compounds of the present invention include enriched or resolved opticalisomers at any or all asymmetric atoms as are apparent from thedepictions. Both racemic and diastereomeric mixtures, as well as theindividual optical isomers can be isolated or synthesized so as to besubstantially free of their enantiomeric or diastereomeric partners, andthese are all within the scope of the invention.

“Treating” within the context of the instant invention, means analleviation, in whole or in part, of symptoms associated with a disorderor disease, or halt of further progression or worsening of thosesymptoms, or prevention or prophylaxis of the disease or disorder.Similarly, as used herein, a “therapeutically effective amount” of acompound of the invention refers to an amount of the compound thatalleviates, in whole or in part, symptoms associated with a disorder ordisease, or halts of further progression or worsening of those symptoms,or prevents or provides prophylaxis for the disease or disorder.Treatment may also include administering the pharmaceutical formulationsof the present invention in combination with other therapies. Forexample, the compounds and pharmaceutical formulations of the presentinvention may be administered before, during, or after surgicalprocedure and/or radiation therapy. Alternatively, the compounds of theinvention can also be administered in conjunction with otheranti-inflammatory agents, anticancer agents and other agents describedherein.

Compounds of the invention may be readily synthesized by techniques wellknown to those of skill in the art. For example, compounds of Formula IAwherein X is C(O) may be prepared by coupling of an amine-bearing Gcomponent with a carboxyl bearing Ar-L-Q, component. Coupling may beeffected, for example, by the use of typical amide-bond-forming reagentssuch as EDC, PyBOP, and the like, or by formation of an acyl halide oractive ester. Thus, any suitable amide-bond forming procedure may beused such as those described in Bodanszky, M. and Bodanszky, A., ThePractice of Peptide Synthesis, Springer-Verlag (1984); or Jones, J.Amino Acid and Peptide Synthesis Ed. Steven G. Davies, Oxford Science(1992). Thionation of the resulting amide may be carried out, forexample, using Lawesson's reagent or the like to give thioamides ofFormula IA or IB (is C═S). Similarly, compounds of Formula IB wherein Xis C(O) may be made, for example, starting with an amine-bearing Ar-L-Qcomponent and a carboxyl bearing G. The ketoamides of Formula IA or IB(respectively obtained by coupling of G-NH₂ and HOOC—C(O)—Ar-L-Q, or bycoupling of NH₂—Ar-L-Q and G′-C(O)—COOH by the methods described above),may be converted to the corresponding oximes (Y is C(═NOH)) by treatmentwith hydroxylamine.

As an example, Scheme 1 shows the synthesis of compounds of the presentinvention where G is a substituted pyrazole.

Thus, substituted phenyl hydrazine hydrochloride is heated with abeta-ketonitrile in a suitable solvent such as benzene, toluene, or thelike, to give the substituted phenyl aminopyrazole as shown. Thecarboxyl-Ar-L-Q component is then coupled to the free amine, typicallywith a coupling agent such as EDC, PyBOP, and the like in the presenceof a suitable base such as DIEA among others. The coupling reaction maybe carried out in any suitable solvent such as methylene chloride, DMF,ethyl acetate, THF/water, and the like. Alternatively, the carboxylcomponent may be converted to an acid halide such as the acid chlorideby exposure to oxalyl chloride, thionyl chloride, or POCl₃ among others.The coupled product is an example of a compound of Formula IA as shownand may be further modified to form other compounds of the invention.

Compounds of Formula II wherein X′ is N may be readily prepared. Theamide bond of compounds of Formula IA and IB (wherein X is C(O)) may bereduced with any suitable hydride such as LAH and the resulting compoundmay be converted to the nitroso derivative by exposure to BuCNO.Cyclization of the nitroso derivative gives a compound of Formula IIhaving the structure IIA. The cyclization may be effected by heating thenitroso compound with a suitable base such as pyridine or the like.

Compounds of Formula II wherein X′ is S have the following formula,

and can be prepared following procedures similar to what has beendescribed in the literature. For instance pyrazole-amide intermediatesof type A1 (synthesis described in Scheme 2, method A) can be brominatedusing bromine or N-bromosuccinimide according to methods described inthe literature to lead to the brominated analogues of type A2 (JustusLiebigs Ann. Chem. 1955, 593:179-199; J. Chem. Soc., 1956, 4974-4977;Bioorg. Med. Chem. Lett. 11, 22, 2001, 2979-2982; J. Chem. Soc. PerkinTrans. 2, 10, 2000, 2049-2053; Bioorg. Med. Chem. 4, 2, 1996, 227-238).

The resulting intermediates A2 can be treated with P₂S₅ using heat tolead to the bicyclic thiazole intermediates of type A3 followingconditions similar to what has been described in the literature (Chem.Heterocycl. Compd. 10, 1974, 813-815).

Alternatively, as shown in Scheme 3, intermediate A2 can be treated witha base such as n-butyl lithium (nBuLi) followed by the addition ofdibenzyl-disulfane to lead to the S-benzyl intermediate A4.Debenzylation of the thioether using HF in anisole (Bull. Chem. Soc.Jpn., 40, 1967, 2164) or using cresol-thiocresol-HF mixture (Int. J.Pept. Protein res. 28, 1986, 498) leads to the free thiol that in turncan cyclize and form a bicyclic thiazole system (Chem. Soc. Jpn., 58,1985, 785-786).

Compounds of Formula II wherein X′ is O have the following formula,

and can be prepared following procedures similar to those described inthe literature. Brominated rings of type A2 described above, such aspyrazoles, can be treated with sodium methoxide in methanol to providethe methoxy intermediate A5 (J. Chem. Soc. Perkin Trans. 1, 1984,63-67).

As shown in Scheme 4, the methoxy intermediate A5 can be transformed tothe corresponding alcohol A6 using any of the numerous methods describedin the literature (J. Org. Chem. 1974, 39, 1427; Synthesis, 1989, 287,J. Am. Chem. Soc. 1981, 103, 7007). Alternatively, the bromointermediate A2 can be transformed directly to the alcohol A6 usingcopper bromide and aqueous sodium carbonate (Chem. Heterocycl. Compd.22, 3, 1986, 265-267). The resulting alcohol type intermediates havebeen described to cyclize directly under heat conditions and thus maynot be isolated providing directly the desired bicyclic oxazole systems(Heterocycles, 22, 10, 1984, 2309-2311).

In accordance with one aspect of the invention, there are providedmethods for preparing cytokine inhibitors of the present invention. Forexample, methods for preparing compounds of Formula IA comprise reactingG-NH₂ with Q-L-Ar—X—OH in the presence of a coupling agent and a base,or reacting G-NH₂ with Q-L-Ar—X—X″ in the presence of a base, to yield acompound of Formula IA, wherein the variables G, Q, and L are defined asin any of the compounds described herein, X is C(O) or C(S), and X″ isan activating moiety. The activating moiety is typically F, Cl, Br, I,—N₃, N-hydroxysuccinimide, 1-hydroxybenzotriazole, pentafluorophenol,pentachlorophenol, para-nitrophenol, or —O—C(O)—OR^(y), wherein R^(y) islower alkyl. Suitable bases include sodium bicarbonate or a suitableorganoamine such as pyridine, N-methylmorpholine, diisopropylethylamineor triethylamine. In one aspect of the invention, a method is providedfor preparing a compound of Formula IA, wherein Ar is —(Y)-naphthyl-, Yis —CH(OH)— or —CH₂— and G is selected from phenyl, pyridinyl,pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl or thienyl. Inanother, a method is provided for preparing a compound of Formula IA Aris —C(O)-naphthyl- and G is phenyl, pyridinyl, pyrazolyl, pyrrolyl,imidazolyl, oxazolyl, isoxazolyl or thienyl. Also provided are methodsfor treating such a compound of Formula IA, wherein Y is —C(O)— withNH₂OR in the presence of a second base to provide the compound IAwherein Y is —C(NOR)—. Typically, the second base is pyridine or anacetate salt. Typically, the reaction is carried out in neat pyridine,in a pyridine/alcohol mixture, or in ethanol in the presence of sodiumacetate and the reaction mixture is heated to a temperature in the rangeof about 40° C. to about 80° C. Hence, the invention provides a methodfor preparing a compound of Formula IA, wherein Ar is—C(═NOH)-naphthyl-, and G is selected from phenyl, pyridinyl, pyrazolyl,pyrrolyl, imidazolyl, oxazolyl, isoxazolyl or thienyl.

In yet another aspect, the invention provides a method for preparing acompound of Formula IA, wherein Ar is —(Y)-phenyl-, Y is —C(O)— and G isselected from cyclopropyl, pyrazolyl, pyrrolyl, pyrrolidiyl, imidazolyl,imidazolonyl, oxazolyl, isoxazolyl, furanyl or thienyl. Also providedare methods for treating such a compound, wherein Y is —C(O)— with NH₂ORin the presence of a second base to provide the compound IA wherein Y is—C(NOR)—, wherein the second base and reaction conditions are asdescribed above. Hence, the invention provides methods for preparing acompound of Formula IA, wherein Ar is —C(═NOH)-phenyl-, and G isselected from pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl,furanyl or thienyl.

Also provided are methods for preparing a compound having Formula IB,the method comprising reacting G-X—OH with Q-L-Ar—NH₂ in the presence ofa coupling agent and a base, or reacting Q-L-Ar—NH₂ with G-X—X″ in thepresence of a base, to yield said compound, wherein the variables Ar, G,Q, and L are as defined herein, X is C(O) or C(S) and X″ is anactivating moiety. In one aspect, a method is provided to preparecompounds of Formula IB, wherein Ar is —(Y)-naphthyl-, Y is —CH(OH)— or—CH₂— and G is selected from phenyl, pyridinyl, pyrazolyl, pyrrolyl,imidazolyl, oxazolyl, isoxazolyl or thienyl. In another aspect, a methodis also provided for preparing a compound of Fomula IB, wherein Ar is-naphthyl-, G is G′-(Y)—, Y is —C(O)—, and G′ is selected from phenyl,pyridinyl, pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl,furanyl or thienyl. Also provided are methods for treating such acompound of Formula IB, wherein Y is —C(O)— with NH₂OR in the presenceof a second base to provide the compound IB wherein Y is —C(NOR)—,wherein the second base and reaction conditions are as described above.Hence a method is provided for preparing a compound of Formula IB,wherein Ar is -naphthyl-, G is G′-C(═NOH)—, and G′ is selected fromphenyl, pyridinyl, pyrazolyl, pyrrolyl, imidazolyl, oxazolyl,isoxazolyl, furanyl or thienyl.

In yet another aspect, the invention provides a method for preparing acompound of Formula IB, wherein Ar is —phenyl-, G is G′-(Y)—, Y is—C(O)—, and G′ is selected from pyrazolyl, isoxazolyl or furanyl. Alsoprovided are methods for treating such a compound of Formula IB, whereinY is —C(O)— with NH₂OR in the presence of a second base to provide thecompound IB wherein Y is —C(NOR)—, wherein the second base and reactionconditions are as described above. Hence, a method is provided forpreparing a compound of Formula IB, wherein Ar is —phenyl-, G isG′-C(═NOH)—, and G′ is selected from pyrazolyl, isoxazolyl or furanyl.

In another aspect, the invention provides a method for preparing acompound of Formula IC, wherein Ring is triazolidine dione, the methodcomprising reacting G-NHNHC(O)O-Et with Q-L-Ar—NCO in an aprotic solventand cyclizing the resulting intermediate in the presence of a base toyield said compound, wherein G, Ar, L and Q are as defined previously.Typically, the aprotic solvent is DCM, chloroform, or THF and the baseis an inorganic base chosen from NaOH, LiOH and K₂CO₃ or an organic basechosen from DBU, DIEA and TEA. Typically, the reaction mixture ismaintained at a temperature in the range of about 0° C. to 60° C.

In another aspect, the invention provides a method for preparing acompound of Formula II, wherein X′ is NH, comprising heatingG(NO)—NH—CH₂—Ar-L-Q with an organoamine to yield said compound, whereinG, Ar, L, and Q are as defined previously. Suitable organoamines includepyridine and the like. Typically, the reaction mixture is heated to atemperature in the range of about 80° C. to about 160° C., and moretypically to about 100° C. to about 140° C.

In another aspect of the invention, there are provided compounds ofFormula III

wherein the pyrazole moiety is substituted at the 1-position,3-position, or at both by one or more R¹, R² or R³;

X′″ is OR^(x) or an activating moiety;

R^(x) is H, substituted or unsubstituted C₁₋₄ alkyl, or substituted orunsubstituted aralkyl;

each R¹ is independently F, Cl, Br, I, cyano, —C(O)R, —C(O)NR₂, —C(O)OR,—OR, —SiR₃, —NR′R′, —S(O)_(m)R, substituted or unsubstituted straight orbranched C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl, substituted orunsubstituted C₃₋₁₀ cycloalkyl, substituted or unsubstituted C₅₋₈cycloalkenyl, substituted or unsubstituted C₇₋₂₀ aralkyl, substituted orunsubstituted saturated or unsaturated 3-11 member heterocyclyl orheterocyclylalkyl containing 1, 2, 3, or 4 heteroatoms selectedindependently from N, O, S(O)_(m);

each R² is independently F, Cl, Br, I, cyano, substituted orunsubstituted straight or branched C₁₋₆ alkyl, substituted orunsubstituted C₆₋₁₀ aryl, substituted or unsubstituted 5-10 memberheteroaryl, —OR′, —OR⁶, —C(O)R′, —C(O)OR′, —C(O)NR′₂, —NR′₂, —NO₂,—S(O)_(m)R″, —NR′SO₂R″, —NR′C(O)NR′R′, —NR′C(S)NR′R′, —NR′C(O)OR′ or—SO₂NR′₂; and

each R³ is independently H, substituted or unsubstituted C₆₋₁₀ aryl,substituted or unsubstituted saturated or unsaturated 3-11 memberheterocyclyl or heterocyclylalkyl containing 1, 2, 3, or 4 heteroatomsselected independently from N, O, S(O)_(m), substituted or unsubstitutedC₃₋₁₂ cycloalkyl, substituted or unsubstituted C₅₋₁₂ cycloalkenyl,substituted or unsubstituted C₇₋₂₀ aralkyl, substituted or unsubstitutedstraight or branched C₁₋₈galkyl, R²⁰C(O)N(R²¹)—, R²²O—, R²³R²⁴NC(O)—,R²⁶(CH₂)_(m)C(O)N(R²¹)—, R²⁶C(O)(CH₂)_(m)N(R²¹)—, substituted orunsubstituted C₂₋₈ alkenyl, or substituted or unsubstituted C₂₋₈alkynyl, wherein one or more methylene groups of the C₁₋₈alkyl, C₂₋₈alkenyl, or C₂₋₈ alkynyl are optionally replaced by O, NH, or S(O)_(m);

R, R′, R″, R²⁰, R²¹, R²³, R²⁴, R²⁶, and m are as defined in any of thecompounds described herein.

The activating moiety is a group which activates the adjacent carbonylfor addition by a nucleophile such as an amine, thiol, alcohol or thelike. Exemplary activating moieties include but are not limited to, F,Cl, Br, or I, substituted or unsubstituted aryloxy groups, substitutedor unsubstituted heterocycloxy groups, and oxyacylalkoxy groups whichform the mixed anhydride. Typically, the activating moiety is F, Cl, Br,I, —N₃, N-hydroxysuccinimide, 1-hydroxybenzotriazole, pentafluorophenol,pentachlorophenol, para-nitrophenol, or —O—C(O)—OR^(y), wherein R^(y) islower alkyl.

The instant invention also provides for pharmaceutical compositionswhich may be prepared by mixing one or more compounds of Formula IA, IB,and IC or II, prodrugs thereof, pharmaceutically acceptable saltsthereof, stereoisomers thereof, tautomers thereof, or solvates thereof,with pharmaceutically acceptable carriers, excipients, binders, diluentsor the like to prevent and treat disorders associated with excesscytokine production. The compositions of the invention may be used tocreate formulations and prevent or a variety of disorders associatedwith excess cytokine production, e.g., diseases and pathologicalconditions involving inflammation. Such compositions can be in the formof, for example, granules, powders, tablets, capsules, syrup,suppositories, injections, emulsions, elixirs, suspensions or solutions.The instant compositions can be formulated for various routes ofadministration, for example, by oral, parenteral, topical, rectal,nasal, vaginal administration, or via implanted reservoir. Parenteral orsystemic administration includes, but is not limited to, subcutaneous,intravenous, intraperitoneally, intramuscular, intra-articular,intrasynovial, intrasternal, intrathecal, intralesional and intracranialinjections. The following dosage forms are given by way of example andshould not be construed as limiting the instant invention.

For oral, buccal, and sublingual administration, powders, suspensions,granules, tablets, pills, capsules, gelcaps, and caplets are acceptableas solid dosage forms. These can be prepared, for example, by mixing oneor more compounds of the instant invention, or pharmaceuticallyacceptable salts or tautomers thereof, with at least one additive suchas a starch or other additive. Suitable additives are sucrose, lactose,cellulose sugar, mannitol, maltitol, dextran, starch, agar, alginates,chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins,collagens, casein, albumin, synthetic or semi-synthetic polymers orglycerides. Optionally, oral dosage forms can contain other ingredientsto aid in administration, such as an inactive diluent, or lubricantssuch as magnesium stearate, or preservatives such as paraben or sorbicacid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, adisintegrating agent, binders, thickeners, buffers, sweeteners,flavoring agents or perfuming agents. Tablets and pills may be furthertreated with suitable coating materials known in the art.

Liquid dosage forms for oral administration may be in the form ofpharmaceutically acceptable emulsions, syrups, elixirs, suspensions, andsolutions, which may contain an inactive diluent, such as water.Pharmaceutical formulations and medicaments may be prepared as liquidsuspensions or solutions using a sterile liquid, such as, but notlimited to, an oil, water, an alcohol, and combinations of these.Pharmaceutically suitable surfactants, suspending agents, emulsifyingagents, may be added for oral or parenteral administration.

As noted above, suspensions may include oils. Such oils include, but arenot limited to, peanut oil, sesame oil, cottonseed oil, corn oil andolive oil. Suspension preparation may also contain esters of fatty acidssuch as ethyl oleate, isopropyl myristate, fatty acid glycerides andacetylated fatty acid glycerides. Suspension formulations may includealcohols, such as, but not limited to, ethanol, isopropyl alcohol,hexadecyl alcohol, glycerol and propylene glycol. Ethers, such as butnot limited to, poly(ethyleneglycol), petroleum hydrocarbons such asmineral oil and petrolatum; and water may also be used in suspensionformulations.

Injectable dosage forms generally include aqueous suspensions or oilsuspensions which may be prepared using a suitable dispersant or wettingagent and a suspending agent. Injectable forms may be in solution phaseor in the form of a suspension, which is prepared with a solvent ordiluent. Acceptable solvents or vehicles include sterilized water,Ringer's solution, or an isotonic aqueous saline solution.Alternatively, sterile oils may be employed as solvents or suspendingagents. Typically, the oil or fatty acid is non-volatile, includingnatural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.

For injection, the pharmaceutical formulation and/or medicament may be apowder suitable for reconstitution with an appropriate solution asdescribed above. Examples of these include, but are not limited to,freeze dried, rotary dried or spray dried powders, amorphous powders,granules, precipitates, or particulates. For injection, the formulationsmay optionally contain stabilizers, pH modifiers, surfactants,bioavailability modifiers and combinations of these.

For rectal administration, the pharmaceutical formulations andmedicaments may be in the form of a suppository, an ointment, an enema,a tablet or a cream for release of compound in the intestines, sigmoidflexure and/or rectum. Rectal suppositories are prepared by mixing oneor more compounds of the instant invention, or pharmaceuticallyacceptable salts or tautomers of the compound, with acceptable vehicles,for example, cocoa butter or polyethylene glycol, which is present in asolid phase at normal storing temperatures, and present in a liquidphase at those temperatures suitable to release a drug inside the body,such as in the rectum. Oils may also be employed in the preparation offormulations of the soft gelatin type and suppositories. Water, saline,aqueous dextrose and related sugar solutions, and glycerols may beemployed in the preparation of suspension formulations which may alsocontain suspending agents such as pectins, carbomers, methyl cellulose,hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffersand preservatives.

Compounds of the invention may be administered to the lungs byinhalation through the nose or mouth. Suitable pharmaceuticalformulations for inhalation include solutions, sprays, dry powders, oraerosols containing any appropriate solvents and optionally othercompounds such as, but not limited to, stabilizers, antimicrobialagents, antioxidants, pH modifiers, surfactants, bioavailabilitymodifiers and combinations of these. Formulations for inhalationadministration contain as excipients, for example, lactose,polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate. Aqueousand nonaquous aerosols are typically used for delivery of inventivecompounds by inhalation.

Ordinarily, an aqueous aerosol is made by formulating an aqueoussolution or suspension of the compound together with conventionalpharmaceutically acceptable carriers and stabilizers. The carriers andstabilizes vary with the requirements of the particular compound, buttypically include nonionic surfactants (Tweens, Pluronics, orpolyethylene glycol), innocuous proteins like serum albumin, sorbitanesters, oleic acid, lecithin, amino acids such as glycine, buffers,salts, sugars or sugar alcohols. Aerosols generally are prepared fromisotonic solutions. A nonaqueous suspension (e.g., in a fluorocarbonpropellant) can also be used to deliver compounds of the invention.

Aerosols containing compounds for use according to the present inventionare conveniently delivered using an inhaler, atomizer, pressurized packor a nebulizer and a suitable propellant, e.g., without limitation,pressurized dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, nitrogen, air, or carbon dioxide. In the caseof a pressurized aerosol, the dosage unit may be controlled by providinga valve to deliver a metered amount. Capsules and cartridges of, forexample, gelatin for use in an inhaler or insufflator may be formulatedcontaining a powder mix of the compound and a suitable powder base suchas lactose or starch. Delivery of aerosols of the present inventionusing sonic nebulizers is advantageous because nebulizers minimizeexposure of the agent to shear, which can result in degradation of thecompound.

For nasal administration, the pharmaceutical formulations andmedicaments may be a spray, nasal drops or aerosol containing anappropriate solvent(s) and optionally other compounds such as, but notlimited to, stabilizers, antimicrobial agents, antioxidants, pHmodifiers, surfactants, bioavailability modifiers and combinations ofthese. For administration in the form of nasal drops, the compounds maybe formulated in oily solutions or as a gel. For administration of nasalaerosol, any suitable propellant may be used including compressed air,nitrogen, carbon dioxide, or a hydrocarbon based low boiling solvent.

Dosage forms for the topical (including buccal and sublingual) ortransdermal administration of compounds of the invention includepowders, sprays, ointments, pastes, creams, lotions, gels, solutions,and patches. The active component may be mixed under sterile conditionswith a pharmaceutically-acceptable carrier or excipient, and with anypreservatives, or buffers, which may be required. Powders and sprays canbe prepared, for example, with excipients such as lactose, talc, silicicacid, aluminum hydroxide, calcium silicates and polyamide powder, ormixtures of these substances. The ointments, pastes, creams and gels mayalso contain excipients such as animal and vegetable fats, oils, waxes,paraffins, starch, tragacanth, cellulose derivatives, polyethyleneglycols, silicones, bentonites, silicic acid, talc and zinc oxide, ormixtures thereof.

Transdermal patches have the added advantage of providing controlleddelivery of a compound of the invention to the body. Such dosage formscan be made by dissolving or dispersing the agent in the proper medium.Absorption enhancers can also be used to increase the flux of theinventive compound across the skin. The rate of such flux can becontrolled by either providing a rate controlling membrane or dispersingthe compound in a polymer matrix or gel.

Ophthalmic formulations, eye ointments, powders, solutions and the like,are also contemplated as being within the scope of this invention. Thecompounds of this invention can be incorporated into various types ofophthalmic formulations for delivery to the eye (e.g., topically,intracamerally, or via an implant). The compounds are typicallyincorporated into topical ophthalmic formulations for delivery to theeye. The compounds may be combined with ophthalmologically acceptablepreservatives, viscosity enhancers, penetration enhancers, buffers,sodium chloride, and water to form an aqueous, sterile ophthalmicsuspension or solution. Ophthalmic solution formulations may be preparedby dissolving a compound in a physiologically acceptable isotonicaqueous buffer. Further, the ophthalmic solution may include anophthalmologically acceptable surfactant to assist in dissolving thecompound. Furthermore, the ophthalmic solution may contain an agent toincrease viscosity, such as hydroxymethylcellulose,hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose,polyvinylpyrrolidone, or the like, to improve the retention of theformulation in the conjunctival sac. Gelling agents can also be used,including, but not limited to, gellan and xanthan gum. In order toprepare sterile ophthalmic ointment formulations, the active ingredientis combined with a preservative in an appropriate vehicle, such as,mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gelformulations may be prepared by suspending the active ingredient in ahydrophilic base prepared from the combination of, for example,carbopol-974, or the like, according to the published formulations foranalogous ophthalmic preparations. Preservatives and tonicity agents canbe incorporated.

Intrathecal administration, via bolus dosage or constant infusion,allows the local administration of a compound to a region of the spinalcord, such as the dorsal horn regions, delivering the compound directlyto the subarachnoid space containing the CSF (cerebrospinal fluid).

Central delivery to the spinal cord regions can also be performed byepidural injection to a region of the spinal cord exterior to thearachnoid membrane. Enhancing permeation of the active compound throughmeningeal membranes may be achieved by using hypertonic dosing solutionsthat encrease permeability of meningeal membranes, or by addition ofpermeation enhancers, such as, but not limited to, liposomalencapsulation, surfactants, or ion-pairing agents.

Besides those representative dosage forms described above,pharmaceutically acceptable excipients and carriers are generally knownto those skilled in the art and are thus included in the instantinvention. Such excipients and carriers are described, for example, in“Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991),which is incorporated herein by reference.

The formulations of the invention may be designed to be short-acting,fast-releasing, long-acting, and sustained-releasing as described below.Thus, the pharmaceutical formulations may also be formulated forcontrolled release or for slow release.

The instant compositions may also comprise, for example, micelles orliposomes, or some other encapsulated form, or may be administered in anextended release form to provide a prolonged storage and/or deliveryeffect. Therefore, the pharmaceutical formulations and medicaments maybe compressed into pellets or cylinders and implanted intramuscularly orsubcutaneously as depot injections or as implants such as stents. Suchimplants may employ known inert materials such as silicones andbiodegradable polymers.

Specific dosages may be adjusted depending on conditions of disease, theage, body weight, general health conditions, sex, and diet of thesubject, dose intervals, administration routes, excretion rate, andcombinations of drugs. Any of the above dosage forms containingeffective amounts are well within the bounds of routine experimentationand therefore, well within the scope of the instant invention.

A therapeutically effective amount of a compound of the presentinvention may vary depending upon the route of administration and dosageform. Effective amounts of invention compounds typically fall in therange of about 0.001 up to 100 mg/kg/day, and more typically in therange of about 0.05 up to 10 mg/kg/day. Typically, the compound orcompounds of the instant invention are selected to provide a formulationthat exhibits a high therapeutic index. The therapeutic index is thedose ratio between toxic and therapeutic effects which can be expressedas the ratio between LD₅₀ and ED₅₀. The LD₅₀ is the dose lethal to 50%of the population and the ED₅₀ is the dose therapeutically effective in50% of the population. The LD₅₀ and ED₅₀ are determined by standardpharmaceutical procedures in animal cell cultures or experimentalanimals.

All publications, patent applications, issued patents, and otherdocuments referred to in this specification are herein incorporated byreference as if each individual publication, patent application, issuedpatent, or other document were specifically and individually indicatedto be incorporated by reference in its entirety. Definitions that arecontained in text incorporated by reference are excluded to the extentthat they contradict definitions in this disclosure.

The present invention, thus generally described, will be understood morereadily by reference to the following examples, which are provided byway of illustration and are not intended to be limiting of the presentinvention.

Examples

The following abbreviations are used throughout the application withrespect to chemical terminology:

-   -   AcOH or HOAc: acetic acid    -   Boc: N-tert-Butoxycarbonyl    -   Bn: Benzyl    -   Cbz: Carbobenzyloxy    -   dba: Dibenzylidene acetone    -   DIEA: Diisopropylethylamine    -   DCM: Dichloromethane    -   DMF: N,N-Dimethylformamide    -   EDC or EDCI: 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide        hydrochloride    -   EtOAc: Ethyl acetate    -   EtOH: Ethanol    -   Fmoc: 9-fluorenylmethyloxycarbonyl    -   HPLC: High Pressure Liquid Chromatography    -   IC₅₀ value: The concentration of an inhibitor that causes a 50%        reduction in a measured activity.    -   LAH: Lithium aluminum hydride    -   MeCN or AcN: Acetonitrile    -   MeOH: Methanol    -   mL: Milliliter(s)    -   μL: Microliter(s)    -   PyBOP: Benzotriazol-1-yl-oxytripyrrolidinophosphonium        hexafluorophosphate    -   rt: room temperature    -   THF: Tetrahydrofuran

Example 1 Synthesis of Indazole Carboxamide Derivatives

3-Amino-5-tert-butyl-2-tolyl-2H-pyrazole (1). A solution of tolylhydrazine hydrochloride (8.0 g, 50 mmol) and4,4-dimethyl-3-oxo-pentanenitrile (6.3 g, 50 mmol) in toluene (30 mL)was heated to reflux overnight. Removal of the volatiles in vacuoprovided a residue, which was purified by silica gel chromatographyusing 30% ethyl acetate in hexanes as the eluent. Concentration in vacuoprovided 3-amino-5-tert-butyl-2-tolyl-2H-pyrazole as a brown solid (10.5g, 92%). LC-MS analysis of the compound indicates the desired product ispresent with a purity>99%. Calculated mass=229. Observed mass=230.

1H-Indazole-3-carboxylic acid(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide (2). To a solution ofindazole-3-carboxylic acid (28 mg, 0.17 mmol), EDC (50 mg, 0.26 mmol),and diisopropylethylamine (61 μL, 0.35 mmol) in CH₂Cl₂ (3.5 mL) wasadded 3-amino-5-tert-butyl-2-tolyl-2H-pyrazole (46 mg, 0.20 mmol). Afterbeing stirred for 14 h at room temperature, the mixture was diluted withwater (10 mL) and extracted with CH₂Cl₂ (2×10 mL). The combined organiclayer was washed with brine, dried (MgSO₄), and concentrated in vacuo.Purification by preparative HPLC (MeCN/H₂O) provided 25 mg of theindazolopyrazole (40%). LC-MS: Calculated mass=373. Observed mass=374.

General Procedure for Preparation of Indazole-3-Carboxylic Acids

5-Methoxy-1H-indazole-3-carboxylic acid (3). In a 1 L round bottom threeneck-flask equipped with a mechanical stirrer, a thermometer and afunnel were added 110 mL of water, 6 mL of concentrated sulfuric acid at−5° C. To the cooled solution was added a solution of 10 g of 5-methoxyisatin, 3.9 g of sodium nitrite, 2.6 g of sodium hydroxide in 65 mL ofwater. After stirring for 15 min, the reaction mixture was allowed towarm up to 0° C. and a solution of SnCl₂ (35 g in 50 mL of concentratedHCl) was added drop wise. Stirring was continued for 1 hour at roomtemperature then the precipitate was collected and crystallized in EtOHproviding 3 g of product ready to use for the next step. LC-MS:Calculated mass=192. Observed mass=193.

Example 2 Synthesis of Imidazolopyrazole Derivatives

2-Alkyl(aryl)imidazolopyrazoles were prepared from5-tert-butyl-2-p-tolyl-2H-pyrazol-3-ylamine (compound 1 above).

Method A General Procedure for N-Acylation of Aminopyrazole

Two different procedures were used to acylate aminopyrazole, as shown inScheme 5 and described below.

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-benzamide (4)

Acylation of aminopyrazole in ethyl acetate/water. 2-Aminopyrazole (115mg, 0.5 mmol) was dissolved in 2.5 mL EtOAc and a solution of NaHCO₃ (46mg, 0.55 mmol) in 1 mL of water was added. To this vigorously stirredmixture was added a solution of benzoyl chloride (57.5 μL, 0.5 mmol) in1.5 mL of ethyl acetate at room temperature. The resulting mixture wasstirred at 60° C. for 4 h. After cooling down to room temperature, ethylacetate was added. The organic phase was washed with 5% Na₂CO₃, water,1N HCl and finally with water again. The organic phase was dried overNa₂SO₄, concentration gave 115 mg NMR pure product (yield: 69%). LC-MS:Calculated mass=333. Observed mass=334.

Acylation of aminopyrazole in pyridine: A solution of the2-aminopyrazole (115 mg, 0.5 mmol), benzoyl chloride (63.3 μL, 0.55mmol) and DMAP (3 mg, 0.025 mmol, 5 mol %) in 2 mL pyridine was shakenat 85° C. over night (15 h). After evaporation and co-evaporation withtoluene, the solid residue was dissolved in 2 mL DCM, subjected tosequential ISCO purification (4 g column, 0-40% B; A=PCM, B=10% MeOH inDCM). Evaporation of the fractions containing product gave 134 mg purematerial. Yield: 80%. Calculated mass=333. Observed mass=334.

General Procedure for Reduction of the Amide with Lithium AluminumHydride

Benzyl-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amine (5). The startingamide (167 mg, 0.5 mmol) was dissolved in 0.5 mL anhydrous THF. To thissolution was added 1.5 mL 1M LAH in THF (1.5 mmol) at 4° C. Theresulting solution was shaken at 60° C. for 7 h. After cooling down withice-water, the reaction mixture was basified with aqueous KOH (pH 9-10).The suspension was filtered with Celite and washed with THF. Thefiltrate was concentrated and the residue was dissolved in ethyl acetateand washed with water. The organic phase was dried over Na₂SO4, filteredand evaporated to dryness to give 156 mg brown oil. The compound wasanalyzed by LC-MS and NMR. Yield: 89%. Calculated mass=319. Observedmass=320.

General Procedure for Nitrosylation of N-alkylaminopyrazole

Benzyl-(3-nitroso-5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amine (6). Twodrops of concentrated HCl and 2 drops of H₂O were added to 1 mL ethanolfollowed by addition of BuONO (270 μL, 2.3 mmol, 5 eq). This solutionwas added dropwise to a solution of N-alkylaminopyrazole (148 mg, 0.46mmol) in 1 mL ethanol at 4° C. The reaction mixture was stirred at 4° C.for 30 min then at room temperature for 2 h. After concentration, thesolid residue was dissolved in 2 mL of DCM and subjected to sequentialcolumn purification (12 g column, 0-40% B; A=DCM; B=10% MeOH in DCM).Yield: 48%, 76.9 mg. LC-MS: Calculated mass=348. Observed mass=349.

General Procedure for Cyclization

3-tert-Butyl-5-phenyl-1-p-tolyl-1,6-dihydro-imidazo[4,5-clpyrazole (7).A solution of the nitroso compound (76 mg, 0.21 mmol) in 3 mL pyridinewas heated in a microwave at 120° C. for 20 min. The reaction mixturewas cooled down to room temperature and the solvent was co-evaporatedwith toluene. The residue was dissolved in 3 mL dichloromethane andsubjected to column purification to give 46.9 mg of product. Yield=68%.LC-MS: Calculated mass=330. Observed mass=331.

Method B General Procedure for O-Alkylation of 4-hydroxy-1-arylaldehydes

4-(Morpholin-4-yl-ethyloxy)-1-naphthylaldehyde (8). A mixture of4-hydroxy-1-naphthaldehyde (258 mg, 1.5 mmol),N-(2-chloroethyl)morpholine hydrochloride (307 mg, 1.65 mmol, 1.1 eq)and K₂CO₃ (915 mg, 6.6 mmol, 4 eq) in 12 mL acetonitrile was stirredvigorously at 80° C. for 7 h. After filtration, the deep blue filtratewas concentrated to give deep green oil, which crystallized slowly.TLC:(silica) R_(f)=0.18 in ethyl acetate. The compound was analyzed byLC-MS. This crude product was carried directly to next step reaction.Calculated mass=285. Observed mass=286.

General Procedure for Reductive Amination of Aminopyrazole

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylmethy]-amine(9). Aminopyrazole (344 mg, 1.5 mmol) and the aldehyde from the previousstep (1.5 mmol, 1 eq) were dissolved in 4 mL EtOH, 80 μL HOAc was added.The resulting solution was shaken at 80° C. for 5 h. After cooling downto room temperature, sodium cyanoborohydride (282 mg, 3 eq) was added.The resulting solution was shaken at room temperature overnight (15 h).After evaporation, the residue was dissolved in ethyl acetate, washedwith aqueous NaHCO₃ then with water. The organic phase was concentratedand the residue was dissolved in DCM and subjected to columnpurification to give 540 mg of a foam. Yield: 72.3%. LC-MS: Calculatedmass=498. Observed mass=499.

3-tert-Butyl-5-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-1-p-tolyl-1,6-dihydro-imidazo[4,5-c]pyrazole(10). The title compound was prepared using the general procedure forcyclization as described above. Calculated mass=509. Observed mass=510.

Example 3 Synthesis of Alpha-Ketoamides Method A: Vianaphthalene-1-yl-oxo-acetic acid

4-[2-(Naphthalen-1-yloxy)-ethyl]-morpholine (11). 2-Hydroxy-naphthylene(1.0 g, 5.37 mmol) was dissolved in acetonitrile (50 mL). To thissolution was added cesium carbonate (4.0 g, 12.3 mmol) or potassiumcarbonate (2.97 g, 21.5 mmol) followed by addition of2-chloroethylmorpholine (0.774 g, 5.37 mmol). The mixture was allowed tostir at 80° C. overnight and then cooled to room temperature. Theresulting mixture was filtered, diluted with EtOAc and extracted withsaturated NaHCO₃ three times, with 0.1 M NaOH one time, washed withbrine, dried over MgSO₄, filtered, and the solvent removed under reducedpressure to give a crude brown oil. The oil was purified by columnchromatography providing the desired compound 11 as a light yellow oilwith a 64% to 83% yield. Calculated mass=257. Observed mass=258.

[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-oxo-acetic acid methylester (12). To a round bottom flask was added CH₂Cl₂ (100 mL) followedby the addition of AlCl₃ (2.2 g, 16.3 mmol). The suspension was stirred5 min at room temperature, methylchloroglyoxylate (1.66 mL, 17.88 mmol)was added and stirred an additional 5 min, followed by the addition of11 (0.841 g, 3.27 mmol). The mixture was stirred at room temperatureovernight, quenched with water, neutralized with NaHCO₃ and extractedwith EtOAc three times. The combined organic extracts were washed withbrine, dried over MgSO₄, filtered and the solvent removed leaving abrown oil. The material was purified by column chromatography (0-5%MeOH/CH₂Cl₂) providing 1.08 g of 12 (97%) as a yellow solid. LC-MS:Calculated mass=343. Observed mass=344.

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide,(13). Compound 12 (0.224 g, 0.653 mmol) was dissolved in THF (20 mL). Tothis solution was added 1 N LiOH (3 eq, 1.96 mmol). The solution wasallowed to stir for 2 hours then neutralized with 4 N HCl in dioxane andthe solvent was evaporated providing a white solid. The residue wasdried under high vacuum at 80° C. for 30 minutes and then suspended inCH₂Cl₂ (50 mL). To the suspension was added oxalyl chloride (0.56 mL,6.53 mmol) and few drops of DMF. The suspension was stirred at roomtemperature for 2 hrs then the solvent evaporated. The resulting solidwas suspended in ethyl acetate (20 mL) and added to5-amino-3-t-butyl-1-(4-methylphenyl)pyrazole (1) (0.159 g, 0.663 mmol)dissolved in ethyl acetate (20 mL) and a 50% NaHCO₃ solution(10 mL) andstirred overnight at 60° C. The mixture was diluted with ethyl acetateand extracted with NaHCO₃. The combined organic layers were washed withbrine, dried over MgSO₄, filtered and the solvent removed leaving abrown oil. The material was purified by column chromatography (50-100%EtOAc/Hexanes) or (0-5% methanol/DCM) providing 0.346 g (98%) of thedesired compound as a yellow solid. LC-MS: Calculated mass=540. Observedmass=541.

Preparation of Additional Building Blocks and General Methods for TheirIncorporation

N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide (14). To anoven dried 250 mL round bottom flask containing 5.0 g (25.73 mmol)5-tert-butyl-2-methoxy-benzene-1,3-diamine, 150 mL DCM was added. Thereaction mixture was cooled to 0° C. after which triethylamine (5.0 mL,36.0 mmol) was added followed by the drop wise addition ofmethylsulfonyl chloride (1.99 mL, 25.7 mmol). The reaction was allowedto stir at 0° C. for 30 min. then warmed to room temperature stirringfor an additional 2 h. The reaction mixture was poured over saturatedsolution of sodium bicarbonate (100 mL) and the layers separated. Theaqueous layer was washed twice more with 50 mL dichloromethane and thecombined organic layers were dried over magnesium sulfate andconcentrated under vacuum to afford a crude oil that was purified byflash chromatography (silica gel, 1:1 EtOAc:Hex) yo yield 6.1 g of thedesired product (87%). Calculated mass=272. Observed mass=273

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(15). The title compound was prepared by the same method described forcompound 13 starting from compound 12 and compound 14. Calculatedmass=583. Observed mass=584.

(4-Hydroxy-naphthalen-1-yl)-oxo-acetic acid methyl ester. To asuspension of AlCl₃ (1.11 g, 8.3 mmol) in 50 mL DCM,methylchloroglyoxylate (1.02 g, 8.3 mmol) was added. The resultingsolution was stirred for 5 min., after which naphthalen-1-ol (1 g, 6.9mmol) was added. After stirring for 2 hrs at room temperature, water wasadded and the phases were separated, after which the organic layer waswashed with water and dried over MgSO₄. The residue obtained afterevaporation of the organic solvent was purified by column chromatography(10-30% EtOAc/Hex), to afford the target compound in 38% yield.Calculated mass=230. Observed mass=231.

[4-(5-Bromo-2-chloro-pyrimidin-4-yl-oxy)-naphthalen-1-yl]-oxo-aceticacid methyl ester. The compound obtained in the previous reaction (1.37g, 6 mmol) was dissolved in 30 mL acetone.5-Bromo-2,4-dichloro-pyrimidine (1.36 g, 6 mmol) and K₂CO₃ (2.05 g, 14.8mmol) was added and the reaction was stirred at 60° C. for 5 hrs. Theacetone was evaporated, the residue was taken up in DCM and the solutionwas run through a bed of silica gel. A white solid in 75% yield wasobtained after evaporation of the solvent. Calculated mass=421. Observedmass=422.

[4-(5-Bromo-2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-oxo-aceticacid methyl ester. The compound obtained as described above (0.50 g,1.19 mmol) was dissolved in THF/Toluene 8/2. Morpholine (0.124 mL, 2.97mmol) and DIEA (0.5 mL, 2.97 mmol) were added and the solution wasstirred at 80° C. overnight. The acetone was evaporated and the residuewas purified by column chromatography (10-30% EtOAc/Hex) to yield 80% ofthe target compound. Calculated mass=472. Observed mass=473.

[4-(2-Morpholin-4-yl-pyrimidin-4-yl-oxy)-naphthalen-1-yl]oxo-acetic acidmethyl ester. The compound obtained above (108 mg, 0.228 mmol) wasdissolved in MeOH/DCM 3/1, 10% Pd/C (30 mg) was added and the compoundwas hydrogenated for 50 min. at 1 atm H₂. The reaction mixture wasfiltered and concentrated in vacuo. The resulting residue was dissolvedin DCM and purified by column chromatography (10-30% EtOAc/Hex) to yield67% of the target product. Calculated mass=393. Observed mass=394.

[4-(2-Morpholin-4-yl-pyrimidin-4-yl-oxy)-naphthalen-1-yl]-oxo-aceticacid (16). The product from the previous reaction (66 mg, 0.168 mmol)was dissolved in DCM and cooled to 0° C. A 1M solution of BBr₃ in DCM(0.2 mL, 0.202 mmol) was added and the reaction was allowed to warm upto rt over 10 min. Water was added to the mixture and the product wasextracted into EtOAc. The organic layer was dried over MgSO₄, evaporatedand the residue was triturated with hexanes to afford the target productquantitatively. Calculated mass=379. Observed mass=380.

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide(17).[4-(2-Morpholin-4-yl-pyrimidin-4-yl-oxy)-naphthalen-1-yl]-oxo-aceticacid (16) obtained above (36 mg, 0.095 mmol) was dissolved in 2 mL DCMand oxalyl chloride (0.08 mL, 0.949 mmol) was added, followed bycatalytic DMF. The reaction mixture was stirred at rt, after whichN-(3-amino-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide (14) (26mg, 0.096 mmol) and DIEA (0.05 mL, 0.284 mmol) were added, and stirringwas continued for 12 hr. The reaction mixture was concentrated in vacuoand the residue was purified by LC/MS (10-100% AcN/H₂O over 8.5 min.)Calculated mass=444. Observed mass=444.

(4-Bromo-naphthalen-1-yl)-oxo-acetic acid methyl ester (18). To asuspension of ALCl₃ (3.20 g, 24 mmol) in 100 mL DCM at 0° C.,methylchloroglyoxylate (2.2 mL, 24 mmol) was added. The resultingsolution was stirred for 5 min., after which 1-bromo-naphthalene (5 g,24 mmol) was added. After stirring for 2 hrs at room temperature, waterwas added and the phases were separated, after which the organic layerwas washed with water and dried over MgSO₄. The residue obtained afterevaporation of the organic solvent was purified by column chromatography(0-30% EtOAc/Hex), to afford 2.6 g of the target compound. ¹H NMR(CDCl₃): 8.92 (1H, d, J=9.3 Hz, H-arom); 8.31 (1H, d, J=9.3 Hz, H-arom);7.82 (1H, d, J=8.8 Hz, H-arom); 7.72 (1H, d, J=8.8 Hz, H-arom);7.57-7.68 (2H, m, H-arom); 3.94 (3H, s, OMe).

2-Chloro-pyrimidyl-4-yl-amine. 2,4-Dichloro-pyrimidine (7.45 g, 50 mmol)was stirred in 150 mL aqueous NH₄OH overnight. Chloroform was added tothe mixture and the organic and aqueous solvents were separated. Theorganic layer was washed with water and dried over MgSO₄. The residueobtained after evaporation of the organic solvent was purified by columnchromatography (0-100% EtOAc/Hex), to afford 1.5 g of the targetcompound and 2 g of the regioisomer. Calculated mass=129. Observedmass=130.

2-Morpholin-4-yl-pyrimidin-4-ylamine. The compound obtained in theprevious reaction (166 mg, 1.286 mmol) was dissolved in 2 mL THF. DIEA(0.1 mL and morpholine (134 mg, 1.5 mmol) were added and the reactionwas stirred at 75° C. overnight. The solvents were removed under reducedpressure, the residue was dissolved in DCM and purified by columnchromatography (50-100% EtOAc/Hex) to yield the target product in 88%yield. Calculated mass=180. Observed mass=181.

[4-(2-Morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-oxo-aceticacid methyl ester. 2-Morpholin-4-yl-pyrimidin-4-ylamine (140 mg, 0.77mmol) and (4-bromo-naphthalen-1-yl)-oxo-acetic acid methyl ester (18)(228 mg, 0.77 mmol) were suspended in 5 mL toluene and Pd(OAc)₂ (5 mg, 3mol %), BINAP (24 mg, 5 mol5) and CS₂CO₃ (753 mg, 2031 mmol) were added.The reaction mixture was stirred at 100° C. for 24 hrs. The cooledmixture was purified by column chromatography (0-100% EtOAc/Hex) toyield 169 mg of target product.

[4-(2-Morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-oxo-aceticacid. The product from the previous reaction (170 mg, 0.433 mmol) wasdissolved in DCM and cooled to 0° C. A 1M solution of BBr₃ in DCM (0.52mL, 0.52 mmol) was added and the reaction was allowed to stir for 35min. Water was added to the mixture and the solvents were evaporated toyield 160 mg of the crude target product, which was used as such in thecoupling reaction.

General procedure for coupling of G-NH, and[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-oxo-aceticacid. The product from the previous reaction (17 mg, 0.044 mmol) wasdissolved in 1.5 mL DMF and the amine component G-NH₂ was added (2 eq.,0.88 mmol), followed by the addition of PyBOP (46 mg, 0.088 mmol), HOBt(14 mg, 0.088 mmol), and DIEA (0.02 mL, 0.088 mmol). The reaction wasstirred overnight and the crude mixtures were purified by LC/MS (10-100%AcN), affording final compounds. The described method was applied toyield compounds as exemplified in Table 1.

4-(5-Bromo-pyridin-2-ylmethyl)-morpholine. Thionyl chloride (0.57 g, 5mmol) in DCM (2 mL) was added dropwise to a stirred solution of(5-bromo-pyridin-2-yl)-methanol (0.3 g, 1.59 mmol) in DCM (5 mL) whilecooling to 0° C. The mixture was allowed to warm to room temperatureand, after 1 h, evaporated to low volume in vacuo. The residue wasdissolved in CHCl₃, and a solution of morpholine (0.41 g, 5 mmol) inCHCl₃ was added at 0° C. After 3 h, the reaction was completed. Thesolvent was evaporated and addition of ether afforded the targetcompound (85%) as a white solid. Calculated mass=257. Observed mass=258

4-(5-Tri-butylstannanyl-pyridin-2-ylmethyl)-morpholine. To a solution ofthe compound obtained above (0.35 g, 1.3 mmol) in dry THF, a solution oftert-Buli 1.7 M (1.7 mL, 2.2 eq) was added while cooling to −78° C.After 10 minutes and at the same temperature ClSnBu₃ (2.2 eq, 1.2 g) wasadded and the reaction mixture was stirred for 15 minutes. Then a pH 7K₂HPO₄/KH₂PO₄ buffer was added and the residue was extracted with EtOAcand dried over MgSO₄ to give the target compound in 81% yield.Calculated mass=467. Observed mass=469.

[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-oxo-aceticacid (20). 4-(5-Tri-butylstannanyl-pyridin-2-ylmethyl)-morpholine (0.47g, 1.59 mmol) and (4-Bromo-naphthalen-1-yl)-oxo-acetic acid methyl ester(18) (0.6 g, 1.3 mmol) and catalytictetrakis(triphenylphosphine)palladium (0) were dissolved in 2 mLanhydrous 2,4-dioxane under nitrogen atmosphere. The tube was heatedunder microwave irradiation for 10 minutes at 150° C. After cooling toroom temperature the mixture was diluted with EtOAc, and a solution ofKF 40% was added. The organic phase was separated and the aqueous layerwas evaporated and purified by LC-MS to afford the target product in 54%yield. Calculated mass=376. Observed mass=376.

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide(302). The target compound 302 was obtained via acid chloride formationand coupling with (1b) as described above. Calculated mass=631. Observedmass=631.

4-(4-Nitro-pyridin-2-yl)-morpholine. To a solution of 2-chloro,4-nitropyridine (0.2 g, 1.27 mmol) in THF (3 mL) was added morpholine(328 mg, 38.1 mmol). The reaction was heated to 80 C and stirredovernight. The solvent was evaporated and the residue purified by columnchromatography (2/1 Hex/EtOAc) to yield 150 mg of the target compound.

2-Morpholin-4-yl-pyridin-4-ylamine. The compound obtained above (40 mg,0.86 mmol) was dissolved in MeOH/DCM 5/2, 10% Pd/C (40 mg) was added andthe compound was hydrogenated for 5 hr. at 1 atm H₂. The reactionmixture was filtered and concentrated in vacuo. The resulting residuewas purified by column chromatography (1/2 EtOAc/Hex) to yield 157 mg ofthe target product.

[4-(2-Morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-oxo-acetic acidmethyl ester (21). 2-Morpholin-4-yl-pyridin-4-ylamine (159 mg, 0.88mmol) and (4-Bromo-naphthalen-1-yl)-oxo-acetic acid methyl ester (18)(260 mg, 0.89 mmol) were suspended in 6 mL toluene/Dioxane 1/1 andPd(OAc)₂ (6 mg, 3 mol %), BINAP (27 mg, 5 mol %) and CS₂CO₃ (858 mg,2.64 mmol) were added. The reaction mixture was stirred from 80° C. to80° C. over 18 hrs. The cooled mixture was purified by columnchromatography (0-100% EtOAc/Hex) to yield 140 mg of product. Thisproduct was subjected to the methods described previously to obtain thefinal compounds of interest.

4-tert-Butyl-2-morpholin-4-ylmethyl-6-nitro-phenol. A solution of4-t-butyl-2-nitro-phenol (980 mg, 5 mmol), morpholine (50 mmol) andparaformaldehyde (1.5 g, 50 mmol) in 20 mL ethanol was heated in asealed vial at 95° C. for 6 hr. After removal of the solvent andmorpholine, the residue was purified via silica gel columnchromatography to afford 1.75 g target compound as a yellow solid.

2-Amino-4-tert-butyl-6-morpholin-4-ylmethyl-phenol. The compoundobtained as described above (294 mg, 1 mmol) was heated with tin(II)chloride dihydrate (1.36 g, 6 mmol) in 2 mL conc. HCl at 90° C. for 2hr. After cooling down, the reaction mixture was diluted with water, anddiethyl ether was added. The reaction mixture was neutralized byaddition of solid K₂CO₃ to pH=9. Extraction was done with diethyl etherand the combined organic phases were dried over sodium sulfate.Evaporation afforded 222 mg pure product as a white solid.

N-(5-tert-Butyl-2-hydroxy-3-morpholin-4-ylmethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(22). To a solution of the product obtained (66 mg, 0.25 mmol) and DIEA(87 μl, 0.5 mmol) in 5 mL DCM, the acid chloride (obtained as describedabove) (0.5 mmol) was added. The resulting mixture was stirred at rtovernight. After aq. sodium bicarbonate work-up and following silica gelcolumn purification the final product was obtained in 59.8 mg yield.Calculated mass=575.7. Observed mass=575.7

4-tert-Butyl-2-methyl-6-nitro-phenol. 4-tert-Butyl-2-methyl-phenol (1.64g, 10 mmol) was dissolved in 15 mL acetic acid, fuming nitric acid (0.47mL, 10 mmol) was added and the resulting solution was stirred at rtovernight. The reaction mixture was then poured onto crushed ice, andextracted with chloroform. The organic phase was washed with water, anddried over sodium sulfate. Evaporation gave 2.02 g the nitration productas a red oil.

N-(5-tert-Butyl-2-hydroxy-3-methyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(23). The nitro-compound obtained (31 mg) was reduced with Pd/C and H₂in 3 mL MeOH at rt for 2 hr. After filtration and removal of the solventthe residue was dissolved in 2 mL DCM, DIEA (0.25 mmol) was addedwidowed by addition of[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-oxo-acetyl chloride (0.1mmol). Stirring was continued at rt overnight. Purification of theresidue obtained after evaporation of the solvent by LC-MS afforded 9.5mg final product. Calculated mass=491. Observed mass=491

5-tert-Butyl-2-methoxy-1-methyl-3-nitro-benzene.4-tert-Butyl-2-methyl-6-nitro-phenol (209 mg, 1 mmol) was dissolved in 3mL acetone. 552 mg K₂CO₃ (4 eq) was added, followed by addition of MeI(0.33 mL, 5 mmol). The reaction mixture was stirred vigorously at 60° C.overnight. After removal of the acetone, the residue was shaken withDCM. Filtration and evaporation of the solution yielded 221 mg productwhich was used as such.

N-(5-tert-Butyl-2-methoxy-3-methyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(24). The product obtained above (56 mg, 0.25 mmol) was reduced withPd/C and H₂ in 5 mL MeOH at rt for 5 hr. After filtration and removal ofsolvent, the residue was dissolved in 4 mL DCM. DIEA (0.5 mmol) wasadded followed by addition of the acid chloride (0.2 mmol). The reactionwas continued at rt overnight. After aq. sodium bicarbonate work-up andsilica gel column chromatography, the final product was obtained in 46.8mg yield. Calculated mass=505. Observed mass=505

4-tert-Butyl-2-chloro-phenol. 4-tert-Butyl-phenol (2.64 g, 17.5 mmol)was dissolved in 1M solution of SO₂Cl₂ in DCM (17.5 mL, 17.5 mmol) andMeOH (0.71 mL, 17.5 mmol) was added. The reaction was stirred at rt andmonitored for progression. Additional 1M SO₂Cl₂/DCM (10 mL) and MeOH(0.36 mL) were added. The reaction mixture was concentrated in vacuo toyield the target compound. Calculated mass=186. Observed mass=187

4-tert-Butyl-2-chloro-6-nitro-phenol. The product obtained above (0.585g, 3.17 mmol) was dissolved in 6 mL AcOH, cooled to 0° C. and HNO₃ (0.16mL, 3.5 mmol) was added. The reaction was allowed to warm up to roomtemperature, after which water was added and the compound was extractedinto EtOAc. The organic layer was dried over MgSO₄, the solution wasconcentrated and the concentrate was filtered through silica gel toyield 0.306 g of target compound. Calculated mass=209. Observed mass=210

5-tert-Butyl-1-chloro-2-methoxy-3-nitro-benzene.4-tert-Butyl-2-chloro-6-nitro-phenol (0.214 g, 0.934 mmol) was dissolvedin 3 mL acetone and K₂CO₃ (0.65 g, 4.7 mmol) and MeI (0.58 mL, 9.3 mmol)were added. The reaction was stirred at 65° C. overnight, after whichthe solvent was removed under reduced pressure. The residue was taken upin DCM, the organic layer was washed with water, dried over MgSO₄ andconcentrated to yield 0.15 g of target product.

5-tert-Butyl-3-chloro-2-methoxy-phenylamine (25).5-tert-Butyl-1-chloro-2-methoxy-3-nitro-benzene (157 mg, 0.646 mmol) wasdissolved in 3 mL concentrated HCl and SnCl₂.2H₂O (0.874 g, 3.87 mmol)was added. The reaction was stirred at 90° C. for 2 hrs, after whichwater was added and the product extracted into diethyl ether. Theorganic layer was dried over MgSO₄ and concentrated. The residue waspurified by column chromatography (2/1 Hex/EtOAc) to yield 100 mg offinal product. Calculated mass=213. Observed mass=214

N-(5-tert-Butyl-3-chloro-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(26). 5-tert-Butyl-3-chloro-2-methoxy-phenylamine (25) (77 mg, 0.36mmol) was dissolved in 10 mL DCM.[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-oxo-acetyl chloride (0.54mmol), prepared as described before, and DIEA (0.37 mL, 1.44 mmol) wereadded and the reaction was stirred on. The reaction mixture wasevaporated and the residue was purified by LC/MS (10-100% AcN).Calculated mass=524. Observed mass=525

4-tert-Butyl-2-trifluoromethyl-phenol. 2-Trifluoromethyl-phenol (2.98 g,18.3 mmol) was dissolved in 12 mL TFA and t-butanol (1.43 g, 19.3 mmol)and H₂SO₄ (0.24 mL) were added. The reaction was stirred at rt for 48hrs, after which water was added and the compound was extracted intoDCM. The organic layer was dried over MgSO₄ and concentrated in vacuo.The residue was purified by column chromatography (2/1 Hex/EtOAc) toyield 2.01 g of the target compound.

4-tert-Butyl-2-trifluoromethyl-6-nitro-phenol.4-tert-Butyl-2-trifluoromethyl-phenol (70 mg, 0.32 mmol) was dissolvedin 3 mL AcOH/1.5 mL water and cooled to 0° C. HNO₃ (1.5 mL) andcatalytic H₂SO₄ were added and the reaction was allowed to warm to roomtemperature. Stirring was continued overnight, after which water wasadded and the compound was extracted into EtOAc. The organic layer wasdried over MgSO₄ and concentrated to yield 34 mg of final compound.Calculated mass=263. Observed mass=264

5-tert-Butyl-2-methoxy-1-trifluoromethyl-3-nitro-benzene. The compoundobtained above (34 mg, 0.163 mmol) was dissolved in 3 mL acetone andK₂CO₃ (112 mg, 0.81 mmol) and MeI (0.1 mL, 1.63 mmol) were added. Thereaction was stirred at 75° C. The mixture was concentrated and theresidue was dissolved in DCM. The organic layer was filtered, dried overMgSO₄ and concentrated. The residue was purified by columnchromatography (10-30% EtOAc/Hex) to yield 30 mg target compound.Calculated mass=277. Observed mass=278

5-tert-Butyl-2-methoxy-3-trifluoromethyl-phenylamine (27). The compoundobtained above (100 mg, 0.0.36 mmol) was dissolved in MeOH, 10% Pd/C (50mg) was added and the compound was hydrogenated at 1 atm H₂. Thereaction mixture was filtered and concentrated in vacuo. The resultingresidue was dissolved in DCM and purified by column chromatography (4/1EtOAc/Hex) to yield 72 mg of the target product. Calculated mass=247.Observed mass=248

N-(5-tert-Butyl-2-methoxy-3-trifluoromethyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(28). 5-tert-Butyl-2-methoxy-3-trifluoromethyl-phenylamine (32 mg, 0.165mmol) was dissolved in 2 mL DCM.[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-oxo-acetyl chloride (0.232mmol), prepared as described before, and DIEA (0.02 mL, 0.50 mmol) wereadded and the reaction was stirred on. The reaction mixture wasevaporated and the residue was purified by LC/MS (10-100% AcN).Calculated mass=558. Observed mass=559

4-[2-(6-Chloro-naphthalen-1-yloxy)-ethyl]-morpholine. To a suspension ofthe amine (1.0 g, 3.67 mmol) in 6M HCl (1.8 mL, 11.01 mmol), NaNO₂ (253mg, 3.67 mmol) was added and the reaction was stirred at 0° C. for 1 hr.To this mixture CuCl (363 mg, 3.67 mmol) was added, whereby gas evolved.The reaction was heated to 100° C. and stirred for 1 hr. The mixture wasextracted with DCM, the organic layer was dried and evaporated to give9% of the target product. Calculated mass=291. Observed mass=291.

[7-Chloro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-oxo-acetic acidmethyl ester. To a suspension of AlCl₃ (430 mg, 3.30 mmol) in DCM,methylchloroacetate (0.30 mL, 3.30 mmol) was added, whereby the AlCl₃dissolved. To this solution4-[2-(6-Chloro-naphthalen-1-yloxy)-ethyl]-morpholine (95 mg, 0.33 mmol)was added dropwise. The mixture was stirred overnight at roomtemperature. The mixture was diluted with DCM, the organic layer waswashed with water, dried over MgSO₄ and evaporated to yield 83% oftarget material. Calculated mass=378. Observed mass=378.

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[7-chloro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(29). To a solution of 5-tert-butyl-2-p-tolyl-2H-pyrazol-3-ylamine (50mg, 0.22 mmol) in 1 mL dioxane, BuLi (0.11 mL, 2M in cHex) was added andthe mixture was left standing for 10 min. To this mixture a solution ofthe ester (83 mg, 0.22 mmol) in 1 mL DMF was added and the resultingmixture was heated in the microwave at 150° C. for 5 min. The mixturewas washed with water, dried over MgSO₄ and evaporated. The residue waspurified by LC/MS to yield 12% of the desired product. Calculatedmass=575. Observed mass=575.

General Procedure for Synthesis of Amido-Anisidine Derivatives Method a

5-t-Butyl-2-methoxy-3-nitrobenzoic acid. To a solution of5-t-butyl-2-methoxybenzoic acid (5.5 g, 26 mmol) in 30 mL AcOH and 30 mLacetic anhydride, a catalytic amount (ca. 5 drops) of conc. sulfuricacid was added. The resulting reaction was stirred at rt overnight.After the reaction, the reaction mixture was poured in ca. 1.2 Lice-water. A white precipitate formed which was filtered and washed withwater. After drying under vacuum at 80° C., 5.98 g (91%) pure product asdetermined by NMR was obtained as white solid. ¹H NMR (500 MHz, CDCl₃):1.39 (s, 9H), 4.08 (s, 3H), 8.02 (s, 1H), 8.32 (s, 1H)

5-tert-Butyl-N-cyclopropyl-2-methoxy-3-nitro-benzamide. To a solution of5-t-butyl-2-methoxy-3-nitrobenzoic acid (759 mg, 3 mmol) in 18 mL DCM,oxalyl chloride (1.8 mL, 15 mmol) was added. After stirring at rt for 2hr the reaction mixture was concentrated to dryness. The resulting acidchloride was dissolved in 30 mL DCM, and DIEA (2.6 mL, 15 mmol) andcyclopropyl amine (0.83 mL, 12 mmol) were added. Stirring was continuedovernight at rt, after which DCM was added to the reaction mixture.After aq. sodium bicarbonate work-up, column chromatography purificationwas performed on ISCO Optix (3×12 g silica gel column) using DCM. 678 mgpure product was isolated as pale yellow solid. Calculated mass=292.Observed mass=295

5-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]2-oxo-acetylamino}-benzamide(30). The compound obtained in the previous step (584 mg, 2 mmol) wasreduced with Pd/C and H₂ in 30 mL MeOH at rt for 3 hr. After filtration,methanol was removed and the crude reduced intermediate was dissolved in25 mL DCM. DIEA (1.0 mL, 6 mmol) was added, followed by addition of theacid chloride (2 mmol). The resulting suspension was stirred at rtovernight, after which DCM was added to the reaction. The organic layerwas washed with aq. sodium bicarbonate and water. The organic phase wasdried over sodium sulfate, concentrated and the residue was purified bysilica gel column purification (ISCO Optix 7×12 gram column) to give 948mg product as light yellow foam (yield: 82.6%). Calculated mass=574.Observed mass=574.

Method b

3-Amino-5-tert-butyl-2-methoxy-benzoic acid.5-t-Butyl-2-methoxy-3-nitrobenzoic acid (1.5 mmol) was reduced with Pd/Cand H₂ in MeOH, and the obtained amine was coupled with acid chloride(1.5 mmol). The reaction was worked up as described above and columnpurification (3×12 g silica gel) gave 211 mg of the target compound.

N-[5-tert-Butyl-2-methoxy-3-(piperidine-1-carbonyl)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(31) 26 mg (0.049 mmol) of the compound obtained above was converted tothe acid chloride by reaction with oxalyl chloride (54 μl, 0.5 mmol) in0.5 mL DCM in the presence of a catalytic amount of DMF (rt, 2 h). Afterremoval of the solvent, the crude acid chloride was dissolved in 1 mLDCM. DIEA (0.2 mmol) was added, followed by the addition of piperidine(0.1 mmol). The resulting mixture was stirred at rt overnight. Aqueouswork-up and purification by LC-MS resulted in 7.6 mg pure product.Calculated mass=602. Observed mass=602

5-tert-Butyl-2-hydroxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzoicacid (32). The starting material (11 mg, 0.02 mmol) was dissolved in 1mL DCM. A solution of BBr₃ in DCM (0.1 mL, 1 M solution) was added at 0°C., and the reaction was allowed to continue at the same temperature for2 hr before quenching with water. Aq. sodium bicarbonate work-up andpurification by LC-MS resulted in 3.6 mg target compound. Calculatedmass=521. Observed mass=521.

General Procedure for Derivatization of Pyrazolyl Containing Compounds

N-(5-tert-Butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide.To a solution of the acid chloride (prepared as before (695 mg, 2 mmol)in 10 mL EtOAc, 5-tert-butyl-2H-pyrazol-3-ylamine (278 mg, 2 mmol) andNaHCO₃ (504 mg, 6 mmol) in 2.5 mL H₂O were added. The solution wasstirred at 60° C. for 15 hr. The layers were separated and the organiclayer was purified by column chromatography (0-6% MeOH/DCM). The targetcompound was obtained as a pale yellow oil in 51% yield. Calculatedmass=450. Observed mass=451.

N-(5-tert-Butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(33). The compound obtained in the previous reaction (17 mg, 0.038 mmol)was treated for 15 hr at 60° C. with phenylsulfonyl chloride (9.8 μL,0.076 mmol) in pyridine (1 mL) in the presence of DMAP (2 mg). The crudereaction mixture was purified by preparative LC/MS to yield 3.1 mg oftarget material. Calculated mass=591. Observed mass=591.

Additional derivatives, such as amide and urea derivatives, weresynthesized by essentially the same methods.

Synthesis of Alpha-Ketoamides Method B: Via 2H-pyrazol-3-yl-oxo-aceticacid

5-tert-Butyl-2-p-tolyl-2H-pyrazole-3-carboxylic acid ethyl ester (R=Me).To a round bottom flask containing 5-tert-Butyl-2H-pyrazole-3-carboxylicacid ethyl ester (0.5 g, 2.6 mmol) stirring in 25 mL DCM was addedPyridine (0.95 mL, 11.7 mmol), p-tolylboronic acid (1.1 g, 8.1 mmol),Cu(OAc)₂ (0.75 g, 4.1 mmol) and 4 A molecular sieves (0.75 g). Thereaction stirred at room temperature for 14 h under air. The resultingmixture was filtered through a pad of diatomaceous earth and thefiltrate concentrated in vacuo to afford a light green solid. The crudematerial was purified by Flash chromatography to afford (0.64 g, 83%)the desired product as a clear oil (0-50% EtOAc:hexanes on silica gel).Expected mass=286. Observed mass=287.

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-methanol (R=Me). To an ovendried round bottom flask containing5-tert-Butyl-2-p-tolyl-2H-pyrazole-3-carboxylic acid ethyl ester (0.64g, 2.2 mmol) was added anhydrous THF (20 mL) followed by the drop wiseaddition of DIBAL-H (0.96 mL, 4.9 mmol) under nitrogen. After stirringat room temperature for 30 minutes the reaction was diluted with 100 mLdiethyl ether and quenched with 5 mL Methanol stirring for an additional30 minutes at room temperature. The resulting slurry was treated with 5g MgSO₄ and filtered through a pad of diatomaceous earth. The filtercake was washed with 3×75 mL portions of ether and the combinedfiltrates concentrated under vacuo to afford the desired alcohol as aclear oil (0.515 g, 96%). No further purification was necessary.Expected mass=244. Observed mass=245.

5-tert-Butyl-2-p-tolyl-2H-pyrazole-3-carbaldehyde (R=Me). To ascintillation vial containing(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-methanol (0.515 g, 2.1 mmol)was added 15 mL DCM followed by the addition of Dess-Martin periodinane(1.1 g, 2.52 mmol). The reaction mixture was allowed to stir at roomtemperature for 20 minutes and poured into a separatory funnelcontaining 30 mL water. The layers separated and the aqueous layerextracted twice more with 50 mL DCM. The combined organic layers werewashed with Brine, dried over MgSO₄ and concentrated under vacuum toafford the crude aldehyde. The crude material was purified by flashchromatography (0-50% EtOAc:Hexanes, silica gel) to yield the desiredproduct as a clear oil (0.5 g, 97%). Expected mass=242. Observedmass=243.

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-trimethylsilanyloxy-acetonitrile(R=Me). To and oven dried flask containing5-tert-Butyl-2-p-tolyl-2H-pyrazole-3-carbaldehyde (0.5 g, 2.0 mmol)stirring in anhydrous THF at 0° C. under nitrogen was added neattrimethylsilyl cyanide (0.29 mL, 2.2 mmol), followed by addition of onedrop of n-butyllithium (2.0 M in hexane). The mixture stirred at 0° C.for 1 h before warmed to room temperature and stirred overnight. Thereaction mixture was concentrated under vacuum to afford the product asthick oil. No further purification was attempted. Expected mass=341.Observed mass=342.

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-hydroxy-acetic acid (R=Me). Toa round bottom flask containing(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-trimethylsilanyloxy-acetonitrilewas added 100 mL concentrated HCl and heated to 80° C. After overnightheating, the reaction was diluted with 150 mL water and extracted withDCM (3×100 mL). The organic layers were washed with brine, dried oversodium sulfate, and concentrated under vacuum. The residue was thenre-dissolved in about 75 mL methanol, followed by the addition of KOH(0.45 g, 8 mmol) and the solution was refluxed for 2 h. The reactionmixture was then cooled to room temperature, concentrated under vacuum.Several pieces of crushed ice were added to the flask with the reactionresidue and acidified with 1N HCl. The mixture was then diluted with 100mL water and extracted with DCM (3×100 mL). The organic layers werewashed with brine, dried over MgSO4, and concentrated under vacuum toyield 0.35 g (60%) of the desired product. No further purification wasattempted. Expected mass=288. Observed mass=289.

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-oxo-acetic acid (34, R=Me). Toa scintillation vial containing(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-hydroxy-acetic acid (0.35 g,1.2 mmol) was added 15 mL DCM followed by the addition of Dess-Martinperiodinane (0.61 g, 1.44 mmol). The reaction mixture was allowed tostir at room temperature for 20 minutes and poured into a separatoryfunnel containing 30 mL 0.5 M HCl. The layers separated and the aqueouslayer extracted twice more with 50 mL DCM. The combined organic layerswere washed with Brine, dried over MgSO₄ and concentrated under vacuumto afford the desired product (purity >80% by NMR). No furtherpurification was attempted. Expected mass=286. Observed mass=287.

2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-2-oxo-acetamide(35, R=Me): To the crude(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-oxo-acetic acid 34 (0.4 g, 1.4mmol) in a 40 mL scintillation vial was added oxalyl Chloride (5 mL) andon drop of DMF. The suspension was stirred at rt for 1 h, andconcentrated under vacuum. The resulting solid was dissolved in EtOAc(10 mL) and added to 4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-ylamine(0.45 g, 1.2 mmol) dissolved in EtOAc (10 mL)/50% NaHCO₃ (10 mL) andstirred overnight at rt. The mixture was diluted with EtOAc andextracted with NaHCO₃. The combined organic layers were washed withbrine, dried over MgSO₄, filtered and the solvent removed affording adark brown oil. The material was purified by column chromatography(50-100% EtOAc/Hexanes) providing 0.357 g (57%) of the desired compoundas a yellow solid. Expected mass=540. Observed mass=541.

Synthesis of α-Ketoamides Method C: Via2H-pyrazol-3-yl-3-oxo-2-(triphenyl-λ5-phosphanylidene)-propionitrile

5-tert-Butyl-2-p-tolyl-2H-pyrazole-3-carboxylic acid. To5-tert-butyl-2-p-tolyl-2H-pyrazole-3-carboxylic acid ethyl ester (0.5 g,1.75 mmol) in a 40 mL scintillation vial was added 2 mL THF and 2 mL 1NLiOH. The reaction was heated at 50° C. for 1 hr after which thereaction mixture was concentrated under vacuum and the crude residue wasdiluted with 5 mL 1N HCl. The reaction slurry was then extracted withDCM (3×25 mL) and the combined organic layers were washed with brine (10mL) and dried over MgSO₄. The resulting solution was concentrated undervacuum to yield the desired product (0.432 g, 96%) in >95% purity. Theisolated material was used without further purification.

3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-oxo-2-(triphenyl-λ5-phosphanylidene)-propionitrile.To a round bottomed flask containing5-tert-Butyl-2-p-tolyl-2H-pyrazole-3-carboxylic acid (0.432 g, 1.67mmol) was added 50 mL DCM, followed by the addition of(triphenyl-15-phosphanylidene)-acetonitrile (0.635 g, 2.0 mmol), EDCI(0.394 g, 2.0 mmol) and DMAP (0.024 g, 0.2 mmol). The reaction mixturewas allowed to stir at room temperature for 16 hr and then concentratedunder vacuum. The crude residue was purified by flash chromatography(0-20% EtOAc:DCM on Silica gel) to yield the desired product as a whitepowder (0.722 g, 81%).

(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-oxo-acetic acid methyl ester:In a 100 mL round bottom flask containing3-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-oxo-2-(triphenyl-15-phosphanylidene)-propionitrile(0.722 g, 1.3 mmol) was added 25 mL DCM and 25 mL methanol. The startingmaterial was allowed to fully dissolve in the solvent mixture, afterwhich dimethyl dioxirane (25 mL, 0.1M in acetone) was added to thereaction. The resulting solution was allowed to stir at room temperaturefor 30 min, after which the reaction mixture was concentrated undervacuum and the crude material was purified by flash chromatography(0-20% EtOAc:DCM on silica gel) to afford the desired keto-ester as awhite solid (0.359 g, 92%).

2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide(35, R=Me). To (5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-oxo-acetic acidmethyl ester (0.359 g, 1.19 mmol) in a 40 mL scintillation vial wasadded 2 mL THF and 2 mL 1N LiOH. The reaction was heated at 50° C. for 1hr after which the reaction mixture was concentrated under vacuum andthe crude residue was diluted with 5 mL 1N HCl. The reaction slurry wasthen extracted with DCM (3×25 mL) and the combined organic layers werewashed with brine (10 mL) and dried over MgSO₄. The resulting solutionwas concentrated under vacuum to afford the desired acid.

The neat acid was then dissolved in a minimal amount of DCM ˜2 mL andoxalyl chloride (5 mL) was added, followed by the addition of one dropof DMF. The suspension was stirred at rt for 1 hr, and then concentratedunder vacuum. The resulting solid was dissolved in EtOAc (10 mL) andadded to 4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylamine (0.41 g, 1.2mmol) dissolved in EtOAc (10 mL)/50% NaHCO₃ (10 mL) and stirredovernight at rt. The mixture was diluted with EtOAc and washed withNaHCO₃. The aqueous layer was extracted twice more with 30 mL EtOAc andthe combined organic layers were washed with brine, dried over MgSO₄,filtered and the solvent removed under vacuum to afford a dark brownoil. The material was purified by column chromatography (0-100%EtOAc/DCM) yielding 0.250 g (47%) of the desired compound as a yellowsolid.

6-Boc-Amino-naphthalen-1-ol. 6-Amino-naphthalen-1-ol (5 g, 31.4 mmol)was suspended in 50 mL 0.5N NaHCO₃ and 50 mL EtOAc. Boc₂O (6.85 g, 31.4mmol) was added and the reaction mixture was stirred at 60° C.overnight. Complete conversion of starting material was achieved. Thesolvent layers were separated, the organic layer was washed with water,dried over MgSO4 and evaporated to yield the target material.

[6-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-carbamic acid tert-butylester. The compound obtained above (8.14 g, 31.4 mmol) was dissolved in100 mL AcN and 4-(2-chloro-ethyl)-morpholine (5.80 g, 34.5 mmol) andK₂CO₃ (15.6 g, 0.11 mol) were added. The reaction was stirred at 75° C.overnight. The mixture was filtered, the solvent evaporated and theresidue was purified by silica gel chromatography (DCM/MeOH: 15/1) toyield 0.51 g of target product. Calculated mass=372. Observed mass=372.

6-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl-Boc-amine (36). The Bocprotected material (1 g, 2.7 mmol) was stirred in 95% TFA/DCM/Et₃SiH atroom temperature for several days. After evaporation the target materialwas obtained. Calculated mass=272. Observed mass=272.

Example 4 Synthesis of Imidazolonopyridines and Imidazolonopyrimidines

2,6-Dichloro-nitro-pyridine or 2,4-dichloropyrimidine coupled smoothlywith various amines in presence of DIEA either in microwave (dioxane,180° C., 10 min) or at r.t. (THF, 70 h) as shown in the scheme above andas described in methods A and B.

Method A

(6-Chloro-3-nitro-pyridin-2-yl)-phenyl-amine. A mixture of2,6-dichloro-3-nitropyridine (386 mg, 2 mmol), aniline (182 μL, 2 mmol)and DIEA (419 μL, 2.4 mmol) in 3 mL dioxane was stirred in microwave at180° C. for 10 min. After removal of the solvent, the residue wasdissolved in 3 mL DCM, subjected to silica gel column purification togive 308 mg (yield 61.7%) (6-chloro-3-nitro-pyridin-2-yl)-phenyl-amine.Calculated mass=249. Observed mass=250.

Method B

(6-Chloro-3-nitro-pyridin-2-yl)-phenyl-amine. A mixture of2,6-dichloro-3-nitropyridine (772 mg, 4 mmol), aniline (364 μL, 4 mmol)and DIEA (838 μL, 24.8 mmol) in 10 mL THF was stirred at r.t. for 70 h.After removal of the solvent, the residue was dissolved in DCM, andsubjected to silica gel column purification to give 735 mg (yield 74%)of the title compound. LC-MS: Calculated mass=249. Observed mass=250.

3-Amino-6-chloro-pyridin-2-yl-p-tolyl-amine. A mixture of6-chloro-3-nitro-pyridin-2-yl-p-tolyl-amine (527 mg, 2 mmol) and tin(II)chloride dihydrate (2.72 g, 12 mmol) in 4 mL conc. HCl was heated at 90°C. for 2 h. After cooling down the yellow suspension was diluted withethyl acetate and treated with aq. K₂CO₃ at 0° C. under vigorousstirring to pH 10. The emulsion was extracted with 5×30 mL EtOAc. Thecombined organic phase was dried over Na₂SO₄. Evaporation gave 479 mg(yield: quantitative) of the title compound, which was pure by LC-MS andused for further reaction without any purification. Calculated mass=233.Observed mass=234.

5-Chloro-3-p-tolyl-1,3-dihydro-imidazo[4,5-b]pyridine-2-one (37). Amixture of 3-amino-6-chloro-pyridin-2-yl-p-tolyl-amine (470 mg, 2 mmol)and DSC (768 mg, 3 mmol) in 10 mL DMF was heated at 80° C. for 15 h.After cooling down the red solution was diluted with EtOAc, washed 2×with sat. sodium bicarbonate solution, 2× with water. Org. phase wasdried over sodium sulfate, evaporation gave 540 mg (quantitative yield)pink solid. TLC showed single spot (Rf=0.32 in DCM/MeOH (15:1)). LC-MSanalysis indicates that the compound was pure and was used as is in thefollowing step. Calculated mass=259. Observed mass=260.

1-Bicyclo[2.2.1]hept-2-yl-5-chloro-3-p-tolyl-1,3-dihydro-imidazo[4,5-b]pyridine-2-one(38) and2-(Bicyclo[2.2.1]hept-2-yloxy)-5-chloro-3-p-tolyl-3H-imidazo[4,5-b]pyridine(39). A mixture of5-Chloro-3-p-tolyl-1,3-dihydro-imidazo[4,5-b]pyridine-2-one (52 mg, 0.2mmol), exo-2-bromonorbornane (103 μL, 0.8 mmol) and Cs₂CO₃ (195 mg, 0.6mmol) in 1.5 mL DMF was heated in microwave at 200° C. for 20 min. Afterfiltration, the filtrate was diluted with EtOAc, washed with water. Theorganic phase was concentrated, the residue was dissolved in a minimumamount of DCM, and subjected to silica gel column purification to give21.2 mg (yield: 30%)1-Bicyclo[2.2.1]hept-2-yl-5-chloro-3-p-tolyl-1,3-dihydro-imidazo[4,5-b]pyridine-2-one(Rf=0.60 in DCM) and 6.2 mg (yield: 9%)2-(Bicyclo[2.2.1]hept-2-yloxy)-5-chloro-3-p-tolyl-3H-imidazo[4,5-b]pyridine(Rf=0.49 in DCM). Calculated mass=353. Observed mass=354.

1-Bicyclo[2.2.1]hept-2-yl-5-phenylamino-3-p-tolyl-1,3-dihydro-imidazo[4,5-b]pyridine-2-one(40). A mixture of1-bicyclo[2.2.1]hept-2-yl-5-chloro-3-p-tolyl-1,3-dihydro-imidazo[4,5-b]pyridine-2-one(19 mg, 0.054 mmol), 15 μL (0.16 mmol) aniline, Ligand (5.1 mg, 0.015mmol), Pd₂(dba)₃ (6.9 mg, 0.0075 mmol), t-BuOK (56 mg, 0.162 mmol) in 1mL dioxane was heated at 100° C. for 6 h. Prep LC-MS gave 3.2 mg TFAsalt of the title compound. Calculated mass=410. Observed mass=411.

2,6-Bis(p-tolylamino)-3-nitro-pyridine (X═C). A mixture of2,6-dichloro-3-nitropyridine (193 mg, 1 mmol), p-tolylamine (236 mg, 2.2mmol) and DIEA (524 μL, 3 mmol) in 3 mL dioxane was stirred in microwaveat 200° C. for 20 min. After removal of the solvent, the residue wasdissolved in chloroform and subjected to silica gel column purificationto give 291 mg (yield: 87%) title compound. Calculated mass=334.Observed mass=335.

2,6-Bis(p-tolylamino)-3-nitro-pyrimidine (X═N). A mixture of2,6-dichloro-3-nitropyrimidine (194 mg, 1 mmol), p-tolylamine (236 mg,2.2 mmol) and DIEA (524 μL, 3 mmol) in 3 mL dioxane was stirred inmicrowave at 200° C. for 20 min. After removal of the solvent, theresidue was dissolved in chloroform and subjected to silica gel columnpurification to give 319 mg (yield: 95%) title compound. Calculatedmass=335. Observed mass=336.

3-Amino-2,6-(bis-p-tolylamino)-pyridine. A mixture of2,6-Bis(p-tolylamino)-3-nitro-pyridine (288 mg, 0.86 mmol) and Tin(II)chloride dihydrate (1.25 g, 5.5 mmol) in 3 mL conc. HCl was heated at90° C. for 2 h. After cooling down the suspension was diluted with ethylacetate and treated with aq. K₂CO₃ at 0° C. under vigorous stirring topH 10. The emulsion was extracted with 5×30 mL EtOAc. The combinedorganic phase was dried over Na₂SO₄. Evaporation gave 254 mg (yield:97%) title compound, which was pure by LC-MS and used for furtherreaction without any purification. Calculated mass=304. Observedmass=305.

3-Amino-2,6-(bis-p-tolylamino)-pyrimidine.2,6-Bis(p-tolylamino)-3-nitro-pyrimidine was treated as described in theprevious procedure to yield the title compound, which was pure by LC-MSand used for further reaction without any purification. Calculatedmass=305. Observed mass=306.

3-p-Tolyl-5-p-tolylamino-1,3-dihydro-imidazo[4,5-b]pyridine-2-one (41).A mixture of 3-Amino-2,6-(bis-p-tolylamino)-pyridine (254 mg, 0.84 mmol)and DSC (323 mg, 1.26 mmol) in 6 mL DMF was heated at 80° C. for 20 h.After cooling down the red solution was diluted with EtOAc, washed 2×with sat. sodium bicarbonate solution, 2× with water. The organic phasewas dried over sodium sulfate, concentrated and subjected to silica gelcolumn purification to give 266 mg (yield: 96%) of the title compound.LC-MS: Calculated mass=330. Observed mass=331.

1-Bicyclo[2.2.1]hept-2-yl-3-p-tolyl-5-p-tolylamino-1,3-dihydro-imidazo[4,5-b]pyridine-2-one(42) and[2-(Bicyclo[2.2.1]hept-2-yloxy)-3-p-tolyl-3H-imidazo[4,5-b]pyridine-5-yl]-p-tolyl-amine(43). A mixture of3-p-Tolyl-5-p-tolylamino-1,3-dihydro-imidazo[4,5-b]pyridine-2-one (33mg, 0.1 mmol), exo-2-bromonorbornane (19 μL, 0.15 mmol) and Cs₂CO₃ (65mg, 0.2 mmol) in 0.5 mL DMF was heated at 180° C. for 3 h. After coolingdown EtOAc was added, and the organic layer was washed with water. Theorganic phase was concentrated, the residue was dissolved in a minimumamount of DCM and subjected to silica gel column purification to give13.4 mg (yield: 32%)1-Bicyclo[2.2.1]hept-2-yl-3-p-tolyl-5-p-tolylamino-1,3-dihydro-imidazo[4,5-b]pyridine-2-one(Rf=0.44 in DCM) and 4.8 mg (yield: 11%)[2-(Bicyclo[2.2.1]hept-2-yloxy)-3-p-tolyl-3H-imidazo[4,5-b]pyridine-5-yl]-p-tolyl-amine(Rf=0.27 in DCM).

Example 5 General Procedure for Difluoro-Acetic Acid Derivatives

Difluoro-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetic acidmethyl ester (44). To a solution of keto-ethyl ester 12 (0.618 g, 1.80mmol) in CH₂Cl₂ (20 mL) was added Diethylaminosulfur trifluoride (1.70mL, 13.8 mmol) and EtOH (3 drops). The solution was stirred at rt for 3days. The mixture was neutralized with saturated NaHCO₃ and extractedwith CH₂Cl₂ (3×20 mL). The combined organic layers were washed withbrine, dried over MgSO₄, filtered and the solvent removed. The crudematerial was purified by preparative LCMS yielding 70 mgs (10% yield) asan oil. Expected mass=365. Observed mass=366.

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2,2-difluoro-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide(45). The Difluoro methyl ester 44 was saponified, converted to the acidchloride and coupled as described previously. Expected mass=562.Observed mass=563.

Example 6 Synthesis of Diamide Derivatives

N-Naphthalen-1-yl-oxalamic acid methyl ester. In a round bottom flaskcontaining 1-naphthyl amine (0.1 g, 0.68 mmol) stirring in DCM (5 mL)was added DIEA (0.18 mL, 1.02 mmol) and chloro-oxo-acetic acid methylester (0.068 mL, 0.748 mmol). The mixture was allowed to stir at roomtemperature for 1 h. The reaction mixture was poured over saturatedsodium bicarbonate and the layers separated. The aqueous layer wasextracted twice more with 3×15 mL DCM. The combined organics were washedwith brine, dried over MgSO₄ and concentrated in vacuo to afford a brownsolid. The crude material was purified by flash chromatography (0-50%EtOAc:Hexanes on silica gel) to yield the desired product (0.14 g, 90%)as an off-white solid. Expected mass=229. Observed mass=230.

N-Naphthalen-1-yl-oxalamic acid. To N-Naphthalen-1-yl-oxalamic acidmethyl ester (0.14 g, 0.61 mmol) stirring in THF (2 mL) was added 2 mLof a 1N lithium hydroxide solution. The reaction was heated to 50° C.and stirred for 2 h. The resulting mixture was concentrated in vacuo toafford a yellow residue that was acidified with 1N HCL. The resultingmixture was extracted with DCM (3×50 mL), dried over MgSO₄ andconcentrated under vacuum to afford crude product. The crude materialwas purified by flash chromatography (0-20% MeOH:DCM, silica gel) toafford the desired product (0.128 g, 98%) as a thick oil. Expectedmass=215. Observed mass=216.

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N′-naphthalen-1-yl-oxalamide(46). In a round bottom flask containing the N-Naphthalen-1-yl-oxalamicacid (0.128 g, 0.6 mmol) stirring in DCM (5 mL) was addeddiisopropylcarbodiimide (0.09 g, 0.72 mmol) and DIEA (0.19 mL, 1.08mmol). The reaction was allowed to stir at room temperature overnightand quenched with 10 mL saturated NaHCO₃. The layers separated and theaqueous layer extracted twice more with 2×25 mL DCM. The combinedorganics were washed with brine, dried over MgSO₄ and concentrated undervacuum to afford a brown oil. The crude mixture was purified by flashchromatography (50-100 EtOAc:hexanes, silica gel) to afford the desiredproduct (184 g, 72%) as an off-white solid. Expected mass=426. Observedmass=427.

Example 7 General Procedure for Formation of Oxime Derivatives

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxyimino-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide(47). Compound 13 (10 mg, 0.018 mmol) and hydroxylamine hydrochloride(50 eqv., 0.92 mmol, 64 mg) were dissolved in 2 mL of EtOH. Pyridine(0.1 mL) was added and the mixture was stirred at 45° C. for 12 h. Thesolvent was then removed in vacuo and the crude solid was purified viaLCMS to yield 6 mg of a white solid (58% yield; mixture of isomers).Expected mass=555. Observed mass=556.

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-methoxyimino-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide(48). Compound 13 (10 mg, 0.018 mmol) and methoxyamine hydrochloride (50eqv., 0.92 mmol, 77 mg) were dissolved in 2 mL of EtOH. Pyridine (0.1mL) was added and the mixture was stirred at 45° C. for 12 h. Thesolvent was then removed in vacuo and the crude solid was purified viaLCMS to yield 8 mg of a white solid (76% yield; mixture of isomers).Expected mass=569. Observed mass=570.

Example 8

4-(Morpholin-4-yl-ethyloxy)-1-naphthylepoxide. To a suspension of NaH(24 mg, 1.0 mmol) in DMSO (1 mL), trimethylsulfoxonium iodide (220 mg,1.0 mmol) was added. After the H₂ evolution ceased, a solution ofaldehyde 8 (285 mg, 1.0 mmol) in DMSO (0.5 mL) was added and the mixturestirred at 20° C. for 12 h. The mixture was diluted with H₂O, extractedwith Et₂O and the combined organic layers dried (MgSO₄) and rotaryevaporated to give a yellow oil which was used in the next step withoutany purification. Expected mass=299. Observed mass=300.

N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-ethylamine(49). To a solution of 5-amino-3-t-butyl-1-(4 methylphenyl)pyrazole (1)(50 mg, 0.2 mmol) in 1,4-dioxane (2 mL), n-BuLi (0.1 mL, 0.2 mmol, 2.0 Min cyclohexane) was added at 20° C. under N₂. A solution of the compoundobtained in the previous reaction in DMF (1 mL) was added and the brownmixture heated for 5 min in the microwave at 150° C. The mixture wasdiluted with CH₂Cl₂, washed with water and the organic layer dried(MgSO₄) and rotary evaporated to give a brown oil which was purified bypreparative LC-MS to give the title compound (8.3 mg, 8%) as a yellowwaxy solid: Calculated mass=528. Observed mass=529.

Example 9 Synthesis of Triazolidine-Dione Derivatives Route A

N′-(3-tert-Butyl-phenyl)-hydrazinecarboxylic acid ethyl ester.3-t-Butylhydrazine hydrochloride (600 mg, 3 mmol) was dissolved in 15 mLDCM, DIEA (1.7 mL, 10 mmol) was added, followed by addition of ethylchloroformate (3 mmol). The reaction mixture was stirred at rtovernight, followed by aq. sodium bicarbonate work-up. The organic phasewas dried over Na₂SO₄, concentrated and subjected to ISCO column (4×12g) purification to give 437 mg product as brown oil.

1-(3-tert-Butyl-phenyl)-4-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-[1,2,4]triazolidine-3,5-dione(50). 4-(2-N-morpholinoethoxy)naphthylamine dihydrochloride (70 mg, 0.2mmol) was dissolved in a cold (0° C.) mixture of 4 mL DCM and 4 mLsaturated NaHCO₃ solution. Stirring was stopped. After addition of 0.36mL ca. 20% phosgene in toluene to the DCM layer, vigorous stirring wasresumed. Reaction was continued at 0° C. for 30 min. The organic layerwas separated, and the aqueous layer was extracted once with DCM. Thecombined organic layers were evaporated. A solution ofN′-(3-tert-Butyl-phenyl)-hydrazinecarboxylic acid ethyl ester (47 mg,0.2 mmol) in 1 mL DCM was added to this crude isocyanate. The reactionmixture was stirred at rt overnight. After removal of the solvent, theresidue was dissolved in DMSO and subjected to preparative LC-MSpurification to afford 8.4 mg of the target compound. The compoundobtained in the previous step (8.4 mg, 0.016 mmol) was dissolved in 1 mLEtOH, and a solution of NaOH (2 mg, 0.05 mmol) in 0.2 mL water wasadded. The resulting mixture was stirred at rt for 2 hr, before it wasneutralized with conc. HCl to pH 4. Purification of the crude materialwas achieved by preparative LC-MS to give 6 mg final product.

Route B

1-tert-Butyl-3-isocyanato-benzene. 3-t-Butyl-aniline (150 mg, 1 mmol)was converted to the isocyanate as described above and then dissolved in4 mL DCM. Hydrazate (104 mg, 1 mmol) was added and the reaction wascontinued at rt overnight. Preparative LC-MS purification afforded 181mg of the target compound as a white solid.

Ethyl 2-[(tolylamino)carbonyl]hydrazinecarboxylate. NBS (121 mg, 0.68mmol) was added to a stirred suspension of1-tert-Butyl-3-isocyanato-benzene (181 mg, 0.65 mmol) in 3 mL DCM and105 μl pyridine at rt. After stirring for another 2 hr, 2 mL of waterwas added, followed by addition of 1 mL conc. HCl. The organic phase wasseparated, and washed with a solution of Na₂S₂O₃ (65 mg) in 3 mL water,saturated NaHCO₃ and water. The organic phase was dried over Na₂SO₄ andconcentrated to give 182 mg of the target compound as a pale red thickoil.

4-(3-tert-Butyl-phenyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-[1,2,4]triazolidine-3,5-dione.(51). A cold solution of the compound obtained above (55 mg, 0.2 mmol)and 1-(2-morpholinoethoxy)-naphthalene (51 mg, 0.2 mmol) in 1.5 mL DCMwas added drop wise to a stirred suspension of ZrCl₄ in 0.5 mL DCM at−30° C. The reaction was continued at −30° C. for 45 min, then it wasallowed to warm up to rt and 1 mL of water was added to quench thereaction. Neutralization was done with saturated NaHCO₃. The organicphase was separated and the aqueous phase was extracted with DCM. Thecombined organic phases were dried over Na₂SO₄, concentrated andsubjected to preparative LC-MS purification to give 22.8 mg of targetcompound.

The compound obtained above (22.8 mg, 0.43 mmol) was dissolved in 2 mLEtOH. A solution of NaOH (4 mg, 1 mmol) in 0.4 mL water was added. Afterstirring at rt for 2 hr, the reaction mixture was neutralized with conc.HCl (to pH=4) and subjected directly to preparative LC-MS purificationto afford 7 mg final product.

Example 10

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-succinamicacid methyl ester (52). To the keto-amide (13b) (250 mg, 0.43 mmol)stirring in toluene was added the ylide (156 mg, 0.52 mmol) and twodrops of diisopropylethyl amine. The reaction was sealed and heated to100° C. overnight. The reaction was cooled to room temperature andconcentrated under vacuum. The crude residue was purified by LCMS,yielding two isomers independently isolated as white solids (105 mg,84%). Both isomers were carried on in the next step.

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-succinamicacid methyl ester (53). A 50 mL round bottom flask containing ethylacetate and the succinamic acid obtained in the reaction above (75 mg,0.12 mmol) was sparged with nitrogen for 5 min. The resulting solutionwas placed under nitrogen and treated with 10% Pd/C (10 mole %). Theatmosphere was then exchanged with hydrogen via a balloon, and thereaction was stirred at room temperature for 16 h. The resultingsolution was filtered through a pad of celite and the filtrateconcentrated under vacuum to yield crude product. The crude material waspurified by flash chromatography to yield the desired product as a whitesolid (65 mg) in 87% yield.

N-(5-tert-butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,5-dioxo-2,5-dihydro-pyrrol-1-yl}-phenyl)-methanesulfonamide(54). In a 40 mL scintillation vial was placed3-(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acrylicacid methyl ester 51 (25 mg, 0.04 mmol), DIEA (13.6 mL, 0.08 mmol), and5 mL THF. The reaction was heated to 80° C., stirring for 16 hours. Theresulting reaction mixture was concentrated under vacuum and the cruderesidue purified by reverse phase preparative LC-MS to afford (10.2 mg,39%) of the desired compound. Calculated mass=607. Observed mass=608.

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,5-dioxo-pyrrolidin-1-yl}-phenyl)-methanesulfonamide(55). In a 20 mL scintillation vial was placed (28 mg, 0.046 mmol)N-(5-tert-butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,5-dioxo-2,5-dihydro-pyrrol-1-yl}-phenyl)-methanesulfonamide,5 mL ethanol, and Pd/C (15 mg, 10 mole %). The vial was sealed with aseptum and the reaction mixture was sparged with house nitrogen for 10minutes. The resulting solution was then sparged with hydrogen gas via aballoon for 5 minutes. After recharging the balloon with hydrogen gasthe reaction was allowed to stir at room temp for 2 hours. The resultingsolution was filtered through a pad of celite and concentrated undervacuum to afford the desired product (27 mg, 100%). Calculated mass=610.Observed mass=611.

Example 11

Hydroxy-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetic acid methylester. To a solution of 12 (1 g, 2.9 mmol) in MeOH (10 mL), Pd/C (10 wt%) was added and the mixture stirred at rt under H₂ atmosphere. Uponcompletion of the reaction (monitored by LCMS), the mixture was filteredthrough celite and the filtrate evaporated to give a yellow oil whichsolidified upon standing. Calculated mass=345. Observed mass=345.

[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetic acid. The yellowsolid (0.5 g) was dissolved in CH₂Cl₂ (10 mL). To this solution TFA (10mL) and Et₃SiH (10 eq., 30 mmol) were added and the mixture was stirredat rt until the reaction was complete (after further addition of 10 eq.of Et₃SiH as indicated by LCMS). The solvent was evaporated and theresidue triturated with hexane. The product which precipitated wasfiltered, washed with hexane, dried in vacuo and taken up in MeOH/THF(1:1, 10 mL). To this solution, 2M NaOH (2.2 mL) was added and themixture was stirred at rt for 4 h. The mixture was neutralized with 6 MHCl and evaporated to give a brown residue. The residue was repeatedlytaken up in a minimum amount of MeOH and filtered from residual NaCl.The solvent was evaporated and the acid dried in vacuo at 50° C.Calculated mass=315. Observed mass=315.

N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide(56). To a suspension of the acid in CH₂Cl₂ (5 mL), oxalyl chloride (10eq) and a drop of DMF were added. The mixture cleared rapidly under theevolution of gas and was left stirring at rt for 4 h. The solvent wasevaporated to give a foamy residue which was dried in vacuo and taken upagain in CH₂Cl₂ (5 mL). To this solution, DIEA (3 eq) and 14 (1.2 eq)were added and the mixture was stirred at rt for 60 h. The brownsolution was washed with H₂O, dried (MgSO₄) and evaporated. The brownresidue was purified by column chromatography on silica with EtOAc aseluent to give the final product as a pale yellow solid. Calculatedmass=569. Observed mass=569.

Example 12

N′-{(5-tert-Butyl-3-sec-butylcarbamoyl-2-methoxy-phenylcarbamoyl)-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-methylene}-hydrazinecarboxylicacid ethyl ester. Compound 30 (44 mg, 0.077 mmol) was dissolved in EtOH(1 mL) and hydrazinecarboxylic acid ethyl ester (24 mg, 0.231 mmol) and1 drop of AcOH were added. The reaction mixture was stirred at 120° C.for 15 hrs, after which the crude mixture was purified by LC/MS. Theisomers separated and the desired isomer was taken on into the nextstep. Calculated mass=660. Observed mass=660.

5-tert-Butyl-N-cyclopropyl-2-methoxy-3-{6-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-3,5-dioxo-2,5-dihydro-3H-1,2,4-triazin-4-yl}-benzamide(57). The compound obtained in the previous step (˜8 mg, 0.1 mmol) wasdissolved in EtOH, and DIEA (0.1 ml, 0.6 mmol) was added. The mixturewas stirred at 120° C. overnight and then purified by LC/MS to yield 2.5mg of target product. Calculated mass=614. Observed mass=614.

Example 13 Inhibition of TNFa Production in THP Cells

The inhibition of cytokine production can be observed by measuringinhibition of TNFa in lipopolysaccharide-stimulated THP-1 cells (seePrichett et al. J. Inflammation, 1995, 45, 97). THP-1 cells (ATCC TIB202, American Type Culture Collection, Rockville, Md.) were maintainedat 37° C., 5% CO, in RPMI 1640 media with 10% fetal bovine serum, 10 mMHepes, 1 mM sodium pyruvate, 4.5 g/L glucose and 0.05 mM2-mercaptoethanol as suggested by ATCC. For the assay the cells andcompounds were diluted in the media above except with 1% fetal bovineserum (assay media). Test compound stocks in DMSO were diluted intoassay media to 6× the final assay concentration, with a final DMSOconcentration of 0.3% in the assay. THP-1 cells were plated at1×10⁵/well in 96 well tissue culture plates. Diluted compounds (or DMSOcontrol) were added and allowed to preincubate with the cells at 37° C.,5% CO₂ for 30 minutes prior to the addition of LPS (Sigma) to a finalconcentration of 1 μg/mL. Cells were then incubated 18-20 h at 37° C./5%CO₂. The assay was terminated by centrifuging the plates for 10 min atroom temperature. Supernatants were removed to clean culture plates andaliquots removed for analysis for TNFa by a commercially available ELISAkit (R&D Systems #DY210, Minneapolis, Minn.). Data was analyzed bynon-linear regression using PRISM 4 software from Graphpad Software (SanDiego, Calif.). The calculated IC₅₀ is the concentration of the testcompound that caused a 50% decrease in the maximal TNFa production.

Example 14

Table 1 lists compounds of the invention prepared using the methods ofExamples 1-13. Each compound was analyzed by LC-MS and displayed theexpected molecular ion. Each of the compounds in Table 1 was tested inthe TNFa ELISA assay (Example 13) and found to have activity therein,with some compounds having IC₅₀s below 10 μM in this assay.

TABLE 1 Compound number Compound Name Calculated MW 21H-Indazole-3-carboxylic acid (5-tert-butyl-2-p-tolyl- 3732H-pyrazol-3-yl)-amide 73-tert-Butyl-5-phenyl-1-p-tolyl-1,6-dihydro-imidazo[4,5- 330 c]pyrazole13 N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 541morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 15N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 584phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide17 N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 634phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide 22N-(5-tert-Butyl-2-hydroxy-3-morpholin-4-ylmethyl- 576phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide23 N-(5-tert-Butyl-2-hydroxy-3-methyl-phenyl)-2-[4-(2- 491morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 24N-(5-tert-Butyl-2-methoxy-3-methyl-phenyl)-2-[4-(2- 505morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 26N-(5-tert-Butyl-3-chloro-2-methoxy-phenyl)-2-[4-(2- 525morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 28N-(5-tert-Butyl-2-methoxy-3-trifluoromethyl-phenyl)-2- 559[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 29N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[7-chloro-4- 575(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 305-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2- 574morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetylamino}-benzamide 31N-[5-tert-Butyl-2-methoxy-3-(piperidine-1-carbonyl)- 602phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide32 5-tert-Butyl-2-hydroxy-3-{2-[4-(2-morpholin-4-yl- 521ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzoic acid 33N-(2-Benzenesulfonyl-5-tert-butyl-2H-pyrazol-3-yl)-2- 591[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 352-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N-[4-(2- 541morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 401-Bicyclo[2.2.1]hept-2-yl-5-phenylamino-3-p-tolyl-1,3- 411dihydro-imidazo[4,5-b]pyridin-2-one 413-p-Tolyl-5-p-tolylamino-1,3-dihydro-imidazo[4,5- 330 b]pyridin-2-one 421-Bicyclo[2.2.1]hept-2-yl-3-p-tolyl-5-p-tolylamino-1,3- 425dihydro-imidazo[4,5-b]pyridin-2-one 45N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2,2-difluoro- 5632-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 46N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N′- 427naphthalen-1-yl-oxalamide 47N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[(Z)- 556hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide48 N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[(Z)- 570methoxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide49 2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylamino)-1-[4-(2- 529morpholin-4-yl-ethoxy)-naphthalen-1-yl]-ethanol 501-(3-tert-Butyl-phenyl)-4-[4-(2-morpholin-4-yl-ethoxy)- 489naphthalen-1-yl]-[1,2,4]triazolidine-3,5-dione 514-(3-tert-Butyl-phenyl)-1-[4-(2-morpholin-4-yl-ethoxy)- 489naphthalen-1-yl]-[1,2,4]triazolidine-3,5-dione 52(E)-3-(5-tert-Butyl-3-methanesulfonylamino-2- 640methoxy-phenylcarbamoyl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acrylic acid methyl ester 54N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl- 608ethoxy)-naphthalen-1-yl]-2,5-dioxo-2,5-dihydro-pyrrol-1-yl}-phenyl)-methanesulfonamide 55N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl- 610ethoxy)-naphthalen-1-yl]-2,5-dioxo-pyrrolidin-1-yl}-phenyl)-methanesulfonamide 56N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 570phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-acetamide 57N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 632phenyl)-2-oxo-2-[4-(2-piperidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-acetamide 583-tert-Butyl-1-p-tolyl-5-(3-trifluoromethyl-phenyl)-1,6- 398dihydro-imidazo[4,5-c]pyrazole 591-(2-Morpholin-4-yl-ethyl)-1H-indazole-3-carboxylic 530 acid(5-tert-butyl-3-methanesulfonylamino-2-methoxy- phenyl)-amide 60N-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- 4472-(2,4,6-trimethyl-phenyl)-acetamide 61 1-Phenyl-cyclopropanecarboxylicacid (5-tert-butyl-2- 373 p-tolyl-2H-pyrazol-3-yl)-amide 62N-[5-tert-Butyl-2-(2,5-difluoro-phenyl)-2H-pyrazol-3-yl]- 5632-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 63N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4- 491yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 64N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 485phenyl)-2-(4-methoxy-naphthalen-1-yl)-2-oxo- acetamide 65N-[5-tert-Butyl-2-(3-chloro-benzoyl)-2H-pyrazol-3-yl]-2- 589[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 66N-[5-tert-Butyl-2-(3-methanesulfonyl-phenyl)-2H- 605pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 674-[(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)- 455methyl]-piperidine-1-carboxylic acid tert-butyl ester 68N-[3-(Benzenesulfonyl-carbamoylmethyl-amino)-5- 574tert-butyl-2-methoxy-phenyl]-2-naphthalen-1-yl-2-oxo- acetamide 69N-(3-tert-Butyl-isoxazol-5-yl)-2-[4-(2-morpholin-4-yl- 452ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 70N-(5-tert-Butyl-3-ethanesulfonylamino-2-methoxy- 656phenyl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-succinamic acidmethyl ester 71 2-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)-N-[4-(2- 541morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 72N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 590morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]- 2-oxo-acetamide 735-tert-Butyl-2-(3-chloro-phenyl)-2H-pyrazole-3- 533 carboxylic acid[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-amide 742-(3-Bromo-4-methoxy-phenyl)-N-(5-tert-butyl-2-p- 456tolyl-2H-pyrazol-3-yl)-acetamide 75N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[3-fluoro-4- 495(2-morpholin-4-yl-ethoxy)-phenyl]-acetamide 76(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-(2,2-dimethyl- 299propyl)-amine 77 2-(4-Benzyloxy-phenyl)-N-(5-tert-butyl-2-p-tolyl-2H-454 pyrazol-3-yl)-acetamide 78N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2- 543[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 79N-[5-tert-Butyl-2-(4-sulfamoyl-phenyl)-2H-pyrazol-3- 606yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 805-tert-Butyl-2-methoxy-3-(1-naphthalen-1-yl-3,5-dioxo- 432[1,2,4]triazolidin-4-yl)-benzamide 812-(4-Bromo-naphthalen-1-yl)-N-(5-tert-butyl-2-methyl- 4142H-pyrazol-3-yl)-2-oxo-acetamide 825-tert-Butyl-2-hydroxy-3-{2-[4-(2-morpholin-4-yl- 520ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}- benzamide 83N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2- 444(4-methoxy-naphthalen-1-yl)-acetamide 84N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 631phenyl)-2-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide 85N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2- 484methylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2- oxo-acetamide 86N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2- 498dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]- 2-oxo-acetamide 87N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-[2- 573(1-oxo-1λ⁴-thiomorpholin-4-yl)-ethoxy]-naphthalen-1- yl}-acetamide 885-tert-Butyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin- 5404-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-thiophene- 2-carboxylic acidmethyl ester 89 N-[5-tert-Butyl-2-(3-methanesulfonyl-phenyl)-2H- 607pyrazol-3-yl]-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 90N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2- 569((2R,6R)-2,6-dimethyl-morpholin-4-yl)-ethoxy]-naphthalen-1-yl}-2-oxo-acetamide 91N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(6- 512morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2- oxo-acetamide 92N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 618phenyl)-2-[7-chloro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 93N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 599phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 94N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(6-morpholin-4- 538ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo- acetamide 955-tert-Butyl-N-cyclopropyl-2-methoxy-3-[2-(4-methoxy- 475naphthalen-1-yl)-2-oxo-acetylamino]-benzamide 964-tert-Butyl-N-[4-(2-piperidin-1-yl-ethoxy)-naphthalen- 4311-yl]-benzamide 97 N-(2-Acetyl-5-tert-butyl-2H-pyrazol-3-yl)-2-[4-(2-493 morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 985-tert-Butyl-N-cyclopropyl-3-{2-hydrazono-2-[4-(2- 588morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-2-methoxy-benzamide 99 N-(5-tert-Butyl-2-methoxy-phenyl)-2-hydroxy-2-(4-408 methoxy-naphthalen-1-yl)-propionamide 100N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2- 361 phenyl-acetamide101 N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 598phenyl)-2-hydrazono-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 102 2,3-Dihydro-indole-1-carboxylic acid(5-tert-butyl-2-p- 374 tolyl-2H-pyrazol-3-yl)-amide 103N-(3,4-Dimethyl-phenyl)-2-[4-(2-morpholin-4-yl- 433ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 104N-(5-tert-Butyl-2-cyclohexyl-2H-pyrazol-3-yl)-2-[4-(2- 533morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 105N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(3,5- 383difluoro-phenyl)-acetamide 106N-(5-tert-Butyl-2-methoxy-phenyl)-2-oxo-2-(4-pyridin- 4393-yl-naphthalen-1-yl)-acetamide 107N-(5-tert-Butyl-isoxazol-3-yl)-2-[(Z)-hydroxyimino]-2- 467[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 108N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 570phenyl)-2-[4-(2-diethylamino-ethoxy)-naphthalen-1-yl]- 2-oxo-acetamide109 N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-[2- 552(3-oxo-[1,4]diazepan-1-yl)-ethyl]-naphthalen-1-yl}- acetamide 1105-tert-Butyl-N-ethyl-2-methoxy-3-[2-(4-methoxy- 463naphthalen-1-yl)-2-oxo-acetylamino]-benzamide 111N-(5-tert-Butyl-2-methoxy-phenyl)-2-oxo-2-{4-[6- 538(tetrahydro-pyran-4-ylamino)-pyridin-3-yl]-naphthalen- 1-yl}-acetamide112 5-tert-Butyl-3-ethanesulfonylamino-2-methoxy-N-[4-(2- 570morpholin-4-yl-ethoxy)-naphthalen-1-yl]-benzamide 1132-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-oxo-N-m- 299 tolyl-acetamide114 N-(2,5-Dimethyl-phenyl)-2-[4-(2-morpholin-4-yl- 433ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 115 Pyrrolidine-1-carboxylicacid (5-tert-butyl-2-methoxy-3- 603{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-amide 1162-(4-Bromo-phenyl)-N-(5-tert-butyl-2-methoxy-phenyl)- 376 acetamide 117N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-oxo-2-{4- 589[2-((S)-1-phenyl-ethylamino)-pyrimidin-4-ylamino]-naphthalen-1-yl}-acetamide 1185-tert-Butyl-3-[1-(2,3-dimethyl-phenyl)-3,5-dioxo- 410[1,2,4]triazolidin-4-yl]-2-methoxy-benzamide 119N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-naphthalen- 3982-yl-acetamide 120 5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 534ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}- benzamide 121N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-methoxy-2- 472(4-methoxy-naphthalen-1-yl)-propionamide 1225-tert-Butyl-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)- 522naphthalen-1-ylmethyl]-3-nitro-benzamide 123N-(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 610ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)- benzamide 124N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2,5- 383difluoro-phenyl)-acetamide 125N-(3,5-Di-tert-butyl-2-methoxy-phenyl)-2-[(Z)- 562hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide126 N′-[1-(5-tert-Butyl-2-methyl-2H-pyrazol-3- 522ylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]- hydrazinecarboxamide 127N-[2-(4-Amino-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2- 544hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-acetamide 1285-tert-Butyl-3-{2-[(Z)-methoxyimino]-2-[4-(2-morpholin- 5394-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-thiophene- 2-carboxylic acidamide 129 Ethanesulfonic acid (5-tert-butyl-2-methoxy-3-{3-[4-(2- 622morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,5-dioxo-2,5-dihydro-pyrrol-1-yl}-phenyl)-amide 1305-tert-Butyl-N-cyclopropylmethyl-2-methoxy-3-{2-[4-(2- 588morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetylamino}-benzamide131 5-Fluoro-1H-indazole-3-carboxylic acid (5-tert-butyl-2- 391p-tolyl-2H-pyrazol-3-yl)-amide 132N-[5-tert-Butyl-2-methoxy-3-(2-methoxy-acetylamino)- 578phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthaten-1- yl]-2-oxo-acetamide133 7-Bicyclo[2.2.1]hept-2-yl-9-p-tolyl-2-p-tolylamino-7,9- 426dihydro-purin-8-one 134N-(5-tert-Butyl-2-isopropoxy-3-methanesulfonylamino- 612phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide135 N-[5-tert-Butyl-2-(3,4-dimethyl-phenyl)-2H-pyrazol-3- 555yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 1363-tert-Butyl-1-(3,4-dichloro-phenyl)-5-phenyl-1,6- 385dihydro-imidazo[4,5-c]pyrazole 137N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-[4-(2- 557thiomorpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 1385-Nitro-1H-pyrazole-3-carboxylic acid (5-tert-butyl-2-p- 368tolyl-2H-pyrazol-3-yl)-amide 139N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 591phenyl)-2-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 1401-(2-Amino-4-tert-butyl-6-{2-[4-(2-morpholin-4-yl- 554ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)- pyridinium 141N-(5-tert-Butyl-2-isopropoxy-phenyl)-2-[4-(2- 519morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 142N-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2,5- 512bis-trifluoromethyl-benzamide 1432-(tert-Butyl-dimethyl-silanyloxy)-N-(5-tert-butyl-2-p- 508tolyl-2H-pyrazol-3-yl)-2-(4-methoxy-phenyl)-acetamide 144N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[(Z)- 556hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide145 5-tert-Butyl-2-methoxy-3-[2-(4-methoxy-naphthalen-1- 434yl)-2-oxo-acetylamino]-benzamide 146N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2- 361 phenyl-acetamide147 5-tert-Butyl-2-methoxy-N-(2-methoxy-ethyl)-3-{2-[4-(2- 592morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetylamino}-benzamide148 (E)-3-(5-tert-Butyl-3-ethanesulfonylamino-2-methoxy- 654phenylcarbamoyl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acrylic acid methyl ester 1491-Isopropyl-3-phenyl-5-phenylamino-1,3-dihydro- 344imidazo[4,5-b]pyridin-2-one 150N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl- 501pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo- acetamide 1512-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)-2-[(Z)- 556hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide152 2-(5-tert-Butyl-2-methoxy-phenyl)-N-[4-(2-morpholin-4- 491yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 153N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2,4- 408dimethoxy-phenyl)-acetamide 154(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 564ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)- carbamic acidmethyl ester 155 3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)- 628naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1- carboxylic acidadamantan-1-ylamide 1563-tert-Butyl-5-phenyl-1-(4-trifluoromethyl-phenyl)-1,6- 384dihydro-imidazo[4,5-c]pyrazole 157N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl- 625ethoxy)-naphthalen-1-yl]-2,4,5-trioxo-imidazolidin-1-yl}-phenyl)-methanesulfonamide 1583-tert-Butyl-1-(3-chloro-phenyl)-5-phenyl-1,6-dihydro- 351imidazo[4,5-c]pyrazole 1595-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-ethoxy)- 510naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2- carboxylic acid amide160 2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-N- 543[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 161N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-(2,6- 553dimethyl-morpholin-4-yl)-ethyl]-naphthalen-1-yl}-2- oxo-acetamide 162N-(5-tert-Butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl- 451ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 163N-[5-tert-Butyl-2-methoxy-3-(propane-1- 598sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 1643-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)- 550naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1- carboxylic acidtert-butylamide 165 1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-(2,3-428 dichlorophenyl)-3′-(carbamic acid ethyl ester)-urea 1662-(3,5-Difluoro-phenyl)-N-[4-(2-morpholin-4-yl-ethoxy)- 440naphthalen-1-yl]-2-oxo-acetamide 1673-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)- 494naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1- carboxylic acid amide168 N-Allyl-5-tert-butyl-2-methoxy-3-{2-[4-(2-morpholin-4- 574yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}- benzamide 169N-(5-tert-Butyl-isoxazol-3-yl)-2-[(Z)-methoxyimino]-2- 481[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 1703-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-1-[4-(2- 489morpholin-4-yl-ethoxy)-naphthalen-1-yl]-pyrrole-2,5- dione 1712-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[(Z)- 480hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide172 3-tert-Butyl-5-o-tolyl-1-p-tolyl-1,6-dihydro-imidazo[4,5- 344c]pyrazole 173 N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[(E)- 376hydroxyimino]-2-phenyl-acetamide 174N-(5-tert-Butyl-2-methoxy-phenyl)-2-hydroxy-2-phenyl- 313 acetamide 175N-(3-Acetylamino-5-tert-butyl-2-methoxy-phenyl)-2-[4- 548(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 1761H-Indazole-3-carboxylic acid (5-tert-butyl-3- 417methanesulfonylamino-2-methoxy-phenyl)-amide 1775-tert-Butyl-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)- 508naphthalen-1-yl]-3-nitro-benzamide 1785-tert-Butyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin- 5754-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-acetylamino}-thiophene-2-carboxylic acid amide 179N-[3-(4-Acetyl-piperazine-1-carbonyl)-5-tert-butyl-2- 645methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 1802-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-N-[4-(2- 515morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2- oxo-acetamide 181N-(5-tert-Butyl-4-methyl-2-p-tolyl-2H-pyrazol-3-yl)-2- 570[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 1822-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- 445N-(2-phenyl-cyclopropyl)-acetamide 183N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(6-morpholin-4- 499ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo- acetamide 184N-(5-tert-Butyl-2,3-dimethoxy-phenyl)-2-[(Z)- 536hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide185 N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2-chloro- 382phenyl)-acetamide 186N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-(4- 538methyl-piperazin-1-yl)-ethyl]-naphthalen-1-yl}-2-oxo- acetamide 187N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 444phenyl)-2-(1H-indol-3-yl)-2-oxo-acetamide 188N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4- 539yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo- acetamide 189N-(4-tert-Butyl-6-trifluoromethyl-pyrimidin-2-yl)-2-[4-(2- 531morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 190N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-o-tolyl- 361 acetamide 1915-tert-Butyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin- 5394-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-thiophene- 2-carboxylic acidmethylamide 192 N-[5-tert-Butyl-2-(3,5-dichloro-phenyl)-2H-pyrazol-3-596 yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide193 N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2- 569((2R,6S)-2,6-dimethyl-morpholin-4-yl)-ethoxy]-naphthalen-1-yl}-2-oxo-acetamide 1943-tert-Butyl-1,5-diphenyl-1,6-dihydro-imidazo[4,5- 316 c]pyrazole 195N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 506imidazol-1-yl-ethyl)-naphthalen-1-yl]-2-oxo-acetamide 1963-tert-Butyl-5-(3-chloro-phenyl)-1-p-tolyl-1,6-dihydro- 365imidazo[4,5-c]pyrazole 197 N-(5-tert-Butyl-2-methoxy-3- 660phenylmethanesulfonylamino-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 198N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-[4-(2- 533pyridin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 1991-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[(pyridin-2- 603ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-imidazolidine-2,4,5-trione 200N-[5-tert-Butyl-2-(3-chloro-phenyl)-2H-pyrazol-3-yl]-2- 561[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2015-Methoxy-1H-indazole-3-carboxylic acid (5-tert-butyl- 4032-p-tolyl-2H-pyrazol-3-yl)-amide 202N-[5-tert-Butyl-2-(6-chloro-pyridazin-3-yl)-2H-pyrazol- 5633-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- 2-oxo-acetamide203 N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 541morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 204N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2- 377methoxy-phenyl)-acetamide 2055-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2- 623morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide 206[(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 670ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)-methanesulfonyl-amino]-acetic acid ethyl ester 207N-(5-tert-Butyl-4-methyl-2-m-tolyl-2H-pyrazol-3-yl)-2- 570[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 208N-[5-tert-Butyl-2-(2,5-dichloro-phenyl)-2H-pyrazol-3- 596yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 209N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 555[1,4]oxazepan-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2101-(5-tert-Butyl-2-methoxy-3-benzamide)-3-(4-methoxy- 459phenyl)-3′-(carbamic acid ethyl ester)-urea 211N-[5-tert-Butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]- 4442-(4-methoxy-naphthalen-1-yl)-acetamide 212N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-4-chloro- 368 benzamide 213N-(2-Bromo-5-trifluoromethyl-phenyl)-2-[4-(2- 551morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2143-Isopropyl-5-phenyl-1-p-tolyl-1,6-dihydro- 316 imidazo[4,5-c]pyrazole215 3,5-Di-tert-butyl-1-p-tolyl-1,6-dihydro-imidazo[4,5- 310 c]pyrazole216 5-tert-Butyl-N-cyclopentyl-2-methoxy-3-{2-[4-(2- 602morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetylamino}-benzamide217 2-[5-tert-Butyl-2-(3-fluoro-4-methyl-phenyl)-2H- 559pyrazol-3-yl]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 218N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(4- 391methoxy-phenyl)-2-oxo-acetamide 2191,3-Di-tert-butyl-5-phenyl-1,6-dihydro-imidazo[4,5- 296 c]pyrazole 2204-(4-Bromo-naphthalen-1-yl)-1-(3-tert-butyl-phenyl)- 438[1,2,4]triazolidine-3,5-dione 221N-[5-tert-Butyl-2-(morpholine-4-carbonyl)-thiophen-3- 580yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 2223-tert-Butyl-5-(3-methoxy-phenyl)-1-p-tolyl-1,6- 360dihydro-imidazo[4,5-c]pyrazole 223N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4- 541yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo- acetamide 2241-tert-Butyl-5-[4-(2-morpholin-4-yl-ethoxy)-naphthalen- 5521-ylamino]-3-p-tolyl-1,3-dihydro-imidazo[4,5-b]pyridin- 2-one 2252-[5-tert-Butyl-2-(3-fluoro-phenyl)-2H-pyrazol-3-yl]-2- 560[(Z)-hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 2265-tert-Butyl-2-p-tolyl-2H-pyrazole-3-carboxylic acid [4- 527(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylmethyl]- amide 2272-[5-tert-Butyl-2-(3-fluoro-phenyl)-2H-pyrazol-3-yl]-N- 545[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2285-tert-Butyl-N-cyclopropylmethyl-2-methoxy-3-[2-(4- 489methoxy-naphthalen-1-yl)-2-oxo-acetylamino]- benzamide 229N-[5-tert-Butyl-3-(3,3-diethyl-ureido)-2-methoxy- 605phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide230 N-[5-tert-Butyl-2-(4-fluoro-phenyl)-2H-pyrazol-3-yl]-2- 545[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 231N-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)-2-[4-(2- 541morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 232N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 583phenyl)-2-oxo-2-[4-(2-piperazin-1-yl-ethoxy)- naphthalen-1-yl]-acetamide233 N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 632phenyl)-2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 234(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 592ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)- carbamic acidisopropyl ester 235 1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2- 540dimethylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione 236N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 633phenyl)-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 2374-(3-tert-Butyl-1-p-tolyl-1,6-dihydro-imidazo[4,5- 376c]pyrazol-5-yl)-2-methoxy-phenol 238N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(3,4- 416dichloro-phenyl)-acetamide 239N-[3-(3-Allyl-ureido)-5-tert-butyl-2-methoxy-phenyl]-2- 589[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2405-tert-Butyl-N,N-diethyl-2-methoxy-3-{2-[4-(2- 590morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetylamino}-benzamide241 N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 598phenyl)-2-[4-(2-[1,4]oxazepan-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 242N-(3-tert-Butyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)- 461naphthalen-1-yl]-2-oxo-acetamide 2435-tert-Butyl-N-ethyl-2-methoxy-3-{2-[4-(2-morpholin-4- 548yl-ethoxy)-naphthalen-1-yl]-acetylamino}-benzamide 244N-[5-tert-Butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3- 542yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 245N-[5-tert-Butyl-2-(4-ureido-phenyl)-2H-pyrazol-3-yl]-2- 585[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 246N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 499dimethylamino-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 247N-(5-tert-Butyl-2-methoxy-phenyl)-2-oxo-2-[4-(2- 539piperidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]- acetamide 248N-[5-tert-Butyl-2-(3-fluoro-4-methyl-phenyl)-2H- 559pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 249 Indazole-1-carboxylic acid(5-tert-butyl-2-p-tolyl-2H- 373 pyrazol-3-yl)-amide 250N-[3,5-Bis-(1,1-dimethyl-propyl)-2-methoxy-phenyl]-2- 575[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2511-Benzyl-3-tert-butyl-5-phenyl-1,6-dihydro- 330 imidazo[4,5-c]pyrazole252 2-(5-tert-Butyl-2-methoxy-3-nitro-phenyl)-N-[4-(2- 536morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2534-{2-[4-(5-tert-Butyl-3-methanesulfonylamino-2- 655methoxy-phenylaminooxalyl)-naphthalen-1-yloxy]-ethyl}-piperazine-1-carboxylic acid ethyl ester 2542-Hydroxy-N-(5-isopropyl-2-p-tolyl-2H-pyrazol-3-yl)-2- 529[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 2551-Bicyclo[2.2.1]hept-2-yl-3-phenyl-5-phenylamino-1,3- 396dihydro-imidazo[4,5-b]pyridin-2-one 256N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2- 555morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]- 2-oxo-acetamide257 N-[5-tert-Butyl-3-(2-dimethylamino-acetylamino)-2- 591methoxy-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 258N-(5-tert-Butyl-2-methoxy-3-{6-[4-(2-morpholin-4-yl- 624ethoxy)-naphthalen-1-yl]-3,5-dioxo-2,5-dihydro-3H-[1,2,4]triazin-4-yl}-phenyl)-methanesulfonamide 259N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(2- 465morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 260(R)—N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2- 363hydroxy-2-phenyl-acetamide 261N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 542phenyl)-2-[4-(2-dimethylamino-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide262 2-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-N-[4-(2- 465morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 263N-[2-(3-Amino-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2- 544hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-acetamide 2642-[5-tert-Butyl-2-(3-chloro-phenyl)-2H-pyrazol-3-yl]-N- 561[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2651,5-Diphenyl-1,6-dihydro-imidazo[4,5-c]pyrazole 260 266N-(5-tert-Butyl-[1,3,4]thiadiazol-2-yl)-2-[(Z)- 484hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide267 N-(5-tert-Butyl-3-{2-hydroxy-2-[4-(2-morpholin-4-yl- 622pyrimidin-4-yloxy)-naphthalen-1-yl]-ethylamino}-2-methoxy-phenyl)-methanesulfonamide 268N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-4-chloro- 368 benzamide 269N-(5-tert-Butyl-2-ethoxy-phenyl)-2-[4-(2-morpholin-4- 505yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 270(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 608ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)- carbamic acid2-methoxy-ethyl ester 271(R)—N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2- 377methoxy-2-phenyl-acetamide 2722-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-hydroxy-N- 543[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 2732-Amino-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2- 413naphthalen-1-yl-acetamide 274N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 582phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-acrylamide 275N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 522imidazol-1-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 276N-(4-Bromo-3-trifluoromethyl-phenyl)-2-[4-(2- 551morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2774-(4-Benzyloxy-phenyl)-1-(3-tert-butyl-phenyl)- 415[1,2,4]triazolidine-3,5-dione 278N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 618phenyl)-2-[8-chloro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 279N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 533phenyl)-2-[4-(2-chloro-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2805-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-ethoxy)- 538naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2- carboxylic aciddimethylamide 281 1-(5-tert-Butyl-isoxazol-3-yl)-3-[4-(2-morpholin-4-yl-493 ethoxy)-naphthalen-1-yl]-imidazolidine-2,4,5-trione 282N-(4-Chloro-3-trifluoromethyl-phenyl)-2-[4-(2- 507morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 2831-Benzoyl-3-(5-tert-butyl-2-methoxy-phenyl)-urea 326 284N′-[1-(5-tert-Butyl-3-ethylcarbamoyl-2-methoxy- 648phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]- hydrazinecarboxylic acid ethyl ester285 3-tert-Butyl-5-(3-fluoro-phenyl)-1-p-tolyl-1,6-dihydro- 348imidazo[4,5-c]pyrazole 2862-[3-Bromo-4-(2-morpholin-4-yl-ethoxy)-phenyl]-N-(5- 556tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-acetamide 2872-(2-Chloro-5-trifluoromethyl-phenyl)-N-[4-(2- 507morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 288N-[5-tert-Butyl-2-(3-chloro-benzenesulfonyl)-2H- 625pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 289(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid 363 p-tolyl ester290 N-(5-tert-Butyl-2-diethylamino-3- 625methanesulfonylamino-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 291N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 527morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 292N-[5-tert-Butyl-2-methoxy-3-(propane-1- 513sulfonylamino)-phenyl]-2-(4-methoxy-naphthalen-1- yl)-2-oxo-acetamide293 Propane-1-sulfonic acid (5-tert-butyl-2-methoxy-3-{4- 640[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-3,5-dioxo-[1,2,4]triazolidin-1-yl}-phenyl)-amide 2943-Amino-5-tert-butyl-2-methoxy-N-[4-(2-morpholin-4- 492yl-ethoxy)-naphthalen-1-ylmethyl]-benzamide 2952-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- 472N-(3-trifluoromethyl-phenyl)-acetamide 2964-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-6-[4-(2- 505morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2H- [1,2,4]triazine-3,5-dione297 N-[5-tert-Butyl-2-(4-trifluoromethyl-phenyl)-2H-pyrazol- 5953-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- 2-oxo-acetamide298 N-[5-tert-Butyl-2-methoxy-3-(propane-1- 619sulfonylamino)-phenyl]-2-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo- acetamide 299N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-phenyl- 347 acetamide 300N-[5-tert-Butyl-2-methoxy-3-(propane-1- 662sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide 301N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 612phenyl)-2-{4-[2-(2,6-dimethyl-morpholin-4-yl)-ethoxy]-naphthalen-1-yl}-2-oxo-acetamide 302N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(4- 428methoxy-naphthalen-1-yl)-acetamide 3033-tert-Butyl-1-cyclohexyl-5-phenyl-1,6-dihydro- 322imidazo[4,5-c]pyrazole 3043-tert-Butyl-5-(4-fluoro-phenyl)-1-p-tolyl-1,6-dihydro- 348imidazo[4,5-c]pyrazole 305N-(5-tert-Butyl-2-methoxy-3-{4-[4-(2-morpholin-4-yl- 612ethoxy)-naphthalen-1-yl]-3,5-dioxo-[1,2,4]triazolidin-1-yl}-phenyl)-methanesulfonamide 306N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-[2- 538(3-oxo-piperazin-1-yl)-ethyl]-naphthalen-1-yl}- acetamide 307N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-[4-(3- 547pyridin-4-yl-propoxy)-naphthalen-1-yl]-acetamide 308N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 603phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-acetamide 309N-[5-tert-Butyl-2-(4-methanesulfonyl-phenyl)-2H- 605pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 3102-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)-2,5- 425dihydro-pyrrole-1-carboxylic acid tert-butyl ester 311N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 565phenyl)-2-[4-(2-imidazol-1-yl-ethoxy)-naphthalen-1-yl]- 2-oxo-acetamide312 N-[5-tert-Butyl-2-(3,5-dimethyl-phenyl)-2H-pyrazol-3- 555yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 313N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 589morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2- oxo-acetamide 314N-{5-tert-Butyl-3-[carbamoylmethyl-(propane-1- 540sulfonyl)-amino]-2-methoxy-phenyl}-2-naphthalen-1- yl-2-oxo-acetamide315 N′-[1-(5-tert-Butyl-2-methyl-2H-pyrazol-3- 551ylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]- hydrazinecarboxylic acid ethyl ester316 5-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2- 560morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}- benzamide 317N-[5-tert-Butyl-2-(3-nitro-phenyl)-2H-pyrazol-3-yl]-2-[4- 572(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 318N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[3-chloro-4- 525(2-morpholin-4-yl-ethoxy)-phenyl]-2-oxo-acetamide 319N-(3-Benzenesulfonylamino-5-tert-butyl-2-methoxy- 646phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide320 3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)- 576naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1- carboxylic acidcyclohexylamide 321 N-[5-tert-Butyl-2-methoxy-3-(2,2,2-trifluoro- 652ethanesulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 322N′-[1-(5-tert-Butyl-3-carbamoyl-2-methoxy- 620phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]- hydrazinecarboxylic acid ethyl ester323 5-tert-Butyl-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)- 584naphthalen-1-yl]-3-(propane-1-sulfonylamino)- benzamide 324N-(5-tert-Butyl-2-methoxy-phenyl)-2-hydroxy-2-(4- 393methoxy-naphthalen-1-yl)-acetamide 325(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 621ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)- carbamic acid2-dimethylamino-ethyl ester 326N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 602phenyl)-2-[7-fluoro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 327N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl- 500pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 3283-tert-Butyl-1-(4-chloro-phenyl)-5-phenyl-1,6-dihydro- 351imidazo[4,5-c]pyrazole 329N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-(4- 365methoxy-naphthalen-1-yl)-2-oxo-acetamide 3302-[5-tert-Butyl-2-(3,4-dimethyl-phenyl)-2H-pyrazol-3- 570yl]-2-[(Z)-hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 331N-(5-tert-Butyl-isoxazol-3-yl)-2-(4-methoxy- 352naphthalen-1-yl)-2-oxo-acetamide 332N-[5-(1,1-Dimethyl-propyl)-2-p-tolyl-2H-pyrazol-3-yl]-2- 557hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-acetamide 333N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]- 5642-[4-(2-dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 334N-(2-Chloro-5-trifluoromethyl-phenyl)-2-[4-(2- 507morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 335N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 603phenyl)-2-[2,3-dichloro-4-(2-morpholin-4-yl-ethoxy)-phenyl]-2-oxo-acetamide 336N-(3-Methanesulfonylamino-2-methoxy-5-methyl- 542phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide337 4-{2-[4-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3- 596ylaminooxalyl)-naphthalen-1-yl]-ethyl}-piperazine-1- carboxylic acidethyl ester 338 (1-Benzyl-1H-benzoimidazol-2-yl)-(5-tert-butyl-2-p- 436tolyl-2H-pyrazol-3-yl)-amine 339N-(3,5-Di-tert-butyl-2-hydroxy-phenyl)-2-[4-(2- 533morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 340N-(5-tert-Butyl-2-naphthalen-1-yl-2H-pyrazol-3-yl)-2- 577[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 341N-(5-tert-Butyl-2-methoxy-phenyl)-2-[4-(2-morpholin-4- 540yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo- acetamide 3424-{2-[4-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3- 612ylaminooxalyl)-naphthalen-1-yloxy]-ethyl}-piperazine- 1-carboxylic acidethyl ester 343 5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 583pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo- acetylamino}-benzamide 344N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 458phenyl)-2-(1-methyl-1H-indol-3-yl)-2-oxo-acetamide 3454-Phenyl-piperidine-4-carboxylic acid (5-tert-butyl-2- 367methoxy-phenyl)-amide 3465-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 520ethoxy)-naphthalen-1-yl]-acetylamino}-benzamide 347N-[2-(4-Acetyl-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2- 569[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 3481-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2- 582morpholin-4-yl-ethoxy)-naphthalen-1-yl]-imidazolidine- 2,4,5-trione 349N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2,3- 383difluoro-phenyl)-acetamide 350N-[5-tert-Butyl-3-(carbamoylmethyl-methanesulfonyl- 512amino)-2-methoxy-phenyl]-2-naphthalen-1-yl-2-oxo- acetamide 351N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[2-methyl- 4294-(2-morpholin-4-yl-ethoxy)-phenyl]-2-oxo-acetamide 352N-[2-(4-Amino-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2- 542[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 353(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 626ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)- carbamic acidphenyl ester 354 N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(2- 451morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 355N-(5-tert-Butyl-2-isobutoxy-phenyl)-2-[4-(2-morpholin- 5334-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 356N-(4-tert-Butyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)- 461naphthalen-1-yl]-2-oxo-acetamide 357N-[5-tert-Butyl-2-(3-methyl-benzoyl)-2H-pyrazol-3-yl]- 5692-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 3585-tert-Butyl-3-{2-[(Z)-hydroxylmino]-2-[4-(2-morpholin- 5254-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-thiophene- 2-carboxylic acidamide 359 1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-chloro- 531pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine- 2,4,5-trione 360(S)—N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2- 363hydroxy-2-phenyl-acetamide 361N-[5-tert-Butyl-2-(2,3-dimethyl-phenyl)-2H-pyrazol-3- 555yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 362N-[5-tert-Butyl-2-(4-nitro-phenyl)-2H-pyrazol-3-yl]-2-[4- 572(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 3632-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-N-[4-(2- 541morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 3642-[(Z)-Hydroxyimino]-N-(3-methanesulfonylamino-2- 557methoxy-5-methyl-phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 365N-[5-tert-Butyl-2-(morpholine-4-carbonyl)-thiophen-3- 595yl]-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 366N-(5-tert-Butyl-2-phenyl-2H-pyrazol-3-yl)-2-[4-(2- 527morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 367N′-[1-(5-tert-Butyl-2-methyl-2H-pyrazol-3- 551ylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]- hydrazinecarboxylic acid ethyl ester368 N′-[1-(5-tert-Butyl-2-methyl-2H-pyrazol-3- 522ylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]- hydrazinecarboxamide 369N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]- 5572-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 3705-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 611ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-N- pyridin-2-yl-benzamide371 N-[5-tert-Butyl-3-(3,3-dimethyl-ureido)-2-methoxy- 577phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide372 5-tert-Butyl-3-{2-[7-chloro-4-(2-morpholin-4-yl-ethoxy)- 568naphthalen-1-yl]-2-oxo-acetylamino}-2-methoxy- benzamide 373N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-m-tolyl- 361 acetamide 3741-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-pyrrolidin-1- 566yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine- 2,4,5-trione 375N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2- 377phenyl-propionamide 3762-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- 456N-quinolin-3-yl-acetamide 3771-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-3-[4-(2- 582morpholin-4-yl-ethoxy)-naphthalen-1-yl]-imidazolidine- 2,4,5-trione 378(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-(3- 387trifluoromethyl-benzyl)-amine 379N-[5-tert-Butyl-2-methoxy-3-(morpholine-4-carbonyl)- 604phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide380 N-[5-tert-Butyl-3-(3-isopropyl-ureido)-2-methoxy- 591phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide381 N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-methoxy-2- 458(4-methoxy-naphthalen-1-yl)-acetamide 382N-(3-Amino-5-trifluoromethyl-phenyl)-2-[4-(2- 487morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 383N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(2- 515morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2- oxo-acetamide 3843-Methyl-1,5-diphenyl-1,6-dihydro-imidazo[4,5- 274 c]pyrazole 385N-(5-tert-Butyl-isoxazol-3-yl)-2-hydroxy-2-[4-(2- 454morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 386N-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- 4452-(2-phenyl-cyclopropyl)-acetamide 3872-{4-[2-(4-Acetyl-piperazin-1-yl)-ethoxy]-naphthalen-1- 625yl}-N-(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-2-oxo-acetamide 3882-(1H-Indol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)- 444naphthalen-1-yl]-2-oxo-acetamide 389N-[5-tert-Butyl-2-(3-fluoro-phenyl)-2H-pyrazol-3-yl]-2- 545[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 3902-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-N-[4-(2- 506morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 391N-[5-tert-Butyl-2-(3,4-dichloro-phenyl)-2H-pyrazol-3- 596yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 392N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl- 502pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetamide 393N-[5-tert-Butyl-2-(2,5-dimethyl-phenyl)-2H-pyrazol-3- 555yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 394N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 588phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-2-oxo-acetamide 395 1H-Indazole-3-carboxylicacid (5-tert-butyl-2-pyridin-2- 360 yl-2H-pyrazol-3-yl)-amide 396N-(4-Chloro-3-trifluoromethyl-phenyl)-2-(4-methoxy- 408naphthalen-1-yl)-2-oxo-acetamide 397N-[5-(1,1-Dimethyl-butyl)-2-p-tolyl-2H-pyrazol-3-yl]-2- 569[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 3981H-Indazole-3-carboxylic acid [5-tert-butyl-2-(4- 389methoxy-phenyl)-2H-pyrazol-3-yl]-amide 399 1H-Indazole-3-carboxylic acid[5-tert-butyl-2-(4- 375 hydroxy-phenyl)-2H-pyrazol-3-yl]-amide 400N′-[1-(5-tert-Butyl-3-methanesulfonylamino-2- 641methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]- hydrazinecarboxamide 401N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N′-[4-(2- 556morpholin-4-yl-ethoxy)-naphthalen-1-yl]-oxalamide 402N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 577phenyl)-2-[4-(2-methylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 403N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[(Z)- 570methoxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide404 5-tert-Butyl-N-cyclopropyl-3-[2-[(E)-hydroxyimino]-2- 490(4-methoxy-naphthalen-1-yl)-acetylamino]-2-methoxy- benzamide 405N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-(2,6- 569dimethyl-morpholin-4-yl)-ethoxy]-naphthalen-1-yl}-2- oxo-acetamide 406N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 602phenyl)-2-[8-fluoro-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 407N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(3-fluoro- 365phenyl)-acetamide 4085-tert-Butyl-N-furan-2-ylmethyl-2-methoxy-3-{2-[4-(2- 614morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetylamino}-benzamide409 N-[5-tert-Butyl-2-(3-trifluoromethyl-benzoyl)-2H- 623pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 410N-[5-tert-Butyl-2-methoxy-3-(propane-1- 661sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo- acetamide 4111-(5-tert-Butyl-isoxazol-3-yl)-3-[4-(2-morpholin-4-yl- 543pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine- 2,4,5-trione 4121-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-[4-(2- 539morpholin-4-yl-ethoxy)-naphthalen-1-yl]-3′-(carbamic acid ethylester)-urea 413 N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 597phenyl)-2-oxo-2-{4-[2-(3-oxo-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}-acetamide 4142-{4-[2-(4-Acetyl-piperazin-1-yl)-ethyl]-naphthalen-1- 566yl}-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo- acetamide 415N-(5-tert-Butyl-2-phenylacetyl-2H-pyrazol-3-yl)-2-[4-(2- 569morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 416N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-[2- 554(3-oxo-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}- acetamide 4172-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[(Z)- 556hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide418 N-[5-tert-Butyl-2-(3-ureido-phenyl)-2H-pyrazol-3-yl]-2- 585[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 419N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 663phenyl)-2-[(Z)-methoxyimino]-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-acetamide 420N-[5-tert-Butyl-2-methoxy-3-(3-oxo-piperazine-1- 617carbonyl)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 4213-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)- 536naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1- carboxylic acidpropylamide 422 5-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2- 624morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide 423N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[2-(4- 554methyl-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}-2-oxo- acetamide 424N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2- 556morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2- oxo-acetamide 4255-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 576ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-N-propyl- benzamide 426N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-hydroxy-2- 393(4-methoxy-phenyl)-acetamide 427N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[(Z)- 480hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide428 N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(3- 440phenoxy-phenyl)-acetamide 429N-(5-Isopropyl-2-methyl-phenyl)-2-[4-(2-morpholin-4- 461yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 4307-Isopropyl-9-phenyl-2-phenylamino-7,9-dihydro- 345 purin-8-one 431(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 641ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)- carbamic acidpyridin-3-ylmethyl ester 432N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 542phenyl)-2-[4-(2-ethylamino-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 433N-(3,5-Di-tert-butyl-phenyl)-2-[4-(2-morpholin-4-yl- 517ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 4342-Amino-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2- 413naphthalen-2-yl-acetamide 435N-[5-tert-Butyl-2-(3-fluoro-4-methyl-phenyl)-2H- 561pyrazol-3-yl]-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 4362-[5-tert-Butyl-2-(3,4-difluoro-phenyl)-2H-pyrazol-3-yl]- 563N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 437N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2- 499methylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]-2- oxo-acetamide 438N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 591morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2- oxo-acetamide 439N-[5-tert-Butyl-2-(2,3-dichloro-phenyl)-2H-pyrazol-3- 596yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 440N-[3,5-Bis-(1,1-dimethyl-propyl)-2-hydroxy-phenyl]-2- 561[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 4414-{2-[4-(5-tert-Butyl-3-methanesulfonylamino-2- 683methoxy-phenylaminooxalyl)-naphthalen-1-yloxy]-ethyl}-piperazine-1-carboxylic acid tert-butyl ester 4423-tert-Butyl-1-naphthalen-2-yl-5-phenyl-1,6-dihydro- 366imidazo[4,5-c]pyrazole 4432-Biphenyl-4-yl-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3- 424yl)-acetamide 444 5-tert-Butyl-N-isopropyl-2-methoxy-3-{2-[4-(2- 576morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetylamino}-benzamide445 N-(5-tert-Butyl-3-diethylaminomethyl-2-hydroxy- 562phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide446 6-Hydroxy-nicotinic acid 3-[5-tert-butyl-2-methoxy-3- 582(propane-1-sulfonylamino)-phenylcarbamoyl]-1H- indazol-5-yl ester 447N-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 590morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]- 2-oxo-acetamide448 N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(2- 514morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]- 2-oxo-acetamide449 N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 633phenyl)-2-[4-(4-morpholin-4-yl-pyrimidin-2-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 450N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2- 506morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 4511,3,5-Triphenyl-1,6-dihydro-imidazo[4,5-c]pyrazole 336 452N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-cyclohexyl- 354 acetamide453 2-[5-tert-Butyl-2-(2-chloro-phenyl)-2H-pyrazol-3-yl]-N- 561[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 4547-Cyclohexylmethyl-9-phenyl-2-phenylamino-7,9- 399 dihydro-purin-8-one455 5-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-ethoxy)- 524naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2- carboxylic acidmethylamide 456 5-tert-Butyl-N-cyclopropylmethyl-2-methoxy-3-{2-[4-(2-574 morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}- benzamide 457N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]- 6062-[4-(2-morpholin-4-yl-pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 458N′-[1-(5-tert-Butyl-3-carbamoyl-2-methoxy- 620phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]- hydrazinecarboxylic acid ethyl ester459 4-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-1-(2,3- 341dimethyl-phenyl)-[1,2,4]triazolidine-3,5-dione 460N-(4-Fluoro-3-trifluoromethyl-phenyl)-2-[4-(2- 490morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 4611-Benzyl-3-phenyl-5-phenylamino-1,3-dihydro- 392imidazo[4,5-b]pyridin-2-one 462N-(5-tert-Butyl-2-methoxy-phenyl)-2-naphthalen-2-yl- 347 acetamide 4632-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1- 466ylcarbamoyl]-pyrrole-1-carboxylic acid tert-butyl ester 464N-(2,5-Di-tert-butyl-phenyl)-2-[4-(2-morpholin-4-yl- 517ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 4652-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- 445N-((1S,2R)-2-phenyl-cyclopropyl)-acetamide 4662-Oxo-23-dihydro-benzoimidazole-1-carboxylic acid 389(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-amide 467N-(2-Methoxy-5-trifluoromethyl-phenyl)-2-[4-(2- 502morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 468N-[2-(4-Bromo-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2- 606[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 4691-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-morpholin-4- 582yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine- 2,4,5-trione 4705-tert-Butyl-2-methoxy-N-methyl-3-{2-[4-(2-morpholin- 5484-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}- benzamide 471N-(5-tert-Butyl-2-methoxy-3-piperidin-1-ylmethyl- 588phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide472 N-(5-tert-Butyl-2-methoxy-phenyl)-2-naphthalen-1-yl- 3612-oxo-acetamide 473N-(2,5-Di-tert-butyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin- 5074-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 474(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-carbamic acid 3794-methoxy-phenyl ester 475 N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-376 naphthalen-1-yl-2-oxo-acetamide 4765-tert-Butyl-N-ethyl-3-{2-[(Z)-hydroxylmino]-2-[4-(2- 577morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-2-methoxy-benzamide 477 4-{2-[4-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-624 ylaminooxalyl)-naphthalen-1-yl]-ethyl}-piperazine-1- carboxylic acidtert-butyl ester 4785-tert-Butyl-N-ethyl-2-hydroxy-3-{2-[4-(2-morpholin-4- 548yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}- benzamide 479N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-naphthalen- 3981-yl-acetamide 480 N-(5-tert-Butyl-2-ethoxy-3-methanesulfonylamino- 598phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide481 N′-[1-(5-tert-Butyl-3-ethylcarbamoyl-2-methoxy- 619phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]- hydrazinecarboxamide 4822-{4-[2-(4-Acetyl-piperazin-1-yl)-ethoxy]-naphthalen-1- 582yl}-N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo- acetamide 4835-tert-Butyl-N-ethyl-2-methoxy-3-{2-[4-(2-morpholin-4- 562yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}- benzamide 4845-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 535ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzoic acid 485N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 590phenyl)-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-acetamide 486N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-dimethylamino- 459pyrimidin-4-ylamino)-naphthalen-1-yl]-2-oxo- acetamide 4875-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-pyridin-4- 558ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}- thiophene-2-carboxylicacid amide 488 2-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-418 N-m-tolyl-acetamide 4895-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-ethoxy)- 525naphthalen-1-yl]-2-oxo-acetylamino}-thiophene-2- carboxylic acid methylester 490 N′-[1-(5-tert-Butyl-3-methanesulfonylamino-2- 641methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(Z)-ylidene]- hydrazinecarboxamide 491N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]- 6052-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 492N-(5-Isopropyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 527morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 493N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl- 452ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 494N-(2-Benzoyl-5-tert-butyl-2H-pyrazol-3-yl)-2-[4-(2- 555morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 4956-Bromo-1H-indazole-3-carboxylic acid (5-tert-butyl-2- 452p-tolyl-2H-pyrazol-3-yl)-amide 4965-tert-Butyl-N-ethyl-3-{2-hydrazono-2-[4-(2-morpholin- 5764-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-2-methoxy- benzamide 497N-(5-tert-Butyl-3-ethanesulfonylamino-2-methoxy- 613phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 498N-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-2-[4-(2- 513dimethylamino-pyrimidin-4-ylamino)-naphthalen-1-yl]- 2-oxo-acetamide 499N-(5-tert-Butyl-thiophen-3-yl)-2-[4-(2-morpholin-4-yl- 467ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 500N-[5-tert-Butyl-2-(4-chloro-phenyl)-2H-pyrazol-3-yl]-2- 561[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 501N′-[1-(5-tert-Butyl-3-carbamoyl-2-methoxy- 591phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]-hydrazinecarboxamide 502N-[5-tert-Butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]- 5572-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 5035-tert-Butyl-3-{2-[7-chloro-4-(2-morpholin-4-yl-ethoxy)- 608naphthalen-1-yl]-2-oxo-acetylamino}-N-cyclopropyl-2- methoxy-benzamide504 N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 597phenyl)-2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}-2-oxo-acetamide 5051-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2- 554morpholin-4-yl-ethoxy)-naphthalen-1-yl]-imidazolidin- 2-one 506N-(5-tert-Butyl-thiophen-3-yl)-2-[(Z)-hydroxyimino]-2- 482[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 5075-tert-Butyl-N-cyclopropyl-3-[2-[(Z)-hydroxylmino]-2- 490(4-methoxy-naphthalen-1-yl)-acetylamino]-2-methoxy- benzamide 508N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[4-(4- 514morpholin-4-yl-pyrimidin-2-ylamino)-naphthalen-1-yl]- 2-oxo-acetamide509 N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]- 5722-[(Z)-hydroxylmino]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 510N-[2-Methoxy-5-(1-methyl-1-phenyl-ethyl)-phenyl]-2- 553[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 5112-[5-tert-Butyl-2-(3,4-dimethyl-phenyl)-2H-pyrazol-3- 555yl]-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 5125-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-pyrimidin-4- 559ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}- thiophene-2-carboxylicacid amide 513 5-tert-Butyl-N-isobutyl-2-methoxy-3-{2-[4-(2- 590morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetylamino}-benzamide514 2-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[(Z)- 556hydroxyimino]-N-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide515 3-tert-Butyl-1-(2,3-dichloro-phenyl)-5-phenyl-1,6- 385dihydro-imidazo[4,5-c]pyrazole 516N-(3,5-Di-tert-butyl-2-methoxy-phenyl)-2-[4-(2- 547morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 5175-tert-Butyl-3-{2-[(Z)-hydroxyimino]-2-[4-(2-morpholin- 5534-yl-ethoxy)-naphthalen-1-yl]-acetylamino}-thiophene- 2-carboxylic aciddimethylamide 518 N-(5-tert-Butyl-2-methoxy-3-methyl-phenyl)-2-[(Z)- 520hydroxyimino]-2-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-acetamide519 N′-[1-(5-tert-Butyl-3-cyclopropylcarbamoyl-2-methoxy- 660phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]- hydrazinecarboxylic acid ethyl ester520 N-Indan-5-yl-2-[4-(2-morpholin-4-yl-ethoxy)- 445naphthalen-1-yl]-2-oxo-acetamide 521N-[5-tert-Butyl-2-(3-chloro-4-fluoro-phenyl)-2H- 579pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 522N-[5-tert-Butyl-3-(imidazole-1-carbonyl)-2-methoxy- 585phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide523 2-(2,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-morpholin-4- 540yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 524N-[5-tert-Butyl-2-(2,4-difluoro-phenyl)-2H-pyrazol-3-yl]- 5632-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 5251H-Indazole-3-carboxylic acid (5-tert-butyl-2-methoxy- 323 phenyl)-amide526 N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-oxo-2-{4-[2- 568(5-oxo-[1,4]diazepan-1-yl)-ethoxy]-naphthalen-1-yl}- acetamide 5273-tert-Butyl-1-p-tolyl-5-(4-trifluoromethyl-phenyl)-1,6- 398dihydro-imidazo[4,5-c]pyrazole 528N-(5-tert-Butyl-3-ethanesulfonylamino-2-methoxy- 598phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide529 3-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)- 536naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1- carboxylic acidisopropylamide 530N-(5-tert-Butyl-[1,3,4]thiadiazol-2-yl)-2-hydroxy-2-[4- 471(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 531N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 649phenyl)-2-[(Z)-hydroxyimino]-2-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-acetamide 532N-[2-(3-Amino-phenyl)-5-tert-butyl-2H-pyrazol-3-yl]-2- 542[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 5333-tert-Butyl-5-{2-[4-(2-morpholin-4-yl-ethoxy)- 570naphthalen-1-yl]-2-oxo-acetylamino}-pyrazole-1- carboxylic acidphenylamide 534 2-(5-tert-Butyl-2-methyl-furan-3-yl)-N-[4-(2-morpholin-465 4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 535N-(5-tert-Butyl-2-o-tolyl-2H-pyrazol-3-yl)-2-[4-(2- 541morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 536N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(2-morpholin-4-yl- 438ethoxy)-naphthalen-1-yl]-acetamide 537N-(5-tert-Butyl-2-methoxy-phenyl)-2-(3-methoxy- 327 phenyl)-acetamide538 5-tert-Butyl-3-{2-[4-(2-morpholin-4-yl-pyrimidin-4- 560yloxy)-naphthalen-1-yl]-2-oxo-acetylamino}-thiophene- 2-carboxylic acidamide 539 N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 586phenyl)-2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-acetamide 540N-[5-tert-Butyl-2-(2,4-dichloro-phenyl)-2H-pyrazol-3- 596yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2- oxo-acetamide 541N-(5-tert-Butyl-isoxazol-3-yl)-2-[4-(3-hydroxy- 396propoxy)-naphthalen-1-yl]-2-oxo-acetamide 542N-(3-tert-Butyl-isoxazol-5-yl)-2-[(Z)-hydroxyimino]-2- 467[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 5431H-Indole-3-carboxylic acid (5-tert-butyl-2-methoxy- 322 phenyl)-amide544 N-[5-tert-Butyl-2-methoxy-3-(propane-1- 612sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 5457-Bicyclo[2.2.1]hept-2-yl-9-phenyl-2-phenylamino-7,9- 397dihydro-purin-8-one 546N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(2,4- 416dichloro-phenyl)-acetamide 5475-tert-Butyl-2-methoxy-N-[4-(2-morpholin-4-yl-ethoxy)- 463naphthalen-1-yl]-benzamide 548N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-[2,3- 443dimethyl-4-(2-morpholin-4-yl-ethoxy)-phenyl]-2-oxo- acetamide 549N-(5-tert-Butyl-2-methoxy-phenyl)-2-(3-fluoro-phenyl)- 315 acetamide 5501-(5-tert-Butyl-2-methoxy-3-benzamide)-3-(2,3- 457dimethylphenyl)-3′-(carbamic acid ethyl ester)-urea 5512-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-oxo-N-(3- 353trifluoromethyl-phenyl)-acetamide 5527-Benzyl-9-phenyl-2-phenylamino-7,9-dihydro-purin-8- 393 one 5532,5-Dihydro-1H-pyrrole-2-carboxylic acid (5-tert-butyl- 3242-p-tolyl-2H-pyrazol-3-yl)-amide 554N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 611phenyl)-2-oxo-2-{4-[2-(5-oxo-[1,4]diazepan-1-yl)-ethoxy]-naphthalen-1-yl}-acetamide 555N-[5-tert-Butyl-2-(3-cyano-phenyl)-2H-pyrazol-3-yl]-2- 552[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 556N-(5-tert-Butyl-2-methoxy-3-phenylacetylamino- 624phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide557 2-(2-Chloro-5-trifluoromethyl-phenyl)-N-[4-(2- 557morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-2- oxo-acetamide 5581-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-piperidin-1- 580yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-imidazolidine- 2,4,5-trione 5592-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)-2-hydroxy-N- 543[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]- acetamide 5605-tert-Butyl-3-{2-[4-(2-dimethylamino-pyrimidin-4- 517ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}- thiophene-2-carboxylicacid amide 561 N′-[1-(5-tert-Butyl-3-ethylcarbamoyl-2-methoxy- 648phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]- hydrazinecarboxylic acid ethyl ester562 N-(3-Methanesulfonylamino-5-trifluoromethyl-phenyl)- 5662-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 563N-(5-tert-Butyl-2-hydroxy-3-piperidin-1-ylmethyl- 574phenyl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1- yl]-2-oxo-acetamide564 2-(1-Methyl-1H-indol-3-yl)-N-[4-(2-morpholin-4-yl- 458ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 565N-(5-tert-Butyl-2-methoxy-phenyl)-2-oxo-2-{4-[2-((S)- 5741-phenyl-ethylamino)-pyrimidin-4-ylamino]- naphthalen-1-yl}-acetamide566 N-[5-tert-Butyl-2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-2- 552[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 567N′-[1-(5-tert-Butyl-3-methanesulfonylamino-2- 670methoxy-phenylcarbamoyl)-1-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-meth-(E)-ylidene]- hydrazinecarboxylic acidethyl ester 568 N-[5-tert-Butyl-2-(3-methoxy-phenyl)-2H-pyrazol-3-yl]-559 2-hydroxy-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen- 1-yl]-acetamide569 N-(5-tert-Butyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl- 576ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-phenyl)- isobutyramide 570N-[5-tert-Butyl-2-(4-methyl-benzoyl)-2H-pyrazol-3-yl]- 5692-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 571N-[5-tert-Butyl-2-(2-chloro-phenyl)-2H-pyrazol-3-yl]-2- 561[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 572N-[5-tert-Butyl-2-(3-chloro-4-methyl-phenyl)-2H- 575pyrazol-3-yl]-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 5732-(4-Bromo-phenyl)-N-(5-tert-butyl-2-p-tolyl-2H- 426pyrazol-3-yl)-acetamide 5742-(5-tert-Butyl-2-methyl-furan-3-yl)-N-[4-(6-morpholin- 5124-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo- acetamide 5754-(4-{4-[2-(5-tert-Butyl-2-methyl-furan-3-yl)-2-oxo- 577acetylamino]-naphthalen-1-ylamino}-phenoxy)- pyridine-2-carboxylic acidmethylamide 576 N-[5-tert-Butyl-2-methoxy-3-(propane-1- 660sulfonylamino)-phenyl]-2-[4-(2-morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetamide 5775-tert-Butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2- 622morpholin-4-yl-pyridin-4-ylamino)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide 578N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 631phenyl)-2-oxo-2-{4-[6-(tetrahydro-pyran-4-ylamino)-pyridin-3-yl]-naphthalen-1-yl}-acetamide 5793-[2-(4-Bromo-naphthalen-1-yl)-2-oxo-acetylamino]-5- 523tert-butyl-N-cyclopropyl-2-methoxy-benzamide 580N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 617phenyl)-2-[4-(6-morpholin-4-yl-pyridin-3-yl)-naphthalen-1-yl]-2-oxo-acetamide 581N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(6- 588morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-2- oxo-acetamide 582N-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy- 532phenyl)-2-oxo-2-(4-pyridin-3-yl-naphthalen-1-yl)- acetamide 583N-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-2-oxo-2-(4- 412pyridin-3-yl-naphthalen-1-yl)-acetamide 5842-(4-Chloro-3-trifluoromethyl-phenyl)-N-[4-(2- 507morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo- acetamide 5854-{4-[2-(4-Chloro-3-trifluoromethyl-phenyl)-2-oxo- 478acetylamino]-phenoxy}-pyridine-2-carboxylic acid methylamide

As will be understood by one skilled in the art, for any and allpurposes, particularly in terms of providing a written description, allranges disclosed herein also encompass any and all possible subrangesand combinations of subranges thereof Any listed range can be easilyrecognized as sufficiently describing and enabling the same range beingbroken down into at least equal halves, thirds, quarters, fifths,tenths, etc. As a non-limiting example, each range discussed herein canbe readily broken down into a lower third, middle third and upper third,etc. As will also be understood by one skilled in the art all languagesuch as “up to,” “at least,” “greater than,” “less than,” and the likeinclude the number recited and refer to ranges which can be subsequentlybroken down into subranges as discussed above. Finally, as will beunderstood by one skilled in the art, a range includes each individualmember. Thus, for example, a group having 1-3 atoms refers to groupshaving 1, 2, or 3 atoms. Similarly, a group having 1-5 atoms refers togroups having 1, 2, 3, 4, or 5 atoms, and so forth.

While certain embodiments have been illustrated and described, it shouldbe understood that changes and modifications can be made therein inaccordance with ordinary skill in the art without departing from theinvention in its broader aspects as defined in the following claims.

1.-93. (canceled)
 94. A pharmaceutically acceptable salt of


95. The pharmaceutically acceptable salt of claim 94, wherein thepharmaceutically acceptable salt is a hydrochloric acid salt.
 96. Apharmaceutical composition comprising

or pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient.
 97. A method of inhibiting TNFa production in asubject comprising administering

or pharmaceutically acceptable salt thereof, to the subject in an amounteffective to inhibit TNFa production.
 98. A method of treating a diseasemediated by cytokines comprising administering to a subject having adisease mediated by cytokines a therapeutically effective amount of

or pharmaceutically acceptable salt thereof.